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Abstract
Chronic Obstructive Pulmonary Disease "COPD" is a chronic condition 
characterised by progressive deterioration in the lung function. COPD co exists with 
other clinical conditions resulting into complex cases. People with COPD suffer from 
progressive functional limitations and participation restrictions.
Pulmonary Rehabilitation "PR" is a multidisciplinary intervention designed to 
improve functional outcomes in people with COPD. Despite the established 
effectiveness of PR, a number of clinical problems in the provision of PR services 
remain unresolved. In order to address these problems an outcome measure that is 
appropriate for implementation in clinical settings is required.
The aim of this thesis was to develop a clinical tool for the measurement of 
functional outcomes of PR in people with COPD. The research process included three 
phases. A "conceptualisation" phase, the phase of “■development”, and a "clinical 
testing" phase.
During the phase of conceptualisation a critical review of the literature was 
performed. This resulted in the development of a framework for the measurement of 
functioning in people with COPD, and the identification of the specifications for a 
clinical outcome measure.
The phase of development resulted in the selection of the TELER method of 
measurement and the development and validation of TELER "function" indicators using 
extensive qualitative research that used indepth interviews and focus groups methods.
The final phase was testing the indicators in clinical PR settings. This resulted in 
providing evidence of the usefulness of the TELER "function" indicators in producing 
informative data appropriate for full clinimetric analysis. The clinimetric analysis of 
TELER data developed new insights about the provision of PR.
This thesis has contributed to the development in the measurement of the 
functional outcomes of PR, by providing a new clinical tool that is underpinned by 
sound theoretical, clinical and empirical knowledge. The tool is appropriate for use in 
clinical evaluation, and has the potential to resolve clinical problems in the provision of 
PR.
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Introduction
The prevalence of chronic diseases 1 is escalating, presenting an increased 
economic burden nationally and worldwide (WHO 2008)2. Chronic diseases are defined 
by the department of health as those diseases that could be controlled, but at present not 
cured (Department of Health 2004). The increased prevalence is explained by the aging 
of the population, and the increased exposure to risk factors resulting from behavioural, 
societal and environmental changes (Rosen et a l 2007).
Chronic respiratory diseases were identified amongst the four leading causes of 
disability worldwide (WHO 2008). There is growing evidence that Chronic Obstructive 
Pulmonary Disease “COPD” coexists with other chronic conditions creating complex 
cases (Yawn and Kaplan 2008) and (Barnes and Celli 2009). Such a complex disease 
requires a complex multidisciplinary intervention to target it. Pulmonary rehabilitation 
“PR” is currently accepted as a standard component of the integrated care for people 
with COPD (NICE 2010)3. Physiotherapists are key to the design and delivery o f PR 
programmes, and frequently involved in leading the program (CSP 2011)4. Delivery of 
PR occurs at clinical, community, and home settings. Moreover, physiotherapists 
facilitate concordance with the exercise program and maintenance o f the long term 
benefits by contributing to the education and self-management components o f PR. The 
overall aim is to improve functional status of the individual patient (BTS 2001)5.
NICE produced two documents containing various sources of evidence 
supporting the effectiveness and efficiency of pulmonary rehabilitation (NICE 2006, 
and NICE 2010). Moreover, evidence from randomised controlled trials “RCTs” 
suggests that intensive multidisciplinary pulmonary rehabilitation resulted in decreased 
length of hospital stay (Griffith et a l 2000) (Griffiths et al. 2001) and reduction in 
readmission with evidence of cost effectiveness (Seymour et a l 2010).
1 The term s chronic, life long, long term , non-com m unicable diseases/ conditions, are used 
interchangeably.
2 The W orld H ealth Organization.
3 The N ational Institute for health and Clinical Excellence.
4 The Chartered Society o f  Physiotherapy.
5 The British Thoracic Society.
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A number of studies reported improved exercise capacity following pulmonary 
rehabilitation (Nici and ZuWallack 2010), (Laccasse et al. 2009), and (Ries et al. 1995). 
However, there is no evidence to show that improvement in exercise capacity translated 
into improved functional performance at home and in the community (Pitta et al. 2008) 
(Bourbeau 2010). One explanation of this could be that functional performance is 
influenced by factors other than those influencing functional capacity. Therefore, it 
should be measured separately (Nici et al. 2006). However, an “appropriate” outcome 
measure of functional performance currently does not exist.
An appropriate outcome measure should be able to trace changes in functional 
performance. Moreover, the outcome measure should be appropriate to the context and 
the population within which it will be implemented. Clinicians working in PR setting 
are critical of the appropriateness of functional status outcome measures used in RCTs 
for use in clinical settings. Despite the ability of existing outcome measures to provide 
evidence of improved functional outcomes at the level of the population, when used in 
clinical setting at the level of the individual these outcome measures have two main 
problems. Firstly, they fail to reflect all clinically significant changes experienced by the 
patient. Secondly, although they include a comprehensive set of items that make a good 
assessment tool, they fail to inform the decision making process during treatment 
(Greenhalgh et al. 2005).
The evaluation of functional outcomes in a clinical setting is an integral 
component of care (Higginson and Carr 2001). Appropriate measurement of outcomes 
improves the quality of care delivered to the individual patient. This is particularly 
relevant to people with chronic conditions, who suffer from progressive functional 
limitations that interfere with their daily life functions. It is proposed that the 
appropriate measurement of outcomes would provide informative clinical data. It might 
be assumed that this could enhance the experience of care of the individual patient, 
facilitates clinical reasoning and decision making, and ultimately improves the 
efficiency and effectiveness of care provided to the whole group of patients (Lakeman 
2004).
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Therefore, this PhD program set out to develop a clinical tool for the measurement 
of functional outcomes during PR. The thesis suggests that an appropriate outcome 
measure for use in a clinical setting should be a valid, reliable and responsive tool that 
enables the translation of improvements realised from the intervention at the level of the 
individual patient into informative clinical data. Moreover, the aggregation of the data 
generated at the level of the individual could provide information at the level of a group 
of patients. It is expected that this would provide informative data for mangers.
In order to develop such a measurement tool a review of the theoretical, clinical 
and empirical knowledge underpinning the disease and the interventions implemented is 
required. It has been highlighted that PR is a multidisciplinary complex intervention. 
The development of outcome measures for complex interventions requires thoughtful 
awareness of the relevant theory and clinical knowledge about the progression of the 
disease. This ensures clarity about what should be measured, and how should it be 
measured (MRC 2008).
While it is customary in a thesis to “perform a literature review, identify the gap 
in the knowledge, formulate research questions, design a study to answer questions 
followed by a discussion of the results”, this thesis is constructed in a different way. The 
rationale for this being that during the literature review a critical lack of theoretical 
knowledge and standardised definitions about the disease and the intervention was 
identified. Subsequently a critical review of the literature was required to synthesise 
existing literature into a framework of measurement that would guide and inform the 
following steps in development.
To define this preliminary critical review of the literature, the term 
“conceptualisation”, that is traditionally used to refer to the definition of the construct to 
be measured, was expanded to refer to a number of conceptual activities. The term 
“conceptualisation” used in this thesis refers to a set of conceptual activities that 
included a critical literature review, a synthesis of clinical and theoretical knowledge 
and empirical and pragmatic research evidence, and a development of a framework for 
the measurement of functioning.
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Moreover, in response to the problem of a lack of knowledge about the 
progression of COPD, this program of research also examined the experience of people 
with COPD and clinicians undertaking PR of COPD. The development of the 
measurement tool was underpinned and guided by the knowledge generated from the 
phase of conceptualisation, the patients’ perspectives and the clinicians’ clinical 
knowledge. Following development the tool was tested in clinical setting to explore the 
usefulness of the indicators, and to provide new knowledge about the delivery of the 
program and the outcomes.
The process of outcome measure development was divided into three phases. The 
first phase is the conceptualisation. During this phase the theories and knowledge 
derived from existing literature about COPD, PR, models of functioning, measurement 
theories and principles of measurement in clinical settings, were used to provide the 
specifications of an appropriate outcome measure of functional outcomes for 
implementation in clinical PR setting. This phase constituted an integral component 
upon which the design and the conduction of the second phase were based.
The second phase was the development of the outcome measure. This involved 
the selection of a method of measurement that fulfilled the specifications of an 
appropriate outcome measure for implementation in clinical PR setting, a qualitative 
exploration of patients’ experiences of the functional limitations resulting from COPD, 
and validation and calibration of the outcome measure with reference to clinicians’ 
clinical knowledge and patients’ perspectives.
The third phase was testing the indicators in clinical PR settings. The aims of the 
different phases and research questions were formulated at the outset of each phase of 
the process of development. They were continuously developed and reviewed according 
to the development of knowledge and understanding resulting from the previous phases. 
Each phase was followed by a discussion to verify the findings and link the knowledge 
generated to the next phase. Figure 1 presents the Phases of the process of development.
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A mixed method approach that used a triangulation of qualitative and quantitative 
methods was employed to achieve the aim of this research process. This included a 
critical review of the literature, an indepth qualitative exploration of the patients' 
perspectives and clinician's experiences, and a quantitative and qualitative evaluation in 
clinical PR settings.
F igure 1 T he Phases o f  developing the m easurem ent tool
* Conceptualisation 
of the knowledge 
underpinlng the 
disease and the 
intevetion in order 
to:
•identify the 
specifications o f  an 
"appropriate outcom e 
measure" o f  PR. 
•Identify and define 
the construct to be 
measured.
•D evelop a fram ew ork 
fo r the m easurem ent 
o f  outcom es o f  PR. 
•Conceptualisation 
of the the theorey of  
measurement and 
measuring scales in 
order to:
•Identify the 
requirem ents o f  the 
theory o f  
m easurem ent and 
m easuring scales. 
•Identify the quality 
standards required for 
m easurem ent in 
clinical settings.
Phase 2: 
Development
•Selection o f an 
appropriate method 
of measurement 
•Qualitative 
exploration of 
pateints pespective 
to guide the 
processes of:
•Item  selection and 
reduction.
•Item  scaling.
•Expert and patient 
focus groups to 
provide further 
calibration and 
validation of the 
indicators.
•Using the tool for 
the measurement of 
the outcomes in a 
group o f patients 
attending PR  to test 
for the usefulness of  
the indicators.
Phase 3: 
Clinical testing
Phase 1: 
Conceptalisation
1 6
The thesis presents a novel process of developing a new outcome measure of 
“functional outcomes” of PR for people with COPD followed by an overall discussion.
The outcome measure developed during this PhD research is the only outcome 
measure that is based on comprehensive conceptualisation and synthesis of clinical and 
theoretical knowledge, and empirical and pragmatic research evidence. The process of 
development was guided by the knowledge and the theoretical framework developed 
during conceptualisation. The definitions of the construct and the categories of the 
outcome measure are clinically significant and grounded into patients’ narratives. It is
i
also the only outcome measure that was formally evaluated in a clinical PR setting.
The overall discussion is presented in two parts. The first part is concerned with 
identifying the need for the measurement of health outcomes in clinical settings. The 
second part is a discussion of the contribution of this thesis to the knowledge in the area 
of developing outcome measures for implementation in clinical settings. This includes a 
reflection on the suitability of the methodologies used and its impact on the quality of 
the outcome measure that was developed.
The discussion also highlights the contribution of the new outcome measure to 
solving clinical problems in PR settings, by providing informative data to the patients, 
clinicians, and managers. A discussion of the new clinical knowledge that has emerged 
about the provision of PR is also provided. This is followed by a reflection on the 
limitations of this research and a discussion of future research. Figure 2 shows a 
diagram presenting the overall structure of the thesis.
j
17
Ph
ase
 1
: C
on
cep
tua
lisa
tio
n 
Ch
ap
ter
 1
: T
he 
kn
ow
led
ge 
un
der
pin
nin
g 
the 
dis
eas
e 
and
 i
nte
rv
en
tio
n
a r/.<u na W§ H■3 « wS's: o rQ a ■*-o a-  TS a-w g« a si/, <y t.es «« a■S ® «a* as S
00
.. Bt ..vi a «  aU=» 4- O
5  2  Si ’S  a . « a f  es -a  «  a6  a es
</>
Phase 1: Conceptualisation Chapter 1: The knowledge underpinning the disease and intervention
Phase 1: Conceptualisation
Chapter 1: The knowledge underpinning the disease and the intervention
• Section 1: Chronic Obstructive Pulmonary Disease (COPD).
• Section 2: Management of COPD.
• Section 3: Models of functioning and disability
Chapter 2: The theoretical underpinnings o f measurement
• Section 1: The theory of measurement and measurement scales.
• Section 2: The quality standards of measurement.
• Section 3: A review of existing outcome measures.
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Phase 1: Conceptualisation Chapter 1: The knowledge underpinning the disease and intervention
Overview of phase 1: "Conceptualisation"
The aims of the literature review are to:
1. Identify the complex and progressive nature of COPD and how this influences 
the design of complex interventions, particularly Pulmonary Rehabilitation.
2. Identify the functional outcomes of PR that should be measured in people with 
COPD.
3. Identify the specifications of an “appropriate outcome measure” of functional 
outcomes of PR, based on the current empirical and pragmatic research 
evidence, and the theoretical and clinical knowledge o f COPD and PR.
4. Establish a framework for the measurement of the outcomes of PR in people 
with COPD.
5. Identify the criteria of outcome measures, which would result in the generation 
of informative data in clinical settings, and have the potential to be implemented 
as self-management tool at home and in the community.
Research questions o f the phase “Conceptualisation”
1. What are the functional outcomes of PR that should be measured in people with 
COPD?
2. What are the specifications of an “appropriate outcome measure” o f the 
functional outcomes of PR in people with COPD?
3. What are the principles of measurement in clinical settings, required to ensure 
the generation of informative data?
4. Do existing outcome measures fulfil the specifications and the criteria required 
of “an appropriate outcome measure” of PR in people with COPD?
Methods o f the literature review
To achieve these aims a critical literature review was performed. Grant and Booth 
(2009) provided a typology of literature reviews and associated methodologies. A 
critical literature review aims to synthesise and conceptually analyse the literature from 
diverse resources. The aim is not to provide answers but to create a multidimensional 
model that represents the current knowledge and theory on the topic. Therefore, while 
acknowledging the quality standards required for the evaluation of research reports, this 
type of reviews does not exclude materials based on a pre-specified criteria.
20
Phase 1: Conceptualisation Chapter 1: The knowledge underpinning the disease and intervention
In the literature review logical decisions are made on the conceptual contribution, 
provided by empirical and pragmatic research evidence, review articles, expert opinions 
and theories, to the development of knowledge and theories underpinning the disease 
and the intervention. However, the author maintained a thoughtful consideration to the 
strengths and weaknesses of each source of information.
Scope o f the literature review
The critical review of the literature is split into two main sections. The first 
section is a review of the knowledge underpinning the disease and the intervention and 
includes:
1. Chronic obstructive pulmonary disease.
2. Pulmonary rehabilitation.
3. Models of functioning and disability.
The second section is a critical literature review of the theoretical underpinnings 
of measurement and includes:
1. The theory of measurement and measuring scales.
2. The principles of measurement in clinical settings.
3. Existing outcome measures currently used in PR.
21
Phase 1: Conceptualisation Chapter 1: The knowledge underpinning the disease and intervention
Chapter 1: The knowledge  underpinning the d isease  and the
in tervention
1 Chronic Obstructive Pulmonary Disease “COPD”
This is the first section of the critical literature review of the disease “COPD” and the 
intervention “PR” to be researched in this thesis. This section is presented in three parts. 
The first part is a review of the burden of the disease. The second part is a critical review of 
the factors that influenced the lack of knowledge about COPD. The third part is a 
presentation of the current knowledge on COPD derived from national and international 
guidelines, expert opinion, and pragmatic and empirical research evidence.
1.1 The burden of COPD
Chronic obstructive pulmonary disease (COPD) is an umbrella term suggested by 
Burrows et al. (1966) to provide a unified definition of a group of disabling conditions that 
affect the function and structure of the pulmonary system, clinically known as chronic 
bronchitis and emphysema (Burrows et al. 1996) and (Department of Health 2010b). 
Globally, COPD is a leading cause of morbidity and mortality with a substantial and 
escalating burden. According to the WHO, 80 million people have severe and moderate 
COPD worldwide. It was estimated that death from COPD amounts to 5% of all deaths 
globally, with 90% of the deaths resulting from COPD occurring in the low and middle 
income countries were accurate prevalence data is lacking (WHO 2008).
The World Health Organisation (2008) ranked COPD as the fourth leading cause of 
death worldwide that is projected to become the third in 2020. This is largely due to 
changes in smoking behaviour that is significantly increasing in the developing world, and 
the aging population in the developed countries with more people living longer, and 
reaching the age when COPD develops (WHO 2008) and (The Global Initiative for Chronic 
Obstructive Pulmonary Disease “GOLD” 2010).
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1.1.1 Prevalence and mortality of COPD
Prevalence data varies substantially. This is due to the variation in the exposure to 
risk factors. It is further compounded by the variation of survey methods which include, but 
not limited to: Self report of a doctor diagnosis, Spirometry and Questionnaires asking 
about respiratory symptoms. The GOLD report suggests that prevalence data based on self 
report of doctor diagnosis are the lowest, constituting (6%) of prevalence data. This reflects 
the widespread under diagnosis and under recognition of the disease (GOLD 2010).
Halbert et al. (2006) conducted a systematic review of population based studies of 
COPD globally and reported 9-10 % prevalence in adults above the age of 40. However, 
Demarco et al. (2004) estimated prevalence based on GOLD (GOLD 2010) definition of 
COPD, and reported this to be 2.5% for stage 1 COPD, and 1% for stage 2 or 3 COPD in 
adults under 45 years living in Europe. They suggested that the prevalence of the disease in 
the UK is about average when compared to other European countries (Demarco et al.
2004).
Stang et al. (2000) estimated 3 million people living with COPD in the UK. 
However, only 900,000 people were correctly diagnosed (British Lung Foundation “BLF” 
2003). In the year 2004, COPD resulted in the death of 27,478 men and women in the UK. 
The majority of those were above the age of 65 (Burney and Jarvis 2006). Interestingly, as 
about twice this number have COPD either in part I or part II of their death certificate, this 
is because COPD usually co exists with other conditions such as ischemic heart disease and 
lung cancer (Burney and Jarvis 2006). This reflects the complexity of the clinical condition 
of people with COPD.
Health inequality that might result from a disparity in the distribution of COPD 
across socioeconomic groups, ethnicities and gender is another important aspect of the 
disease. There is a strong urban rural gradient in mortality rates in England with higher 
rates in the north of England (Hansell et al 2003). Moreover, there is a major social 
inequality with unskilled men employed in manual occupations being 14 times likely to die 
from the disease (British Thoracic Society “BTS” 2001). Ethnic and gender disparities also 
exist with growing evidence suggests that black men living in urban areas and female 
gender (BLF 2005,and GOLD 2010) are more susceptible to the disease.
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1.1.2 Social and economic burden of COPD
The potential for sever disability in COPD results in a substantial social and 
economic burden that is reflected by days lost from work, early retirement and the time and 
effort of family members caring for people with COPD. These aspects of the economic 
burden are not adequately acknowledged when calculating the direct and indirect costs of 
COPD, where emphasis is being placed on the costs of health care utilization, which is on 
its own substantial (Pauwels and Rabe 2004). This also reflects the dearth of research about 
an important aspect of COPD that is the functional limitations and participation restrictions 
associated with COPD.
The Department of health (2005) reported 1.4 million primary care consultations for 
COPD which is four times more than angina. Within respiratory diseases COPD is the most 
common cause for hospital emergency admissions, and ranked the second just after 
pneumonia for total beds per day (BTS 2001).The direct health costs of COPD are reported 
by the Chief Medical Officer (Department of Health 2005) to account for more than £800 
million. However, the indirect health costs are substantial and very difficult to quantify, 
with an estimated 24 million lost days from work per year (Department of Health 2005).
The escalating burden of COPD resulting from high mortality rate and progressive 
disability, taken together with health inequality implications makes COPD a health priority 
as stated by the vision of the new white paper on public health (Department of Health 
2010c). The strategy of this white paper is developed to tackle social determinants of health 
inequalities and help people live longer and healthier (Department of health 2010c).
The burden of COPD is described in the literature in terms of data on prevalence, 
mortality, morbidity, direct and indirect health costs, the existence of co morbidities and 
quality of life. It is worth noting that this data is variable and greatly underestimates the 
actual burden of the disease (Pawels and Rabe 2004). This variation could be explained by 
two main factors. The first is the differences in the reporting and research methods used to 
collect these data (Mannino et al. 2002). The second factor is scarcity of knowledge about 
COPD and inconsistent definitions of the disease.
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1.2 The factors that influenced the lack of knowledge about COPD
Lack of knowledge about COPD is related to certain attributes of the disease such as 
multiple risk factors, and the progressive natural history that has adverse impact on the life 
of people with the disease. The risk factors of COPD are naturally diverse and include 
environmental exposure and behavioural factors “smoking”. The result is a heterogeneous 
distribution of the disease across geographical areas, socioeconomic classes, and gender 
(Pawels and Rabe 2004).
The heterogeneous distribution of the disease results in heterogeneous population. 
This should be thoughtfully considered when designing and evaluating interventions for 
this population. Conclusions drawn from a certain group of people with COPD might not 
be relevant for implementation in another context and within another group. This highlights 
the pressing need for shifting from a disease oriented approach to a patient centred 
approach when designing and evaluating interventions (Higginson and Carr 2001). It might 
be suggested that this shift should be supported by tools that facilitate individualised 
delivery and evaluation of care. Therefore, an outcome measure that enables measurement 
of outcomes at the level of the individual patient is required.
The onset of the symptoms of COPD was described in the literature as "insidious" 
where clinical signs and symptoms are not recognised until the disease is moderately 
advanced (Kornmann et al 2003) and (Mannino et al. 2002). Even when the disease is 
clinically evident the stigma of the self inflicted disease and the misconception of 
symptoms as aging rather than COPD has resulted in reluctance of patients to seek medical 
advice, this is known in the literature as "under reporting".
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The slow and silent progression of the disease resulted in a lack of knowledge about 
the early stages of the disease and its development. This was further complicated by the 
scientific conception that once the disease is moderately advanced it is "irreversible" 
(Hansen et al. 1999). The result was a broad negligence that contributed to the shortage of 
knowledge about the disease, its mechanisms and its impact (Barnes and Kleinert 2004). It 
is suggested that the lack of the clinical and theoretical knowledge underpinning the disease 
has prohibited the development of valid outcome measures that are based on sound theory 
and knowledge (Ninci et al. 2006). It might be suggested that this gap in the knowledge 
could be filled by involving the perspectives and experiences of the patients when 
developing new outcome measures.
The slow and progressive course of COPD as well as persistent disability has 
implications on how health outcomes should be identified and measured. It is suggested 
that it would be more informative to measure changes in the pattern of the disease at a 
number of points in time, rather than one clinical end point. This will provide more 
information about the changes experienced by the patient as a result of treatment. This will 
also enable the clinician to implement changes in treatment when no change or 
deterioration occurs (Higginson and Carr 2001).
Next is a critical review of the literature on the definition and symptoms of COPD. 
Risk factors and co morbidities are presented with their impact on the development of 
complex interventions. This will inform the identification of the specifications of an 
outcome measure for this population.
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1.3 A review of the current knowledge on COPD
1.3.1 Definition of COPD
The definition of Chronic Obstructive Pulmonary Disease (COPD) continues to 
evolve as our knowledge about the disease advances. This continuous reform is due to the 
development of new laboratory technologies, expanding research, and the publication of a 
number of guidelines that are applauded for increased awareness of the impact of the 
disease and its burden (ATS/ERS, GOLD, NICE, the COPD national strategy, and an 
Outcomes Strategy for Chronic Obstructive Pulmonary Disease (COPD) and Asthma in 
England).
1.3.1.1 Physiological definition o f COPD
Current COPD guidelines Highlighted airflow limitation as the main characteristic 
of COPD (ATS/ERS, GOLD, NICE). Airflow limitation results form a combination of 
airway obstruction and parenchymal damage. This is defined and classified based on two 
main spirometric measures, the FEVi: Forced Expiratory Volume in 1 second, and the 
FEVi/FVC: Forced Expiratory Volume in 1 second/ Forced Vital Capacity (Table 1).
27
Phase 1: Conceptualisation Chapter 1: The knowledge underpinning the disease and intervention
Table 1 G O LD classification o f spirom etric definitions o f COPD. Adapted from  GOLD (2010)
GOLD stage Characteristics
0: At Risk • Chronic symptoms.
• Exposure to risk factors.
• Normal spirometry.
I: Mild • FEVj/FVC < 70%.
• FEV, >80%.
• With or without symptoms.
II: Moderate • FEVi/FVC < 70%
• 50% <FEVi < 80%
• With or without symptoms
III: Severe • FEVi/FVC < 70%
• 30% < FEVi < 50%
• With or without symptoms
IV: Very Severe • FEVi/FVC < 70%
• FEVi/FVC < 30% or FEVi/FVC < 50% with presence of 
chronic respiratory failure or right heart failure
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The guidelines provide different standards for defining COPD based on spirometry. 
While it is scientifically established that airflow obstruction is best measured by 
FEVI/FVC, establishing a diagnosis of COPD using spirometric criteria is currently 
questioned with a plea for revising current guidelines arising from a number of editorials 
(Miller et al. 2009, Townsend 2007, Marco 2008 and Culver 2006) and emerging new 
research evidence (Vaz Fragoso 2009; and Vaz Fragoso 2010).
Conventionally, establishing a threshold for defining people with the disease has been 
based, in medical research, on studies that compare the distribution of markers of the 
disease in the clinically diagnosed and healthy controls (De Marco 2008). Another method 
to establish this threshold is by conducting longitudinal studies that follow up the 
development of risks or complications related to the disease (De Marco 2008). Existing 
definitions of COPD are not based on such evidence and there is an urge to validate or 
redefine physiological thresholds of COPD (Miller et. al. 2009), (Townsend 2007), and 
Culver 2006).
This suggests that there is a lack of appropriate research evidence to validate existing 
physiological definition. This has implication on the potential availability of clinical 
knowledge to inform the development of new outcome measures. This further emphasises 
the importance of the inclusion of knowledge generated qualitatively from patients and 
clinicians to formulate an adequate understanding about the disease.
1.3.1.2 Pathological characteristics o f COPD
Recent literature is adopting a pathological perspective of the definition. A literature 
review by Cazzola et al. (2007) defined COPD as "a chronic inflammatory process in the 
pulmonary tissue". COPD is a complex disease process that is not fully understood. The 
slowly progressive course precludes easy validation of targets, and significant pathological 
changes are already evident by the time the disease is diagnosed.
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Our current knowledge about the pathogenesis of COPD is derived from 
observational studies of the pathology and its interaction with host etiological factors, and 
from in vivo and in vitro disease models (Sabroe et al.2008). The study of the pathology of 
COPD started recently and evidence is still emerging. A detailed review of the pathogenesis 
is beyond the scope of this thesis and has been extensively reviewed elsewhere (MacNee
2005) (Barnes and Kleinert 2004). However, it can be seen that unlike cardiovascular 
diseases there are no lifelong population based study looking at the natural history of 
COPD and the development of irreversible loss of lung function (Kohansal et al. 2009)
Currently there is a lack of appropriate research evidence to define physiological and 
pathological parameters. Accurate knowledge about physiology and pathology of COPD is 
still emerging and might be difficult to achieve due to the progressive nature of the disease 
and the insidious onset of clinical signs and symptoms. Moreover, there is a long 
subclinical phase that could not be defined. This notion implies that currently there is not 
enough clinical knowledge upon which to base the development of standardised 
measurement tools. Due to this significant gap, it is suggested that outcomes of treatment in 
terms of the impact of the disease on patients’ life, rather than physiological and 
pathological outcomes, might provide more information and enhance the knowledge about 
the disease.
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1.3.2 The natural history of COPD
A World Health Organization document (2007) defined COPD as "a 
heterogeneous disease, with various clinical presentations". COPD is a disease process; 
each stage is characterised by distinctive clinical manifestations and symptoms. It is 
well known that people with COPD present with varying severities and seek medical 
advice at various stages of the disease.
During the course of the disease some symptoms become more prominent at a 
certain stage. Mannino et al. (2002) suggests that the heterogeneous nature of the 
disease is well evident, with different potential interventions still emerging. On the 
other hand a new approach to understanding COPD views the disease as a network of a 
number of components. The nature of key components varies within the disease 
overtime, but this variation follows a certain pattern, that is not explored yes (Sabroe et 
a/. 2008).
The National Heart, Lung, and Blood Institute/World Health Organization 
workshop (2001) described COPD as "a disease state". COPD presents as a disease 
status that is resistant to treatment, it is actually resulting from the interaction of 
multiple active processes that perturbate "health status" and operate against the 
immunity and body defence mechanisms resulting in the new status quo (Sabroe et 
<2/. 2008).
Petty (2006) described COPD as "a disease spectrum" reflecting the progressive 
nature of the disease and the varying characteristics of different stages. The word 
“spectrum” reveals the multi component nature of the disease. Current evidence 
suggests that the progression of COPD is influenced by the interaction of a number of 
pathological, personal and environmental factors resulting in a downward spiral where 
persistent and progressive pathological and physiological changes give rise to a number 
of clinical presentations that is signs, symptoms, and functional limitations that develop 
over time and contribute to disease severity (Sabroe et al.2008).
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Current knowledge about the natural history of COPD is incomplete. Moreover, 
COPD is currently defined from a medical perspective only; viewing the patient as a 
complex deposit of anatomical components and physiological systems (Agglleton & 
Challmers 2000). This has resulted in devising concepts that are inadequate to 
encompass the full process and impact of the disease. An example is provided in the 
latest GOLD report (2010), where "Emphysema" and "chronic bronchitis" have been 
frequently used in the definition of COPD.
The report highlighted the flawed use of these terms in the definition of COPD. 
The report suggested that Emphysema is a pathological term that has been used 
clinically and it describes only one of a number o f structural changes in the alveoli. On 
the other hand chronic bronchitis is a useful clinical term, but it only describes two 
clinical symptoms “cough and sputum production”, and does not reflect the full impact 
of these symptoms on the disease progression, the clinical endpoints (GOLD 2010), and 
the functional status. The limited physiological and pathological knowledge about the 
natural history of COPD, and the chronic progressive disease that interferes with day to 
day life highlights the importance of adopting a biopsychosocial perspective when 
identifying the progression and the clinical endpoints of the disease.
1.3.3 Symptoms of COPD
Symptoms of COPD have a pronounced impact on patients' everyday life and 
interfere with most functional activities, resulting in functional limitations and 
participation restrictions (International Classification of functioning disability and 
health "ICF" 2001). The updated GOLD document (2010) highlighted the importance of 
educating patients, health care professionals and the community in which people with 
COPD live that breathlessness, cough and sputum production are not trivial symptoms 
and that they are significant public health problems that should be monitored and 
addressed. Thus the document identified relieving symptom as an essential aspect of the 
management of COPD. In order to identify the symptoms associated with COPD and its 
impact on functioning in daily life a presentation of symptoms most commonly reported 
by people with COPD is provided next.
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1.3.3.1 Nasal symptoms “rhinorrhoea”
Although the inflammatory reactions associated with COPD occur mainly in the 
lower airways, a large proportion of people with COPD present with nasal symptoms. 
This is explained by the anatomical continuity of the upper and the lower airways, and 
their mutual function (Hurst et al. 2004). The most commonly reported upper airway 
symptom is rhinorrhoea (Hurst et al. 2004). This is particularly significant because 
nasal symptoms were found to result in impaired quality of life in 88 % of a cohort of 
65 patients with COPD as assessed by the 20-item Sino-Nasal Outcome Test (SNOT- 
20) (Hurst et al. 2004).
Objective assessment of upper airway symptoms is very difficult due to poor 
correlation between nasal symptoms, clinical makers and radiological changes (Hurst et 
al. 2004). Moreover, there was a poor correlation between SGRQ score, a disease 
specific quality of life measure in COPD, and SNOT-20 scores in a cohort o f people 
with COPD (Hurst et al. 2004). The authors explained this by the significant impact of 
the lower airways' symptoms assessed by the SGRQ that have masked the impact of 
symptoms of the upper airways.
This highlights the need for moving from attempting to measure symptoms to 
measuring the impact of symptoms on activities of daily life that could be observed and 
properly reported by patients themselves. The SNOT-20 Items questionnaire claims to 
measure the impact of nasal symptoms on quality of life, however, the way questions 
are formulated seems to enquire answers about "how much problematic is a certain 
symptom". These ill defined questions probably do not provide sufficient information 
about the concept "quality of life"; rather it is descriptive of the symptoms themselves. 
There is a pressing need for reviewing measurement tools used in the literature, in the 
light of the principles of the theory of measurement, and sound definition of the 
concepts being measured. This review is presented in section three of the second chapter 
of this thesis.
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1.3.3.2 Cough and sputum production
Cough is usually the first sign, and might be unproductive initially. However, it is 
usually misinterpreted as normal aging process, or a usual smoker cough, thus patients 
do not seek medical advice at this stage of the disease (Pauwels and Rabe 2004). 
Regular sputum production for three months in two consecutive years is clinically 
defined as chronic bronchitis. However, patients present with varying patterns of 
sputum production which makes it difficult to use the clinical definition for 
characterising people with COPD (Pauwels and Rabe 2004). This emphasises the need 
for adopting an individualised approach to the evaluation and management. This also 
further emphasises the need for shifting from the evaluation of symptoms to the 
evaluation of the impact of symptoms on function.
1.3.3.3 Dyspnoea and fatigue
Dyspnoea and fatigue are the most commonly reported symptoms, and result in 
exercise intolerance which is the main factor limiting activity and participation (Nici et 
al. 2006). Exercise intolerance is associated with anxiety and poor motivation resulting 
into further activity limitations and participation restrictions (Nici et al. 2006).This 
highlights the importance of evaluating the impact of symptoms on activities in people 
with COPD.
Dyspnoea or shortness of breath on exertion usually drives patients to seek 
medical help. It interferes with patients' ability to perform daily activities before the 
disease progress to more severe stage (Pauwels and Rabe 2004). The actual mechanism 
by which dyspnoea develop is not fully understood (Jolley and Moxham 2009). The 
most accepted mechanism proposes central sensitisation as mediator of perceived 
breathlessness, emphasising the role of personal factors in influencing dyspnoea 
(Undem and Nassensteina 2009) and (Manning and Mahler 2001).
Fatigue is identified as a factor limiting exercise tolerance in people with COPD. 
The mechanism of the development of fatigues has not been investigated (Saey 2003). 
Although it might be expected that fatigue is related to muscle wasting and peripheral 
muscle weakness, a qualitative exploration of patients’ experiences of fatigue linked 
fatigue to laboured breathing (Small and Lamb 1999). Further investigation of the 
mechanisms of fatigue and its impact of the performance of daily life functions is 
required.
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Breathlessness and fatigue, which are frequently reported clinical symptoms of 
COPD are subjective in nature and best defined with reference to people’ experience of 
the symptoms and their impact on their lives. The knowledge about the disease could 
not be developed without adopting a holistic approach and involving the perspectives of 
patients when attempting to research and describe the processes of development of 
functional limitations in people with COPD. A qualitative exploration is an integral 
component for developing enhanced understanding of the impact of COPD on 
functioning in people with COPD. This will consolidate current knowledge and provide 
empirical qualitative evidence that would inform the development of new outcome 
measures. Outcomes should be formulated in terms of patients’ needs and priorities, and 
in the light of the multidimensional impact of the disease.
1.3.3.4 Systemic manifestations o f  COPD
Systemic symptoms are present when the disease has progressed to the sever 
stage, these include: weight loss, loss of muscle mass, anorexia, and fatigue (Pauwels 
and Rabe 2004). The reality that COPD is a long term condition with progressive 
detrimental effects on functioning, resulting in activity limitations and participation 
restrictions; invites anxiety and depression. These psychological symptoms have been 
reported to be prevalent in 50% of people with COPD (Mikkelsen et al. 2004).
It is worth noting that the symptoms of COPD are not only respiratory but extend 
to involve other systems as the disease progresses, this emphasizes the significance of 
adopting a holistic approach to the management of COPD (Bellamy et al. 2006) and a 
multidimensional framework for evaluating interventions used in the management of 
COPD (MRC 2008).
A number of studies reported that symptoms are strongly related to quality o f life, 
and this relation is stronger than that existing between quality of life and the severity of 
the disease as defined by GOLD based on physiological parameters (FEV1). Quality of 
life is directly influenced by functional limitations experienced by the individual 
(Victorson et al. 2009).
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One of the purposes of the measurement of health outcomes is to diagnose causes 
of functional limitations (Duncan and Velozo 2007). Thus when identifying the 
outcomes of interventions, the relation between quality of life and symptoms institute 
symptoms as a more credible parameter than disease severity. However, objective 
assessment of symptoms is difficult due to their subjective nature and poor correlation 
with clinical markers. Hence measuring the impact of symptoms merits consideration.
The impact of symptoms on daily life activities is evident early in the disease 
progression (Pauwels and Rabe 2004), it might be more appropriate to evaluate the 
impact of symptoms on activities, rather than attempting to evaluate the symptoms. This 
is because symptoms of COPD are subjective “dyspnoea and fatigue”, and difficult to 
quantify, while the impact of symptoms on daily activities could be observed and 
reported by the patients themselves.
The impact of symptoms on daily life activities is best described by the patients' 
perspective of the disease. This perspective could be scientifically investigated using 
rigorous qualitative research (Ritchie and Lewis 2003). The knowledge emerging from 
this qualitative research could then be used to inform the development of measurement 
tools. There are a number of questionnaires that were developed to evaluate the impact 
of symptoms on daily life of people with COPD; however there are lots of issues in 
these questionnaires. A review of existing outcome measures is provided later.
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1.3.4 Risk factors of COPD
Identification of risk factors is essential for developing strategies for preventing 
and managing diseases (GOLD 2009). This is particularly important in COPD as the 
disease result from the interaction of a number of risk factors most of them could be 
modified and avoided. Although smoking is frequently reported as the main risk factor 
for COPD, emerging evidence suggest that COPD result from the interaction between 
host risk factors and environmental exposure.
Smoking is generally accepted as the main risk factor (Mannino and Buist 2007). 
The main preventative strategy of COPD is based on "smoking cessation"(Viegi et al. 
2007); this implies a behavioural component involved in the disease progression. Other 
risk factors include biomass exposure, outdoor pollution, environmental exposure, 
childhood respiratory infections, genetic and developmental abnormalities of the 
respiratory system (Mannino and Buist 2007), (Viegi et al. 2007) (ATS/ERS 2004), 
(GOLD 2010) and (NICE update 2010); all implying personal, environmental, and 
socioeconomic components of the disease. This complex set of risk factors necessities a 
holistic and patient centred approach to management as the limited focus on the medical 
basis of the disease is very unlikely to result in interventions that would modify the 
progression of COPD.
The interaction of multiple of risk factors and the coexistence of other co 
morbidities has implications on the experience of living with the disease. Qualitative 
studies exploring patients' experiences o f living with the disease reported a detrimental 
impact because of the chronicity and the multidimensional nature of the condition. 
Leidy and Haase (1999) suggested that living with COPD has created challenges for 
preserving individual integrity and the efficacy of managing the long term disability 
resulting from the disease.
The British Thoracic Society (2001) has recommended the incorporation of 
behavioural components in the long term management of this group of people. This has 
resulted in the development of complex management programmes; however this was 
not accompanied by the development of outcome measures that are appropriate for the 
measurement of the outcomes of such complex interventions.
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1.3.5 Co morbidities
There is emerging evidence that COPD co exists with other diseases resulting in 
complex cases. The most commonly reported co morbidities are: Age, anxiety and 
depression, lung cancer, coronary artery disease with arrhythmias, and venous thrombo­
embolism. Most of the evidence on COPD and co morbidities investigated 
cardiovascular conditions and COPD. Longitudinal studies, matching participants with 
COPD with non COPD participant and identifying the prevalence of cardiovascular 
conditions in both groups were conducted. All studies concluded that the prevalence of 
cardiovascular diseases was higher in patients with COPD (Mapel et al. 2005), (Sidney 
et al. 2005), (Suellen et al. 2006). Marquis et a l (2005) reported that patients with 
COPD usually have one or more components of a metabolic syndrome, including 
diabetes. The evidence of the relationship between COPD and lung cancer is still 
emerging (Strange 2010)
However, the growing body of evidence supporting the fact that COPD co exists 
with other chronic conditions creating complex cases has opened a new realm of 
investigations, the scientific community is currently advocating a new hypothesis based 
on pathological and clinical knowledge that view the coexistence of COPD and other 
comorbidities as a new syndrome characterised by a systematic inflammation in 
response to a triggering stimulus. The triggering stimulus has been frequently reported 
as smoking and biomass fuel (Sabroe et al. 2008), (Fabbri et al. 2008) and (Yawn and 
Kaplan 2008). However, recent guidelines adopt a more holistic approach identifying 
the triggering stimulus as a combination of risk factor (GOLD 2010) and (WHO 2008).
Proponents of the new systemic inflammation theory are calling for a new 
approach for the management of COPD, advocating a shift from an organ multi 
pharmacological treatment based approach to a patients centred approach, that 
emphasise is oncontrolling risk factors, particularly smoking. However, in order for this 
movement to succeed it is important to support it by appropriate research evidence 
based on realistic clinical evaluation of complex interventions (Pawson 2003), and the 
measurement of outcomes at the level of the individual. This implies that outcomes of 
the interventions should be patient centred and defined from the perspective o f patients. 
Moreover, an outcome measure that is appropriate for the measurement of clinical 
outcomes at the level of the individual and is appropriate for implementation in clinical 
settings should be developed.
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1.4 Summary
In order to be able to identify the specifications of an appropriate outcome 
measure for people with COPD, it is important to understand the complexity of the 
disease. A critical review of the literature on the current knowledge on COPD has 
identified a number of important issues.
1. COPD is a leading cause of mortality and morbidity with a substantial and 
escalating burden that affects the individual and the society.
2. The potential for severe disability results in a substantial social and economic 
burden that is not fully captured because of the paucity of research on the impact 
of COPD on functioning in daily life.
3. Currently there is a significant lack of knowledge about the physiology and 
pathology of the disease and the natural history of the progression of the disease. 
This lack of knowledge has been attributed to a number of factors related to the 
nature of the disease and its progression. Amongst these factors are the 
heterogeneous population which result in a difficulty with the generalisation of 
research evidence form one context to another. Other factors are related to the 
insidious onset of the disease, the stigma of the self inflicted disease, and the 
confusion of symptoms of COPD such as breathlessness and fatigue with natural 
ageing processes resulting into lack of knowledge about the early stages of the 
development of the disease.
4. The symptoms of COPD are multiple and extend from respiratory symptoms to 
systematic manifestations. Amongst the most commonly reported symptoms are 
dyspnea and fatigue. These are subjective symptoms perceived differently by 
different patients. The mechanisms of development of these symptoms are not 
fully understood.
5. New approaches to understand COPD adopt a theory of systematic inflammation 
that is triggered by a number of risk factors resulting into the development of co 
morbidities.
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All of these issues have implications on the knowledge required to the 
development of new measurement tools for the measurement of clinical outcomes of 
COPD.
1. There is a need to shift from a medical model of management to a bio 
psychosocial model. This requires the measurement of functional outcomes of 
interventions rather than physiological and pathological outcomes.
2. There is a need to shift from a disease oriented approach of measurement to a 
patient oriented approach. This requires the measurement of outcomes at the 
level of the individual.
3. Due to the lack of knowledge about the natural history of COPD, it is required to 
measure changes in the pattern of the disease at multiple follow up points and 
not clinical endpoints.
4. Due to the subjective nature of symptoms and the lack of knowledge about the 
underlying mechanism, measurement should emphasise the impact of symptoms 
on functioning form the perspective of patients.
Having identified the knowledge underpinning the disease, it is important to 
identify the knowledge underpinning the intervention. This is undertaken in order to 
enhance the understanding about the potential outcomes of the management approaches 
in COPD, and how these outcomes should be measured. The next section is a critical 
literature review of the management of COPD.
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2 Management of Chronic Obstructive Pulmonary Disease
In the last section it was identified that COPD is a chronic condition resulting in 
progressive physiological and pathological impairments, and functional limitations that 
follow a downward trajectory. Moreover, COPD usually co exists with other chronic 
conditions such as ageing, cardiovascular diseases, osteoporosis, depression and anxiety. 
This creates complex cases that require complex interventions. Therefore, the acute care 
model, which focuses on a cure, is deficient in meeting the complex needs of the individual 
patient (Nici et al. 2009). Appropriate management of COPD requires a new chronic care 
model that implements effective communication and collaboration across disciplines. This 
model should adopt an integrated multidisciplinary provision (Nici et al. 2009).
This section provides an introduction to the model of integrated care, the aims of 
integrated care in the management of COPD, and the contribution of PR to the integrated 
care of people with COPD. However, this PhD set out to respond to the clinical problem of 
the measurement of outcomes in clinical PR settings. Therefore, the literature on PR will be 
critically reviewed with a focus on identifying the specifications of an outcome measure 
appropriate for implementation in clinical PR settings. The specifications will be identified 
in terms of:
• The clinically significant outcomes of PR that contribute to the delivery of 
integrated care.
• The current clinical problems in the provision of PR services and the specifications 
of an outcome measure required to inform clinical practice in order to resolve these 
problems.
2.1 The integrated care model
The world health Organization defined integrated care as "a concept bringing 
together inputs, delivery, management, and organization o f services related to diagnosis, 
treatment, care, rehabilitation, and health promotion" (Grone and Garcia-Barbero 2001, 
p:7). The application of the concept of integrated care to the management of COPD should 
be performed with considerable attention to the natural progression of COPD. This requires 
designing and delivering lifelong care plans.
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Current evidence suggests that COPD is influenced by the interaction of a number of 
pathological, personal and environmental factors resulting in a downward spiral of 
functional loss. Persistent and progressive pathological and physiological changes give rise 
to various clinical presentations (Sabroe et al.2008). This implies that efficient integration 
of care in the management of COPD should be guided by reasonable decisions about the 
effective and the timely provision of the right therapy that is appropriate and specific to the 
individual patient (Nici et al. 2009).
Management of COPD includes a number of therapeutic options such as: smoking 
cessation, promotion of healthy life style by increasing activity and adherence to regular 
exercise, collaborative self-management strategies, optimal pharmacotherapy, palliative 
therapy, and end of life care (Ries et al. 2007). Due to the wide variation in therapeutic 
options available for COPD, integrated care should be provided collaboratively at a system 
wide multidisciplinary level. However, it should be tailored to the individualised needs of 
the patients. People with COPD should also be involved in making choices about their own 
care (Troosters et al. 2005).
The ultimate aim of adopting an integrated care paradigm for the management of 
COPD is three folds. Firstly, is to address the lifelong functional limitations and 
participation restrictions, and facilitate the integration of the individual in the community. 
Secondly, is to facilitate early discharge while ensuring that the individuals are fully 
supported in their homes and in the community. Thirdly, is to facilitate the delivery of care 
closer to home enabling early detection of deteriorations and the prevention of hospital 
readmissions (Seemungal and Wedzicha 2006).
Pulmonary rehabilitation programmes are individualised by definition and encompass 
a multidisciplinary provision of a number of therapeutic options. Therefore, they fulfil the 
assumptions of the WHO concept of integrated care. However, pulmonary rehabilitation 
should be viewed as one component of the integrated care of COPD patients, while 
integrated care has a broader system wide emphasis.
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Although some patients who are severely limited may not be eligible for the complete 
pulmonary rehabilitation program, its components such as activity promotion, self­
management strategies, and education should be provided as part of the integrated care of 
COPD (Nici et al. 2009). This suggests that the decision on which components to deliver 
should be guided by patients' needs and clinical problems presented.
A caveat is that in order for PR to be established as an effective component of the 
integrated care it is important that the benefits resulting from PR contribute to the aims of 
the integrated care in people with COPD. It might be suggested that PR should contribute 
to the improvement of functioning in daily life, improving self-management and patients’ 
control of the clinical condition, and the reduction of hospitalisation in order to fit 
effectively within the integrated care model.
Next is an exploration of pulmonary rehabilitation, this will include: the definition of 
PR, the benefits of PR, and the clinical problems in the provision of PR.
2.2 Pulmonary Rehabilitation
Pulmonary rehabilitation is now a standard of care and has been recommended in 
national and international guidelines such as the American Thoracic Society/ European 
Thoracic Society statement on pulmonary rehabilitation “ATS/ERS” (2004), Nici et al. 
(2006), the British Thoracic Society Standards of Care Subcommittee on Pulmonary 
Rehabilitation “BTS” (2001), the Global initiative for chronic obstructive lung disease 
“GOLD” (2010), and the National Institute for Health and Clinical Excellence “NICE” 
(2010). Efforts should now be directed towards improving the effectiveness of the 
intervention in clinical settings, increasing awareness and recognition of its importance 
amongst patients and health professionals, improving access and enhancing patients' 
concordance with the program (Nici et al. 2009).
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2.3 Definition of Pulmonary Rehabilitation
The American Thoracic Society/ European Thoracic Society statement on pulmonary 
rehabilitation defined pulmonary rehabilitation as "evidence based, multidisciplinary, and 
comprehensive intervention fo r patients with chronic respiratory diseases who are 
symptomatic and often have decreased daily life activities. Integrated into the 
individualized treatment o f  the patient, PR is designed to reduce symptoms, optimize 
functional status, increase participation, and reduce health care costs through stabilizing 
or reversing systematic manifestations o f the disease." (P: 1391, ATS/ERS 2004).
The definition identifies three important features of the PR program (Ries et al. 
2007):
• The program adopts a multidisciplinary, individualised approach to delivery. The 
program is tailored to fulfil the patient’s needs, with focus on physical and social 
function.
• PR programs for patients with chronic lung disease are well established as a mean 
of enhancing standard therapy to control and alleviate symptoms and optimise 
functional capacity.
• The primary goal is to restore the patient to the highest level of independent 
function, this is accomplished by improving patient’s knowledge about the disease, 
the treatment, and coping strategies.
It is worth noting that pulmonary function testing using spirometry is a gold standard 
for the diagnosis of COPD. However, it is not considered a selection criterion for PR. 
Referral to PR is based on the individual's report of compromised functional status 
presented as functional limitations and participation restrictions despite optimal medication 
and stabilised clinical condition (Nici and ZuWallack, 2010). This highlights the 
importance of researching the impact of COPD on functional status, and how 
improvements realised from PR translate into improved functioning. This also emphasises 
the importance of the measurement of functional outcomes of PR.
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2.4 Aims of Pulmonary Rehabilitation
The short term aims of PR are to control symptoms, enhance exercise capacity, and 
improve Health Related Quality Of Life. Its long term aims are to maintain gained 
improvements following the program and to ensure that the benefits of PR are translated 
into improved functioning in daily life and improved self management and disease control. 
The ultimate goal is to reduce health care resources utilization, especially through hospital 
admission prevention, reduced length of hospital stay and limiting dependence on 
professional health care (NICE 2010). It could be seen that the long term goals of PR 
conform to the aims of the integrated care of COPD. Therefore, long term benefits of 
COPD will be explored in further details.
Whilst the effectiveness of a PR program in achieving its short term goals is well 
established, evidence of achieving the long term goals is controversial. In order to 
investigate this controversy and identify the causes, a summary of current evidence on short 
term benefits and a critical review of the literature on the long term benefits of PR are 
presented next.
2.4.1 Benefits of Pulmonary Rehabilitation
There is now high level evidence from randomised controlled trials “RCTs”, meta­
analyses (Salman et al. 2003) and systematic reviews of RCTs (Lacasse et al. 2002) that PR 
improves exercise capacity, symptoms and quality of life (Nici et al. 2009). Emerging 
evidence suggests that it also reduces health care utilisation. Established benefits of PR 
include controlling and alleviating the impact of symptoms, particularly dyspnoea and 
fatigue, improved functional capacity, and improved health related quality of life ( Mador 
et al. 2001) (Nici et al. 2010), (Laccasse et al. 2002),(Ries et al. 1997) and (Ries et al. 
1995).
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A number of issues should be recognised while interpreting current evidence on the 
effectiveness of PR in order to make clinical inferences.
Firstly, despite established effectiveness of PR in improving functional capacity, 
alleviating symptoms and improving HRQOL, these improvements did not translate into 
improved functional independence in daily life (GOLD 2010). This could be explained by 
the following.
• It might be suggested that improvements in daily life functions is independent from 
the short term benefits of PR, therefore these should be measured separately (Nici et 
al. 2009).
• It might be suggested that there are other factors that influence performance in the 
patients’ environment that are not existent in the clinical PR settings. Therefore, 
functional outcomes vary in response to these factors and become difficult to 
maintain.
• While evidence form RCTs suggest that PR work for people with COPD, at the 
level of the population, there is no evidence of the optimum method of delivery for 
the individual patient in clinical settings. It might be suggested that the evidence 
that has come from RCTs has not addressed existing clinical problems in the 
provision of PR. This has resulted in a suboptimal delivery of clinical PR 
programmes which have prevented patients from experiencing the long term 
benefits of PR.
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Secondly, while there is evidence to support the effectiveness of PR in achieving its 
short term goals, the evidence is inconsistent. This inconsistency should be thoughtfully 
considered when attempting to implement the findings in the clinical context. A number of 
factors have contributed to this inconsistency.
• The first factor is related to the study sample. During the literature review on 
COPD, it was highlighted that the population of COPD is heterogeneous, and the 
disease has various clinical presentations. Evidence on the effectiveness of PR is 
mainly drawn from a quantitative research paradigm that strives to control bias by 
controlling confounding variables. The result is a research population that is 
homogenous and does not reflect the heterogeneous presentation of patients in 
clinical settings.
• The second factor is related to the protocol of PR implemented within the research 
studies. This is related to the definition of PR as an individualised intervention 
(Lacasse et al. 2002). This has resulted in a lack of standardisation in the protocol in 
different research studies. While this might be theoretically the “optimal” method of 
delivery in clinical settings (Higginson and Carr 2001), it hinders the 
generalisability of results from one context to another. What works for one group of 
patients does not necessarily work for another. Moreover, none of the studies has 
undertaken a clinical evaluation of an individualised delivery at the level of the 
individual, using an appropriate research design.
• The third factor is related to the outcome measures used. This is not only related to 
the lack of standardisation of outcome measures used but also to the measurement 
of different outcomes (Troosters et al. 2005). This suggests that there is a lack of 
consensus on the appropriate outcome measure and what constitutes a significant 
outcome of PR.
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It might be suggested that in order to overcome these problems a realistic clinical 
evaluation of the provision of PR in clinical settings is required (Cazzola 2009). Moreover, 
the optimum method of delivery at the level of the individual within the clinical contest 
should be established. In order to achieve this, new research methods should be 
implemented, full guidance on the selection and implantation of research methods to 
evaluate clinical complex interventions is provided by the MRC (2008). These new 
methods should be supported by the appropriate outcome measures.
Therefore, the next part of this review is concerned with identifying the significant 
outcomes of PR and the current problems with the provision of the service in order to 
identify the specifications of an appropriate outcome measure of PR, for implementation in 
clinical PR settings.
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2.5 Identifying the significant outcomes of PR
For the purposes of this literature review the significant outcomes of PR are defined 
as the long term benefits of PR that contribute to the aims of integrated care of people with 
COPD. Based on the literature on PR these outcomes are identified as improving function 
and the maintenance of the short term benefits of PR. It is suggested that improved 
functioning and maintenance of the benefits of PR will ultimately result into facilitated 
early discharge and reduced hospital admissions (BTS 2001).
2.5.1 Improve functioning
The central aim of PR is to improve functioning (BTS 2001). This highlights 
functioning as an important outcome of PR. PR has no direct effect on airflow limitation, 
such as forced expiratory volume in 1 sec (FEVi); nonetheless its established effectiveness 
is explained by ameliorating the systemic effects and the co morbidities of the disease (Nici 
et al. 2009).
Evidence shows that patients with COPD have decreased exercise capacity and 
substantial limitations in their daily activities. The American lung association (2002) 
showed that 51 % of all COPD patients report limitations in their ability to work, 70% in 
normal physical exertion, 56% in household chores, 53% in social activities, 50% in 
sleeping, and 46% in family activities. These findings are supported by direct 
measurements of physical activity at home (Pitta et al. 2005). Decreases in functional 
exercise capacity and physical activity appear to be related to increased health care 
utilisation and mortality in COPD (Gosselink et al. 1996).
Observational data link higher levels of physical activity with better outcomes, 
including a lower risk of hospitalisation, a lower rate of decline of lung function and 
improved survival (Ries et al. 2007). This highlights the importance of improving 
functional activity levels in people with COPD.
Steele et al. (2008) found that an intervention designed to enhance adherence to 
exercise programme did improve adherence and exercise capacity, but did not result into 
improved activity levels. They explained these results by the "disappointing" measurement
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characteristics' of the accelerometer Steele et al. (2008). Other studies showed increased 
activity levels after the PR intervention (Sewell et al. 2005 and Pitta et al. 2008).
It should be noticed that activity monitors reflect changes in the level and intensity of 
activities performed over a specific period of time. However, they do not specify the type 
of the activity performed, the difficulty associated with performing the activity, and the 
factors influencing performance. Therefore, the information generated by activity monitors 
is limited in terms of providing data informative for making clinical decisions. This 
highlights the need for a clinical outcome measure of functioning that is able to reflect the 
translation of physiological benefits of exercise into improved functioning in daily life. 
This outcome measure should provide informative clinical data.
Nici et al. (2009) suggested that improvements in physical activity may not 
necessarily be related to improvements in exercise capacity. This is because of the 
multidimensional input of pulmonary rehabilitation that is not limited to exercise training. 
Non exercise components may also promote activity, independent of improvements in 
exercise capacity. For example, improved pacing and increased self efficacy directly 
contribute to the enhanced functioning. Further investigation of the effect of PR on 
functioning and the factors influencing functioning is needed Nici et al. (2009). A 
multidimensional outcome measure of functioning that is designed based on qualitative 
narratives of patients' on the factors influencing functioning such as exercise habits, self 
efficacy, and internal and external barriers is required.
Moreover, although Sewell et al. (2005) provided evidence for improved activity 
levels following exercise program they failed to provide evidence for the superiority of the 
individually targeted exercise training. This could be explained by the limitation imposed 
by the outcome measures and the study design they used. An individualised measurement 
tool that could trace changes in the individual patient over time is required to establish the 
effectiveness of the intervention at the level of the individual.
PR is a multidisciplinary individualised treatment plan that addresses all aspects of 
the disease over time and is incorporated in the life long integrated care of patients with 
COPD (Nici et al. 2009). Therefore, if delivered and measured appropriately, evidence of 
the effectiveness of PR in the improvement functioning in daily life in people with COPD 
could be established.
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2.5.2 Maintenance of the benefits of rehabilitation
Maintenance of the benefits of PR is an important goal. Bourbeau (2010) suggested 
that one of the criteria of a successful PR program is it its ability to implement behavioural 
changes in physical activity that could be maintained. Lack of exercise maintenance 
following PR, resulted in a controversial evidence of the long term benefits of PR (Brooks 
et al. 2002) and (Ries et al. 2003).
Maintenance of the effects of PR on functional performance requires vigilant 
attention to barriers and facilitators to performance, and the implementation of methods that 
could influence them on the long run (Bourbeau 2010). Currently there is no empirical 
evidence describing the factors influencing functional performance of people with COPD. 
It is suggested that those are best described from the perspective of patients living with the 
disease.
In order to ensure maintenance of the benefits of PR it is important that patients 
concord with a self-managed exercise program or remain functionally active during daily 
life. Strategies that ensure maintenance of effect following PR should be an integral part of 
the program. Moreover, patients should be equipped with skills and knowledge that enable 
them to maintain maximum functioning following PR. They should also be equipped with 
knowledge and tools that enable them to monitor and self-mange changes in functioning 
(Nici et al. 2009).
An important factor to consider in the evaluation of the maintenance of benefits 
gained is the occurrence of clinical exacerbation. Currently the most clinically acceptable 
definition of COPD exacerbation is “a sustained worsening o f the patient’s condition, from  
the stable state and beyond normal day-to-day variations, that is acute in onset and 
necessitates a change in regular medication in a patient with underlying COPD”. 
(Rodriguez-Roisin 2000, P: 398S).
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COPD exacerbations result in clinical and functional deterioration beyond that 
experienced by the natural progression of COPD. This suggests that exacerbations 
significantly contribute to the functional loss and lack of maintenance following PR (Cote 
et al. 2007). Therefore, a patient reported outcome that enables the patients to detect initial 
deterioration in clinical and functional status before it develops into full exacerbation is 
required.
Having identified the significant outcomes of PR in terms of improving function and 
maintenance of gained benefits, the next part of this review examines the current clinical 
problems in the delivery of PR. This is performed in order to identify the specifications of 
an appropriate outcome measure that would enable the provision of informative clinical 
data. It is proposed that informative clinical data would enable the resolution of these 
clinical problems.
2.6 Current clinical problems in the provision of PR
These are problems in identifying the optimum mode of delivery. It is important to 
highlight that the provision of PR should be individualised and tailored to the needs and 
clinical problems of the individual patient. This requires making evidence based decisions 
on the effective components, the optimum duration, the optimum settings of the program, 
and the prediction of response to PR. Below is a review of research evidence on the 
optimum provision of PR.
2.6.1 Components of pulmonary rehabilitation
Pulmonary rehabilitation programs involve patient assessment, exercise training, self­
management intervention, nutritional intervention, and psychosocial support. PR 
programmes are viewed as a continuum of intervention strategies incorporated into the 
lifelong management of patients with chronic respiratory disease and involve 
multidisciplinary input from the health care providers and the involvement of the family, 
and the wider community of the patient (Nici et al. 2009).
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In this review two components directly related to the significant outcomes of PR 
which are improving functioning and the maintenance of the benefits gained are examined. 
These components are exercise training and self-management.
2.6.1.1 Exercise training
The overall aim of exercise training in COPD is to improve functional capacity and 
physical fitness by reducing the impact of symptoms particularly breathlessness and 
fatigue. Although the loss of lung function in COPD is irreversible the rational for the 
inclusion of exercise in PR programmes is to increase functional capacity by inducing 
physiological adaptation in peripheral muscles, and improving the efficiency of the 
cardiovascular system (Bourbeau 2010). Exercise training could improve functional 
capacity without altering lung function. For example exercise training and oxygen therapy 
could improve exercise tolerance by delaying the onset of ventilatory limitation resulting 
from hypoxia and deconditioning. Physiological responses to exercise in people with 
COPD and their impact are presented in (Appendix A.l).
Physiological factors limiting exercise performance have been widely investigated 
(ATS/ERS 2004); however factors limiting exercise from the perspective of the patient 
were not studied. This highlights the importance of identifying the factors limiting 
performance by exploring the experience of people living with the COPD.
Moreover, it remains unknown whether these physiological improvements translate 
into improved functional performance of daily life activities. An appropriate outcome 
measure of functional performance is required to demonstrate changes in this construct 
during and following PR. An appropriate outcome measure should measure the construct 
“functional performance” and fulfil the requirements of the measurement theory (Stevens 
1946). A review of existing outcome measures in the area of PR is presented in the third 
section of chapter 2 of this thesis.
Another problem with the exercise component is adherence to exercises during and 
after PR. Due to the progressive nature of COPD Physiological benefits gained during PR 
gradually diminish after the end of the training program (Wedzicha et al. 1998). In order to 
maintain benefits of exercise, an exercise behaviour change should be induced. Studies 
performed in chronic disease populations reported self efficacy and expectations of
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beneficial outcomes as predictors of adherence to exercise (Brassington et al. 2002) and 
(McAuley et al. 1993).
Confusion and depression were reported as predictors of poor adherence (Brassington 
et al. 2002). Moreover, Rhodes et al. (1999) reported that education level and past exercise 
behaviours were positively correlated with regular exercise behaviour, while self­
perception of fatigue and poor health were reported as barriers to the adoption and 
maintenance of exercise.
Qualitative studies on adherence to exercises in COPD population reported 
progression of the disease, associated co morbidities (Nault et al. 2000), and frequent 
exacerbations as reasons for exercise non adherence (Brooks et al. 2002). Moreover, 
Soicher et al. (2009) reported previous exercise habits and 6 min walk test as factors 
differentiating compliers from non-compliers to exercise program. This implies the 
inclusion of maintenance interventions in PR programmes.
Concordance with the exercise program is a new term that emphasises the importance 
of involving patients in setting the goals of treatment and taking charge of their own care. It 
might be suggested that concordance could be improved if patients are provided with 
appropriate feedback that enables them to realise the beneficial impact of exercise on 
outcomes important to them. Evidence suggests that an individualised exercise program 
that is designed based on mutually agreed treatment goals might improve concordance 
(Bourbeau and Bartlett 2008). However, this should be supported by a patient reported 
outcome measure that measures clinically significant outcomes. These clinically significant 
outcomes should be defined from the perspective of the patients in order to provide them 
with meaningful feedback.
The concept of concordance was introduced to facilitate a shift in the dynamics of the 
relationship between the patients and health professionals to support the patients move from 
passive recipients of care to active collaborators in the provision of their own care. Self 
management techniques were introduced to facilitate this new approach to care delivery 
(De Silva 2011). While the aim of this thesis is to develop a clinical measurement tool, it is 
proposed that an outcome measure of functional outcomes of PR might have the potential
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to be used a self management tool by providing meaningful feedback to the patients about 
their clinical condition. An exploration of self management is presented next.
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2.6.1.2 Self-management
The introduction of the expert patient program to the NHS in 2001 has driven 
consequent self management and disease prevention initiatives. Recently the “generic 
long term condition model” was introduced advocating a case management approach, 
patient centred long term planning, and equipping patients with resources to support self 
care (Department of Health 2001).
Self management techniques include a continuum of interventions that range from 
passive education to more proactive techniques of self monitoring and implementing 
treatment. The components of the self management intervention vary from one chronic 
condition to another. The need for specific components also varies between individuals. 
Therefore, an individually targeted intervention program should be designed (Jones
2006).
The design of effective and appropriate self management interventions should 
involve the patients’ experience and needs, other stakeholders and collaborators through 
systematic user centred designs (De Silva 2011). An example of such comprehensive 
design was presented by Nasr et al. (2010), who reported an interdisciplinary user 
centred approach using empirical and theoretical knowledge in the development of a set 
of concepts for the design of a self management system for stroke patients. It might be 
suggested that such research should be reviewed and implemented in the area of PR.
The proposed benefits of incorporating self-management in PR is to enhance 
independence in functional performance and boost health behaviours resulting into 
improved coping and control of the disease (Bourbeau 2010). Moreover, it is thought 
that self-management education is the best method to ensure maintenance of the 
beneficial outcomes of PR, by preserving optimum functioning (Bourbeau 2010).
In a Cochrane review Self-management interventions have shown a reduction in 
COPD related hospital admissions (Effing et al. 2007). Another systematic review 
showed a positive impact of an integrated self-management intervention in the chronic 
care model on health care utilization (Adams et al. 2007). However, there is limited 
research in COPD on the impact of self-management on the maintenance o f physical 
activity and functional status (Bourbeau 2010). Developing a patient reported outcome 
measure of functioning that could be used as a self-management tool would enable 
generating such evidence.
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The ultimate goal of self-management education should be shifting 
responsibilities of management from health care to patient (Bourbeau 2010). This 
implies helping the patient to acquire knowledge of the disease, and action planning 
strategies. Action planning includes monitoring and controlling symptoms, initiating 
appropriate medication and seeking medical help in crisis or exacerbation (Bourbeau 
2010 ).
To achieve optimal monitoring and control of the disease the patient should have 
an objective method of recording changes in health status that could be communicated 
effectively to health care professionals. Although a number of general and disease 
specific health status measures were developed for use by people with COPD, none was 
a purposely developed self-management tool. In order to facilitate self-management the 
outcome measure should be patient reported, it should also provide informative and 
meaningful data to the patients about their current clinical condition.
Self-management should be integrated in PR and should be tailored to ensure 
concordance with medication and exercise, symptom control, mastering breathing 
techniques, and energy conservation techniques. Currently the provision of self 
management in COPD is delivered with focus on information provision and self 
efficacy improvements. Providers of pulmonary rehabilitation programmes should 
ensure that self-management interventions are operationalised in an effective way to 
induce a change in health behaviour that could be maintained and monitored following 
PR (Bourbeau 2010). This could be achieved by the inclusion of technical skills and 
technology in the design of self management interventions.
Effective self-management requires ongoing collaboration between the patient and 
the health professionals. This could be achieved by mutual development and 
implementation of an individualised action plan. This action plan should be supported 
by tools that enable the patient to recognise early changes in their health status and 
implement self-care strategies or seek professional help (Bourbeau et al. 2003). A self 
reported outcome measure that is responsive to early changes in functional status might 
be a valuable tool for such a purpose.
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2.6.2 Duration of pulmonary rehabilitation
Designing the optimal PR program is influenced by available resources and how 
to best allocate them. This raises the question of the optimum duration of the program to 
induce long term changes in functional status (Nici et al. 2009).
Currently the standardised provision of PR is in the form of short courses ranging 
from (6 to 12) weeks (Troosters et al. 2005). The ERS/ATS (2004) Guidelines 
recommended a minimum of 20 sessions given at least 3 times per week. Clinical trials 
that have followed participants up to (12 to 18) months post intervention found that 
beneficial effects of PR gradually decline, but remain above baseline (Ries et al. 1995, 
Strijbos et al. 1996, Engstrom et al. 1999, Griffiths et al. 2000, Guell et al. 2000, Ries et 
al. 2003, and California Pulmonary Rehabilitation Group 2004).
While some components of the PR program should be maintained after the end of 
the program, such as self-management and psychological support, the length of exercise 
programmes studied varied with longer programmes yielding larger training effects. 
However, the minimum duration that would result in the maximum potential 
improvement is not established yet (ATS/ERS 2004).
Studies that examined the effect of several follow up programmes following the 
initial intervention, reported variable effects (Foglio et al 2001, Brooks et al 2002, and 
Wijkstra et al. 1995). This could be explained by different study protocols, baseline 
characteristics of participants and outcome measures used.
Foglio et al. (2001) reported that the main benefit o f additional PR is reduced 
exacerbations represented by reduced number of hospitalisations. The authors reported 
no impact of additional PR on physiologic outcomes (Foglio et al 2001). This finding 
could be explained by the progressive nature of the disease, especially that authors 
compared intervention group with the control group a year after the additional 
rehabilitation program, a time period that is sufficient for the beneficial outcomes to 
diminish naturally (Wedzicha et al. 1998).
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This raises the question of the appropriateness of the pre-post experimental design 
for the evaluation of PR programmes. It could be that the pre post method of 
measurement was not able to detect the change that was detected by looking at the 
number of hospital admissions. Frequency of hospital admissions provide information 
on the number of occasions patients were admitted to hospital over time. Although this 
is not a direct measure of change over time, it highlights the importance of measuring 
change over time when evaluating PR programmes.
COPD is of progressive nature, where patients experience multiple exacerbations 
and continuous decline in health status. Moreover, PR is a complex intervention that is 
tailored to induce behavioural change through multidimensional modalities. These 
factors imply that a research design based on pre- post measurement will hide lots of 
valuable information about the changes in the disease trajectory and patients' status over 
time. This inappropriate method of evaluation has led to conflicting judgments on the 
long term benefits of PR.
It is suggested that in order to provide accurate measurement of the long term 
benefits of PR, measurement should be performed at regular intervals during and 
following PR. it should be expected that functional status is going to decline naturally. 
The purpose of measurement should be to identify the time at which a follow up PR is 
required.
In order to establish the minimum duration of the program that would result in 
maximum clinical benefit, and identify the time for referring the patient for a follow up 
PR, an appropriate outcome measure is required. This should be an individualised, 
outcome measure that could trace changes in functional performance as well as 
reflecting no change when a plateau in functional performance has occurred. The 
outcome measure should be able to detect the point when that patient has achieved 
maximum potential clinical improvement and maintained it for a clinically significant 
period of time. An outcome measure that has the ability to detect clinically significant 
changes and no changes over a period o f time is the TELER.
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TELER is an acronym for Treatment Evaluation by the LeRoux method. The 
TELER system is a concept of evaluation developed during the 1980s by Le Roux. It is 
based on the concept of using clinically significant change over clinically significant 
time periods as a measure of effective and efficient intervention (Mawson, 2002). 
Currently there are no TELER function indicators developed for use in people with 
COPD to evaluate the outcome of PR.
2.6.3 The settings of PR
Bourbeau (2010) suggested that providing PR at various settings that is tailored to 
the individual's needs improves accessibility and concordance. Evidence for 
effectiveness of PR has been provided in various settings; inpatient/outpatient hospital 
based programmes, community based programmes, and home based programmes. 
Home based programmed are usually confused with community based programmes. 
The difference is that community based programmes require direct patient supervision 
and entails, a consumption of heath care resources that is equivalent to hospital based 
programmes. Home based rehabilitation is a self monitored training (Puente-maestu et 
al. 2000) and (Bourbeau 2010).
Benefits of PR will gradually wear out due to the progressive nature of the disease 
(Wedzicha et al. 1998). Maintenance of benefit requires continuous input at home after 
discharge. The delivery of the service at home setting should be investigated further. 
However, the delivery of PR at home should be supported by an appropriate patient 
reported outcome measure to facilitate the communication of changes in the clinical 
condition between the patients and the health professionals.
2.6.4 The prediction of response to PR
Whilst the effectiveness of pulmonary rehabilitation has been supported by 
significant research; analysis of response to PR showed that there is a portion o f patients 
who are not responding to PR. Previous studies that have stratified patients according to 
baseline airflow limitation were inconclusive regarding differences in patients' response. 
It has been shown earlier that COPD is a progressive disease that has a 
multidimensional impact on patient’s life. The experience of disability resulting from 
COPD is unique and experienced differently by each patient (Sabroe et al.2008).
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It is suggested that in order to differentiate responders from non-responders an 
outcome measure that measures changes at the level of the individual should be 
implemented. Current methods of evaluating the outcome of PR provide an average 
score that is not specific to any individual patient in the group. Developing an outcome 
measure that is able to detect changes within the individual patient is a necessity. This 
will enable identifying non responders, and altering the treatment delivered to them in 
order to induce a response. This will eventually save wasting resources resulting from 
delivering a treatment that is not specific and ineffective for these patients.
2.6.5 Limited delivery of PR
Another issue that remains unresolved despite established effectiveness o f PR is 
limited access (Bourbeau 2010). A report by the Health care commission showed that 
only 64 % of 326 hospitals included in the audit had a formal rehabilitation unit, many 
of which have a very small capacity for patients, and did not have secured funding 
(Commission for Healthcare Audit and Inspection, 2006). Although NICE Guidelines 
recommended that all patients experiencing functional disability as a result of COPD 
should be refereed to PR, only 3%of patients with COPD are being referred for PR 
(National Statistics 2006). The National Statistics (2006) suggested that GPs should be 
encouraged to refer patients to PR; however more services need to be commissioned.
To address this issue it is important that outcome measures used to evaluate PR 
provide data that is informative for managers and commissioners. The outcome measure 
should be able to provide data that could be analysed at different levels to provide such 
evidence. A method of measurement that provides such data is the TELER. This 
emphasises the need for developing TELER function indicators for use in people with 
COPD in PR.
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2.7 Summary
• The integrated care model provides the basis for bridging the gap between health 
and social care. It places the patient and the context within which the patient live 
at the centre of the process of care delivery. It aids specific and effective care for 
complex cases and long term conditions such as COPD. The aims of integrated 
care in the management of patients with COPD are:
1. To manage the chronic functional limitations and participation restrictions in 
people with COPD, and facilitate the integration of this group in the community.
2. To facilitate early discharge by providing full patients’ support in the 
community.
3. To enable early detection of deteriorations in order to prevent hospital 
admissions.
• PR is a multidisciplinary intervention that is part of the integrated care for 
people with COPD. The long term goals of PR contribute to the provision of 
integrated care to people with COPD through the improvement of functioning 
and the maintenance of the benefits gained from PR.
• The effectiveness of PR in inducing short term changes in the control of 
symptoms, the improvement of functional capacity, and the improvement of 
HRQOL is well established. However, these changes do not translate into 
improved functional independence and are difficult to maintain.
• A qualitative exploration of patients’ perspectives on the factors influencing 
functioning in their own environment is required.
• At this stage of the thesis the significant outcomes of PR were identified as the 
improvement of functioning and the maintenance of the benefits of PR.
• During the review of the role of PR in the improvement of functioning in people 
with COPD a number of issues were identified.
1. Evidence suggests that patients with COPD have reduced levels of physical and 
functional activities.
2. Reduced levels of physical and functional activities were linked to higher health 
care utilisation in this group of people.
3. Studies that evaluated physical activity in people with COPD used most 
frequently activity monitors for the measurement of activity levels.
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4. Activity monitors provided limited information that does not inform clinical 
decisions.
• During the review on the maintenance of the outcomes of PR a number of issues 
were identified.
1. It was suggested that the maintenance of the benefits o f PR could be achieved by 
equipping the patients with self-management skills and a patient reported 
outcome measure that could provide informative feedback for the patients about 
their clinical condition.
2. Maintenance of the benefits requires early detection of COPD exacerbation and 
preventing them.
• A number of clinical problems in the provision of PR were identified. These 
included:
1. Identifying the appropriate components and the optimum delivery o f those 
components. It was identified that optimum delivery o f the exercise components 
requires establishing patients’ concordance with exercise. While optimum 
delivery of the self-management component requires equipping the patient with 
the tools to self monitor their condition.
2. Identifying the optimum duration of the program. This requires the identification 
of when improvements occur and when to provide a follow up PR.
3. Identifying the optimum setting for PR. It was shown that the effectiveness of 
PR is established at hospital and community settings. However, maintenance of 
the benefits requires establishing the effectiveness of PR at home settings.
4. Identifying response to PR. This requires the identification of non-responders in 
order to change the treatment and induce a response.
5. Limited delivery of PR was influenced by limited commissioning. An outcome 
measure that is informative to clinicians and commissioners is required to 
facilitate the commissioning of PR.
• To resolve the above problems, it is required to shift from the RCTs to a new 
research paradigm that implements methods of clinical evaluation such as the 
realistic evaluation (Pawson 2003). It is also required to shift from the pre-post 
measurement designs to the longitudinal measurement of outcomes at the level 
of the individual. However, this transition should be supported by appropriate 
clinical tools. Currently a clinical tool that measures change at the level of the 
individual, and provide informative clinical data does not exist. In order to
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develop such a tool it is important to identify the specifications of an appropriate 
outcome measure for implementation in clinical settings.
• From the findings of the literature review on PR, a number of specifications 
were identified. These are:
1. The outcome measure should trace changes in the patients’ condition 
over clinically significant time periods.
2. The outcome measure should provide informative data to the patients, to 
the clinicians and to the mangers and commissioners.
3. The outcome measure should be patient reported.
4. The outcome measure should be a multidimensional outcome measure of 
functioning.
The central aim of rehabilitation is to improve functioning, which is a 
multidimensional concept influenced by a number of factors. Full definition of the 
construct “functioning” requires the incorporation of theoretical knowledge as well as 
patients’ perspective. Therefore, the next section is a critical review of the literature on 
the models of functioning in order to define the construct “functioning”, and identify a 
framework for the measurement of the domains of functioning.
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3 Functioning/Disability: Models and definition
3.1 Introduction to the construct “functioning”
In the previous chapter functioning was identified as the central aim of PR. An 
important outcome of PR was to reduce the disability resulting from COPD (BTS 
2001). GOLD (2010) suggested that health status is an important area o f evaluation 
following PR. In the national and international guidelines on PR, recommended areas of 
evaluation appeared to reflect aspects of functioning or a broader health status and 
quality of life concepts. However, there was no consensus on the recommendation of a 
particular outcome measure for a certain area of evaluation. A standardised definition of 
functioning was not provided by major guidelines, and research in the area lacked 
consensus on the definition (Leidy 1994). This was evident by the wider range of 
linguistic expressions used to refer to aspects of functioning.
This ambiguity around the construct "functioning" could be explained by the fact 
that "functioning" is a multidimensional concept that is used to represent a humanistic 
phenomenon (Macdonald and Friedman 2002). Therefore, it is important to define the 
construct “functioning” based on theoretical background and clinical knowledge. This 
decision was made to ensure that subsequent qualitative enquiry is guided by sound 
theoretical knowledge that conceptualise the complex dimensions of the phenomenon. 
Moreover, the eventual aim of this enquiry on "functioning" is to identify the 
specifications of an appropriate outcome measure. This mandates appropriate theoretical 
definition to ensure construct and content validity (Ware 1987). Ware (1987) suggests 
that the "definition is the blueprint underlying the construction of health measures" 
(Ware 1987, P: 473).
Development of outcome measures of abstract concepts has started in the early 
twentieth century, when psychologists attempted the development of outcome measures 
of personal traits (Bartholomew 1995) and (Williams et al. 2003).The first step in 
operationalisation, i.e. the definition of a construct according to how it is measured, is a 
theoretically sound definition of the construct that identify the dimensions and the 
factors influencing it (Macdonald and Friedman 2002).
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Appropriate Definition of the construct being measured is important to standardise 
understanding and ensure the validity of the measurement tool. An important criterion 
of scientific measurement is that the meaning inferred from the outcome measure should 
be “singular” i.e. that the measurement tool measures one thing and one thing only 
(Stevens 1946). This mandates identifying the dimensions of the construct. Moreover, 
the measurement tool should account for all of the factors influencing the construct 
being measured. This is particularly important in a chronic disease such as COPD that is 
progressive, incurs multisystem manifestations, influenced by multiple factors, and 
results in multiple functional limitations, and participation restrictions (WHO/ 
International Classification of Functioning Disability and Health “ICF” 2001).
In order to be Realistic in identifying all possible factors influencing the construct, 
it was decided to limit this investigation to a specific group of people. That is people 
with COPD eligible for PR. The reasoning for this selection; first is the huge burden of 
the disease and its impact on functional status, second is that a patient report of being 
functionally limited is the main criterion for referral to PR.
3.2 Definition of functioning
In the Oxford Dictionaries functioning was derived from the origin “function” : an 
activity that is natural to, or the purpose of a person or thing. This definition has three 
main components; first "activity" denoting action and involvement. Second is "natural" 
denoting daily involvement. Third is the "purpose of person" denoting value and 
fulfilment of roles. In the literature the entire domain of functioning is referred to as 
“Functional status” (Leidy 1994). It was not possible to identify the linguistic difference 
between "functioning" and "functional status" except that the word status in the Oxford 
dictionary is interpreted as the relative position in relation to other indicating some sort 
of ranking item. For the purpose of standardising language this thesis will espouse the 
term "functioning" unless the concerned literature has stated otherwise.
66
Phase 1: Conceptualisation Chapter 1: The knowledge underpinning the disease and intervention
Improvement in functional status has frequently been referred to as an important 
outcome of patient centred care (ATS/ERS 2004). Despite this importance there was a 
proliferation of terms “health status, functional status, quality of life etc.” that were used 
interchangeably and lacked standardisation (Leidy 1994). It is important to highlight 
that Quality of life is a socially constructed concept that could be equally applied to 
people with or without a health condition (Engel 1977). While it is recognised that 
functioning is a dimension of quality of life, the focus of this thesis is the definition and 
measurement of functioning.
Health status is another generic concept that has sometimes been used 
interchangeably with quality of life. However, a number of authors who studied the 
concept quality of life believed that health status constitutes a dimension of quality of 
life (Ware 1987) and (Guyatt et al. 1993). Health is a multidimensional concept that 
encompasses physical, mental and psychological health. Similar to quality of life, health 
is a socially constructed concept. It is also a personally constructed perception of being 
ill or healthy manifested by seeking professional help (Engel 1977).
Functioning was identified by Ware (1987) as an aspect of health. This is in 
agreement with more recent classifications of health status such as the International 
classification of functioning, disability and health (WHO/ICF 2001). An important 
notion is that most existing outcome measures place greater emphasis on the negative 
aspect o f health. This has resulted in quantitative loss of information when the 
measurement tool was not able to reflect the interindividual variation. A qualitative loss 
of information is also manifested by measuring disability on the account of functioning. 
Therefore, any attempt to define constructs for the purpose of developing measurement 
tools should identify positive as well as negative aspects of the construct. The ICF has 
conquered this dichotomous presentation of concepts and to comply with this, 
"functioning/disability" will be both presented in thesis.
Leidy (1994) suggested that previous models and definitions of functioning had 
problems. They were very broad and too encompassing to guide specific treatment 
planning and outcome measurement. On the other hand sometimes the definitions were 
too constrained. Therefore, they failed to account for all aspects influencing functional 
status, and to reflect how physiologic improvements in performance translate into 
improved day to day performance. Existing models also failed to demonstrate an 
important distinction between functional capacity and functional performance.
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Moreover, Leidy (1994) criticised the inclusion o f a number o f constructs under a 
single label. It was suggested that this inclusion has resulted in the use o f terms 
interchangeably leading to further terminology misuse. Other authors suggested that the 
practice o f including a number of constructs under one label is not harmful. Actually it 
is necessary when one general construct like quality o f life is multidimensional and 
should be analysed (Ware 1974). What is needed is a standardised use o f the constructs 
and classifications. An example o f models and definitions on each o f the previous 
problems is provided in (Table 2).
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The literature also presented different descriptions of the term, with some 
overlapping, such as role functioning, physical functioning, psychological functioning, 
cognitive functioning, etc. This confirms that the concept is multidimensional. 
Therefore, this thesis adopts a comprehensive definition o f functional status 
’'functioning" provided by (Leidy 1994, p: 2).
“Functional status is a multidimensional concept characterizing one’s ability to 
provide for the necessities o f  life; that is, those activities people do in normal course o f  
their lives to meet basic needs, fulfil usual roles, and maintain their health and 
wellbeing. Necessities include, but are not limited to, Physical, psychological, social, 
and spiritual needs. There are four dimensions o f  functional status: Capacity, 
performance, reserve, and capacity utilization.”
To ensure a systematic approach to the definition, so that it could inform the 
development of outcome measures, it was decided to support this definition by a 
theoretical framework. This will be achieved by developing an 
“analytical/classification” framework” that provides a classification o f the “necessities 
of life”, factors influencing the “necessities of life” and analysis of the dimensions of 
the concept functioning.
The following statements provide the set o f standardised terms that will be used to 
ensure consistency:
• Although Leidy (1994) used the term functional status, this will be substituted 
by the term “functioning”.
• Necessities o f life are activities people do in the normal course o f their lives to 
meet basic needs, fulfil usual roles, and maintain their health and wellbeing. 
These will be referred to as “functions" o f any type, including physical, 
cognitive, psychological, spiritual, and social (Leidy 1994). These are classified 
by the ICF (WHO 2002) into “activities and participation”. That is:
“Activities”
“Functions”
“Participation”
• Figure 3 shows different types of functions as proposed by Leidy (1994).
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F igure 3 T ypes o f  functions
Physical
Social Cognitive
Types of 
functions
Spiritual Psychological
It is worth mentioning that
Figure 3 is not a classification of the types of functions, neither an exhaustive list. 
It is just to show how these concepts provided by other definitions fit within the adopted 
definition of functioning.
3.2.1 Defining the dimensions of functioning
Leidy (1994) suggested that a complete analysis of functioning requires a 
simultaneous consideration of all dimensions. This is consistent with Duncan and 
Velozo (2007) view of the measurement of the outcomes of rehabilitation. Duncan and 
Velozo (2007) suggested that a full evaluation of the outcomes of rehabilitation requires 
using a tool box of a number of outcome measures, each of which is specific for the 
purpose of measuring one dimension. However, meaningful measurement requires 
separate consideration and measurement of one dimension at a time. Leidy (1994) 
identified four conceptual dimensions of functional status: functional Capacity, 
functional performance, functional reserve, and functional capacity utilisation (Figure
4).
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F igure 4 C onceptual d im ensions o f  functioning. A dapted from  Leidy (1994).
Functional reserve
Functional performance
Functional capacity utilization
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3.2.1.1 Functional capacity
"Functional capacity is defined as one's maximum potential to perform those 
activities people do in the normal course o f  their lives to meet basic needs, fu lfil usual 
roles, and maintain their health and wellbeing. The term refers to potential in any 
domain, including physical, cognitive, psychological, spiritual, and sociodemographic." 
(Leidy 1994, P: 198).
Leidy (1994) highlighted a number o f outcome measures that have been used to 
measure capacity in different domains such as physical, psychological, spiritual, 
cognitive etc. The author ascertained that the capacity of the person to perform certain 
functions is influenced by resources available. A person with a given potential to 
perform might not choose to perform up to capacity (Leidy 1994). Whilst functional 
capacity provides the maximum potential to perform, the actual level of performance is 
influenced by a number of contextual factors that either facilitate or hinder performance 
(WHO/ICF 2001). It is important to notice that capacity is implied by appropriate 
functioning of body structures and organs.
3.2.1.2 Functional performance
"Functional performance is defined as the physical, psychological, social, 
occupational, and spiritual activities that people do in the normal course o f  their lives 
to meet basic needs, fu lfil usual roles and maintain their health and wellbeing." (Leidy 
1994, P: 198).
The level of functional performance is influenced by a number of factors mainly 
patients' perception of what is important and available capacity implied by optimal 
functioning of body structures and organs (Leidy 1994). Measurement at this level 
should be directed by patients' goals, and clinical determination of what is achievable. 
This suggests that an appropriate outcome measure of functional performance should be 
based on functional goals mutually selected by patients and clinicians. This notion 
points out the importance of a qualitative investigation of patients' perspective. The 
study should find out factors influencing functional performance, as well as patients' 
functional goals. This should also be verified by clinical experts.
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Leidy (1994) classified functional performance into components "domains" 6 
depending on the domain of activities. For example the physical domain includes 
activities of daily living, the psychological domain includes hobbies or favourite past 
time such as reading or music, the social domain includes attending parties and family 
gathering, and the spiritual domain includes meditation and worship services. An 
important notion here is that fne performance of activities in a certain domain is 
influenced by the collective potential and resources available to the person in all 
domains of life. That is the performance of a certain function like shopping requires a 
combination of physical, cognitive and psychological capacity to perform it. Moreover, 
the performance of a certain function is influenced by contextual factors such as 
environment, assistive devices, and support from others.
3.2.1.3 Functional reserve
"Functional reserve is the difference between capacity and performance, one's 
functional latency and dormant abilities that can be called upon in time o f  perceived 
need." (Leidy 1994, P: 199).
Leidy (1994) suggested that functional reserve constitutes the difference between 
functional capacity and functional performance. The author used that difference to 
propose an empirical relationship between capacity and performance that is 
synchronised by the amount of perceived exertion. That is, the closer the level of 
performance to capacity the more exertion the person will experience. Thus to move for 
the next level of performance without increasing exertion, capacity should be increased. 
It is thought that this is an over simplification of a complex relationship that is regulated 
by a number of factors that are not fully investigated.
It is believed that Leidy's conclusion has resulted from assuming a liner modelling 
of interaction between the dimensions of functioning. Actually this linear model and the 
empirical relationship suggested by Leidy (1994) do not explain why benefits gained by 
people with COPD following PR are not related to improvement in lung function which
6 Leidy used the w ord "com ponent", but it was replaced by "domain" to ensure standardisation 
throughout the thesis.
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is an outcome measure of physiological capacity. It also does not explain why people 
with COPD with the same level of capacity have different levels o f performance.
Finally, it does not explain why improvements in capacity do not translate into 
improved functional performance (Ninci et o/.2009). However, Leidy’s model partially 
explained the later issue by introducing the concept "functional capacity utilization".
3.2.1.4 Functional capacity utilization
" This term refers to the extent to which functional potential is called upon in the 
selected level o f performance". (Leidy 1994, P: 199). However, Leidy's model does not 
show what factors influence the utilization o f capacity. This means measurement tool 
based on this model alone will lack the ability to reflect changes in the construct 
measured resulting from all the multidimensional factors influencing the construct.
While the framework suggested by Leidy (1994) provides an analytical tool for 
identifying dimensions o f functioning, defining them and standardising concepts. It fails 
to provide a classification system for the wide ranging types of functions “necessities of 
life” i.e. physical, psychological, occupational, etc. It also lacks the ability to reflect the 
impact of disease on functioning. Particularly complex chronic conditions such as 
COPD, where a linear model fails to identify the multidimensional impact on functional 
status. Whilst this linear model provides a good analytical framework, it doesn’t 
accommodate for the multiple factors influencing functioning. A multidimensional 
framework that provides a classification system for functioning is the International 
Classification of Functioning, Disability, and Health (WHO/ICF 2001). This presented 
next.
3.3 The International classification of functioning disability and health “ICF”
3.3.1 Introduction to the ICF
One important point to highlight at the beginning o f this part is that the ICF 
claims that the classification system classify health and health states. However, based 
on the foregoing literature review it is believed that concepts provided by the 
classification represent functioning as influenced by the health o f the individual rather 
than being a comprehensive classification o f the overall health o f the individual. 
Although it is logical to propose that overall functioning is a reflection of health, it was 
found more appropriate to use the ICF framework as a classification o f functioning and
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how it is related to the presence or absence of a health condition rather than a 
classification o f health states.
It is believed this is a justified decision given that in the WHO (2001) document 
the proposed classification provided definitions of functioning and aspects of 
functioning, but not a single definition o f health. Moreover, the concepts offered in the 
classification represent "functioning" as defined by (Leidy 1994). Therefore, the term 
"health" was replaced by "functioning".
3.3.2 Characteristics of the ICF
The development of a multidimensional measurement tool o f functioning requires 
standardised definition o f the construct and identifying all the factors influencing it 
(Ware 1974). The ICF (2001) defines “Functioning” as “an umbrella term 
encompassing all body functions, activities and participation; similarly, disability serves 
as an umbrella term for impairments, activity limitations or participation restrictions” 
(WHO 2001, P:7). This presents a classification rather than a standardised definition of 
the construct. The International classification o f functioning, disability and health 
provides a unifying framework for classifying functioning in relation to health status.
The framework provides a model o f interaction between different aspects of  
functioning as influenced by "health", this facilitates identifying factors influencing 
certain aspects o f functioning and the impact o f health condition on functioning. On the 
other hand Leidy (1994) provided a comprehensive definition supported by analytical 
framework resulting in standardised construct identification, which could guide 
outcome measures development.
The WHO family of international classification provides assessment tools to 
describe and classify the health o f the population in an international context. While the 
ICD-10 provides information on mortality, the ICF provides classification o f the 
functional outcomes o f health (WHO 2001). Of interest to this thesis is the ICF.
The ICF provides a systematic representation to the various aspects of  
functioning. This provides a standardised framework for identifying aspects o f  
functioning where outcome measures should be developed. This ensures a holistic 
evaluation o f functioning. This could be accomplished by developing outcome measures 
for each aspect of functioning.
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The ICF is a valuable tool for the assessment of functioning in chronic conditions. 
It facilitates the identification o f aspects o f functioning that are not addressed by current 
interventions, so that new strategies are incorporated in management programs 
supporting the provision o f integrated care (IMPRESS 2008).
An important feature of the ICF is that it reflects individuality by considering 
contextual factors “environmental and personal” as factors influencing functioning. Two 
individuals with the same diagnosis and the same functional capacity might have 
different functioning profiles. This is particularly significant in chronic conditions like 
COPD where the progression and the experience o f the disease are unique to each 
individual (Sabroe et al. 2008). This also facilitates the delivery o f patient centred care 
and the development of individualised outcome measures.
To be scientific a classification system should state clearly three main properties: 
the universe o f the classification, the scope, and the units o f the classification.
3.3.3 The universe of the ICF
The classification includes all aspects o f functioning in relation to the health of 
the person. It classifies those aspects into functioning domains and functioning related 
domains. From outcome measurement perspective functioning domains are viewed as 
the areas that constitute the primary outcomes of care delivered, while functioning 
related domains constitutes factors that influence functioning domains “facilitate or 
hinder”. The classification reflects the broad context o f health. However it does not 
include domains that might influence persons’ functioning but are not health related; 
such as socioeconomic factors. For example participation restrictions because o f race 
are not included in the classification (WHO 2001).
An important feature of the universal application o f the ICF is that it provides a 
classification system for all people whether they have a disability or not. This facilitate 
the use o f positive language, prevent the stigma inflected by the disease, and provides 
common grounds for comparing functioning profiles of people (WHO 2001). This is 
particularly relevant in a disease such as COPD, where the stigma o f the self inflected 
disease is one of the main factors restricting participation (Okasheh et al. 2010).
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3.3.4 The scope of the ICF
The ICF provides a framework for organising information on human functions 
and its restrictions. Information is organised in two parts. Part 1 functioning and 
disability, and part 2 contextual factors. Each part has two components (Figure 5) 
(WHO 2001).
F igure 5 The com ponents o f  the IC F
• Body component (Body systems and 
body structures)
• Activities and participation 
component
I________________________
• Environmental factors
• Other contextual factors
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A list of the definitions applicable to the above components is provided in the text box 
below (Adapted from WHO 2001):
Definitions
In the context o f  health:
Body functions are the physiological functions o f  body system s (including 
Psychological functions).
Body structures are anatom ical parts o f  the body such as organs, limbs and their components. 
Impairments are problem s in body function or structure such as a significant deviation or loss. 
Activity is the execution o f  a task or action by an individual.
Participation is involvem ent in a life situation.
Activity limitations are difficulties an individual may have in executing activities.
Participation restrictions are problems an individual m ay experience in involvem ent in life 
situations.
Environmental factors m ake up the physical, social and attitudinal environm ent in which people live 
and conduct their lives.
Although personal factors constitute a component of the contextual factors a 
classification of personal factors is not provided by the ICF, because they are highly 
variable and individualised nature.
The components of functioning and disability can be described to indicate a 
problem related to health condition that is impairment, activity limitation, and 
participation restriction or absence of problem “body function and structure, activity and 
participation” (WHO 2001). This feature enables identifying aspects of functioning 
influenced by the health problem. This is important in a progressive disease that has a 
multidimensional impact such as COPD. This is because it aids identifying functions 
where individuals were able to cope with the disease and maintain optimal performance, 
and functions that were lost as a result of the disease.
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3.3.5 Unit of classification of the ICF
The unit of classification is categories within functioning and functioning related 
domains (WHO 2001). An important issue is that persons are not the unit of 
classification, but it provides a classification o f functioning of each individual. This 
highlights the individualized nature o f the classification and its usefulness in guiding the 
development of outcome measures that measures functioning at the level of the 
individual. The description o f functioning is provided within the context of personal and 
environmental factors (WHO 2001). This is particularly relevant to patients with COPD, 
where studies reported the impact of environmental factors such as weather on 
exacerbations (Nault et al. 2000) and personal factors such as anxiety and depression on 
functional outcomes (Kim et al. 2000).
3.3.6 Overview of the ICF classification
3.3.6.1 Body functions and structures and impairments
Body refers to the human organism as a whole. Body functions constitute the 
basic human functions, while body structures constitute the structures responsible for 
performing the function. Therefore, the classifications o f body functions and structures 
are designed to be used in parallel (WHO 2001). The classification of body functions 
and structures is guided by knowledge at the sub cellular or molecular level. However, 
this level is not presented in the classification. Impairment represents an anomaly, 
defect, loss, or significant deviation from the generally accepted populations’ standard 
of biomedical status. This classification is recorded using codes, the nature o f the 
impairment “temporary, permanent; progressive, regressive; static, intermittent” is 
verified using qualifiers after the code (WHO 2001).
It is worth noting that impairment is different from the underlying pathology and 
is the manifestation of the pathology. Moreover, impairment is not dependent on 
aetiology. This is important in a disease like COPD where the manifestations o f the 
disease appear to be an exaggerated response to an initially trivial stimulus (Sabroe et 
al. 2008) Moreover, COPD might coexist with other health conditions resulting in 
impairments that are not directly related to COPD (Curtis et al. 1997).
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3.3.6.2 Activities and participation/ activity limitations and participation restrictions.
One list is used to provide the domains for all activities and participation. These 
are qualified by performance and capacity qualifier. Figure 6 shows a list of the 
domains.
F igure 6 The dom ains o f  the activ ities and participation . A dapted from  (W H O  2001)
Domains
Qualifiers
Performance Capacity
d l learning and applying knowledge
d2 Genera! tasks and demands
d3 Communication
d l Mobility
d5 Self-care
dO Domestic life
d7 Interpersonal interactions and 
relationships
d8 Major life areas
d9 Community, social and civic life
The performance qualifier is described in relation to the current environment of 
the person. It represents “involvement in a life situation” or “the lived experience” of 
people (WHO 2001, P: 15). This highlights the importance of considering contextual 
factors when attempting to create a framework for the measurement of functional 
performance.
The capacity qualifier is described as the ability of the person to perform a certain 
task or function in a standardised environment, which is a neutral environment that has 
no impact on performance. This allows for assessing the impact of the person's current 
environment on performance and allow for modifications to enhance performance 
(WHO 2001). However, it is questionable whether this standardised environment is 
achievable, and whether there is an international standard for creating such 
environments to allow universal comparisons.
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The ICF identifies capacity as a qualifier of activities and participation, and is 
described as "an individual's ability to execute a task or an action It is the highest 
probable level o f  functioning that a person may reach in a given domain at a given 
moment. It is assessed in a standardised environment." (WHO 2001. P: 15).The concept 
of capacity provided in Leidy’s framework is totally different to that provided by the 
International classification o f functioning, disability and health (ICF). The reason for 
this conceptual difference is that Leidy's framework is an analytical framework that 
identifies dimensions o f functioning, while the IFC is a classification system that 
provides a description o f functioning.
It might be suggested that capacity as defined by the ICF is a lose concept. It is 
believed to be a replication of the definition of performance, but in a standardised 
environment. Whilst this is important in identifying environmental impact on 
functioning, it lacks the ability to provide meaningful information for clinicians and 
mangers on targeting interventions, or developing outcome measures. That is whether 
the individual patient would benefit from interventions that target capacity in terms of 
impairment of body structure and functions, or performance in terms o f the ability to 
execute certain tasks or functions.
This is particularly relevant in the case of COPD where PR programmes resulted 
in physiological improvements that did not translate into improved functioning in daily 
life. Moreover gained improvements were found to be not related to pulmonary function 
(Nici et a l  2009). This highlights the importance o f the distinction between capacity 
and performance in terms of interventions and outcome measurement.
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3.3.6.3 Contextual factors
Contextual factors include two components: environmental factors and personal 
factors. “Environmental factors make up the physical, social and attitudinal 
environment in which people live and conduct their lives''’ (WHO 2001, P: 16). 
Environmental factors influence the individual’s functioning by facilitating or hindering 
functioning. Environmental factors are organised into two levels: the individual level 
which constitutes the direct environment of the person “home environment” and close 
family interaction. The societal level which is the community or society settings and all 
interaction and services provided in the community.
Personal factors are the individual’s inherent characteristics, psychological assets 
and behavioural features such as gender, age, race, fitness, lifestyle, self efficacy, 
experiences etc. these vary widely between people and are not classified in the ICF. The 
identification of personal factors and their impact on functioning requires in-depth 
qualitative inquiry of people’s perspective. Figure 7 provides an overview of the ICF 
parts, components, domains, and constructs.
F igure 7 O verview  o f  ICF. A dapted from  (W H O  2001)
Part 1: Functioning and Disability Part 2: Contextual Factors
Com ponents Body Functions 
and Structures
Activities and 
Participation
Environmental
Factors Personal Factors
D om ains
Body functions 
Body structures Life areas (tasks, actions)
External influences 
on functioning ami 
disability
Internal influences an  
functioning and 
disability
Constructs
Change in body 
functions 
(physiological)
Change in body 
structures 
(anatomical)
Capacity 
Executing tasks in a 
standard environment
Performance 
Executing tasks in die 
current environment
Facilitating or 
hindering impact of 
features of the 
physical, social and 
attitudinal world
Impact of attributes of 
the person
Positive aspect
Functional and 
structural integrity
Activities
Participation Facilitators not applicable
Functioning
Negative aspect
Impairment Activity limitation  
Participation 
restriction Bat i iers /  hindrances not applicable
Disability
E-3B&iEnKZ3
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3.4 Framework for the measurement of functional status based on models of
functioning and disability
The emergence of a phenomenon that is socially disruptive or individually 
distressing , is associated by pressing needs for understanding the phenomenon and 
reversing its impact (Engel 1977). One way of understanding a certain phenomenon is 
by devising a model to describe it and study it. A model is defined as "a belief system 
utilised to explain natural phenomena, to make sense o f  what is puzzling or disturbing." 
(Engel 1977, P: 130). In health the belief system could adopt a reductionist perspective 
where conceptual and experimental tools that illustrate and analyse biological systems 
are of physical nature (Engel 1977). Another belief system is based on the 
biopsychosocial approach that employs a dynamic interaction between physiologic, 
psychologic, and psychosocial factors that perpetuate health status and results in 
disability (WHO 2001).
Fundamental to the conflict between advocates of the biomedical model and those 
supporting new holistic model is what aspects of the health status resulting from disease 
should be treated. The biomedical model implies that patient care is summarised in 
reversing the systematic manifestations resulting from pathological disease process. 
That is our interventions should be tailored to target impairments of body function and 
structures. This exclusion of the psychosocial components could distort the whole 
process of care. A good example is problems slich as "functioning/disability" in chronic 
conditions, which is a central aspect of health status, and is influenced by bothr 
biomedical and psychosocial factors, "functioning/disability" has been highlighted 
earlier as the central outcome of rehabilitation, {therefore a framework that could informj 
the development of outcome measures in this area is required. i
In the previous section the international classification of functioning, disability^ 
and health was presented (WHO 2001). It was evident that this classification system? 
was comprehensive and adopted a multidimensional approach to the classification o f  
functioning. The classification reflected how activity limitations and participation 
restrictions result from the multidimensional interaction between disease processes, 
resulting in impairment of body functions and structures, and the environment within! 
which the person is functioning, as well as personal and behavioural factors. Therefore, 
the biopsychosocial model presented by the ICF will be adopted as a basic framework\ 
for the study of functioning in people with COPD. Figure 8 presents the bio
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psychosocial model of functioning, disability and health provided by the ICF (WHO 
2001).
Figure 8 The ICF m odel o f  d isability  and functioning. A dapted  from  (W H O  2001).
Hrahh rendition 
(divxder or d iv a w
i
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A caveat here is that the above model provides an explanation of the phenomenon 
"functioning/disability". It is a descriptive model that provides a dynamic presentation 
of the factors influencing functioning. Whilst this model could serve a good function as 
an assessment tool it lacks an important feature that would enable it to inform the 
development of outcome measures in the area. That is the scientific analysis of the 
dimensions of the construct "functioning" and precise definition of the dimensions.
Such an analytical framework was provided by Leidy (1994) and described earlier 
in this section. However, this framework was linear and lacked the ability to account for 
various factors influencing functioning. It is suggested that a comprehensive framework 
that could inform the development of outcome measures that have construct validity 
could be achieved by merging Leidy’s analytical framework in the multidimensional 
ICF model.
The question here is where to fit the framework. On the ICF model it could be 
seen that the central part of it represents the phenomenon "functioning/disability" while 
the upper and the lower part represents factors influencing "functioning/disability". 
Therefore, the proposed framework is presented in (Figure 9).
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F igure 9 A proposed fram ew ork for the m easurem ent o f  function ing
F»<!<»«■> inftiiracist ftthciioiui
an
It is clear that functioning is a multidimensional construct, thus it is imperative to 
determine which dimensions should be measured. Looking at the model above 
“functional performance” is the construct that should be measured to represent 
“activities and participations”. Functional capacity represents “body functions and 
structures”. Thus functional capacity is measured in terms of physiological outcome 
measures. Impairment of body functions and structures results in a number of symptoms 
such as breathlessness, fatigue, coughing, and sputum production in the case of COPD.
Leidy (1994) described symptoms as precursors of performance or a result of 
performance at a certain level rather an element of performance i.e. a breathless patient 
might not be able to go upstairs because of his breathlessness. Or going upstairs might 
induce breathlessness. In both cases the patient is unable to perform or complete the 
activity. Similarly, psychological symptoms such as anxiety and depression are a result 
of impairment and precursors to performance i.e. anxiety resulting from breathlessness 
might stop the patient from performing certain function, or result in a lower level of 
performance.
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The biomedical model has dominated the health care system for a long time 
(Engel 1977). This has resulted in positive advances in the physiological outcome 
measures i.e. measures of impairment representing functional capacity (Alder 2009). 
However, these outcome measures failed to show how improvements in functional 
“exercise” capacity resulting from PR translate into improved Performance (Bourbeau 
2010). Functional performance constitutes what people actually do in their daily life and 
thus represent meaning and value for them. Therefore, it is proposed that while a 
comprehensive profile o f functioning could npt be achieved with measuring outcomes
representing all dimensions of functioning. Functional performance is a key dimensionj
that should be measured.
‘One of the problems associated with quantifying functional performance is with 
identifying relevant functions “activities and participation”. These could be activities 
limited by symptoms; particularly those that are perceived as important to the 
individual. One way of identifying these activities is by asking patients about the 
activities in which they experience limitationsf because of the disease and to rank those 
in terms of importance (Guyatt et al. 1987b).
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3.5 Identifying the “functions” and factors influencing them
Central to the proposed definition of functioning, is the persons' ability to provide 
for the necessities of life. Necessities were defined as basic needs, usual roles and 
maintenance of health and wellbeing. An important question here is who defines basic 
needs, usual roles and health and wellbeing. In an era of patient centred care it is 
believed that patients' perspective is a key aspect of the definition (IMPRESS 2008).
Full identification of the impact of health condition “COPD”, what functions are 
affected, the values attached to those functions and what are the factors hindering the 
functions could not be achieved without accounting for patients' perspective. It might be 
suggested that a qualitative study guided by the proposed framework is required to 
consider these issues. This will provide a comprehensive profile of functioning in 
people with COPD. This profile will suffice to guide the development of outcome 
measures of functioning because it poses two qualities. First, the theoretical background 
based on the definitions and models of functioning generated from the literature. 
Second, an empirical knowledge derived from the qualitative inquiry.
However, before investigating patients’ perspectives and developing the outcome 
measure, two main issues should be verified. First, what are the criteria required by the 
measurement tool other than accurate definition of the construct measured. This 
mandates a literature review on the theory of measurement and measuring scales and the 
principles of measurement in clinical settings. Second, what is the content of existing 
outcome measures of functioning? And do they fulfil the criteria required by the 
measurement theory and the principles of measurement in clinical settings?
The next chapter provides a review of the literature on the theory of measurement 
and measuring scales and the principles of measurement in clinical settings in order to 
identify the criteria required by a clinical outcome measure o f functioning. This is 
followed by a review o f the existing outcome measures in the light of the identified 
criteria.
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Chapter  2: The th eo re t ica l  u nderp inn ings  o f  m e a s u r e m e n t
4 Section 1: The theory of measurement and measurement scales.
The aim of the following section is to identify the criteria required by the 
scientific measurement scale and an appropriate outcome measure of functional 
performance following PR for people with COPD.
4.1 Introduction
The fact that functional performance is a qualitative attribute implies thoughtful 
consideration to Psychological measurement in the next literature review on 
measurement. This is due to the discussions and concerns expressed by scientists 
regarding the quantification of qualitative attributes in the area of psychological 
measurement. The literature on the theory of measurement and measuring scales is 
reviewed to identify the criteria required to construct a scientific measurement scale. 
Scientific scale means it could be falsified, i.e. it could be tested empirically by 
experiment or observation to be rejected or accepted (Kerry et al. 2008).
4.2 Definition of measurement
Historically, the definition of measurement was the focus of argument between 
advocates of different epistemological perspectives. This discussion became prominent 
in the mid-20th century, when Campbell and other physicists of the time described 
psychological measurement as short of fulfilling the requirements of scientific 
quantification. Measurement was then described as a form of empirical quantification 
that could be accepted or rejected experimentally (Campbell 1928, cited in Luce and 
Suppes 2001). At the time Stevens, a leading psychologist, responded by contending 
that this was rather narrow definition that disheartens the scientific status o f psychology. 
He then proposed a new definition of measurement:
“Assignment o f  numerals7 to objects or events according to rules-any rule” 
(Stevens 1946, P: 677).
7 Numerals, by which is meant simply a group of conventional signs or marks on a piece o f paper, obtain their order by convention 
(Campbell 1928).
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Stevens (1946) stated that measurement could be achieved at different levels 
determined by the process of measurement, and the formal mathematical properties of 
the relations established between empirical observations and mathematical structures. 
This has resulted is four types of measurement scales (nominal, ordinal, interval and 
ratio). Although Michels (1983) argued that nominal scales satisfy the logical 
requirements o f measurement, there was an apparent consensus in the literature that 
nominal scales are classifications rather than measurement scales (Luce and Suppes 
2001). However, ordinal scales created most o f the confusion and debate (Luce and 
Suppes 2001).
Michell (1997) presented a critique o f measurement in psychology condemning 
the quantification of attributes that are not quantitative in nature. He used this argument 
to validate an exclusive reference o f the term "measurement" to "quantification". 
Michell (1997) suggested a highly restrictive definition o f measurement:
"The estimation or discovery o f  the ratio o f some magnitude o f  a quantitative 
attribute to a unit o f  the same attribute" Michell (1997, P: 29).
The implication that scientific measurement is only restricted to measurement of 
quantitative attributes is deficient. It pays no heed to a whole paradigm of scientific 
evidence that deals with the study of qualitative attributes. Whilst the author totally 
concurs with the logic o f "the estimation o f ratio of a quantitative attributes" Michell 
(1997, P: 29). This logic could not be used to undermine the scientific qualitative 
enquiry. Thorndike (1904) cited in Michell (1997) contended that measurement o f  
qualitative attributes "by relevant position" is different to measurement o f quantitative 
attributes "by amount o f some unit". He states:
"Measurement by relative position in series gives as true, and may give as exact, a 
mean o f measurement as that by amount" (Thorndike 1907, P:19) cited in Michell 
(1997).
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Morgan provided a coherent debate of Michell's notion of scientific measurement:
"Michell has little time fo r  ordinal scales, and presents them as desperate 
inventions o f  S. S. Stevens to deflect attention from the failure o f  ratio scales. I  do not 
follow the reasons fo r  this severity. Other sciences have worked quite happily with 
scales that are not continuous, and which therefore fa il to satisfy the Holder axioms. 
For example, classical genetics used a unit called (as it happens) the morgan or 
centimorgan. This was the distance apart between two genes measured by the 
probability o f  recombination. The fact that centimorgans turned out in many cases to be 
additive was taken as. evidence fo r  the linear arrangement o f  genes on chromosomes. 
But it is clear that this scale never had a hope o f  being continuous, since genes are 
discrete. Similarly, molecular biologists now happily measure the genome in kilobases. 
Again, this cannot be continuous because the number o f  bases is discontinuous. The 
requirement o f  continuity fo r  a scientific measurement scale is fa r  too restrictive A 
(Morgan 1997, P: 399,340)
Stevens (1946) ascertained that in order for measurement scales to be scientific 
the following should be made explicit: First, the rule of assigning numerals. An 
important point to highlight here is that representational measurement is not just 
representation via numerals. It is how components of the observed structure and the 
mathematical structure relate to one another according to scientific theories and 
knowledge (Luce and Suppes 2001). Second, the mathematical properties of the 
resulting scales. Third, the use of appropriate statistical operations. Failing to account 
for the above requirements resulted in the faulty assumption that numerals represent 
numbers “implying quantities”. This has led to the misuse of Stevens's definition to 
legitimise absurd acts of measurement (Michels 1983).
The broad concept of measurement provided by Stevens implies that measurement 
is a process that includes a number of steps ranging from simple classification and 
ending with the more complex quantification. The process aims to generate data form 
observations. This is achieved by establishing relationships between the observation and 
a mathematical system.
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To ensure scientific quality o f the resultant measurement scale one should be able 
to provide a scientific evidence for the isomorphism between the observation and the 
assigned mathematical structures. A definition that adequately represents this process 
was provided by Michels (1983):
"Measurement is the act o f  converting observations into data, and includes 
classifying, counting, ranking, and q u an tify in g (Michels 1983, P: 210).
Michels (1983) identified three logical requirement of measurement. First is 
identifying a dimension o f interest, in the case o f this thesis "functioning”. Second, 
operationally define the dimension; this includes conceptualisation and modelling the 
dimensions and the factors influencing the construct. Third, define two or more 
categories of the unit so that they are mutually exclusive and exhaustive. Michell (1997) 
referred to those requirements as instrumentalisation. It follows then that the assignment 
of numerals to categories on the scale should follow a rule that does not change under 
different conditions (Ellis 1986 cited in Michels 1983). It is worth mentioning that all 
previous requirements should be underpinned by theoretical, clinical and empirical 
knowledge. The only arbitrary aspect of scale development is the choice o f the unit 
(Campbell 1927 cited in Luce and Suppes 2001).
Next is a presentation o f the appropriate type of scales for the measurement of 
"functioning" and the mathematical relation o f the numeral system implied by that 
scale.
4.3 Scales of measurement and the theory of measuring scales
In the previous chapter "functioning" was defined and a model was developed to 
identify the dimensions of the construct. "Functional performance" was identified as one 
dimension of functioning and was highlighted as an important outcome o f pulmonary 
rehabilitation. Functional performance is a qualitative attribute that varies between 
individuals and within the individual with varying conditions and influencing factors. 
Functional performance o f an individual could be observed and categorised in different 
levels of performance depending on the existing functional capacity and influencing 
factors.
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Levels of functional performance “categories” could be rank ordered in a 
hierarchical structure. The unit of measurement is an arbitrary unit that reflect clinically 
significant changes in functional performance, resulting from clinically significant 
amount of treatment “Pulmonary rehabilitation”. This unit by convention is “clinically 
significant change”. Representational measurement is achieved by collecting data from 
empirical observations and arranging them logically in terms of familiar mathematical 
structures (Luce and Suppes 2001). This raises two questions. First what is the logic of 
arrangement? Second what is the appropriate mathematical structure?
What is the logic of arranging categories?
In identifying the logic of arrangement the author refers to previous work on 
measurement in physiotherapy. Mawson (2002) suggested that measurement of clinical 
change should be supported by clinical knowledge. Reflecting on COPD, the way we 
order the observed components of performance of a certain function should be 
underpinned by theoretical and clinical knowledge of the disease process and the 
development of disability resulting from the disease.
It has been highlighted earlier that COPD is a progressive disabling disease that 
usually co exists with other conditions creating complex cases. This suggests that 
theoretical and clinical knowledge is not sufficient on its own. In order to provide an 
exhaustive definition of the categories on the scale, patients' experiences o f the 
development of disability should be incorporated.
What is the appropriate mathematical structure?
In order for the outcome of measurement to be meaningful, an appropriate 
measurement scale should be selected (Stevens 1946).Clearly there are only few 
qualities that could be claimed about the construct functional performance. First it is 
qualitative. Second it could be observed providing empirical evidence, in terms of 
qualitative description, about a certain level of performance. Different levels of 
performance (categories) could be arranged in a hierarchal structure ranging from lack 
of ability to perform to optimum performance. A mathematical structure that represents 
relative order of categories in relation to each other is the ordinal scale (Stevens 1946).
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A measurement scale results from numerical relation system and a mapping from 
the empirical to the numerical relation system, which preserves the observed order of 
categories (Luce and Suppes 2001). However, Stevens (1946) identified three properties 
that should be imposed by an empirical observation that is measured by an ordinal scale. 
This ensures that the resultant measurement scale is a scientific measurement scale8. 
These properties are transivity, asymmetry and connectivity9.
Mawson (2002) suggested that definition of categories based on clinical 
knowledge ensures that that the resulting empirical structure satisfies the requirements 
of the theory of measuring scales, the author states:
"The concept that clinical change is significant only i f  it can be supported by 
clinical knowledge ensures that the definition o f  the points o f  the ordinal scale fu lfil the 
requirements specified by the theories o f  measuring scales (Stevens 1946), i.e. that they 
have the properties o f  transivity, asymmetry and connectivity. This concept also ensures 
that the indicator has face validity." (Mawson 2002).
Stevens (1946) suggested that the real concern should be the meaning of 
measurement. It follows that any statistical manipulation of data generated by any scale 
should ensure that the scale remain invariant, thus preserving meaningfulness. 
Therefore, data generated by an ordinal scale are only ordinal numbers and could not be 
subjected to operations of algebra (Michels 1983). Nunnally asserted this principle by 
stating:
"In the use o f  descriptive statistics, it makes no sense to add, subtract, divide, or 
multiply ranks" (Nunnally 1967, P: 18) cited in (Michels 1983).
It is worth mentioning that some statisticians highlighted this issue of using 
appropriate statistics as a misconception resulting from the confusion between 
measurement theory and statistical theory (Lord 1953). In a statement on statistical tests 
of null hypothesis Lord (1953) states:
"The numbers do not know where they came from "  (Lord 1953, P: 751)
8 Scientific scale m eans it could be falsified, i.e. it could be tested em pirically (experim ent or
observation) to be rejected or accepted (K erry et al. 2008)
9 Transitivity means that if  m easurem ent "a" is larger than m easurem ent "b", and m easurem ent "b" is
larger than m easurem ent "c", then m easurem ent "a" is larger than m easurem ent "c".
C onnectivity means that i f  m easurem ents "a", "b" and "c" have m eanings that are unique and 
different, then the can be ordered.
A sym m etry m eans that "a" is related to "b", but "b" is not related to "a".
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It is believed that this is confusion between numbers and numerals. Numerals on 
the ordinal scale do not denote anything more than a rank order. They fall short of 
satisfying the properties o f quantification (Campbell 1927 cited in Luce and Suppes
2001). Therefore, any statistical manipulation beyond that permitted by the theory of 
appropriate statistics will render the results meaningless and difficult to interpret 
(Stevens 1946).
4.4 Summary
Three logical requirements of measurement should be ensured before embarking 
on measuring a certain construct these are:
1. Identifying the dimension of interest and verifying whether it is a quantitative or 
a qualitative attribute. If it was claimed to be quantitative then it should be 
proved that the construct fulfils the Holder's axioms (Michell 1997).
2. Operationally define the construct and factors influencing the construct.
3. Define categories o f the construct so that they are mutually exclusive and 
exhaustive.
Functional performance is a qualitative attribute, and concerns were reported in 
the literature on the quantification o f qualitative attributes. To overcome this problem 
Stevens (1946) proposed a new definition o f measurement that revolutionised the 
approach to the measurement o f qualitative attributes. He ascertained that measurement 
is not restricted to the act of quantification.
Stevens (1946) defined measurement as assigning numerals to events or 
observations according to rules. However, to ensure that this wider concept of 
measurement does not undermine the scientific basis o f measurement, the following 
standards should be ensured:
1. The rule for assigning numerals should be made explicit. This could be achieved 
by identifying how the components of the observed structure and the 
mathematical structure relate to each other.
2. Identifying the level of measurement and the mathematical properties o f the 
resulting scale. This could be achieved by providing evidence of the 
isomorphism between the observed structure and the assigned mathematical 
structures.
3. The use of appropriate mathematical and statistical operations.
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Finally, three qualifiers o f the process o f measurement should be ensured, these
are:
1. Ensuring that the meaning o f measurement is always preserved, from the stage 
of calibration, through to implementation and analysis of data generated by the 
scale.
2. Defining an arbitrary unit of measurement.
3. Appropriately use numerals or numbers on the scale depending on the level of 
the measurement.
This section has identified the logical requirements, the standards and the 
qualifiers of measurement imposed by the theory o f measurement and measurement 
scale to ensure that an outcome measure is a ’’scientific measurement scale". The next 
section is concerned with establishing the principles o f measurement in clinical settings 
to ensure the outcome measure is an "appropriate outcome measure" for the clinical 
context.
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5 Principles of measurement in clinical settings
5.1 Introduction to measurement in clinical setting
There is a national drive for the provision of efficient, patient centred care. Measuring 
the outcomes of interventions using "appropriate outcome measures" that reflect quality 
and efficiency is a cornerstone in addressing such a demand.
When performed appropriately, measurement in clinical practice provides informative 
data for the clinician and the patient to trace changes in response to treatment. It serves as a 
feedback tool for clinicians to facilitate informed decisions about managing patients, thus 
improving patients’ experience of care. Additionally, when accompanied with appropriate 
documentation, measurement provides legitimate and legal credentials that justify practice 
and assist clinical reasoning (Roach 2006).
The aim of this section is to identify the criteria required by an "appropriate outcome 
measure" of functional performance for use in people with Chronic Obstructive Pulmonary 
Disease “COPD” attending Pulmonary Rehabilitation “PR”. The word "appropriate" is 
defined in the online Oxford Dictionary as "suitable or proper in the circumstances". This 
implies that in order to claim appropriateness of an outcome measure; one should identify 
the setting “contextual factors” and the population within which the outcome measure will 
be implemented (Kirshner and Guyatt 1985).
5.2 The rational for developing clinical outcome measures
Health care systems are facing continuous reorganisations, with the aim of 
developing new integrated health care models. The new health care model places the 
patient at the centre of the process of care (Fitzpatrick et al 1998). This has resulted in a 
proliferation of measurement tools that were tailored to measure patient centred outcomes 
such as quality of life, health status and functional status (Fitzpatrick et al 1998). It was 
highlighted earlier that COPD coexists with other conditions creating complex cases that 
are best targeted by adopting an integrated health care model (Kruis et al 2010). Therefore, 
a number of generic and disease specific quality of life outcome measures were developed 
in the area, for example chronic respiratory questionnaire, St. George's respiratory 
questionnaire, and others.
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Moreover, the proliferation in patient centred outcome measures was accompanied by 
an increasing demand on physiotherapists and other health professionals to provide 
convincing scientific evidence in the form of quantitative data (Feinstein 1983). This has 
moved the focus of the scientific community from developing analytic tools that aid clinical 
reasoning and facilitate communication between patients and health professionals 
(Lakeman 2004). The dominant attitude was to develop measurement tools for research 
purposes with less focus on the appropriateness for clinical, home and community settings 
(Patient reported outcome measurement group, Oxford 2009).
It is thought that such distraction has resulted from the belief system created by the 
prevailing scientific policy that regards clinical data as "soft" and short of fulfilling the 
requirements of scientific evidence (Feinstein 1983). Ultimately there is a significant lack 
of measurement tools that translate clinical observations into meaningful scientific data.
The need for the measurement of patient centred outcomes using tools appropriate for 
use in clinical settings is justified by the following facts. Firstly, there was an impressive 
development of scientific measurement tools that assess clinical parameters of COPD, such 
as the measurement of pulmonaiy function using spirometry, x-ray, and oxygen saturation 
monitors. However, researchers were not able to provide evidence of a relation between 
these parameters and patient centred outcomes such as symptoms, and functional 
performance (Nici et al 2009). This could be explained by the lack of scientific rigour in 
describing, analysing and measuring patient centred outcomes in clinical settings.
Secondly, improvements in clinical parameters of COPD were not translated into 
improved performance in daily life (Steele et al 2008). This could be explained by the 
inappropriateness of the measurement tools to account for changes implied by the home 
environment.
Thirdly, a measurement tool that has adequate psychometric properties at the level of 
the group and performs satisfactorily in the measurement of outcomes in clinical research is 
not necessarily appropriate for the evaluation of clinical outcomes at the level of the 
individual in the clinical settings (Greenfield and Nelson 1992).
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Physiotherapists and other health professionals were resistant to accept clinical tools 
that have not been tested in clinical trials, due to the fears of losing the intellectual status of 
the quantitative experimental science (Michels 1983). Moreover, practice guidelines have 
always been formulated in the light of the hierarchical evidence pyramid, placing 
randomised controlled trials at the top (Mant 1999). This has resulted in ignorance not in 
the "instrumental methods" they use in terms of the techniques of data collection and 
analysis, although this happens quite often, but more importantly in the "logic" of research 
practice and understanding the relevance of research finding to the clinical environment 
(Michelle 1997).
The ignorance of logical inferences in a clinical practice and even in research has 
detrimental effect on the progression of the profession of physiotherapy. This is particularly 
relevant when the research evidence does not provide adequate rational justification of the 
effectiveness of the costly and lengthy treatment of complex cases that physiotherapists 
face at the rehabilitation units such as people with COPD attending PR. It might be 
suggested that in order to provide evidence of the quality and effectiveness of treatment in 
clinical settings, a clinical tool that conforms to the principles of measurement in clinical 
settings is required. Moreover, the tool should provide informative data to support clinical 
decision making in the clinical context.
This highlights the urgent need for developing and evaluating new outcome measures 
of patient centred outcomes such as functioning, which are appropriate for use in the 
clinical setting, and have the potential to be transferred to home and community settings. 
However, in order to develop such tools it is important to identify the principles of 
measurement in a clinical setting.
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5.3 A framework for the measurement in clinical settings
Clinimetrics emerged in the eighties of the last century to provide an intellectual 
framework for the process of providing scientific clinical data (De vet et al. 2003). Similar 
to biometrics and psychometrics, clinimetrics has developed as a methodological discipline 
focusing on the quality of measuring human clinical phenomena. This is achieved by 
developing clinical measurement scales appropriate for the demands of clinical setting 
(Feinstein 1983). A clinical phenomenon include the types, severity, and impact symptoms, 
progression of illness, co morbidities, health status including functional status, adherence to 
therapy, or any other subjective clinical experience that requires identification, analysis and 
measurement (Feinstein 1983).
Feinstein (1983) suggested that the quality of clinical measurement mandates the 
assurance of the quality of the measurement tool and the quality of the measurement 
process. This could only be achieved by an iterative process from development to 
implementation in clinical settings. If the measurement tool was found to lack reliability for 
example then it should be modified and items revised to ensure reliability in the context of 
implementation (Feinstein 1983).
It is worth noting that there has been some criticism of Clinimetrics. Streiner (2003) 
suggested that the term was an unnecessary distinction and probably a harmful invention of 
terminology. The author viewed Clinimetrics as an attempt to reinvent the wheel, 
suggesting that it might cut off scale development form an established literature on 
developing and evaluating measurement scales in psychometrics (Streiner 2003).
The author concurs that the literature on psychometrics is well established. However, 
it has been highlighted earlier that, particularly in pulmonary rehabilitation, current practice 
in scale development does not give appropriate consideration to the purpose of the tool and 
the context of implementation. Psychometrics developed as a methodological science for 
the evaluation of the rigour and quality of the measurement tool at the level of the group. 
However, measurement in clinical settings requires establishing the rigour and quality of 
the measurement tool at the level of the individual. This necessitates a scientific framework 
to refocus attention particularly to the clinical relevance and meaningfulness of 
measurement in clinical practice (Kirshner and Guyatt 1985).
101
P h a se l: C oncep tualisa tion C hapter 2: T he theoretical underp inn ings o f  m easurem ent
In order to provide clinical measurement that would contribute to resolving clinical 
problems and provide evidence based practice, it is important that the development of 
measurement tools and evaluation of its quality and rigour be performed in the light of the 
principles of measurement in clinical settings. The ultimate goal is to preserve the meaning 
of measurement and clinical relevance throughout the process of development and testing 
(Hinds et al. 2002).
For the purposes of this thesis the following definition is suggested for clinimetrics.
Clinimetrics is a methodological framework for the development, evaluation and 
implementation o f clinical measurement tools. The framework should be informed by 
adequate conceptualisation o f the knowledge underpinning the clinical condition, the 
intervention, and the clinical phenomenon being measured, and the principles o f  
measurement in the clinical settings.
Next is a review of the requirements of measurement in clinical settings.
5.4 Principles of clinimetrics
5.4.1 Clinical assessment versus evaluative measurement
It is important to determine at the outset of the process of developing any tool 
whether it is an evaluative measurement tool or an assessment tool. The clinical assessment 
of patient is different form evaluative measurement. The aim of a clinical assessment is to 
identify clinical problems and propose solutions. Measurement observes whether the 
clinical status of the patients has changed in response to the intervention and the pattern of 
the change. The purpose of assessment is different to the purpose of evaluative 
measurement, although measurement could be performed as part of the overall process of 
assessment. In pulmonary rehabilitation the focus of clinical assessment is to identify 
current activity limitations and participation restrictions, to identify underlying 
impairments, set treatment goals and design appropriate rehabilitation program (British 
Thoracic Society Statement 2001).
Roach (2006) suggested that a fundamental aspect of measurement in clinical settings 
is identifying the purpose of the tool, as this enables the definition of the set of rules that 
will control the measurement process.
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Measurement tools could have either diagnostic (discriminative and predictive) or 
evaluative purposes (Kirshner and Guyatt 1985). Evaluative measurement tools could be 
used for research purposes, routine clinical practice, or by patients as a self-management 
tool in the community and home settings (Dekker 2005). Evaluative measurement tools 
should demonstrate certain attributes based on the context and the population within which 
they would be implemented. Evaluative measurement tools or "evaluative indexes" as 
reported by Kirshner and Guyatt (1985) are defined as a measurement tool that is used to:
"Measure the magnitude o f longitudinal change in an individual or group on the 
dimension o f interest." (Kirshner and Guyatt 1985, P: 28).
If the measurement tool is to be used for research purposes then the specifications 
required by measuring tools vary with the study design (Guyatt et a l 1989). However, 
when the tool is to be used in clinical settings then the specifications of the tool vary with 
the nature of the clinical condition treated, the nature of the intervention, the nature of the 
clinical outcome being measured, and the clinical characteristics and the needs of the 
patient mix attending that clinical settings.
Attempts to combine assessment with measurement are not always easy and maybe 
misleading. Considering the COPD Assessment Test “CAT”, the tool was developed to 
assess the overall impact of COPD on overall health (Jones et al. 2009). The items on the 
tool might serve a good function in providing comprehensive and simple representation of 
potential clinical problems in people with COPD. However, scaling each item on the 
questionnaire and generating an overall score has resulted in measurement tool that do not 
fulfil the logical requirements of the theory of measurement and measuring scales.
103
P h a se l: C onceptualisa tion C hapter 2: T he theoretical underp inn ings o f  m easurem ent
5.4.2 Measurement at the level of the individual patient
When measuring at the level of the individual patient the requirements for the quality 
of the instrument are higher than in the research settings (Dekker et al. 2005). Measurement 
in clinical settings requires the collection of data at the level of the individual (De vet et al. 
2003). Measurement at the level of the individual inflicts high demand for reliability and 
responsiveness. When measurement is done at the level of the group, a common practice is 
to average the results to reduce measurement error. This is not attainable at the level of the 
individual (De vet et al. 2003). Moreover, the measurement tool should be highly 
responsive to subtle changes in functioning that might be clinically significant and 
meaningful to the patient (Guyatt et al. 1987a).
Another important issue when measuring at the level of the individual is that 
researchers usually differentiate between the significance of change scores of a certain 
magnitude in the individual as compared to the same magnitude in the mean score of a 
group. A classical example is a change of 2 mmHg in blood pressure. While this is 
considered trivial and within the range of measurement error at the level of the individual, it 
was shown that a change of 2 mmHg in the average blood pressure in a group of patients 
was associated with reduced numbers of stroke in that population (Guyatt et al. 1987a).
Reflecting on the measurement of functional performance, it has been shown that 
functional performance is a highly individualised experience and extremely variable even 
within the individual patient in COPD. Therefore, it should be measured at the level of the 
individual. Considering the high variability in individual responses (Guyatt et al. 2002), 
and the qualitative nature of the attribute "functional performance" implies that calculating 
the mean is both unscientific and meaningless. The generated value does not reflect the 
clinical condition of any individual in the group.
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5.4.3 Measurement of individualised outcomes
Functional performance is a qualitative attribute that is experienced by each patient 
differently. The impact of COPD on functional performance resulting in activity limitations 
and participation restrictions is best described by patients' narratives. Adequate analysis and 
understanding of the phenomenon “functional performance” and the factors influencing it 
could not be achieved without involving patients’ perspective. Therefore, adequate 
construct validity could not be achieved unless the items are generated and the pattern of 
functional loss is described by patients themselves (De vet et al. 2003).
It is important to ensure that the patient's perspective is included using a systematic 
and rigorous qualitative research methods. Moreover, the requirements of the theory of 
measurement and measurement scales should be addressed to ensure that the resultant 
measurement tool provide valid and reliable scientific data.
5.4.4 The feasibility of measurement in clinical setting
If the measurement tool is to be used in routine clinical practice then contextual 
factors such as small sample size, patient characteristics, and time and resources limitations 
should be considered (Whitty et al. 1996). This suggests that certain factors should be 
considered, such as the time required for measurement, ease of administration, staff training 
implications, and acceptability by patients and clinical staff (Patient reported outcome 
measurement group, Oxford 2009).
Another important aspect of feasibility that is not reported when providing evidence 
of the feasibility of the measurement tool is the value of time required for measurement. 
The time required for the performance of measurement should not be at the expense of 
treatment. Also an important question to ask is whether patients benefit from outcome 
measurement. Outcome measurement in clinical practice should be used in the context of 
quality improvement and not only for management and research purposes (Dekker et al. 
2005). This suggests that the measurement tool should provide clinical data to inform 
clinical decision making and improve the care provided to the patient.
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Lakeman (2004) cautioned that routinely collected outcome measures in its current 
form fail to capture the richness of the experience of care of individuals. He suggested that 
reducing clinical data to a meaningless aggregate of numbers is very seductive and 
simplistic and does not inform clinical decision making.
Moreover, Lakeman (2004) warned that simple and short outcome measures that 
claim feasibility do not necessarily reflect a valid outcome of care. There should not be a 
trade-off between simplicity, and informative and in depth approach to the analysis of the 
experience of care. A feasible clinical outcome measure should account for the process of 
care and not a predetermined end point (Lakeman 2004).
5.4.5 Meaningfulness10 of measurement
Meaningfulness of measurement is the degree to which one can assign meaning to 
scores (Dekker et al. 2005). A definition that pays attention to the intended audience 
defined meaningfulness as a quality of the measurement tool that ensures:
"The intended audience must understand the magnitude o f the effect" (Guyatt et al. 
2002).
In order for the measurement tool to provide meaningful data, it should be developed 
by reference to the measurement theory and the definition of measurement: "assigning 
numerals according to rules" (Stevens 1946, P: 677). It has been highlighted earlier that the 
rule should make explicit the isomorphism between the empirical observations, the 
mathematical structure, the arbitrary unit of measurement, and the mutually exhaustive and 
exclusive definition of categories (Michel 1983). Moreover, the process of development 
should involve patients, clinicians and decision makers to generate categories that describe 
meaningful changes to them. The definition of the categories on the measurement scale 
should be performed using statements that provided singular11 meanings. Finally the 
measurement system should allow the analysis of data at the level of the individual and at 
the level of the group, thus outcomes are meaningful to patients, clinicians, and mangers.
10 The literature used interpretability and meaningfulness to refer to the same construct. For the purposes of
standardisation meaningfulness will be used in this thesis.
11 Singular means that the statement describing the category has one meaning and one meaning only.
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Guyatt et al. (2002) highlighted the widespread scope of the clinical context, and that 
it should not be confined to the clinicians. Therefore, an endeavour to make outcomes 
meaningful should address patients, clinicians, and managers.
Measurement should be meaningful to the patients by providing feedback about their 
clinical conditions and the changes in the clinical condition in response to the treatment or 
to the progression of the disease. For clinicians, meaningful measurement should provide 
information about the patient’s response to treatment and whether a change in the treatment 
should be implemented. Moreover, the measurement should inform clinicians about when 
the patient has achieved the maximum potential benefit, when to discharge the patient and 
whether the clinical condition of the patient is successfully maintained (Greenfield and 
Nelson 1992).
Commissioning services is the requirement of all managers. In order to inform 
decisions about the impact of resource allocations on patients, the measurement should 
provide meaningful data to managers.
Guyatt et al (2002) proposed a number of statistical manipulations in order to assign 
meaning to scores. This thesis contends that whilst it is important to device methods for 
assigning meaning to scores, this has two main problems. First using statistical 
manipulation brings us back to the initial problem of clinical versus statistical significance. 
(Beaton et al. 2001). Second a significant conflict emerged in the literature on interpreting 
the meaning of statistical processes aimed at interpreting the meaning of scores. It is 
suggested that instead of attempting to assign meaning to scores, it could be more fruitful to 
develop outcome measures that generate meaningful scores (Lakeman 2004), if they do not 
exist.
107
P hasel: Conceptualisation Chapter 2: The theoretical underpinnings o f  measurement
5.4.6 The definition of clinical significance
This requires identifying clinically significant outcomes and clinically significant change.
5.4.6.1 Identifying clinically significant outcomes
Kazdin (1999) defined clinical significance as:
“The practical or applied value or importance o f the effect o f an intervention-that is, 
whether the intervention makes a real (e.g., genuine, palpable, practical, noticeable) 
difference in everyday life to the clients or to others with whom the client interact. ” 
(Kazdin 1999, P: 332).
Identifying clinically significant outcomes is important because the way the outcome 
of the intervention is presented influence the inclination of clinicians to intervene or not. 
For example; when data from clinical trials suggests that the increase in life expectancy and 
mortality benefits are trivial, then clinicians are less enthusiastic to intervene. This is 
particularly critical when the intervention reported not to have an effect on mortality could 
actually improve the quality of life or the functional status of the individual patient in 
clinical settings. Moreover, it is worth noting that patients appreciation of certain benefits 
vary considerably. Additionally, the same patient may place a different value on the same 
benefit with varying circumstances. In the context of clinical settings or clinical trials, for 
the outcomes to be useful they should be meaningful to the intended audience that is 
patients, clinicians, and policy makers (Guyatt et al. 2002).
The values attached to outcomes are central in clinical management decisions. This 
has highlighted the importance of including patients in the decision making process. This 
inclusion should be performed in a systematic manner that involves presenting patients 
with available options and eliciting their response. A caution here is that patients should 
understand the meaning of benefits expected form treatment and the feasibility of achieving 
those benefits given the existing impairments (Kirshner and Guyatt 1985).
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Kazdin (1999) suggested that an appropriate outcome measure of clinical significance 
should be developed based on a typology of abstract goals of treatment. These goals should 
be mutually developed between the patient and the therapist. A clinically significant 
outcome should be defined with reference to goals that are feasible, realistic and 
conceptually compatible with the proposed impact of treatment.
The central aim of PR is to improve functioning. Whilst the programme might have 
an impact on symptoms, improvements in symptoms are less likely to be reported as 
clinically significant outcomes (Okasheh et al. 2008). However, improved ability to control 
symptoms, cope with them and ultimately improved functional performance constitutes a 
clinically significant outcome that warrants appropriate measurement (Okasheh et al. 
2008).
When attempting to identify the clinically significant outcomes it is important to refer 
to patients’ perspectives and expectations. That is patients' goals of seeking professional 
help (Verrill et al. 2009). Much of the early symptoms of COPD such as coughing and 
breathlessness are related to aging or natural response to smoking. Therefore, patients do 
not seek treatment or professional advice until they become functionally limited as a result 
of symptoms (Okasheh et al. 2008). It follows that the clinical gain for patients is 
interpreted in terms of functional improvement rather than reversal of symptoms. 
Moreover, the lack of association between symptoms and functional ability has been 
frequently reported (Nici et al. 2009). This suggests that a clinically significant outcome of 
PR is best described by patents in terms of changes in functional performance.
Once the construct that constitutes clinically significant outcome is defined from the 
perspective of patients based on the goals of treatment, the clinically significant change 
should be established (Kazdin 1999).
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5.4.6.2 Identifying clinically significant change12
The amount of treatment required to induce a clinically significant change is 
dependent on the type of problems treated and the progression of the disease. Kazdin 
(1999) asserted that clinically significant change as a result of treatment should be 
established apart from the statistical significance. It should capture the actual impact of 
treatment on everyday life with reference to the individual patient. Kazdin (1999) states:
"The question for any measure or index o f clinical significance is the extent to which 
the measure in fact reflects a change that does have an impact on the individual's 
functioning in everyday life or a change that makes a difference" (Kazdin 1999, P: 336).
This prompts the question of how to establish the clinically significant change that 
has resulted from treatment. The usefulness of establishing the clinically significant change 
is due to the link it creates between the significant change and treatment decisions in 
clinical practice. It also highlights the importance of patient’s perspective (Guyatt et al.
2002). Clinically significant change is defined as:
"The smallest difference in score in the domain o f interest which patients perceive as 
important either beneficial or harmful, and would lead the clinician to consider a change in 
the patient's management". (Guyatt et al. 2002, P: 377).
Guyatt et al. (2002) argued that the clinically significant change represents significant 
improvement or deterioration as reported by the patient. He described that as “subjectively 
significant change”. It is argued that it is not a subjective construct; rather the minimum 
clinically significant change is a “qualitative significant change”. It could be measured 
objectively by creating a hierarchical structure of clinically important outcomes over time, 
based on clinical knowledge and patient experience. The unit of measurement should be 
calibrated so that it represents one clinically significant change.
12 This is referred to in the literature as the minimum important difference. However, the author decided not 
to use this to avoid confusion by using the word minimum, as the clinically significant change 
might be a large change that requires large amount o f therapeutic input, particularly in chronic 
conditions.
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Anchor-methods to establish clinically significant change based on global rating have 
been frequently reported in the literature (Guyatt et al. 2002), (Beaton et al. 2001), 
(Jacobson and Traux 1991), (Wyrwich et al. 1999), and (Redelmeier et al. 1996).
Kazdin (1999) cautioned about the backward reduction of outcome measurement to 
global ratings that are not theoretically or scientifically established measurement tools. 
They ascertained the importance of establishing empirical connections between observed 
changes in clinically significant outcomes and standardised outcome measures.
Kazdin (1999) highlighted methodological issues in establishing clinical significance 
based on existing "validated” outcome measures using anchor methods and cut off points. 
Anchor methods are based on establishing relationships between global ratings and 
outcomes of experimentally established effective treatment (Guyatt et al. 2002). A caveat 
about using global ratings to establish clinically significant change is that the results 
represent perceived rather than actual change. It should be expected that patients might 
report themselves as "much better" while the construct measured has not significantly 
changed. Similarly patients might report themselves as not changed while the construct 
measured has changed as measured by the measurement tool. This is conceptually 
analogous to type I and type II error in experimental research (Kazdin 1999).
Kazdin (1999) highlighted two problems with establishing cut off point for normative 
data in order to establish clinically significant change. First, normative data is not based on 
data collected from the standardised sample on two separate occasions. Therefore they do 
not provide comparable pool of data to that collected using a pre post measurement study 
design. Second, a score within the normative range for someone in a community sample 
might not hold the same correlate or meaning for a score in the normative range for 
someone who has an impairment and received treatment.
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Evidence of the improvement in daily life functioning following PR could not be 
provided unless functional outcomes of PR are measured using an appropriate measurement 
tool. This problem might be resolved by the development of an outcome measure that 
directly measures empirically observed changes in clinically significant outcomes. The unit 
of measurement should be “one unit of clinically significant change”. A measurement 
system located in the literature that enable such measurement is the Treatment Evaluation 
by the LeRoux “TELER” method (LeRoux 1993).
5.5 Quality standards of the measurement tool
In order to provide informative clinical data it is important to establish the quality and
rigour of the measurement tool. This involves providing evidence of the validity, reliability 
and responsiveness of the measurement tool.
“Measurements are taken to provide information, but the result may be
misinformation i f  the quality o f  measurements is not ensured”. (Task Force on Standards
for Measurement in Physical Therapy 1991, P: 592).
A number of issues should be considered when providing evidence of the rigour and 
quality of the measurement tool. Firstly, a measuring scale has two components: the
measurement scale, and the translating medium i.e. the mechanism that converts an 
attribute into a point on the measuring scale (LeRoux 2003). Secondly, a high quality 
measurement is the result of an interaction between the clinical knowledge of the rater and 
the refined design of the measuring scale.
5.5.1 Validity of the measurement
The validity of the measurement should be ensured during development by adequate 
conceptualisation of the knowledge underpinning the disease and the intervention, and the 
definition of the construct based on theoretical and clinical, and empirical and pragmatic 
research evidence to ensure appropriate translation of the construct into points on the scale. 
In COPD the translating medium is the perceived experience of the patient and the 
knowledge and experience of the clinician. Moreover, the theory of measurement and 
measuring scales should be considered to ensure the validity of measurement.
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Kazdin (1999) suggested that outcome measures of clinical significance should be 
validated in relation to the conceptualised definition of clinical significance. Therefore face, 
content, and construct validity should be ensured during development of the tool by 
involving clinical and theoretical knowledge, perspectives of experts, and a representative 
sample of the population within which the outcome measure will be implemented.
The Task Force on Standards for Measurement in Physical Therapy (1991) 
ascertained that the best evidence of face, content and construct validity is provided based 
on logical argumentation of clinical and theoretical knowledge of the construct being 
measured and its dimensions. Further evidence of construct and criterion validity should be 
based on inferred meaningful interpretations of relations between the outcome measure and 
other outcome measures considering contextual factors “environment and population”. This 
highlights the importance of preserving clinical meaning while providing evidence of 
validity rather than reducing this to statistical tests and mathematical formulations (Kazdin 
1999) and (poolman et al. 2009).
5.5.2 Reliability of measurement
Three important points should be highlighted when providing evidence that a 
measurement tool is reliable when used in clinical settings for the purpose of evaluating 
clinically significant changes. First is that measurement in clinical settings is performed at 
the level of the individual, thus the evidence should show that the tool is reliable for 
measurement of changes at the level of the individual patient (Kirshner and Guyatt 1985). 
Second, is that the clinical knowledge of the rater and the ability to identify and recognise 
change is an important factor to ensure the reliability of the measurement. The third point is 
related to the main purpose of the evaluative measurement tool which is detecting clinically 
significant changes in response to treatment. Therefore, the criteria required by the 
measurement tool to be reliable is to show small within subject variance in stable subjects, 
and a large change in score when the construct "functioning" has improved or deteriorated 
(Kirshner and Guyatt 1985).
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Functioning in people with COPD is naturally variable and is influenced by a number 
of factors. Functioning changes from day to day and even diumally. If the measurement 
tool is to be responsive enough to pick these changes, then this seems like a trade off 
between reliability and responsiveness. Therefore, the approach to provide evidence of 
reliability of a measurement tool that measures functional performance in this group of 
patients should be different. Reliability of such a tool is established by providing logical 
evidence that changes on the tool could be explained as changes resulting from a certain 
factor that is known to induce changes in functioning in this group of people (Guyatt et al. 
1987a). Roach (2006) ascertained that reliability is not a stable characteristic of the 
measurement tool; rather it is influenced by the purpose of measurement, context of 
measurement and patient group.
Reliability of the measurement tool could be improved by improving the reliability of 
the measurement process. This could be achieved by a number of ways. Firstly, using 
language appropriate and understandable by the group of patients within which the tool is 
going to be implemented. Secondly, training the rater whether this is the clinician, the 
researcher, or the patient to correctly use and record changes using appropriate 
documentation. Scores could be documented using hospital databases or specialised 
software. Thirdly, if the outcome measure is to be implemented as a patient reported 
outcome in home or community setting, then appropriately designed patient diary that is 
user friendly should be implemented. Finally, to increase the reliability of measurement the 
documentation should make explicit the environment within which measurement occurred, 
and any potentially influencing contextual factors.
5.5.3 Responsiveness of measurement
An important characteristic of an evaluative instrument is its ability to correspond to 
clinically significant changes resulting from treatment (Guyatt and Kirshner 1985), (Guyatt 
et al. 1987a) and (De Bruin et a l 1997). Whitty et al. (1996) suggested that responsiveness 
is an important attribute of evaluative health outcome measures that should be tested early 
in the process of developing the instrument. Responsiveness is concerned with the study of 
the ability of the measurement tool to correspond to "change". Streiner and Norman (1991) 
suggest that the overall goal of any treatment is to induce "change".
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The evaluation of the amount and quality of "change" induced influence clinical 
decisions about the effectiveness of treatment and rationing health resources without 
compromising patients’ care. Thus the ability of the measurement tool to correspond to 
changes detected by the rater is an important quality of the measurement tool that should be 
evaluated.
Most of the studies on the psychometric properties of measurement tool are 
concerned with providing compelling evidence for reliability and validity but rarely for 
responsiveness. This has resulted in confusion on the definition and methods of providing 
evidence for responsiveness. The literature on the definition and the evaluation of 
responsiveness is controversial (Beaton et al 2001).
Terwee et al. (2003) suggested that the confusion is mainly arising from varying 
descriptions of the type of change that the instrument is supposed to detect. In request to 
resolve this confusion “A taxonomy for responsiveness” was provided by Beaton et al 
(2001), following an extensive review of the literature on the responsiveness of health 
status measures. They concluded that the confusion on the definition and interpretation of 
responsiveness could be alleviated by considering responsiveness as a contextualised 
attribute of the measurement tool. They suggested defining the context of the study of 
responsiveness by identifying who is being analysed, which scores are contrasted and what 
type of change is being measured. Considering a measurement tool that is appropriate for 
implementation in clinical settings, then the context of the study would be identified as 
follows:
• The analysis is at the level of the individual.
• The scores contrasted are within person change.
• The type of change measured is clinically significant change.
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5.5.3.1A proposed method for the evaluation of responsiveness at the level o f the 
individual
The measurement tool should be constructed so that the unit of measurement is 
clinically significant change. Scaling of the measurement tool should be based on 
categories coded to represent clinically significant changes in the construct being measured. 
Definition of clinically significant changes should be determined based on clinical 
knowledge and patient experience. Each code on the scale should represent an observable 
patient centred treatment objective that it proposed to result from clinically significant 
amount of therapeutic input (Mawson 2002).
• Chi square goodness of fit 
In order to establish the responsiveness of a measure, the chi square test could be 
used to test the association between true change in the construct and the random change. 
Theoretically a change could result from an effective treatment, the natural progression of 
the disease, or from changes in the parameters that influence the construct. One way of 
establishing responsiveness of the measure is to induce change, by for example introducing 
an intervention that is designed to influence the construct being measured and then assess 
the significance of the association between observed changes and the probability of random 
changes.
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6 Summary
An increased number of measurement tools of quality of life have resulted in the 
provision of information on health status, well-being and functioning. Although evidence of 
appropriate psychometric testing was provided, these outcome measures did not inform the 
improvement of care or enhanced recovery (Liang 2000). This could be explained by a 
number of factors. Firstly, data provided by existing measurement tools are difficult to 
interpret by patients and clinicians; therefore it did not inform clinical practice. Secondly, a 
clinician doing a pre post measurement is actually assessing the patient at two time point 
rather than doing appropriate evaluation that could inform decision making. This would 
result in missing a significant number of critical changes occurring during treatment that 
would imply changing the provision. Thirdly, outcome measures used are usually designed 
to measure groups of individuals; therefore they are less responsive to changes at the level 
of the individual patient (Liang 2000).
To overcome these problems standards of developing or selecting measurement tools 
for clinical practice should conform to the principles of measurement in clinical settings
• Principles of measurement in clinical settings have been described in the literature 
on clinimetrics, this includes
1. The distinction between assessment activities and evaluative measurement activates. 
The former enable the clinician to identify problems and needs, the latter are the 
actual tool for informing decision making and modifying management resulting in 
improved patients’ experiences of care.
2. Measurement at the level of the individual. In clinical settings clinicians are 
responsible for providing effective and efficient care for the individual patient. 
Therefore, an appropriate measurement tool should be able to detect within person 
changes. This demands high level of responsiveness.
3. Measurement of individualised outcomes. Patients are considered as health 
customers. Therefore, outcomes should be described from their perspective and 
account for their needs. This is particularly important when the concept measured is
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qualitative in nature such as functional performance. However, during the 
development of this type of outcome measures thoughtful consideration should be 
given to the logical requirement and the standards required by the theory of the 
measurement and measuring scales. This ensures that the resultant measuring scales 
are scientific. This means the generated data represents true reality removing the 
influence of guessing or memory.
4. Feasibility: this quality ensures that the outcome measure is appropriate given the 
limited time and resources at clinical setting. However, it should be ensured that 
there is no trade-off between validity and feasibility.
5. Meaningfulness: This quality implies that the data generated from measurement 
should be meaningful to the patient and the clinician without the need for statistical 
manipulations. The measurement tool should meet two requirements to ensure the 
results are readily meaningful to the patient and the clinician. First, direct 
measurement of clinically significant changes that is the unit of measurement 
should be one clinically significant change. Secondly, the ability to detect clinically 
significant change. Meaningfulness should be ensured during development and is 
actually the first qualifier of the measurement process required to ensure that the 
resultant measurement scale is scientific.
Quality standards required by the measurement tool are validity, reliability and 
responsiveness. These qualities should be evaluated considering contextual factors, that is 
the setting and the population within which the measurement tool will be implemented. 
Evidence of quality should be logical and based on scientific and theoretical inferences that 
preserve clinical meaning. To date evidence for the psychometric properties of 
measurement tools is provided in the form of statistical and mathematical models. This 
form of statistical evidence fails to provide evidence of the appropriateness of the tool to 
the purpose and context. It is also difficult to interpret.
Confusion in the interpretation of statistical tests has already been reported in the 
literature between researchers. To avoid this confusion the theory of measurement and 
measuring scales and the theory of appropriate statistics should be considered when 
performing psychometric tests. Lack of compliance with these theories has significantly 
hindered the ability of clinicians to select the appropriate outcome measure for clinical 
practice.
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The next section is a review of outcome measures currently used in clinical practice.
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7 Section 3: A critical Review of existing outcome measures
7.1 Introduction to the review of existing outcome measures
The aims of this chapter are: First, to identify the outcome measures of functional 
performance and outcome measures of quality life that include subscales measuring 
functional performance currently used in clinical practice in the area of pulmonary 
rehabilitation. Second, critically review them based on the criteria identified during the 
previous sections to find out whether or not they fulfil the requirements of a "scientific 
measurement scale" and an "appropriate outcome measure of pulmonary rehabilitation for 
people with COPD".
7.2 Identifying outcome measures for review
It is important to highlight the fact that due to the inconsistency in terminology used, 
for example: quality of life, functioning, functional status, health status, physical activity, 
physical functioning, and activities of daily life, it is very difficult to provide an exhaustive 
list of all outcome measures reported in the literature for use in people with COPD.
The aim of this chapter is not to systematically review all existing outcome measures. 
The aim is to identify a set of outcome measures that have been reported in clinical 
guideline, that "might have the potential" to be appropriate for the main purpose of 
measurement following pulmonary rehabilitation which is the measurement of clinically 
significant changes in functional performance.
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To further clarify what is meant by "might have the potential" the following exclusion 
criteria were developed. Any outcome measure that does not meet the exclusion criteria is a 
potentially appropriate outcome measure.
1. The outcome measure is generic, i.e. not a disease specific outcome measure. The 
justification for the criteria is in two parts. First, there is accumulating evidence that 
a disease specific outcome measure is more responsive than a generic outcome 
measure (Guyatt et al. 1987b, and Jones et al. 1991). Responsiveness was 
highlighted in the previous chapter as an important quality standard in evaluative 
outcome measures. Second: the purpose of the outcome measure is to evaluate the 
changes in functional performance in people with COPD. There is evidence that the 
pattern of the development of functional limitations as a result of COPD is different 
to other health conditions and to functional limitations resulting from aging or 
sedentary life style in the healthy population (Eisner et al. 2011).
2. The outcome measure or sub domains of the outcome measure do not measure 
functional performance. That is it measures factors influencing functional 
performance such as functional capacity, symptoms, personal factors for example 
self efficacy, and environmental factors.
3. The outcome measure does not measure clinically significant change in functional 
performance, but attempts to quantify the construct by using factors such as time, 
speed, and energy expenditure.
4. The outcome measure does not measure clinically significant change in functional 
performance, but measures dependency in functional performance. That is how 
dependant or independent the patient is in performing the activity.
121
P h a se l: C onceptualisa tion C hap ter 2: T he theoretical underp inn ings o f  m easurem ent
7.3 Searching for existing outcome measures of functional performance
It has been highlighted earlier that there was a proliferation of outcome measures of 
quality of life and functioning for people with COPD. As the focus of this thesis is 
implementation in clinical setting, the identification of outcome measures to include in the 
review was based on reviewing clinical guidelines rather than the literature. Moreover, four 
clinical inpatient and outpatient pulmonary rehabilitation services were approached and 
asked about the outcome measures currently implemented in their practices. This was 
further verified by networking and clinical contacts with physiotherapists and other 
clinicians at conferences and workshops.
A list of the clinical guidelines on the management of COPD and Pulmonary 
rehabilitation was identified by literature search of Google web, Google scholar, and 
Pubmed using the following combination of key words.
• COPD OR Chronic Obstructive Pulmonary disease AND clinical guidelines.
• COPD management OR Chronic Obstructive Pulmonary disease management AND 
clinical guidelines.
• Pulmonary rehabilitation AND clinical guidelines.
This has resulted in identifying seven guidelines and statements. None of the 
guidelines made an explicit recommendation of outcome measures. Some of the guideline 
the ATS/ERS, the BTS, the general practice airway groups and the consultation documents 
mentioned certain outcome measures and discussed their properties without making a 
recommendation. These are presented in Table 3.
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Table 3 O utcom e m easures reported by major clinical guidelines on pulmonary rehabilitation and CO PD
Guideline or statements Outcome measures of health related quality of life, 
health status, functioning, ADL (Activities of 
Daily Life)
Global Initiative for Chronic Obstructive Lung 
Disease
The St. George's Respiratory Questionnaire 
(SGRQs).
The Chronic Respiratory Questionnaire (CRQ).
The medical outcome study short form (SF36).
The primary care evaluation o f  mental disorders 
(PRIM EM D) patient questionnaire.
The jo in t American thoracic Society/European 
Thoracic Society on Pulmonary Rehabilitation.
The St. George's Respiratory Questionnaire 
(SGRQs).
The Chronic Respiratory Questionnaire (CRQ). 
Physical activity monitors.
American Association o f  cardiovascular and 
pulmonary rehabilitation
The St. George's Respiratory Questionnaire 
(SGRQs).
The Chronic Respiratory Questionnaire (CRQ).
Ferrans and Powers quality o f  life pulmonary 
version.
The British Thoracic Society statement on pulmonary 
rehabilitation.
The medical outcome study short form (SF36).
The Quality o f  Well Being Scale (QWB).
The Psychosocial Adjustment to Illness Scale-Self 
Report (PAIS-SR).
The St. George's Respiratory Questionnaire 
(SGRQs).
The Chronic Respiratory Questionnaire (CRQ).
The pulmonary functional status scale.
The pulmonary functional status Dyspnea scale.
The London Chest Activities o f  Daily Living 
Questionnaire.
The M anchester Respiratory Activities o f  Daily 
Living questionnaire.
Physical activity monitors.
The General Practice Airway Groups Opinion on 
pulmonary rehabilitation.
Lung information needs questionnaire (LINQ).
The Hospital Anxiety and Depression scale (HAD).
The Clinical COPD Questionnaire (CCQ).
The St. George's Respiratory Questionnaire 
(SGRQs).
The Chronic Respiratory Questionnaire (CRQ).
NICE clinical guidelines for COPD No recommendations or reports on implementing 
outcome measures.
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Guideline or statements Outcome measures of health related quality of life, 
health status, functioning, ADL (Activities of 
Daily Life)
Consultation on a Strategy for Services for Chronic 
Obstructive Pulmonary Disease (COPD) in England.
The COPD Assessment Test (CAT).
Reported by clinicians The COPD Assessment Test (CAT).
The M edical Research Council Dyspnea scale 
(MRC).
The Hospital Anxiety and Depression scale (HAD).
The Clinical COPD Questionnaire (CCQ).
The St. George's Respiratory Questionnaire 
(SGRQs).
The Chronic Respiratory Questionnaire (CRQ).
7.4 Selection of relevant outcome measures for review
Outcome measures reported in the guidelines were further reduced using the above 
exclusion criteria. Table 4 provides the reference and a basic description of the selected 
outcome measures. Selected outcome measures were reviewed based on the quality 
standards of outcome measures reviewed in the previous section. The aim is not to identify 
all problems in each outcome measure, but to use them as examples on problems in existing 
outcome measures.
Published reports on the development of the questionnaires were also reviewed. It is 
very difficult to evaluate the development process and the structure of the questionnaire 
separately. This is because problems in development would preclude the resultant structure 
from fulfilling the criteria of "a scientific measuring scale" and the quality standards of "an 
appropriate measurement tool".
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7.5 Evaluation of existing outcome measures
Quality standards of outcome measures should be evaluated considering contextual 
factors, that is the setting and the population within which the measurement tool will be 
implemented. Evidence of quality should be logical based on scientific and theoretical 
inferences that preserve clinical meaning.
7.5.1 Measurement at the level of the individual
Existing outcome measures have been tested in a group of individuals. Their 
appropriateness for evaluating change within a specific individual patient has not been 
critically studied (ATS/ERS 2004). Measurement at the level of the individual inflicts high 
demand for reliability and responsiveness (Kelly et al. 2005).
7.5.2 Measurement of individualised outcomes
During the process of development items for the questionnaires reviewed were 
generated from qualitative work involving patients. Ideally this should result in items that 
are relevant to the individual patient. However, the reduction of items by experts, such as in 
the CCQ, or using statistical models, such as in the LADCL, implies that the decision on 
the importance and weighting of items were not individualised. Ideally the generation of 
items, the reduction, and the weighting should be performed by patients. Experts and 
clinicians should be consulted during the design of the theoretical framework of the 
construct being measured and to ensure scientific and clinical knowledge underpinning the 
resulting measurement tool (McDowell 2006).
The authors of the LADCL reported robust criteria for reducing items. However, one 
of the criteria for excluding items was association with demographic variables such as age. 
A caveat here is that COPD is a complex disease that develops later in life. Therefore, 
aging is an important factor that limits functional performance. It might be suggested that 
because functional performance is a multidimensional experience, it would be meaningless 
to the patient to exclude items that are associated with a certain age. There is no evidence 
that the items excluded are only influenced by age and not influenced by COPD.
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Another criterion for item reduction in the LADCL was the exclusion of items that 
showed poor repeatability on repeat testing. It is suggested that due to the continuously 
changing functional status in people with COPD, this might has resulted in the removal of 
the more responsive items.
An important point to consider is that irrelevant or inappropriate items create burden 
on the patient. This could lead to lack of willingness on the side of the patient to respond in 
a focused and honest way adversely affecting the quality of resultant measurement (Kelly et 
al. 2005).
7.5.3 Feasibility
Feasibility is described in terms acceptability by patients and clinicians, ease of 
administration and scoring, and resources required for administration. Resources include 
time, cost, required equipment, and professional involvement. Questionnaires such as the 
PFSS and the PFSDS are very lengthy and less applicable in clinical setting. Therefore, a 
modified shorter version of both questionnaires was developed. An important question here 
is about the methods of item reduction. Only items that are problematic, relevant to the 
patient and have the potential to improve with the intervention administered should be 
retained (McDowell 2006). Unfortunately existing outcome measures have used strategies 
to reduce items, such as statistical models and expert opinions, which are unlikely to ensure 
the preceding three requirements (Lakeman 2004).
Another important point to consider is that feasibility has been described in terms of 
time required to complete the measurement. More importantly and less frequently discussed 
is the value of time required for measurement. This should be described in terms of the 
benefits the patient gain from the measurement process (Lakeman 2004). Existing outcome 
measures provide information that is more suitable for administration and managerial 
decisions not to inform clinical decision making. That is they do not inform the process of 
care. The value of measurement in informing the process of care is indicated by the 
meaningfulness of the measurement to the clinician and the patient. This is reviewed next.
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7.5.4 Meaningfulness
This quality requires ensuring the meaningfulness of measurement. This is achieved 
by ensuring the following: first, the scoring system provides singular measurement. This is 
measurement that is unambiguous in the sense that it means one thing and one thing only 
(Kazdin 1999). Second, the meaning of measurement is maintained under any 
transformation or statistical and mathematical operations.
Scoring systems of existing outcome measures have resulted in the loss of the 
meaning of measurement. Hinds et al. (2002) states:
"It is possible to have a reliable and valid measure o f a clinical phenomenon but to score 
the measure in a way that inaccurately represents the clinical meaning o f the measured 
phenomenon" (Hinds et al. 2002, P: 345).
Three main problems were identified in the literature when using inappropriate 
scoring. The first is providing ambiguous measurement, the second is the dilution or the 
exaggeration of meanings on individual scales (Hinds et al. 2002). The third is that patients 
with different patterns o f responses might have the same total score, resulting in initiating 
similar clinical actions for two different clinical profiles (Greenfield and Nelson 1992).
Next are examples of scoring systems of existing outcome measures that lack 
meaningfulness as a result of the scoring systems.
7.5.4.1 Example of scoring systems that resulted in ambiguous measurement
Unambiguous measurement is achieved by addressing the third logical requirement of 
measurement and the first requirement of the theory of measurement and measuring scale. 
These are "defining categories of the construct so that they are mutually exclusive and 
exhaustive" and "The rule for assigning numeral should be made explicit" respectively.
An example is provided using the scoring system of the MRADL (Figure 10). The 
instructions on scoring the MRADL indicate that: "much more slowly; quite a lot more 
slowly; most of the night; for 1-2 hours" are scored 0, and "a little more slowly; for 1/2 
hours; not at all more slowly" are scored 1. This scoring system implies that there are three 
presumably different categories given the same score, resulting in three possible meanings 
for 0 and three possible meanings for 1.
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Figure 10 Exam ple o f two questions from the M RADL
7.5.4.2 Example o f scoring system that resulted in the dilution or exaggeration o f clinical 
problems
An example is provided using the LCADL (Figure 11)
Figure 11 H ypothetical scoring o f the LAC DL
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Following the authors instructions the above questionnaire is scored as a total of 44. 
While the authors did not define a unit of measurement it is not known what this 44 means. 
The presence of two score 4 and 5 coded to give the same meaning which is the inability to 
perform the activity it is difficult to decide on the score that represents maximum disability. 
However provisionally this will be set as 5 multiplied by 15 items and the maximum
13disability is represented by a score of 75 Assuming a maximum score of 75 representing 
maximum disability resulting from breathlessness interfering with functional performance, 
then this patient has approximately 60% loss of function as a result of breathlessness, which 
is suggested to have a significant impact on daily life.
Looking at the Reponses to individual items, it is recognized that within the same 
domain "self-care" the level of disability varies considerably. That is the patient has no 
problem drying self "20 % loss of function", but gets very breathless putting shoes on "80 
%loss of function", and is unable to wash hair "80% loss of function". This suggests that a 
total score of 44 "60% loss of function" has resulted in the dilution of 2 clinical problems 
and the exaggeration of one clinical problem.
7.5.4.3 Example o f scoring system that results in one score for two different patterns o f
clinical problems
A theoretical example on this problem is provided from the CCQ and presented in (
Figure 12). The figure shows that both patient Q  and ©  have a total average score of
3.3 indicating moderately poor control of clinical problems as indicated by the scoring
instructions of the CCQ. Patient 0  reported being short of breath doing physical activities
many times while patient ©  reported experiencing that almost all of the time. Patient @ 
reported coughing and producing phlegm a great many times and many times respectively,
while patient ®  reported this to happen a few times. This shows that the two patients were
having different clinical problems. The predominant symptom that patient ©  has is
breathlessness on exertion, while the predominant symptoms that patient ©  have appear to 
be coughing and producing phlegm.
Ij The author is aware that these are not interval level measurement and therefore should not be summed to 
generate a total score; however this hypothetical example follows the instructions o f  calculating 
the score o f  the questionnaire.
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The pattern of functional limitation is also different in the two patients. Patient 0  reported 
being slightly limited with moderate activities but totally limited is social activities. On the
other hand patient G  reported being extremely limited in moderate physical activities, but 
moderately limited in social activities.
While one might argue that one presentation or the other does not make sense. In 
practice the patient might give thousand reasons for contradicting scores, and the clinician 
could only accept. This is because the scale is unscientific and scoring could not be falsified 
empirically by observation or experimentation. Giving patients such a scale means that 
clinicians have to accept patients scoring as the ultimate truth. Else they are limited in 
interpreting the score, and identifying the type of clinical problems that limit the patient's 
functional performance.
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Figure 12 Tw o clinical profiles on the CCQ with the sam e average score
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7.5.5 Validity of measurement
Unfortunately the authors of existing outcome measures did not provide a logical 
argument to support evidence of the face and content validity of the questionnaire. 
Involvement of experts was limited to generating and reducing the items and not 
systematically reviewing the structure of the questionnaire. Judgment of face and content 
validity should be based on the adequate representation of the construct being measures in 
the items of the questionnaire. This could not be achieved without providing a 
comprehensive definition of the construct and the factors influencing it (Hinds et al. 2002).
7.5.5.1 Defining the construct
Only the authors of the clinical COPD questionnaire provided a definition of the 
construct being measured (Molen et al. 2003). Appropriate definition of the construct and 
the factors influencing the construct is essential to ensure the face and content validity of 
the measurement tool. However, existing outcome measures failed to account for factors 
influencing the construct. For example the London Activity of Daily Living Questionnaire 
and the Pulmonary Functional Status Dyspnea Scale are concerned with impact of 
dyspnoea only on activities (Garrod et al. 2000).
Failure to provide a definition of the construct measured questions the construct 
validity of existing outcome measure. Moreover, it has detrimental impact on the meaning 
of measurement. An example from the MRADL is provided. MRADL was designed to 
assess "respiratory disability". However, without providing theoretical or logical evidence, 
the construct was reduced to asking questions about breathlessness and activities o f daily 
life. Moreover, the questions were not designed appropriately to reflect how breathlessness 
impacted the performance of activities of daily life.
The MRADL lists a number of ADL and asks the patients to respond to each listed 
activity by choosing one of the following four categories: not at all, with help, alone with 
difficulty, alone easily. The design of the questions has two main problems. First it does not 
account for other factors that might influence the activity other that breathlessness. This is 
particularly important in a disease like COPD where impairments are multiple and many 
factors influence the performance of activities. Second it lacks uniqueness in the sense that 
each question asks about two things. That is whether the patient is independent in
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performance indicated by the response "with help". And the difficulty of performance 
indicated by the responses "Alone with difficulty and alone easily".
Another important issue is the appropriateness of items “contents of the outcome 
measure” to provide valid clinical information. This is presented with an example from the 
PFSS (Figure 13)
Figure 13 An item from  the PFSS
2. How much difficulty do y ou have getting dressed?
(0)
Carnot do tIn­
activity because
of otlier health 
problems
(1)
C aiuiot do this 
activity 
because of my 
lung problem
(2)
Extreme
difficulty
(3)
Moderate
difficulty
(4)
A
little difficulty
(5)
No
difficulty
□ □ □ □ □ □
This item provides three potential functional states: the patient is unable to perform 
the activity, the patient performs the activity with difficulty, and the patient has no problem 
performing the activity. Considering these information in the clinical context, the clinician 
would not have sufficient information to answer the following clinical questions: what is 
preventing the patient from performing the activity? What is the type of difficulties 
interfering with activity? Could these difficulties be eliminated with the type of treatment 
provided? This suggests that the information this item provides is invalid for informing 
clinical decision making.
7.5.5.2 Identification o f the construct "Qualitative or Quantitative"
Adequate identification of the construct is in three parts. First is providing evidence 
of whether the construct quantitative or qualitative. Second is to operationally define the 
construct. Third is to define categories of the construct so that they are mutually exclusive 
and exhaustive. Existing outcome measures are all based on the assumption that the 
construct measured is quantitative without providing convincing evidence. Evidence that 
the construct is quantitative is provided by showing that the construct fulfils the Holder's 
axioms (Michell 1997).
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An example is provided from the Chronic Respiratory Questionnaire (CRQ). The 
authors state the aim of the questionnaire as:
“A measure o f quality o f life for patients with chronic airflow limitation designed for  
use in clinical trials” (Guyatt et al. 1987b, P: 773).
Quality of life is a qualitative constructs, and items for the questionnaires were 
derived from literature review and qualitative interviews with patients. However, the 
scoring results are presented as mean score per dimension which is obtained by dividing the 
total score in each dimension by the number of questions in that dimension. Addition and 
division could not be applied to the level of data presented in the questionnaire.
Failure to recognise the qualitative structure of the construct “quality of life”, which 
is the first logical requirement of measurement, or using statistics appropriate to the level of 
data presented, precluded the fulfilment of the theory of measurement and measuring 
scales. The authors assumed that the 7 point scale they used to incongruously quantify 
items on the questionnaire is interval. This is not compatible with structure of the construct 
being measured which is qualitative. Moreover, the arrangement of the categories in the 
questionnaire is at best a classification of domains rather than being arranged in a hierarchy 
that poses the attributes of asymmetry, connectivity and transitivity, to create an 
isomorphism with an ordinal mathematical structure.
In its current structure the CRQ should be used as an assessment tool that provides an 
extensive list of items representing various domains of the construct “quality of life “ and 
classify them into four domains. It fails to fulfil the three scientific requirements of the 
theory of measurement and measuring scales.
Another example is presented in the structure of the PFSS and the PFSDS. Both use a 
likert type scale for measuring functional status assuming an interval level of measurement 
without providing evidence of an isomorphism between the structure of the construct 
“functional scale “ and interval level mathematical structure. No definition of the unit of 
measurement was provided.
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Current reports on the validity of existing outcome measures focus on providing 
statistical evidence of significant negative and positive correlations with existing outcome 
measures. This practice reduces the ideally complex iterative process of providing evidence 
of face, content, and constructs validity to a statistical index. Accepting the fact that “this is 
what everybody does”, it still raises the question of the translational validity of the 
generated index. That is how “truly random” and representative is the sample, within which 
the correlations where studied, of the individual patient in clinical practice (Kelly et al. 
2005). This also applies to the type of evidence provided for the reliability and the 
responsiveness of outcome measures (Kelly et al. 2005).
7.6 Summary
This review suggests that existing outcome measures of functional performance fail 
to fulfil the logical requirements of measurement, the standards required by the theory of 
measurement and measuring scales and the principles of measurement in clinical settings. 
Evidence of the psychometric quality of existing outcome measures is performed at the 
level of the group in isolation of the clinical context.
This has resulted in meaningless measurement that is incapable of informing clinical 
decision making and improving the process of care for people with COPD attending PR. 
This mandates a search for a measurement system that fulfil the preceding requirements 
and quality standards, and to develop new functional performance indicators for people 
with COPD attending PR. Next is a discussion of the conceptualisation phase.
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Discussion of phase 1: "Conceptualisation"
The commonality of risk factors across most chronic conditions, such as COPD, 
asthma, diabetes, heart disease and stroke, as well as aging create complex cases with many 
older patients living with two or more chronic conditions (Department of Health 2004). 
This has a significant impact on the quality of life of individuals with chronic conditions, 
and their families (Department of Health 2010c). This highlights two important 
specifications of an appropriate outcome measure. First, it should be multidimensional to 
account for the multifactorial impact of the co-existence of multiple co morbidities. Second, 
the significant impact on quality of life suggests that the outcome measure should consider 
the measurement of constructs that constitute the dimensions of quality of life.
One proposed model of health care for chronic conditions that embrace the notion of 
enhanced recovery and facilitated early discharge, as well as high quality care is the 
integrated health care model. The integrated health care model places the patient at the 
heart of the process of care, and shifts the mode of delivery form “one professional” 
delivering care for “all”, to a system where all health professionals and social services 
integrate to deliver care to the “one”. The integrated care model responds to the changes in 
the needs for care, resulting from the complex cases created by the aging population with 
multiple chronic conditions (Lloyd and Wait 2005). Lloyd and Wait (2005) Stated:
“Integrated care seeks to close the traditional division between health and social 
care. It imposes the patient’s perspective as the organising principle o f  service delivery and 
makes redundant old supply driven models o f care provision. Integrated care enables 
health and social care provision that is flexible, personalised, and seamless. ” (Lloyd and 
Wait 2005, P: 7).
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The integrated care model ensures that when the patients are discharged, they are 
fully supported in the community. In the chronic conditions, early discharge requires 
establishing patients’ safety as well as the ability to cope and take charge of the 
management of the disease. Therefore, patients should be empowered by the knowledge 
and the tools that enable them to make decisions and take control over their own care. 
Patients should be assured that they are fully supported by the services at the community 
(Lloyd and Wait 2005).
However, this model of care delivery has resulted in the design and the delivery of 
complex interventions with multiple components. This mandates a thoughtful consideration 
to the evaluation of the process and outcomes of care to ensure the quality of care provided 
(Rosen et al. 2007). Outcome measures of such complex interventions should able to detect 
small changes that might take long time to develop (Medical Research Council “MRC” 
2008). Outcome measures should be able to trace changes in the status of the individual 
patient by providing informative data about when the patient has reached the maximum 
potential to improve and could be discharged. Moreover, these outcome measures should 
have the potential to be implemented in the community and be reported by the patient to 
facilitate self-management.
The phase of conceptualisation in this thesis provided the theoretical knowledge that 
resulted in a conceptual framework for the measurement of functioning in people with 
COPD. It also provided theoretical knowledge upon which the design and methods of the 
following phases were based. Hinds et al (2002) suggested that a conceptual analysis of a 
clinical phenomenon identifies the dimensions of the phenomenon, and the personal and 
contextual factors influencing it. This can provide valuable indications of what dimension 
of the phenomenon should be measured and how to measure it (Hinds et al. 2002).
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The conceptual analysis resulted in identifying functional performance as an in 
important outcome of pulmonary rehabilitation. Functional performance was defined as:
"the physical, psychological, social, occupational, and spiritual activities that people 
do in the normal course o f their lives to meet basic needs, fulfil usual roles and maintain 
their health and wellbeing" (Leidy 1994, P: 198).
It is important to highlight the fact that existing reports on the development of 
measurement tools of functional outcomes of PR for people with COPD lacked adequate 
conceptualisation. Guyatt and Kirshner (1985) ascertained that developing outcome 
measures of quality of life should start with appropriate definition of the construct to be 
measured. It is argued that quality of life is a multidimensional construct, and a 
standardised definition of it does not exist. Therefore, it is important that the 
conceptualisation is not limited to defining the construct but should extend to include the 
theoretical underpinnings of the disease and the intervention, and the models describing the 
construct. Conceptualisation should provide specifications that guide following phases of 
the development.
An important point that emerged during the review on the conceptualisation 
underpinning existing outcome measures of functioning is whether to measure symptoms or 
the impact of symptoms on activities.
Guyatt et al. (1993) suggested that symptoms should be measured separately in order 
to understand the dynamics between performance of activities and symptoms. The question 
is whether we could exclude the symptoms or the impact of symptoms when assessing 
performance in people with COPD. In the review of functional performance instruments 
performed by Stull et a l (2007) certain questions enquire about “ability” by asking “how 
limited were you, or how difficult is it for you to do? or have you had difficulty?”. In this 
type of questions the assumption is implicit that the source of limitation is symptoms. Other 
questions ask "does your health now limit?” the use of the word health is an ambiguous 
replacement for symptoms. The SGRQ directly enquire about the impact of symptoms on
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the activity by asking questions like “how your activities may be affected by your breathing 
problem?”
It is clear that measurement of functional performance is isolation from the impact of 
symptoms is impossible particularly in patients with COPD, where the main factor limiting 
performance is dynamic hyperinflation resulting in breathlessness (Eisner et al 2011). It 
might be suggested that it would be more appropriate to measure changes in functional 
performance considering symptoms as an influencing factor.
Another problem in the conceptualisation underpinning existing outcome measures is 
that it provided no heed to the theory of measurement and measuring scales Figure 14, and 
to the quality standards of measurement in clinical settings. This has resulted in outcome 
measures that contravene the theory of measurement and are inappropriate for use in 
clinical settings. Evidence that existing outcome measures do not fulfil the requirements of 
the theory of measurement and measuring scales was provided with examples in “chapter 2/ 
section 3”.
Existing outcome measures were developed based on a fallible assumption that the 
construct being measured is quantitative. This has resulted in the incongruous use of 
interval or ratio structure to quantify a qualitative phenomenon. Moreover, even when the 
correct mathematical structure was used, the theory of measurement was contravened by 
using inappropriate statistics and mathematical operations. This has resulted in the loss of 
meaning of measurement particularly at the level of the individual.
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Figure 14 A them atic presentation o f the theory o f m easurem ent and m easuring scales
Logical requirements of measurement:
identifying whether the construct is 
qualitative or quantitative.
• defining the construct and factors 
influencing it,
1 exclusive and exhaustive defmiton of catgories.
Qualifiers o f measurement: 
Ensuring meaningfullness.
' Defining an arbitrary unit of measurement.
• Appropriately use 
numerals or numbers on the scale depending on the 
level of the measurement
Scientifc standards of 
measurement:
4 The rule for assigning 
numeral should be made 
explicit.
•  Identifying the level o f 
m easurem ent and the
m athem atica l properties o f 
th e  resulting scale.
•  The use o f appropriate  
m athem atica l and statistical
operations.
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Hinds et al. (2002) stated, that measurement should reflect the theoretical 
underpinnings of the construct being measured. This implies that the nature of the 
phenomenon whether it is qualitative or quantitative determines the mathematical structure 
that can be appropriately used in measuring the phenomenon, and the mathematical 
operations that could be performed on the data generated from the measurement. The 
phase of conceptualisation resulted in a theoretical framework that will guide the next two 
phases: development and clinical testing. This is presented next.
8 The Theoretical framework
The theoretical framework for this thesis is based on the following knowledge that 
emerged from the phase of conceptualisation:
• Our knowledge about COPD is incomplete. Therefore, the patients’ lived 
experience of the disease and the clinicians’ experiences and observation, constitute 
integral components of developing a new outcome measure. This is to ensure that 
the resultant outcome measure is underpinned by sound theory and clinical 
knowledge.
• The outcome measure should be informative to the patients, the clinicians, and the 
managers.
• An outcome measure informative to the patient should be patient reported. The 
items should be relevant and reflect the individual’s experience of functional loss. 
The language and structure should be understood by and acceptable to the patient. 
Patients should be involved in generating the items, the categorisation, and the 
formulation of the codes of the measurement tool.
• An outcome measure informative to the clinician should facilitate clinical reasoning 
and clinical decision making. It should provide measurement that supports evidence 
based decisions about treatment provided, and changes implemented in treatment.
• An outcome measure informative to the managers should support the decisions on 
the quality of care delivered at the clinical department, the cost implications and the 
commissioning of resources.
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• Goals of treatment should be negotiated rather than imposed, to ensure that the 
outcomes measured are individualised, meaningful to the patient and the clinician 
and clinically significant.
• PR is a multidisciplinary complex intervention designed to address the 
multidimensional functional limitations and participation restrictions resulting from 
COPD. This requires the use of multidimensional outcome measures. This is not 
attainable without adequate understanding of the factors influencing functional 
limitations and participation restrictions in people living with COPD.
• PR is designed to address the progressive functional limitations and participation 
restrictions “disability” resulting from COPD. This requires the use of an outcome 
measure that traces changes, and lack of changes, in functional performance. This is 
not attainable without adequate understanding of the development of functional loss 
in people living with COPD.
• The theory of measurement and measuring scales and the principles of measurement 
in clinical settings should provide the basis for the development and the evaluation 
of clinical outcome measures.
The next phase is a development of a new outcome measures based on the theoretical 
framework identified during the conceptualisation. The first chapter of the next phase is a 
review of a valid measurement system that was located in the literature on stroke 
rehabilitation, and the development of new indicators for pulmonary rehabilitation based on 
that system.
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Phase 2: Development of “TELER" function 
indicators
Chapter 3: The selection of a method o f measurement “TELER”. 
Chapter 4: Item selection, reduction and scaling.
Chapter 5: item calibration and validation
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Overview of phase 2:"Development"
The previous critical review of the literature identified the need for developing a new 
outcome measure of pulmonary rehabilitation that measures clinically significant changes 
in "functional performance". Therefore, the aim of the second part of this thesis is to 
develop this outcome measure. Following adequate conceptualisation of the construct, the 
process of development should start by the selection of an appropriate method of 
measurement14. The method of measurement should fulfil the following:
• The specifications of an outcome measure of functional performance for people
with COPD following PR. These are: multidimensional, measure maintenance of 
effect, traces changes and lack of changes in functional performance, individualised, 
patient reported, informative to the patient, the clinician, and the managers.
• The requirements of the theory of measurement and measuring scales.
• The quality standards of measurement in clinical settings.
• The selection of the items of functional performance that should be measured is
indicated by the patients’ needs and the theoretical underpinning of the intervention. 
The steps of the process of developing the new outcome measure are based on the 
literature of developing outcome measures of quality of life. This is because 
functional performance was identified as an aspect of functioning, which is an 
integral component of quality of life.
The following steps are involved in constructing a measurement scale (Kirshner and 
Guyatt 1985):
1. Selection of a method of measurement.
2. Identifying clinically significant outcomes and the factors influencing them.
3. Selection of the item pool and item reduction.
4. Item scaling “categorisation and calibration”.
14 . Appropriate was defined in the literature review as “fit for purpose” , an appropriate method o f  
measurement ensures the usefulness o f  the measurement scale and the measurem ents generated 
by such scale.
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5. Determination of usefulness.
Kirshner and Guyatt (1985) suggested that the reliability, validity and responsiveness 
of the outcome measure should be ensured during the development.
An overview of the process of the development of functional performance indicators 
and methods used is presented in Figure 15. A detailed description of the methods used is 
provided in relevant chapters on each step.
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Figure 15 A diagram  representing the stages o f  developm ent o f T ELER  function indicators
l.Seiection of a method 
of measurment.
Methods:
S.Determination of 
usefulness, validity, and 
reliability.
Methods: 
Consensus methods 
"patients and experts". 
Clinical testing
Literature review.
Continuous theoretical review to ensure:
• Fulfilling the principles o f  measurement in 
clinical settings.
• Fulfilling the specifications o f an outcome 
measure o f functional performance for 
people with COPD attending PR.
•  Fulfilling the requirements o f the theory o f 
measurement and m easuring  scales.
2. Identifying clinically 
significant outcom es and 
the factors influencing 
them.
Methods:
Qualitative study
4. Item scaling "categorisation and 
calibration'.
Qualitativestudy
Steering groups and supervisory group 
discussions.
Consensus methods "patients and 
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Methods:
Qualitative study.
Mapping to  the ICF
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Chapter 3: The selection of a method of measurement "TELER"
9 The TELER method of measurement
The theoretical structure of a clinical phenomenon determines the appropriate 
mathematical structure to measure the phenomenon of interest (Narens and Luce 1986). 
Having defined "functional performance” and identified its qualitative nature, the next step 
is to decide on the best method of measuring it. Hinds et al. (2002) states:
"The selection o f the method by which the phenomenon is measured, depends upon 
the clinical meaning o f the measured phenomenon and the clinical interpretability o f the 
resulting score". (Hinds et al. 2002, P: 346)
To ensure that the clinical meaning is preserved, the selected method of measurement 
should fulfil the specifications of the outcome measure of functional performance identified 
in the literature review, the requirements of the theory of measurement and measuring 
scales, and the quality standards of measurement in clinical settings. Fulfilling the 
preceding requirements ensures that the resultant outcome measure is a useful, valid, 
reliable and responsive outcome measure of functional performance for people with COPD 
attending PR. A method of measurement that was located in the literature on stroke 
rehabilitation, and fulfils the preceding requirements is the TELER method of 
measurement.
9.1 Definition of the TELER method of measurement
The acronym TELER stands for Treatment Evaluation by the LeRoux method. It is a 
concept of evaluation developed during the 1980s by Le Roux. The use of the TELER 
method was reported in areas such as wound care (Grocott 1997), stroke rehabilitation 
(Mawson 1993) and acquired, non-progressive neurological damage (Alderman et al. 
1999). A common feature upon the three clinical areas is the complexity of the clinical 
condition and the intervention.
151
Phase 2: Development Chapter 3: The selection o f  a method o f  measurement “TELER”.
In COPD the complex nature of the clinical condition mandates the design of a 
multidisciplinary and an individualised interventions to target multiple and progressive 
disabilities. However, the evaluation of such complex interventions has been performed 
inappropriately resulting in the loss of information on the process of recovery at the level of 
the individual (Lakeman 2004). Evidence of the effectiveness of complex individualised 
interventions requires the implementation of high quality measurement methods.
The TELER method facilitates employing clinical expertise in the development of 
clinical indicators. This enables the clinicians to trace changes in functional performance at 
the level of the individual. The TELER indicators are used conjointly with a system of 
clinical note making. This aids the process of clinical decision making and changing the 
plan of treatment in response to clinical changes in patient’s status. The TELER software 
generates indices representing the effectiveness of care delivered to the patient. This 
facilitates the aggregation of data to provide informative inferences to managers about the 
quality of care delivered to a group of patients (Le Roux 2003).
The TELER method of note making provides a dynamic interface for recording 
clinical data. However, the completion of the TELER form requires the explicit use of 
formal and informal clinical knowledge. Clinical knowledge ensures that the appropriate 
indicators are used for the patient, and the deteriorations and the improvements are detected 
and acted upon without a delay (LeRoux 2003).
9.2 The structure of TELER
TELER has two components, the TELER method of clinical note making and the 
TELER method of measurement; the TELER indicator. The method of clinical note making 
uses a form that enables recording clinically significant information in a systematic manner. 
The form provides information such as the number of visits, the goals of treatment “in 
terms of the indicators titles” relevant to the patient, treatment plan, a record of changes and 
no changes on the TELER indicators, and indices representing the quality of care delivered 
to the patient (LeRoux 2003).
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The TELER indicator is a six point ordinal outcome measuring scale that traces 
changes and no changes in different types of problems. Of interest to this thesis are 
functional problems. The TELER indicator has 6 reference points coded with numerals 0,1, 
2, 3, 4, and 5. The title of the indicator identifies the goal of treatment (LeRoux 2003).
Code 0 denotes a problem that is relevant to the patient and is amenable to change 
with the proposed intervention. Code 5 denotes the resolution of the problem in terms 
specific to the population in question. For example in people with COPD the full recovery 
of the functional problem is not attainable due to the limitation imposed by functional 
capacity as a result of persistent physiological impairments (Leidy 1994). Therefore code 5 
represents the optimum possible improvement within the limit of persistent impairments. 
The remaining codes represent intermediate outcomes of the process of recovery. In order 
to provide a better understanding, the concept of TELER is reviewed and its relevance to 
the evaluation functional performance is highlighted.
9.3 The concept of TELER
“TELER” is based on the concept of using clinically significant change over 
clinically significant time periods as a measure of effective and efficient intervention 
(Mawson, 2002). TELER measures changes in the impact of symptoms on functional 
performance, rather than amount of symptoms (LeRoux 2003).
The TELER method is based on the following set of assumptions:
• The essential purpose of care is to induce or prevent change.
• The care provided must be specific to the patient.
• The care delivered must be grounded in theory.
• Change or lack of change occurs in clinically significant steps over clinically
significant period of time.
• Change or lack of change can occur spontaneously, and the model for spontaneous 
change is constrained random walk.
• Change or lack of change which is unlikely to have occurred by chance was 
induced.
153
Phase 2: Development Chapter 3: The selection o f a method o f  measurement “TELER”.
• The effects of clinically significant changes are not necessarily measurable on 
interval or ratio scale but can be observed.
9.4 TELER the “appropriate” method of measurement
The assumption that the aim of care is to induce or prevent change is in accordance 
with the central aim of pulmonary rehabilitation which is to improve functioning, and 
prevent progressive deterioration of functional status. The impairments, the activity 
limitations, and the participation restrictions resulting from COPD occurs progressively 
over a clinically significant period of time (Sabroe et al. 2008). This suggests that the 
reversal of the impact of the disease or the prevention of further loss as a result of the 
intervention would occur in clinically significant steps over clinically significant periods of 
time. The main purpose of measurement in rehabilitation setting is to trace changes in 
clinical and functional status at the level of the individual (Duncan and Velozo 2007). In 
that sense TELER fulfils the specification of an outcome measure of functional 
performance by tracing change and lack of change over a clinically significant period of 
time.
One of the assumptions of TELER is that the treatment provided to the patient should 
be underpinned by the theoretical and clinical knowledge. This includes the measurement 
of the outcomes of treatment. The formulation of treatment goals should be based on 
patients’ needs and clinical knowledge of the outcomes amenable to change with the 
treatment delivered. Moreover, theories of the intervention and the clinical knowledge 
enable the description of the process of recovery as a result of the intervention, and the 
definition of indicator codes that have face validity. Clinical knowledge ensures that the 
definition of codes fulfil the requirements of the theory of measuring scales. That is the 
codes have the properties of transitivity, connectivity and asymmetry (Stevens 1946).
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TELER mandates the use of explicit clinical knowledge in the definition of the 
indicators. This ensures that the definitions are multidimensional and account for all 
possible factors influencing functional performance. TELER requires that care must be 
specific the patient. This is relevant to pulmonary rehabilitation programmes which are 
designed to meet the needs and the abilities of the individual patients. Pulmonary 
rehabilitation is defined as a multidisciplinaiy individualised intervention (BTS 2001). This 
assumption also fulfils one of the quality standards of measurement in clinical setting 
which requires the measurement of individualised outcomes.
The definitions of the codes of the TELER indicator use a language that can be 
understood by the patients, the carers, the clinicians and the mangers. The title of the 
TELER indicator identifies a treatment goal that is relevant to the patient. The goal of 
treatment is mutually selected by the patient and the clinician rather than imposed. 
Therefore, the TELER indicator is informative to the patient, and could be reported by the 
patient. Moreover, it has the potential to be used as a self-management tool, because it 
traces changes in functional performance using a language meaningful to the patient. The 
outcome of measurement using TELER could be easily interpreted by the clinicians and the 
managers. This is because each code on the indicator should be unique and measures one 
thing and one thing only.
The TELER form creates a critical link between clinical measurement on the 
indicators and the care delivered to the patient. It is informative to the clinician because it 
facilitates the process of clinical reasoning, evidence based treatment, and the justification 
for the implementation of a change in the treatment plan. The TELER indices provide 
quantitative summary of the treatment delivered to the patient. This informs the mangers to 
make appropriate decisions on the quality of care delivered and the use of resources 
(LeRoux 2003).
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An important point to highlight is that in clinical practice the treatment is delivered to 
patients with the belief that up to the knowledge of the clinician this is the best available 
evidence based treatment. Therefore, if using the TELER form the clinician could identify a 
correspondence between an observed pattern of change or lack of change, this could be 
taken as evidence that the care provided was effective. However, it remains unknown what 
aspect of the multidisciplinary care provided to the patient has resulted in the occurrence of 
change. An observed pattern of change or lack of change is unlikely to have occurred by 
chance if it is statistically significant. Nevertheless, accurate identification of the cause of 
an observed pattern of change or lack of change is only possible when TELER is used in an 
appropriate research design.
TELER fulfils the requirements of the theory of measurement and measuring scales 
(Stevens 1946). This is because it defines an arbitrary unit of measurement “a unit of one 
clinically significant change”. It uses an ordinal mathematical structure to measure 
qualitative attributes; therefore it does not contravene the theory of measuring scales by 
imposing an interval or ratio scale on structures that are not quantitative. TELER uses 
numerals not numbers to define codes, and uses permissible statistics to analyse ordinal 
level data.
Definitions on the codes of the indicators are based on explicit knowledge of the 
disease and the intervention, and the incorporation of patients’ experiences of the trajectory 
of change in functional performance resulting from COPD. This ensures that TELER 
indicators are responsive to changes in functional performance. This documented trade off 
between responsiveness and reliability is not relevant to ordinal measurement scale (Roach 
2006). This is because unlike the interval and ratio scales the size of the unit of 
measurement is undefined. On interval and ratio level scales the reduction in the size of the 
unit to increase responsiveness results into reduced reliability. In the ordinal scale 
responsiveness is increased by the use of sound knowledge in defining the codes, while 
reliability is ensured by improving documentation, and training of the patients and 
clinicians in undertaking the measurement (LeRoux 2003).
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9.5 Summary
Theoretically the TELER method of measurement appears to fulfil the requirements 
of an "appropriate" outcome measure of functional performance. Based on the assumptions 
of TELER it fulfils the following:
1. The identified specifications of an outcome measure of functional performance for 
people with COPD attending PR.
2. The requirements of the theory of measurement and measuring scales.
3. The quality standards of measurement in clinical setting.
However, TELER "function" indicators for use in people with COPD attending PR, 
currently does not exist. Therefore, the next three chapters are concerned with the 
development of these indicators. Whilst the validity, reliability and responsiveness of the 
indicators should be ensured during the process of development (Kirshner and Guyatt 
1985), evidence of the usefulness of the indicators could only be provided by clinical 
testing of the indicators in clinical setting. The next chapter describes the process of 
generating the indicators.
157
Phase 2: Developm ent Chapter 4: Item selection, reduction and scaling.
Chapter 4: Item selection, reduction and scaling
10 Qualitative exploration of patients’ perspective
When developing a new measurement tool, the decision on what should actually be 
measured is a mutual decision between the clinician and the patient. The clinician has the 
clinical knowledge to suggest what clinical outcomes could be influenced by a particular 
intervention. The patient is the most legitimate decision maker on what is problematic and 
what is important to them (Jones et al 2005).
As acknowledged earlier the measurement of clinical significance should be driven 
by adequate definition of clinically significant outcomes and the factors influencing them. 
This would guide the development of a valid outcome measure that adequately reflects the 
multidimensionality of clinical outcomes. The definition of clinical outcomes should 
include consultation of patients’ perspective on what constitutes a clinically significant 
outcome and the factors influencing the outcome (Kazdin 1999).
Moreover, during the phase of conceptualisation it was highlighted that due to the 
progressive nature of COPD, it is important to define the trajectory of change of the 
patients’ clinical outcomes. Clinical knowledge should be incorporated to define the 
continuum of the process of functional recovery. However, the current knowledge about the 
disease and the intervention is incomplete. Therefore, it is important to describe the 
development of functional loss or the recovery of function following PR, by reference to 
the experience of people living with the disease.
Having identified the trajectory of change in the functional problems, the next step 
would be to identify and categorise clinically significant changes to generate the codes of 
the measurement scale. The categorisation and scaling should fulfil the requirements of the 
theory of measurement and measuring scales (Kazdin 1999).
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10.1 Aims of the qualitative study
This qualitative study represents steps two, three, and four of the process of 
development of an outcome measure of functional performance. Specifically the aims are: 
identifying clinically significant outcomes and the factors influencing them, item selection 
and reduction, and item scaling “categorisation and calibration”.
1. Identify the functions “activities and participations” that constitute clinically 
significant outcomes, and the factors influencing functional performance 
“facilitators and barriers”.
2. Item selection and reduction: identify a set of functions "activities and 
participations", important to patients with COPD, which are expected to improve 
following PR.
3. Categorization: Describe the pattern of the development of functional loss 
“functional limitations and participation restrictions”. The description should be 
presented as successive steps between the maximum potential functional limitation 
and the maximum potential functional performance.
10.2 Objectives of the qualitative exploration
1. Explore the perspectives of people with chronic lung disease on the functional 
outcomes they want to achieve following pulmonary rehabilitation.
2. Describe the values and weightings people with chronic lung disease attach to 
certain functional activities of daily living.
3. Describe the dimensions of the experience of people with COPD during the 
performance of daily life functions.
4. Describe the process of the development of functional loss in people with COPD.
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10.3 Research questions
1. What are the functional outcomes people living with COPD want to achieve 
following pulmonary rehabilitation?
2. What are the functional activities of daily living identified as clinically significant 
by people with COPD?
3. What are the changes in the performance of daily life functions that result from 
living with COPD?
4. What are the factors influencing the performance of daily life functions in people 
with COPD?
10.4 Design of the qualitative exploration
A qualitative study using in depth semi structured interviews, focus group methods, 
and framework analysis methods.
10.4.1 Philosophical and methodological approach
The “approach ” within this thesis
This qualitative study is part of a larger PhD project concerned with the development 
of a new outcome measure of functional outcomes following PR in people with COPD. 
Therefore, it is important to highlight how this qualitative study and the knowledge 
expected to emerge from it relate to other components of the thesis.
First, it is perhaps useful to emphasise two key aspects of the context in which this 
qualitative study will be used. A primary influential factor is the nature of clinical research, 
where quantitative methods dominate the practice of scientific enquiry. The second factor is 
the epistemology of patient safety within clinical research that requires producing research 
evidence that has been developed using rigorous methods, that is valid and unbiased, and 
has wider application based on mathematical and statistical inferences (MRC 2006). This 
suggests that the clinical research paradigm does not lend itself to be fitted in a recognised 
school of qualitative research.
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However, three important realities should be recognised. First the clinical 
environment is not uniform and entails sophisticated human interaction between health 
professionals and the patients. Therefore, occasions occurred when quantitative research 
evidence failed to support clinical decisions or understanding (Higginson and Carr 2001).
Second, the growing epidemic of complex chronic conditions that is influenced by 
behavioural risk factors demanded a shift in the models of care delivery and the methods of 
evaluation. This shift requires the involvement of people experiences and perspectives to 
enhance the knowledge and understanding of clinical conditions (Lloyd and Wait 2005).
Third, the prevailing health care policy views patients as consumers of health and 
envision integrating health into social care (Department of Health 2006). Therefore, 
patients are placed at the centre of the process of care that is designed based on patients’ 
needs and demands (Department of Health 2006). This has amplified the need for the 
adoption of qualitative research methods in the clinical context.
Therefore, during this PhD the researcher has adopted a pragmatic approach that 
responded to the nature of the problems and research questions. The appropriate 
methodology for answering such questions was selected. This has resulted in the use of 
qualitative methods in response to the nature of questions that emerged during the phase of 
conceptualisation. However the data generated from the qualitative study will be used in the 
development of a quantitative outcome measure and test in clinical setting using 
quantitative methods.
The following sections therefore map the key parameters within which this qualitative 
study will be conducted.
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Ontological position
The researcher adheres most closely to what Hammersley (1992) describes as “subtle 
realism”. It is accepted that although truth exists independently of the individual’s 
subjective understanding, it is only accessible through respondents’ interpretation. 
However, it should be emphasised that respondents’ interpretation will be further verified 
and interpreted by the researcher. In relation to this PhD research it was identified during 
the phase of conceptualisation that knowledge about the progression of functional loss in 
COPD is incomplete.
COPD was identified as a heterogeneous disease (Mannino et al. 2002). Therefore, 
this qualitative study seeks to improve current understanding about the progression of 
functional loss in COPD. It is therefore accepted that diverse perspectives on the experience 
of functional loss would exist. However, this does not negate the possibility of the 
existence of an external reality about the pattern of progression that could be captured.
Epistemologicai position
The epistemologicai perspective of the researcher reflects the fact that the historical 
context is largely that of quantitative research. Therefore, the researcher adopts an approach 
that adapts the concepts of scientific enquiry to qualitative explorations. However, the 
researcher is also a proponent of a parallel adaptation of quantitative research methods. 
This is to accommodate the reality of clinical settings, where lack of standardisation and 
heterogeneous presentation is the standard. This is in line with the current MRC Guideline 
(MRC 2008) for the evaluation of complex interventions and the growing field of realistic 
evaluation (Pawson 2003).
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A key feature of the researcher perspective is objectivity and neutrality in the 
collection, interpretation, and presentation of the data. However, the researcher is aware 
that this could not be fully achieved. Particularly, due to the adoption of subtle realism that 
entails the co construction of interpretations of the participants and the researcher (Ritchie 
and Lewis 2003). The research adopts a constructive approach that seeks to synthesise 
clinical and theoretical knowledge with participants’ perspectives. The researcher relies on 
theoretical and clinical knowledge to interpret participants’ accounts. However, when there 
is lack of knowledge to verify certain accounts, particularly in relation to the experience of 
functional loss, the interpretations of patients are taken as the primary source of 
explanation.
Due to the complex nature of the co-construction of knowledge, the researcher 
recognises the importance of reflexivity in assuring the trustworthiness and credibility of 
the research findings (Lincoln and Guba 1985). Therefore, the researcher strives to ensure 
that findings are grounded in the data and not the researcher’s previous knowledge. This is 
further explained in the section on data analysis.
The approach of the researcher embraces aspects of interpretivism. This is reflected 
by emphasising the importance of understanding the perspectives of patients in the context 
of COPD and the circumstances of their environment and lives. Therefore, the researcher 
seeks to develop in depth understanding of the contextual factors influencing people’s lives. 
The researcher also emphasises the importance of the interpretation of findings in the light 
of clinical and theoretical knowledge, given these are clearly delineated from the views of 
participants. During the process of interpretation the researcher values the individualised 
experience, but seeks to identify and synthesise the accounts of a number of participants.
Finally, the qualitative approach used is both inductive and deductive in turn. The 
researcher identifies emerging themes and patterns derived from the exploration of 
participants’ perspectives. The data is then tested is subsequent data collection and analysis. 
The data is analysed to develop an increased understanding of patients’ perspective on 
functional loss, functional performance, and the factors influencing it.
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However, it should be noted that the qualitative exploration is guided by the 
theoretical and clinical knowledge that has influenced the decision of the selection of 
methods. Moreover, the data generated from the qualitative exploration will be synthesised 
with existing theoretical and clinical knowledge. This new knowledge will be used to 
validate the definition and the framework for the measurement of functioning developed 
during the phase of conceptualisation. This will be achieved through a deductive conceptual 
activity that uses evidence as the genesis of a conclusion (Ritchie and Lewis 2003).
10.4.2 Sampling methods
A sampling method was required that ensured the recruitment of a sample that was 
small enough in order to ensure in depth exploration of individual’s perspective without 
precluding the generation of original and rich data (Sandelowski 1995). The sample also 
needed to be large enough to ensure the breadth of people with different perspectives 
(Bowling 1997). Purposeful sampling was therefore adopted. This method allows for 
demographic heterogeneity and variation (Sandelowski 1995). It was proposed that the 
sample would be demographically heterogeneous in terms of gender, and age. People with 
varying degrees of severity of the disease "mild, moderate, severe" were recruited to 
achieve variation.
10.4.3 Research participants
10.4.3.1 Participants’ recruitment
Participants were recruited through self support groups in the community. These were 
"Breathe Easy” and “Breezers" in the South Yorkshire area. The study was first introduced 
at one of the monthly group meetings at a social venue. Participants’ information sheet was 
provided for people expressing interest in taking part in the study (Appendix B.l). 
Participants expressing interest were given a week to reflect on whether they wished to be 
interviewed. They were contacted again by the researcher a week after the first meeting. 
Participants who agreed to take part after the second part were given the opportunity to ask 
further questions about the study and were asked to sign an informed consent form 
witnessed by the researcher.
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10.4.3.2 Inclusion criteria
People considered candidates for pulmonary rehabilitation as described by The 
British Thoracic Society Standards of Care Subcommittee on Pulmonary rehabilitation 
(2001) were recruited. That is “patients with lung disease whose lifestyle has been 
adversely affected by chronic breathlessness.” (British Thoracic Society 2001, P. 829). A 
self report of diagnosis was accepted for inclusion in the study.
Only people who were able to give informed consent were included. The ability to 
speak and understand English was a requirement. This is because English is the language 
that the researcher could communicate in, and no translation was available due to time 
limitation. Moreover, the issue of language is important in the development of TELER 
function indicators. The aim of the researcher was to ensure that the description of the 
codes on the indicators is as close as possible to the language used by participants. This is 
to facilitate the use of indicators as a patient reported outcome measure. Moreover, the 
TELER method of measurement requires the selection of the words of the indicators 
carefully to ensure that they provide singular meaning and reflect the underpinning clinical 
knowledge.
10.4.4 Ethics issues related to the qualitative exploration
There were a number of ethical issues in interviewing people with COPD. The study 
was approved the Faculty Research Ethics Committee / Faculty of Flealth and Wellbeing - 
Health and Social Care Division -Sheffield Hallam University (Appendix B.2). Further to 
advice from the supervisory team, and by approaching NHS Research Ethics Committee 
members at an ethics training day, it was advised that no NHS ethics was required. This is 
because participants were approached through community support groups not through NHS 
staff or premises. Moreover, none of the participants included were currently attending PR 
program.
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All participants were given sufficient verbal and written information about the study 
(Appendix B.l). All participants completed an informed consent form (Appendix B.3). The 
researcher ensured confidentiality and informed participants about the methods used to 
ensure confidentiality. This included anonymysing transcribed reports and storing all data 
in a secured cabinet at the university premises and password secured university computer. 
Participants were informed the anonymous records of data will be shared with the 
supervisory team and direct quotes will be used in the research reports.
There was a potential that a participant might become distressed when discussing 
negative experiences related to the disease. Therefore, all participants where assured that 
they have the right to stop at any point and withdraw their consent for the use of data even 
after the interview or the focus group without giving a reason.
10.4.5 Methods of data collection
The process of data collection included two stages. The first stage included in depth 
semi structured interviews and the second stage included a focus group. A topic guide was 
used to facilitate discussion in the interview and elicit appropriate and relevant responses. 
The topic guide was developed based on the framework of the measurement of functional 
performance that was developed during the conceptualisation phase. The topic guide 
included four main sections, the first was personal history and the experience of diagnosis, 
the second was performance of daily life activities, the third was the management of 
activities, and the fourth about the expected outcomes of PR. It was piloted in an initial 
interview and minor changes were made.
However, following the third interview the wording of questions in the topic guide 
was changed. This is because it was felt that some words like goals and management were 
not comprehended adequately by participants. Other words like problematic were found to 
trigger negative responses and make participants feel uncomfortable; therefore these were 
avoided or replaced. Participants felt offended when asked about smoking history. This is 
because of the stigma of the self-inflicted disease. Therefore, this information was not 
elicited and left to the participant to bring it to discussion if they wanted. The final version 
of the topic guide is shown in (Appendix B.4)
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A different topic guide was used in the focus group (Appendix B.5). Questions 
focused on eliciting responses related to the specific type of activities influenced by COPD 
and the steps of the progression of functional limitations.
10.4.5.1 Stage 1: Semi-structured in depth interviews
The aim of the interviews was to generate in depth understanding of the perspectives 
of people with COPD on functional activities that are affected by the disease. Seven in- 
depth semi-structured interviews were conducted with people with COPD attending 
“Breezers”, and "Breathe Easy" self support groups. However, the data from the first 
interview were not included in the analysis, as this was a pilot to test the interview 
schedule. The interviews were conducted during November/December 2008.
Participants were offered the option of being interviewed at their own home, at 
university premises, or at the community venue at which the community support group 
used to meet. Three participants decided to be interviewed at their homes. This provided a 
relaxed and comfortable environment for the participant, as they were empowered by being 
at their own environment. The safety of the researcher was ensured by leaving contact 
details, and time and venue of the interview with two colleagues at the research centre and 
a family member. The researcher called on arriving and on leaving the venue to confirm 
safety. The other three participants were interviewed at the “Breathe Easy” group venue “a 
local restaurant”. This also provided a quiet and comfortable environment for both the 
researcher and the participants. The sample characteristics of the participants is presented in 
Table 5.
167
P hase 2: D evelopm ent C hapter 4: Item  selection, reduction  and scaling .
Table 5 Sample characteristics o f the indepth interviews
Number Age Gender COPD severity Marital status Employment
1 64 Female Severe Married Retired
2 70 Male M oderate Married Retired
3 74 Male M oderate Married Retired
4 60 Male Severe Married Retired
5 67 Female Severe Married Retired
6 80 Female Very severe Married Retired
All interviews were audio-taped and transcribed. During the interview the researcher 
recorded notes about the environment, and the emotional and general status of the 
participant. The interviews lasted between 40 and 60 minutes. Issues arising in early 
interviews provided insight and influenced the discussion at the following interviews.
Ritchie and Lewis (2003) suggested that the use of in-depth interviews is particularly 
valuable when the nature of data sought has to be related to the personal context of the 
individual. In-depth semi-structured interviews were used for the exploration of the 
participants' perspective on significant functional outcomes in the context of their personal 
experience. It is suggested that the use of the in-depth semi structured interviews followed 
by the focus group will enhance the understanding of participants' decision about what they 
set as functional outcomes of pulmonary rehabilitation (Ritchie and Lewis 2003).
The researcher wanted to identify the type of activities affected by the progression of 
COPD and the factors influencing the performance of daily life activities. Therefore, 
participants were encouraged to talk about a standard day in their life and the type and 
nature of challenges to performance they confront in their daily life.
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10.4.5.2 Stage 2: Focus groups
One focus group including six people with COPD and two carers was conducted 
following the interviews. The aim of this focus group was verification and reflection on the 
findings of the in-depth interviews (Ritchie and Lewis 2003). Participants were invited to 
discuss the interpretation and the conclusions of the research generated from the in-depth 
interviews. In addition to verifying the findings from the interviews the focus group was 
designed to provide a focused insight to reduce the activities generated during the 
interviews to a core set of significant activities. Another aim was to refine the accounts of 
the participants in the interviews about the progression of functional loss and generate 
categories describing the steps of the development of functional loss.
The focus group was conducted in January 2009. The focus group took place at the 
“Breezers” group social meeting venue. Table 6 shows the sample characteristics of the 
focus group.
Table 6 Sam ple characteristics o f focus group participants
Number Age Gender COPD severity Marital status Employment
1 Carer/ Male
2 73 Female Severe Married Retired/Cleaner
3 74 Male Severe Married Retired/not
reported
4 56 Female Moderate Married Employed /cleaner
5 67 Male Severe Widowed Retired/ Steel 
worker
6 63 Male Moderate Married Employed/ not 
reported
7 60 Male Severe Married Retired/Engineer
8 77 Male Severe Married Retired/ steel 
worker
9 Carer/ Female
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Gibbs (1997) suggests that the benefit of the focus groups is ‘to gain insights into 
people’s shared understanding of everyday life’. This is directly related to the main aim of 
this study which is about exploring patients’ perspective about the functional outcomes 
important to them.
Focus groups are useful when there is a power gap between participants and 
professionals (Gibbs 1997). This was the main drive for doing this study, which has 
emerged from the idea of empowering people with chronic lung disease to voice their needs 
and set their own treatment goals. And the development of outcome measures that account 
for the experience of recovery of the individual patient.
The focus group lasted for approximately 70 minutes. It was facilitated by the 
researcher. Another PhD/ physiotherapy student from the Health and Social Care Research 
Centre accompanied the researcher and made field notes about the environment, the 
discussion, and the interaction amongst participant. The focus group was audio taped and 
fully transcribed.
The focus groups resulted in ‘illuminating the research issue’ (Ritchie and Lewis 
2003) through group discussions, and interactions among participants. Through talking to 
each other a range of patients’ perspectives were identified. Participants were able to 
review their thoughts against those of others, reflect on and refine them (Ritchie and Lewis 
2003). Moreover, the social context within which the group process occurred addressed the 
aim of describing the values and weightings participants attach to functional activities of 
daily living. Thus reducing the set of activities generated from the interviews to those 
relevant and important to patients.
Functional limitation is a common problem among patients with chronic lung disease. 
Participants shared this experience, and discussed it in the group setting (Ritchie and Lewis 
(2003). This has resulted in the categorisation of the process of functional limitations and 
participation restrictions for selected activities. The group environment minimised the 
personal influence of the researcher on the perspectives of participants (Ritchie and Lewis 
2003).
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10.4.6 Methods of data analysis
The adoption of a pragmatic approach with an ontological approach of subtle realism 
has influenced the selection of data analysis methods. Framework analysis as described by 
Ritchie and Lewis (2003) was selected. Framework analysis was selected because it firstly 
allows for the exploration and understanding of patients’ perspectives about an external 
existing reality. Secondly, it accommodates the existing knowledge of the researcher and 
allows for transparent interpretation of the researcher by the development of a systematic 
framework for the data analysis.
A thematic framework was used to organise data according to emerging themes. The 
thematic framework was based on the theoretical underpinnings of COPD and PR identified 
during the conceptualisation phase and the framework for the measurement of functional 
performance. The process included five stages:
1. Familiarization. This involved the researcher getting introduced and making sense 
of the size and diversity of the data. In this qualitative study adequate familiarisation 
was ensured through the transcription of the records by the main researcher. The 
researcher listened to the audio tapes, transcribed records and listened again to 
verify transcription.
2. Identifying thematic framework. This involved coding the data based on a 
theoretical framework identified from the literature and the identification of 
emerging themes. Themes relevant to the aims of the study were retained for further 
indexing.
3. Indexing. An index of themes and subthemes was developed and applied to 
transcripts. This is presented in (Appendix B .6)
4. Charting. This involved the development of a central chart that allows for across 
cases comparisons. A separate chart for each theme is created and descriptive 
accounts are formulated. Only themes related to the performance of functional 
activities, the factors influencing performance, and management of activities were 
subjected to further refinement and categorisation.
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5. Mapping and interpretation. This involved using the charts to interpret the data and 
identify patterns and associations among themes. A conceptual framework 
representing themes related to the performance of functional activities, the factors 
influencing performance, and management of activities was created.
It is worth mentioning that new themes were added when new data emerged that 
could not be represented by existing themes. This was performed to ensure adequate 
coverage of all potential dimensions that might influence the formulation of the categories 
of the measurement tool. No themes were eliminated unless it became evident that they 
could be better represented by another existing theme or a new emerging theme. For 
example “shock” and “event of diagnosis” were removed and data was organised under two 
subthemes of “diagnosis” which are “social response” and “emotional response”.
Further analysis included identifying elements and dimensions of functional activities 
and mapping the data to the ICF activity and participation core set for COPD (ICF research 
branch 2010). After that, patients’ narratives of performing certain activities were arranged 
into categories describing different levels of functional performance.
One key feature of undertaking qualitative research is the difficulty of the prevention 
of imposing researcher’s knowledge on data. The clinical background of the researcher and 
the strong theoretical and clinical knowledge created a risk of over interpretation of 
participants’ accounts. Although the synthesis of clinical and theoretical knowledge along 
with patients’ perspective was an important aim, there was a threat of biasing interpretation 
by the clinical intuition of the researcher.
In order to control for this bias a number of measures were undertaken. Firstly it was 
decided not to attempt to develop the analysis into abstract conceptualization, establishing 
typologies, and explanatory accounts. The reasoning is related to the aim of this study 
which is developing a patient reported outcome measure of functional performance. 
Therefore, the maintenance of the language and wording used by participants was a 
priority. Any further analysis could have resulted in the loss of the initial narratives.
172
Phase 2: D evelopm ent C hapter 4: Item  selection , reduction  and scaling .
Secondly, the researcher maintained reflexivity though all of the stages of the 
qualitative exploration. This was achieved by providing transparent account about the 
research activities. A study file was created and all research activities and analysis was 
discussed with the supervisory team. Moreover, during analysis the researcher maintained 
vigilant attention to delineate clinical and theoretical interpretation from clinical intuition 
by continuous reference to the evidence underpinning the interpretations.
Quality and rigour of data interpretation was ensured by using a set of techniques to 
meet the criteria of “trustworthiness”. This is presented in Table 7.
Table 7 techniques used to m eet the criteria o f  “ trustw orthiness”
Criteria Explanation Techniques used to meet the 
criteria
Credibility
This refers to the “precision” o f 
the result in accurately reflecting 
the perspectives o f  the population 
on the topic o f  intended 
investigation
Discussion with supervisory team 
regarding the interpretation o f  
data.
Discussion o f  emerging themes 
and interpretations at the support 
group meetings.
Transferability
Generalising from the context o f 
the research study to other 
contexts
Ongoing verification o f 
interpretation in subsequent 
interviews.
Feedback and summarising 
techniques during the interview.
Dependability
The replicability o f  research 
findings
M arinating a transparent record o f 
research processes and activities.
Confirmability
The control for the bias o f  the 
researcher
Self-reflection by the researcher.
Adapted from Tod (2003) with reference to Lincoln and Guba (1985), and Ritchie 
and Lewis (2003)
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10.5 Results of the qualitative study
10.5.1 The context of the qualitative study
In order to identify the context for this qualitative study it is important to start with 
the sample to verify whether there was adequate variation in the sample. The sample for 
both the focus group and the interviews provided a good representation of both males and 
females. The age range of participants was between 56 and 80. The sample included a 
variety of severities including moderate, severe and very severe as reported by participants. 
However there was a predominance of “severe COPD” across the sample. Whilst this could 
have resulted in a bias related to lack of representation of people with mild COPD, this has 
actually provided a sample with a rich experience about the progression of functional loss. 
An important point to consider is ethnicity. All of the participants were from a “white” 
ethnic background; this could have implications on the transferability of results to other 
ethnic groups.
During the interviews the participants responded positively and engaged in the 
discussion. However, certain issues has emerged that needed to be addressed, and that 
possibly had an impact on the nature of the data. One concern was related to the 
environment of the interview. One lady, who was interviewed at the restaurant, expressed 
inconvenience regarding the warm room. This has made her uncomfortable and slightly 
impacted on the focus of the discussion as she talked a lot about the impact of the 
environment and the weather on the symptoms.
Another important issue was related to smoking. Interviewees became upset when 
asked about their smoking history. This probably could be related to the stigma of the self - 
inflected disease. One participant said that he does not like to talk about it, because people 
are judgmental and don’t understand why he could not stop, even though it makes him ill. 
Therefore, the researcher decided not to ask about smoking history unless participants 
raised it in the discussion.
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It is thought that this did not have an impact on the results as smoking histoiy was not 
directly related to the aims of the study, although it could have been interesting to discuss 
whether quitting smoking had an impact on functional performance. Participant 3 in the 
focus group said:
“yeah, but I  felt much better when I  stopped smoking, and I ’m still coughing though. ”
Although the researcher was interested in eliciting responses about both negative and 
positive experiences about the performance of functional activities, the balance of the 
discussion around these issues was not easily maintained. The researcher was interested in 
exploring the progression of the functional loss, the current impact of the disease on 
performance and the current functional potential of participants and how they manage 
difficult activities. However, participants did provide lengthy and moving accounts about 
the sense of loss and the profound impact of limited performance on their personal integrity 
and social life.
Some participants became distressed when they were talking about the functional loss 
and the limitations to performance they experience on a daily basis. However, due to the 
background of the researcher as a clinician, this was smoothly addressed and settled. The 
researcher had to refocus the discussion on the potential and how they manage problems of 
performance. At this point in the discussion the participants were offered the opportunity to 
stop the interview, but no participant decided to withdraw. This sometimes resulted in loss 
in the thread of the discussion. This did not directly affect the data and the interpretations, 
because most of the time participants returned to continue the story but in a less emotional 
state.
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An important point that was considered during the interviews is that just talking 
results in increased ventilatory demand and can precipitate breathlessness in people with 
COPD. Therefore, the participants were given a rest every 10 minutes, and refreshments 
were available if needed. As this was planned and expected the researcher took the 
necessary measures to ensure the thread of the discussion was not lost. This included, 
planning break slots “usually two to three minutes”, keeping a note about the last thing the 
participant was talking about, and avoiding any distracting discussion during the break.
Next is a presentation of the main finding of the qualitative study.
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10.5.2 The findings of the qualitative study
The same thematic framework was used to organise the data of both the individual 
interviews and the focus groups. However, a different topic guide was used for the focus 
group. This is because both methods were used to answer the same questions with different 
levels of detail. The focus group was performed to verify and reflect on the data from the 
interviews as well as providing more focused discussion about the performance of activities 
and the specific type of activities that present challenges on daily basis.
The results of this qualitative study are presented in three parts. The first part presents 
the themes that emerged following the analysis of both interviews and the focus group. The 
second part presents the validation, using patients’ narratives, of the ICF core set for COPD 
and the framework of the measurement of functional performance that was developed 
during conceptualisation. The third part presents the development of the first draft of 
TELER “function” indicators.
10.5.2.1 Part 1: A presentation o f the themes that emerged from the qualitative study
Between 11 main themes and 78 subthemes emerged from data. The themes were 
continuously modified through analysis. A final set was generated after the focus group at 
the end of the familiarization stage. A thematic chart was developed and data was mapped 
across all the themes. The chart was continuously modified as new data became available 
and themes were continuously reviewed following each interview.
The thematic chart was contentiously revisited to ensure that no data relevant to the 
development of the TELER function indicators were missed. Only the themes which are 
relevant to developing the categories for TELER function indicators were subject to further 
analysis. These are themes describing functional performance. Themes that were further 
analysed included: Functions “activities and participations”, management of functions, and 
pulmonary rehabilitation. A conceptual framework representing the impact of COPD on 
“functions” and “management of functions” themes and the interaction between them is 
presented in the Figure 16. Another conceptual framework representing patients’ 
perspectives on the delivery and outcomes of pulmonary rehabilitation is represented in 
Figure 17.
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The reasoning for developing separate conceptual frameworks for functions and for 
PR is that they serve different purposes in the development of TELER “function” 
indicators. The themes related to functions contribute to defining the titles of the indicators 
“goals of the treatment”, and the clinically significant outcomes to be achieved. The PR 
themes contribute to identifying the nature of the therapeutic input required to induce 
clinically significant change.
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Figure 17 A conceptual fram ew ork representing patients’ perspectives on the deliver)' and outcom es o f  pulm onary  
rehabilitation
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1. Functions activities and participations”
Interviewees emphasised the impact of COPD on the performance of daily life 
activities. Participants reported that the presence of COPD affects almost all daily 
functions. A general perception was that indoor activities were easier to control than 
outdoor activities and that it required more confidence and control to perform the same 
activity outdoor.
“like when you’re getting ready to go out because you're going out your adrenaline goes up 
naturally so you have to learn to do it slowly, do it in stages so your adrenalin doesn't get 
pumping too fast so you don't get breathless. ” Participant 5: Individual interview.
The impact of COPD on performance was described in terms of a reduced level of 
performance as compared to their level of performance before the progression of the 
disease. The conceptual term used to refer to this reduction in the level of performance is 
“change”. Patients also compared their current level of performance to other people not 
affected by COPD. This change was expressed in terms of slower performance, need for 
support or complete inability to perform certain functions.
“For a year after I  were diagnosed I  were walking 6 miles a day. but I  can't walk for 6 min 
now I  keep walking round house. I  couldn't go out on my own now before I  was working 
and things and I  could do things by myself but now I  can’t go out because I  can't walk very 
far. It takes me to do what I  used to do like that "clicking with fingers" you know, but it take 
quite well... three times as long. I  can't do gardening now. But I  do pot plants in front o f the 
house ”. Participant 1: Individual interview.
Participants also described the impact of COPD on functional performance in terms 
of variation in the level of activity. They experienced variation in the level o f activity, 
across seasons, from day to day and even diumally. From the perspective of the participants 
this variation was a result of a number of factors influencing activities. The main factor 
influencing activity was reported to be symptoms, particularly breathlessness and fatigue.
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An important finding was that breathlessness appeared to interfere with their 
performance, but if the activity is performed for a longer duration or it had more than one 
component then fatigue starts to interfere with performance as well.
“3: well I  now get out o f breath when I'm digging in the garden, but I'm still engaging, but 
after about half an hour it becomes tiring you know.
R: so is it tiring because o f weak muscles or because o f breathing?
3:both. so fatigue is a problem as well as breathlessness?
3: well after that time yes”. Participant 3: Individual interview.
Coughing was another symptom reported by participants. However, from the 
perspective of participants coughing has no direct impact on performance. This is because 
unlike breathlessness coughing is not precipitated by the performance of activities. 
Coughing was identified as “embarrassing” creating a barrier to participation.
“you lose your confidence, because,,,,, you know when you go out amongst people and you 
start coughing it's a bit embarrassing and so you don't,,,, you start thinking, I'm not going,, 
you know you are too embarrassed to meet people and what if  you start coughing, because 
sometimes when you start coughing you know you're choking and people just stop and stare 
sort o f thing. ” Participant 1: Individual interview.
Other factors that influence the performance of activities and induce variation in the 
level of performance include weather and feelings. Weather influenced performance 
indirectly by impacting symptoms.
“The thing that bothers me is the weather, the thing that pulls me in is the weather, i t ’s the 
wind and rain and cold I  really feel the cold and it makes me very breathless”. Participant 
4: Individual interview.
Negative feelings made people less active and less engaged in activity, resulting into
more sedentary life style.
“To keep trying, and to be active, obviously we are not feeling well you know all the time 
and this very depressing. I  think if  you don 7 keep active mentally and physically as much 
as you can, it is no good for you at all. You know you ’ve got to keep tiying at least. ” 
Participant 6: Individual interview.
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Finally, an important issue that emerged from the data is “recognising limits”. 
Participants identified certain activities that they gave up because of a negative experience 
of being severely breathless as a result of performing the activity. Some participants 
reported stopping the activity as a result of symptoms interfering with performance. It was 
observed that people responded differently to the challenges imposed on performance. 
People who did not attend PR yet were more likely to give up the activity, while people 
who attended PR managed the factors influencing performance. This is presented next.
2. Management of activities
One of the most important techniques participants used to manage difficult activities 
was slowing and pacing.
“you ’ve got to walk on your own pace because I ’m not going to try and keep ap with others 
so I ’m going to walk on my own pace and I  can walk all day these things you ’ve got to 
educate yourself to do ” Participant 7: Focus group
Other methods of management included using support either from others of by using 
mechanical aids. They also modify their environment.
“I mean I have a stair lift, I ’ve got a stair lift put in, I've got a bath seat put in in, at 
the toilet frame around the toilet, but all these are aids to give me better quality o f life, I  
would have a wet room instead o f a bathroom ” Participant 4: Individual interview.
Participants also reported planning as a method of conserving energy and avoiding 
the precipitation of breathlessness.
“To do things on scales now, where I've just used to go and do everything. You know like 
when I  go upstairs to put washing away I  perhaps plan it to do not go back until Ifinish all 
the things I  got to do there, and then rest for 5 minutes and then I  come back so I  just take 
things in moderation ” Participant 1: Individual interview.
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3. Pulmonary rehabilitation
Participants expressed uncertainty about describing the improvement of functional 
activities following PR. They suggested that doing exercises in a standardised environment 
with all the support and supervision from health professionals is very different to 
performing daily life activities. However, they thought they had experienced some sort of 
functional improvement such as doing things for longer, having more control on breathing, 
and improved self efficacy and confidence.
Improved confidence led to improved participation and more outdoor activities.
“I'm going out more, you know. I  have oxygen and I  was a hit embarrassed about 
going out with it but I  learnt to live’'’ Participant 1: Individual interview
Another participant described functional improvement resulting from PR by saying:
“It certainly keeping me fit actually, doing that every week and I  gradually do more at 
home every week. It keeps me active my arms, chest, legs and generally my body” 
Participant 3: Individual interview.
Describing improved breathing control one participant said:
“I  recover quicker because I'm breathing now from here (pointing to abdomen) instead o f  
here (pointing to upper chest). It’s the diaphragm you've got to build your diaphragm. Most 
people breathe from the chest, so they've to stop. So you've got to build your diaphragm 
muscles up. And you can do it a little bit longer” Participant 4: Individual interview
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Participant reported that in addition to improved fitness as a result of exercise, other 
components such as education and psychological support resulted into improved 
knowledge, confidence and control. These are crucial to induce functional improvement in 
daily life activity.
“you've got to do a rehab which teaches you then self-management, relaxation, 
confidence, and then you've got the ability to do things yourself ’ Participant 4:Focus group.
Participants referred to the inability to realise the full benefit of PR because of limited 
resources and difficulty of I accessing to the venue of PR.
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10.5.2.2 Part 2: Validation o f the ICF core set o f activities and the framework fo r  the 
measurement offunctional performance
1. Validation of the framework for the measurement of functional 
performance
Empirical evidence supporting the framework for the measurement of functional 
performance was generated during this qualitative study. The framework is based on the 
ICF model of functioning, disability and health. Patients’ narratives on the factors 
influencing functional performance were all classified as personal or environmental factors 
(Appendix B.7). Moreover, patients described how symptoms particularly breathlessness 
and fatigue influenced performance. This is represented on the framework as health 
condition “disease or disorder”.
One of the themes that resulted from the qualitative study was “recognising limits”. 
This theme represents patients’ experience of stopping or giving up certain activities. 
Patients’ reported that they had to stop the activity because breathlessness was so severe 
that they could not control it. This was conceptualised on the framework in terms of 
functional capacity. Functional capacity was defined as:
"one's maximum potential to perform those activities people do in the normal course 
of their lives to meet basic needs, fulfil usual roles, and maintain their health and 
wellbeing. The term refers to potential in any domain, including physical, cognitive, 
psychological, spiritual, and sociodemographic." (Leidy 1994, P: 198).
One’s maximal potential to perform is influenced by the impairments resulting from 
the disease represented by symptoms. In patients with COPD higher levels of performance 
results in increased ventilatory demands and precipitates symptoms (Lahaije et al. 2010). 
Symptoms interfere with performance creating limits on the maximal potential for 
performance. This limit is described in the framework as functional capacity. Participants 
also described limits to performance imposed by factors other than just capacity. This had 
occurred when a patient decided to give up the activity as a result of a negative experience 
of exacerbation during performing certain activities. The multidimensional framework 
allow for the consideration of personal factors.
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2. Validation of the ICF core set for COPD
During analysis the ICF core set of functions “activities and participations” for people 
with COPD was used to classify patients’ narratives (ICF research branch 2010), this is 
presented in (Appendix B.8). It was found that there was no need to develop new categories 
to accommodate the narratives, suggesting adequate representation of the ICF core set of 
the perspectives of patients in this study.
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10.5.2.3 Part 3: the development o f the first draft o f TELER “function” indicators using 
patients’ narratives.
1. Item selection and reduction
During the focus group participants were asked to discuss a list o f activities generated 
from previous interviews. The discussion was identified a set of activities that constitute 
important and challenging activities. Participants thought there is a great variation amongst 
them in terms of the activities that are important to them. This variation was related to their 
roles and the support available to them. However, participants placed greater importance on 
activities related to moving from one place to another such as walking on level, walking up 
hill, and going upstairs. Another two activities that were identified as important and 
challenging for all participants were showering and bending.
A set of six Activities were selected by patients during the focus group to be 
translated into TELER “function” indicators this included:
1. Generic activity indicator.
2. Walking.
3. Walking uphill.
4. Bending forward.
5. Showering.
6. Going upstairs
2. Item scaling “Categorisation ”
Categories of functional performance were developed by translating participants’
narratives into functional performance descriptors and arranging them into a hierarchy.
These are presented in Appendix B.9.
The categories generated following the qualitative study need to be refined and
standardised to meet the requirements of the TELER method of measurement. The next
chapter presents the process of calibration and validation of TELER function indicators
using consensus methods.
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Chapter 5: Item  C alibration and va lida tion  o f  TELER "fu n c tio n "
in d ica to rs
The aims of this chapter are firstly, to refine and standardise the categories developed 
during the qualitative study to generate TELER codes. Secondly, to calibrate the codes to 
generate ordinal measurement scales. Thirdly, to validate the definitions of the codes of the 
indicators from the perspective of patients and experts.
11 Generating TELER codes from performance descriptors
This involved standardising and refining the categories to fulfil the requirements of 
TELER:
• The codes of the indicators should be unique, that is the language used should 
provide singular meaning13. Therefore the words “gave up and could” were replaced 
by “unable to and able to do”.
• The statements were modified to allow for wider application, this was achieved by 
using a standardised language that enhances understanding by providing a 
clarification that preserves the meaning.
15 The term singular denotes that the statement on the code means one thing, and is not perceived differently 
by different people.
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An example of the process of conversion is provided using the TELER “generic 
activity” indicator this is show in Table 8
Table 8 T E LE R  “generic activity” indicator
Performance descriptors TELER codes
I gave up the activity Unable to do the activity
I could still do it but it would get me out o f  breath Able to start the activity but cannot complete it
I could do the activity but I have to keep stopping 
for rest
Able to do the activity but has to keep stopping for 
a rest.
I could do the activity without stopping but it takes 
longer than usual (slow process)
Able to do the activity without stopping but with a 
slow pace
I could do the activity without stopping for a rest in 
a normal rate but I would start breathing rapidly
Able to do the activity without stopping for rest in 
an optimal pace, but would start breathing rapidly.
I could do the activity without stopping in a normal 
rate maintaining controlled breathing.
Able to do the activity and maintains controlled 
breathing
The statement “I could still do it but it would get me out of breath” became “Able to 
start the activity but cannot complete it”. This change was performed because the phrase 
“get me out of breath” implies that the patient was not able to complete the activity but the 
clinical condition is controlled or the patient was not able to complete the activity and 
experienced an exacerbation as a result of attempting the activity. There are two levels of 
performance that should be differentiated. There is a level of performance which is just 
before a complete loss of function occurs. At this level of performance the patient is still 
determined to maintain the ability of performing the activity. This is a different level of 
performance compared to a patient who is completely unable to tackle the activity either for 
physical or psychological reasons. Participant #1 said described the inability to perform the 
activity:
“NO I  doubt it, it's very,,,,, no I  would not attempt it because I've tried it a couple o f  times 
and it made me ill. You know because I  did try just doing the bottom o f it but it didn't work I  
ended up in hospital ”
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However participant # 4 described the ability to start the activity but the inability to 
complete by saying:
“I  mean like decorating i t ’s too frustrating that it took that long, i t ’s annoying you know 
and you tend to try and rush it but I  won’t rush anything, I  just have to plod on, I  mean I  
could only work 3 hours a day, which to me is rubbish, I  mean I  used to go for 8 hours, but 
now I  coidd only do 3 hours, and I ’ve had it I  just have to pack in. ”
Another example on modifying the language used is provided using the functional 
walking indicator. The findings of the qualitative study suggested that the impact of COPD 
on performance is manifested by slower performance. Therefore, the fourth category on the 
functional walking indicator was described as “I could walk outside home with a normal 
pace without stopping for a rest but since I start talking, I get breathless”.i
On this category the word “normal” was replaced by the word “optimal”. This is 
based on the findings of the qualitative study and on clinical and theoretical knowledge. 
The findings of the qualitative study showed that People with COPD tended to compare 
themselves to their previous level of functional performance before the progression of the 
disease, one carer in the focus group said:
“While she were walking up or ride very quickly she turned to walking up and struggling”
Or they compared themselves to other people in the community who do not have 
functional limitations, patient #2:
“But when I  get to the event it's the walking part which has to take me time to do it. When 
I'm walking I  notice that people pass they are 10 times quicker than I, they are miles ahead, 
which emphasize that I'm slow. ”
Based on those findings and on the fact that COPD is a progressive disease, and so 
precludes recovery of normal pace, it was decided to replace normal pace with optimal 
pace. Optimal pace is defined as the maximal functional pace achieved by the person given 
the available functional capacity within a certain context “personal and environmental 
factors”.
The next step was the calibration and validation of the resulting categories by experts 
and patients’ focus groups.
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12 Expert and patient validation
12.1 Introduction
The aims of this section are to:
1. Validate the construct, the content, and the clinical knowledge underpinning the 
TELER “function” indicators by experts.
2. Validate the construct, and the content from the perspective of the patients.
3. Test the acceptability of the indicators by patients.
4. Ensure that the outcomes on the indicators are clinically significant outcomes that 
are potentially influenced by PR, from the perspective of patients and experts.
5. Ensure that the hierarchical stepwise regain of function on the indicators is a valid 
representation of the recovery of the functions as experienced by patients and 
experts.
12.2 Validation of TELER function indicators by patients
12.2.1 Methods
The patients’ validation process included a presentation followed by a focus group 
discussion. The aim of the patients’ focus group was to verify the content and construct 
validity of the indicators from the perspective of a different group of patients who were not 
involved in the generation of the indicators. Participants were recruited from a “Breath 
Easy” group. Participants were already familiar with the study as the researcher had been 
regularly attending the monthly meeting of the group to present and review the findings of 
the qualitative study. All participants received a participant information sheet a week before 
the focus group. The study was approved by the Faculty Research Ethics Committee / 
Faculty of Health and Wellbeing - Health and Social Care Division -Sheffield Hallam 
University (Appendix B.2).
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12.2.2 Patients’ focus group
The group consisted of seven patients and one carer. All participants completed an 
informed consent form. The presentation included the findings of the qualitative study and 
the final draft of the indicators. Following the presentation, each participant received a 
printed copy of the final draft of the indicators, and they were given 10 minutes to read and 
reflect on them. After that the researcher read each indictor and the participants were asked 
to:
• Comment on the clarity of the language used
• Express their views on the truthfulness of the description of the codes, as it applies 
to them by attempting to score themselves on the indicators.
• Comment on the range of functions included and whether there is any important 
function not included.
The topic guide for this focus group is presented in Appendix B.10
12.3 Validation of TELER function indicators by experts
12.3.1 Methods
A scientific meeting was held for experts that included a presentation followed by 
focus group discussion. The scientific meeting was held in a room at Sheffield Hallam 
University. The focus group method was selected because the aim was not to achieve a 
consensus instead the aim was to create an environment that would facilitate discussion, 
constructive criticism and improvement of the indicators. Kitzinger (1995) suggested that 
focus groups provide an invaluable method for critical discussion and providing solutions if 
the aim of research is to improve products or services. In addition focus group discussions 
were identified as “ideal” for reviewing the contents of questionnaires or instruments 
(Bolton and Kitzinger 1994) and (Morgan and O’Brian 1993).
No NHS research ethics approval was required as participants were recruited through 
clinical interest groups and networks at national conferences, not through NHS services or 
organisations. However, all participants received an invitation letter and a brief about the 
study with references on the TELER method two months prior to the meeting in order for 
them to have time to consider participation (Appendix B.l 1).
193
Phase 2: Developm ent Chapter 5: Calibration and validation.
12.3.2 Experts’ focus group
A range of expertise was recruited. The group was comprised two TELER experts, 
two clinical leads on pulmonary rehabilitation programs, one COPD research expert, and 
two clinical “physiotherapists”. The meeting consisted of two parts. The first part was a 
series of short presentations each followed by a facilitated discussion. Topics of the 
presentations included the outcomes of the conceptualisation phase, a description of the 
TELER method of measurement, and the process of developing TELER function indicators 
for people with COPD. The second part was a focus group discussion and was facilitated 
using a questionnaire for the assessment of the validity of the TELER “function” indicators 
(Appendix B.12).
12.3.3 Findings of the Expert and patients validation of TELER “function” indicators
Although patients and experts focus groups were held at separate occasion the results 
are reported together because they addressed the same issue. In addition there was 
agreement on the concepts and issues raised by both groups.
The process of patient and expert validation resulted in a number of changes on the 
indicators that improved the content and concurrent validity of the indicators, and 
suggestions to improve the reliability of the indicators.
Content validity
Evidence that the indicators codes provide a valid account of the clinical problems 
and trace changes in the presentation of the problem should be established (Grocott 2001). 
Evidence that the indicators have content validity was achieved during the focus groups 
involving experts and patients validation. During the focus groups the indicators were 
reviewed to identify:
1. Whether the definitions of the codes represented a valid clinically significant statement 
of the problem.
2. Whether the codes were able to trace changes in the clinical problem as experienced by 
the patient or observed by the clinician.
An example is provided using the showering indicator Table 9.
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T ab le  9 T h e sh o w er in g  in d ica tor
Showering indicator submitted for review Showering indicator reviewed
0. Unable to shower
1. Able to wash head and body in sitting but 
unable dry self
2. Able to wash head and body while sitting 
and dry self
3. Able to wash head and body while 
standing but unable to dry self
4. Able to shower and dry self, but feels 
exhausted.
5. Able to shower
0. Unable to shower
1. Able to wash body but unable dry self
2. Able to wash body and dry self but feels 
exhausted
3. Able to wash body and dry se lf and does 
not feel exhausted
4. Able to wash head and body and dry self, 
but feels exhausted
5. Able to shower
The changes that were made can be summarised as follows:
Patients reported that describing the position “sitting or standing” is not relevant and 
does not affect performance it is a matter of individual preference. Clinicians agreed and 
added that the ability to stand is a different function that requires another indicator and 
should not be included with the showering indicator.
Clinicians suggested that washing the head is a difficult function that involves 
elevation of the arms over the head. This involves a shift in the function of the accessory 
muscles of respiration to partake in arm elevation. This places increased demand on the 
already strained main muscle of respiration “the diaphragm” (Velloso et al. 2003). 
Therefore, it was suggested that washing the head should not come early on as an indicator 
because it requires a larger amount of therapeutic input than washing the body only.
Clinicians found it unreasonable that exhaustion was only mentioned at code 4 and 
suggested that it is more likely to interfere with the activity at lower levels of performance.
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Concurrent validity
TELER “function” indicators are designed to measure changes in functional 
performance “individualised outcome”. Moreover, changes should be measured at the level 
of the individual. Therefore, evidence of concurrent validity should prove that TELER 
“function” indicators conform to the following theoretical assumptions:
1. The measurement of functional performance should be directed by patients' perspective.
2. The measurement of functional performance should be directed by clinical 
determination of what is achievable.
An example is the “bending to do an activity” indicator. This used to be a dressing 
indicator describing putting shoes on. Both patients and clinicians suggested that while 
bending is an important clinical problem that could be improved by the “PR” intervention, 
patients are more likely to use aids to put shoes on rather than bending to put shoes on. 
Therefore, it was suggested to change this indicator to a “bending to do an activity” 
indicator, with a focus on the function “bending”.
Suggestions to improve the reliability of TELER function indicators
It was suggested by the experts’ focus group, that the reliability of some indicators to 
detect clinically significant changes could be improved by adding an indicator of self- 
efficacy. An example was the walking indicator. Clinicians explained that improvement on 
the walking indicator from code 1= able to walk freely inside house to code 2 = Able to 
walk freely outside the house but pace is slow is sometimes due to self efficacy and 
confidence to leave home rather than physiological capacity and available resources.
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The final version of the indicators following patient and expert validation is presented 
Table 10. The next chapter is "clinical testing" of the indicators in clinical PR setting to test 
the usefulness of the indicators.
Table 10 The final version o f  the indicators follow ing patient and expert validation
Functional walking
0. Unable to walk freely inside 
house
1. Able to walk freely inside 
house only
2. Able to walk freely outside 
the house but pace is slow
3. Able to walk freely outside 
the house with an optimal 
pace, but needs to keep 
stopping for a rest
4. Able to walk outside the 
house with an optimal pace, 
without stopping for a rest 
but unable to do another 
function (task) whilst 
walking (i.e. talking, 
carrying shopping)
5. Able to achieve functional 
walking
Slope walking and talking
0. Unable to walk few steps on 
slope
1. Able to walk a few steps on 
slope but gets breathless 
and doesn't continue
2. Able to walk on slope with a 
slow pace* and needs to 
keep stopping for a rest
3. Able to walk on slope with 
an optimal pace but has to 
keep stopping for a rest
4. Able to walk on slope with 
an optimal pace without 
stopping for a rest
5. Able to walk on slope and 
talk
Going upstairs
0 . do not go upstairs
1. go upstairs crawling
2 . go upstairs but has to stop 
for a rest several times
3. go upstairs but it is very 
slow and has to stop for a 
rest once
4. go upstairs without stopping 
for a rest with controlled 
breathing
5. go upstairs without stopping, 
with optimal pace and with 
controlled breathing
Showering
0. Unable to shower
1. Able to wash body but 
unable dry self
2. Able to wash body and dry 
self but feels exhausted
3. Able to wash body and dry 
self
4. Able to wash head and body 
and dry self, but feels 
exhausted
5. Able to shower
Bending to do an activity
0. Unable to touch table in 
front.
1. Able to bend forward with 
back upright and reach 
forward.
2. Able to bend forward and 
touch feet distance but 
unable to maintain.
3. Able to bend forward touch 
feet and maintain position 
but unable to do another 
task.
4. Able to bend forward 
perform am activity but has 
to rest before completing the 
task.
5. Able to bend forward 
maintain it and complete the 
task.
Activity (any activity identified
by the patient as a problematic
activity)
0. Unable to start the activity 
(gardening)
1. Able to start the activity but 
cannot complete it.
2. Able to complete the activity 
but has to keep stopping for 
a rest.
3. Able to complete the activity 
without stopping but with a 
slow pace
4. Able to complete the activity 
without stopping for rest in 
an optimal pace, but doesn't 
control breathing.
5. Able to do the activity and 
controls breathing.
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Discussion of phase 2: "Development"
The aim of this phase of the phase was to develop TELER function indicators based 
on the knowledge established during the phase of conceptualisation. The process of 
development included a number of steps these are:
1. Selection of a method of measurement.
2. Identifying clinically significant outcomes and the factors influencing them.
3. Selection of the item pool and item reduction.
4. Item scaling “categorisation and calibration”.
5. Determination of usefulness, reliability, and validity.
The TELER method of measurement was selected because it fulfilled the 
specification of an outcome measure of functional performance for use in people with 
COPD in PR clinical setting.
During the conceptualisation phase it was established that “function” in functional 
performance is represented by the physical, psychological, social, occupational, and 
spiritual activities people do to fulfil certain purposes. Therefore, it is important to identify 
these activities from the perspective of the patients using qualitative methods. Two 
important points should be highlighted. First is the selection of the activities for inclusion in 
the measurement tool should be in terms of importance and clinical significance and second 
is the method of reduction of activities.
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Item selection and reduction
Selection of activities for inclusion in the development of TELER function indicators 
was based on patients’ perception of importance rather than difficulty. However, the degree 
of difficulty and the factors influencing the performance of each activity considered 
important need to be established in order to enable the categorisation of the levels of 
performance of the selected function. An example is provided from the CCQ. During the 
development of the CCQ, the authors attempted to weight items in term of difficulty. 
However, there was an apparent lack of consensus on the classification of activities as 
strenuous, moderate or light (Molen et al 2003). This highlights the importance of 
evaluating each single activity separately. The activity to be evaluated should be selected 
by the patient based on relevance, and importance.
Item reduction in this study was achieved by patients’ consensus during focus group. 
However, it should emphasised that the selection of items is an individualised exercise. 
Appropriate application of the TELER method requires mutual agreement between the 
patient and the clinician at the outset of treatment. The therapist should have the clinical 
knowledge to develop TELER indicators in response to patient’s needs. However, for the 
purposes of this thesis a set of activities representing functions that are important to patients 
and potentially influenced by PR was created.
Item reduction by statistical models and by experts risk making the resulting 
measurement tool irrelevant to the individual patient. For example the ranking of the 
importance of symptoms by experts and clinicians in the CCQ (Molen et al 2003) was 
different to that generated by patients in the qualitative study in this thesis and by other 
qualitative studies (Williams et al 2007).
An important component of this stage was the qualitative exploration of patients’ 
perspectives on functional activities of daily life. The aim of the qualitative study was to 
gain an insight into how COPD impacts the performance of daily life functions. This 
enabled the identifications of the items to be included in the development of TELER 
function indicators, and to describe the pattern of the development of functional loss.
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The categorisation of the process of the development of functional limitation was 
performed by identifying the factors influencing performance and the process of 
management of challenging activities as experienced by people living with COPD. In-depth 
description of the impact of COPD on functional performance and the development of 
functional limitation was achieved using a structured process of different qualitative 
techniques to obtain and validate data by patients and experts.
The participants in the qualitative study reported breathlessness as the main symptom 
interfering with the performance of daily life functions. This is similar to the finding of 
other qualitative studies (Barnett 2005) and (Christenbery 2005). However, this qualitative 
study provided an insight into how participants responded to or controlled breathlessness 
during performance of daily life activities. Participants also reported the impact of fatigue 
being secondary and not directly influencing performance unless the activity lasted for 
longer or had more than one component. This is similar to findings of Small and Lamb 
(1999) who found that patients with COPD cope well with fatigue so that it does not 
significantly limit performance.
Another important finding of this study that is consistent with the findings of 
(Chritenbery 2005) was the patients’ report of managing challenging activities by slowing 
and pacing. Patients in this qualitative study described different levels of performance 
based on a number of factors related to both physical and psychological capacity, 
suggesting the important role of self efficacy and confidence in the performance of daily 
life activities. This is similar to the findings of (Liedy and Hasse 1999) who reported the 
impact of COPD on personal integrity and self-efficacy resulting in reduced activity and 
participation alongside by a more sedentary life style and increased social isolation.
The nature of clinical outcomes experienced by participants following PR implied the 
treatment needs for this group of patients. Participants in this qualitative study reported the 
benefits of PR in terms of functional improvement, self-efficacy, quality of life and 
education resulting into improved control of the symptoms and the disease.
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This finding is important because it enables the identification of the type of the 
therapeutic input required to induce a change and achieve clinically significant outcomes in 
the performance if activities. While a number of qualitative studies reported similar 
findings relating to the benefits of PR (Christenbery 2005, Fischer et al 2007, Camp et al. 
2000), this is the first study that links these benefits to the changes in the performance of 
daily life functions.
Participants’ reported similar concerns to those reported by Fischer et al. (2007) 
regarding the uncertainty and the difficulty of achieving functional improvement following 
PR, as well as barriers to participation, difficult access and lack of follow up . However, 
this study has resulted in the development of a measurement tool that has the potential to 
provide informative clinical data required to address these issues. The usefulness of TELER 
function indicators in clinical settings is tested in the next phase “clinical testing”.
Item calibration and validation 
This was a critical stage that included the synthesis of patients’ perspective and clinical 
knowledge of the experts to calibrate and validate TELER function indicators. An initial 
categorisation was achieved by translating patients’ narratives into performance descriptors. 
Those were further calibrated using expert clinical knowledge and patients’ experience 
through focus groups. This process, along with the consideration of the specifications of the 
appropriate outcome measure that were identified during the conceptualisation, ensured that 
the resultant function indicators are valid, reliable and responsive. However, the usefulness 
of the indicators could not be established without testing them in clinical settings.
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Phase 3: Clinical testing
Chapter 6: D eterm in ation  o f  the usefu lness o f  TELER "fu nction  "
in d ica to rs
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Overview of phase 3 "clinical testing"
The aim of the “clinical testing” was to test the usefulness of the newly developed 
TELER "function" indicators, in the evaluation of the functional outcomes of pulmonary 
rehabilitation in people with Chronic Obstructive Pulmonary Disease “COPD”. The 
evaluation complies with the theoretical specifications of the outcome measure and the 
theoretical principles of measurement in clinical settings, derived during the phase of 
conceptualisation. The theoretical principles upon which the development of TELER 
"function" indicators was based is as follow:
• TELER function indicator is an outcome measure of individualised outcomes
• TELER function indicator is designed to be used as a patient reported outcome 
measure.
• TELER function indicator measures the construct "functional performance".
• TELER function indicator is a clinical measurement instrument that was developed 
to evaluate the outcome of complex intervention (Pulmonary rehabilitation) in 
clinical setting16.
• TELER function indicator is an ordinal scale. The title of the indicator defines a 
treatment goal that is identified as relevant and important by the patient and the 
carer. Six codes on the ordinal scale define clinically significant outcomes. These 
are arranged to represent the hierarchical stepwise regain of function. The definition 
and the hierarchical arrangement of the clinically significant outcomes were 
performed by patients, carers and clinical experts.
• TELER function indicator traces changes (improvements or deteriorations) and no 
changes in functional performance.
These theoretical principles have implications for the methods used to evaluate the 
usefulness of TELER function indicators in clinical pulmonary rehabilitation settings. This 
will be explained in further details in the methods section.
16 Clinical setting refers to the setting within which PR is delivered this could be in the community, a 
specialist rehabilitation centre or hospital.
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Chapter 6: Determination of the usefulness of TELER “function"
indicators
13 Usefulness of measurement tools
The usefulness of measurement tools was described in the literature in terms of the 
feasibility of application and the psychometric properties of the measurement tool. 
Psychometrics, when applied in accordance with the theory of measurement, provides 
scientific quantitative evidence on the appropriateness and rigour of the measurement tool 
to serve its function. However, methods of psychometric analysis are based on testing the 
measurement tool in a random sample of the population in standardised clinical research 
settings (De Vet et al. 2003). This provides evidence of the usefulness of the measurement 
tool at the level of the group, in a specific population and a specific context. This does not 
necessarily reflect the heterogeneous population that the clinician is confronted with in 
clinical practice.
The TELER function indicators were developed to solve problems of measurement in 
a clinical PR setting. The critical review of existing outcome measures identified the lack of 
appropriate measurement tools for use in a clinical setting. Moreover, the review 
highlighted the inability of existing outcome measures to provide informative data, to 
achieve full clinimetric analysis when used at the level of individual patient or group of 
patients in clinical setting, despite their established psychometrics properties. Therefore, 
evidence of the usefulness of TELER function indicators should be provided in terms of 
their ability to generate data appropriate for full clinimetric analysis of a clinical 
phenomenon of interest.
Clinimetrics is a clinically based, patient centred approach to measurement that 
requires ensuring the appropriateness of the measurement tool for implementation in 
clinical settings, the quality of the performance of measurement in clinical setting, and the 
provision of meaningful data that could inform clinical practice (Fette 2006).
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One way of ensuring appropriate clinimetric analysis is by linking the outcomes of 
measurement to clinical notes. The clinical notes should be recorded systematically to 
provide relevant clinical observations by the clinician and critical clinical incidents as 
reported by the patient.
During the phase of conceptualisation, it was highlighted that an “appropriate 
measurement tool” of functional performance for use in clinical PR settings should fulfil 
the theoretical specifications of the measurement tool and the principles of measurement in 
clinical setting. The development of TELER “function” indicators was informed by the 
knowledge that emerged during the phase of conceptualisation. Evidence was established 
during the phase of development that they fulfil the principles of measurement in clinical 
setting. A measurement tool that fulfils the principles of the measurement in clinical setting 
is expected to provide data appropriate for full clinimetric analysis.
The knowledge resulting from clinimetric analysis should enhance the experience of 
recovery for the patient, facilitate clinical reasoning and decision making for the clinician, 
and assist the commissioning process for managers and decision makers. Therefore, 
analysis to demonstrate the clinically informative data generated by the TELER function 
indicators is performed at different levels to inform the patients, the clinicians, and the 
mangers.
Moreover, the measurement in clinical settings should serve a predefined purpose. 
Therefore, the usefulness of the measurement tool is determined by providing evidence of 
its ability to fulfil the purpose of measurement (Sperlinger 2002). Duncan and Velozo 
(2007) suggested that a main purpose of measurement in PR setting is to track changes in 
clinical and functional status at the level of the individual patient. Other purposes of 
measurement in clinical setting include providing evidence of the quality of care delivered 
to the patient and the efficiency and effectiveness “outcome” of treatment.
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TELER function indicators were purposely developed to track changes in functional 
performance. A measurement tool that is designed to track changes over time, should be 
responsive to changes in the construct being measured. The ability of the measurement tool 
to correspond to changes in the construct being measured is defined as responsiveness 
(Beaton et al. 2001). Therefore, evidence of the responsiveness of the measurement tool 
should be established to demonstrate the usefulness of the measurement tool.
Once responsiveness is established, evidence is needed that data provided by TELER 
function indicators is appropriate for clinimetric analysis at the level if the individual and at 
the level of the group. At the level of the individual a qualitative and quantitative analysis 
of the patient's experience is required to provide evidence of the quality and the outcome of 
care delivered to the individual patient. Interpretation of the data should be performed 
using qualitative reasoning with reference to clinical knowledge, the clinical characteristics 
of the individual patient and the specifications of the clinical setting (Grocott and Campling 
2009).
Moreover, Duncan and Velozo (2007) suggested that measurement tools should 
inform policy and decision making. Thus the usefulness of TELER function indicators 
should be demonstrated in terms of providing data that could be aggregated and analysed at 
the level of the group to achieve full clinimetric analysis. This will provide evidence of the 
quality and outcome of treatment at the level of the group.
The outcomes should be attributed to treatment in order to provide a valid evidence of 
the effectiveness of care provided (Duncan and Velozo 2007). Therefore, demonstrating the 
usefulness of TELER indicators requires providing evidence that the data generated could 
be used to provide evidence of attribution. Attribution requires establishing a cause and 
effect relationship. When used in a clinical setting, TELER indicators could provide 
evidence that the observed effect is not random and could be attributed to some cause by 
establishing statistical significance of treatment effectiveness. However, they do not 
establish a cause and effect relationship. In order to establish evidence of attribution, 
TELER indicators should be used in an appropriate research design (LeRoux 2003).
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However, this clinical testing study is not concerned with establishing evidence of 
the effectiveness of PR. The clinical testing presents the methods of calculating statistical 
significance of the outcome of treatment at the level of the individual patient and the group. 
This clinical testing is concerned with providing evidence of the appropriateness of the 
quality and quantity of data generated by TELER function indicators to achieve full 
clinimetric analysis of a clinical problem in patients with COPD, which is functional 
performance. This will be achieved by using quantitative and qualitative methods of data 
analysis.
13.1 Clinical testing study design and data collection
The study was a prospective follow up of people with COPD commencing pulmonary 
rehabilitation. A baseline measurement on the TELER indicators was performed at the start 
of the rehabilitation program. TELER measurements were performed twice weekly as the 
patients attended the rehabilitation session; a final measurement on the TELER indicators 
was performed at the end of the program. These intervals were chosen to reflect as much 
changes as possible in patients' functional performance as this construct is known to change 
continuously in patients with COPD. Also these intervals correspond to the intervals at 
which a therapeutic input was provided to the patient.
All patients were assessed before and after PR, in accordance with the policy of the 
pulmonary rehabilitation unit involved. This included a full range of Physiological, 
psychological and health related quality of life assessment. A list of the instruments used is 
provided in (Appendix C.l).
13.1.1 Ethics
The study was approved by the Yorkshire and Humber ethics committee (Appendix 
C.2). Patients who attended a first assessment and booked a rehabilitation session at 
Breathing Space were sent an invitation letter with information about the study. On their 
first session patients interested in participation received full information sheet with 
explanation from the researcher about the study (Appendix C.3). All participants completed 
an informed consent form (Appendix C.4).
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13.1.2 Recruitment and Sample Characteristics
As this is an exploratory study a sample of 1 (^participants was recruited. People with 
a diagnosis of COPD attending Pulmonary Rehabilitation program at a specialist 
rehabilitation centre, at an ex mining area with high prevalence of COPD, were approached 
by the physiotherapist. To be eligible the patient had to have an established diagnosis of 
COPD, confirmed by spirometry. Demographic data for the study sample is presented in 
Table 11.
Of the sample 60% were males and 80% were above 60 (< 50 years 1%, 51-60 years 
1 %, 61-70 years 5% and >70 years 3 %). All patients had a spirometry established 
diagnosis of COPD. of patients 40 % had an established clinical diagnosis of existing co 
morbidity. All patients were ex-smokers, except one who was still a smoker at admission 
but quitted during the rehabilitation program.
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13.2 Analysis of TELER data
TELER software was used to analyse the data. Chi square test (Field 2009) was used to 
provide statistical evidence for treatment effectiveness and responsiveness of TELER 
function indicators. Qualitative framework analysis (Ritchie and Lewis 2003) of clinical 
notes was used to provide qualitative evidence for the qualitative analysis at the level of 
the patient.
The qualitative analysis involved only charting o f responses across a predefined 
framework, which is the same framework used during the qualitative study in this 
thesis. This is because the aim of the analysis was to provide an organising framework 
for the data, to enable creating meaningful links with and explanations o f the TELER 
scores. Figure 18 shows an outline of the different levels and methods of analysis 
performed.
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Figure 18 An outline of the different levels and methods of analysis perform ed.
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13.3 Usefulness of TELER function indicators
13.3.1 Responsiveness
The aim was to evaluate the ability o f TELER function indicators to correspond to 
clinically significant changes in the performance of functional activities, experienced by 
the patient and observed by the clinician, in the context of a clinical intervention. That is 
finding out whether TELER indicators could correspond to clinically significant 
changes in the performance of: generic activity selected by the patient, functional 
walking, going upstairs, slope walking and talking, and showering. Clinically 
significant changes are expected to occur due to the introduction of pulmonary 
rehabilitation. However, during the assessment there needs to be a determination that a 
clinically significant change has occurred (De Bruin et al. 1997). The determination that 
a clinically significant change has occurred should be based on the clinical knowledge 
and observation of the clinician as well as patient report of experiencing the occurrence 
of change.
For the purposes of providing evidence of responsiveness the definition of 
responsiveness that was developed during the phase of conceptualisation was adopted: 
responsiveness is the ability of the measurement tool to correspond to change, or no 
change in the construct being measured, the change should be experienced and 
recognised by the patient and observed by the clinician. The construct in the context of 
this study is “functional performance” and is defined in terms of five functional 
activities of daily living identified as relevant and important by the people with COPD 
during the qualitative study in this thesis. Change is defined as one unit of clinically 
significant improvement or deterioration on the TELER "function" indicator (LeRoux 
2003). Contextual factors related to changes in functional performance were presented 
in the phase of conceptualisation within the third section of chapter one. Based on the 
taxonomy of responsiveness developed by Beaton et al. (2001) changes are measured 
and presented at the level of the individual. The scores contrasted are within person 
changes.
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Scores on TELER “function” indicators are compared to the scores on the CAT 
“COPD Assessment Test” (Jones et al. 2009). The difference between changes recorded 
on CAT and changes recorded on TELER function indicators were compared using Chi- 
square test (Field 2009). The change recorded on TELER function indicators should be 
observed meaningful clinically significant change. However, the changes recorded on 
CAT are based on the participants’ self scoring Observed changes and no changes on 
both tools were recorded.
The reasoning for the selection o f CAT is that it is a newly developed outcome 
measure and has been widely used in clinical trials and data analysed at the level o f the 
group (Dodd et a l 2011). The aim was to find out the responsiveness o f this outcome 
measure when used in clinical setting, using data generated at the level o f the 
individual.
A qualitative analysis o f the responsiveness o f TELER function indicators was 
performed using the themes on factors influencing the performance o f activities 
generated during the qualitative study. This was performed to account for the role o f  
clinical knowledge and patient experience o f change in establishing evidence o f  
responsiveness. The reasoning being that the responsiveness of the measurement tool is 
dependent on the interaction between the design o f the measurement scale and the 
person recording changes in the construct on the scale (LeRoux 2003).
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13.3.2 Clinimetric analysis
13.3.2.1 Analysis o f  data at the level o f  the individual
Analysis of data at the level of the individual patient provides evidence that 
treatment had an effective impact on the patient experience of treatment delivered ( Le 
Roux 2003). Effective outcome is established if the patient and the clinician were able 
to achieve the goals of treatment. The main goal of PR is the restoration of functional 
loss within the limits of available capacity, within a specific context “personal and 
environmental factors”, and the maintenance of the recovered function. Personalised 
goals of treatment are developed at the beginning of PR. In the current context of the 
clinical testing study personalised goals were identified in terms of selecting a set of 
relevant and important functional activities. LeRoux (2003) states:
"Whatever the goal, the analysis is guided by the hypothesis that a change or lack o f  
change seen in a patient or client was produced by the treatment or care received by the 
patient or client. A correspondence between an observed and expected pattern o f  
change or lack o f  change suggests that the treatment or care had been effective. 
Alternatively a lack o f  correspondence between an observed and expected pattern o f  
change or lack o f  change suggests that the treatment or care had lacked effectiveness." 
(Le Roux 2003, PP: 65).
Two types of analysis were performed; quantitative and qualitative. A TELER 
function indicator is an ordinal scale. However the data for the quantitative analysis 
consists of counts of clinically significant improvement. This provides an interval level 
of data; this is explained by the number theory and is presented in the discussion (Le 
Roux 2003).
• Quantitative analysis
The quantitative analysis is in two distinct parts; statistical significance and the 
calculation of TELER index. The first part provides evidence of statistical significance 
by testing the number of improvements and deteriorations recorded on the indicators. A 
Statistically significant change indicates that an outcome “clinically significant change” 
has resulted from the intervention and has not occurred by chance (Le Roux 2003).
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The second part of the quantitative analysis provides a description of the quality 
of treatment in terms of six index numbers. These are: the performance index, the 
maintenance index, the effectiveness index, the change index, the health change index, 
and the health status index. The TELER software automatically calculates these indices. 
Formulae for the indices are provided for registered TELER users (Longhand data 
Limited 2011). Definitions and values of TELER indices are presented in Table 12 
(Longhand data Limited 2011).
The quality of the treatment received by a patient is based on the results of an 
analysis of the data in the Patient Report provided by the TELER Spread sheet. Quality 
of treatment is defined in terms of the patient outcome and is described as good, 
satisfactory or poor for each patient. Each level is defined in terms of data provided by 
the Effectiveness Index, and the Maintenance Index.
The definitions of the quality of treatment used in this study were based on the 
classification of outcome provided by (Longhand Data Limited 2011). However, the 
classification of the values of the effectiveness index was changed. This is due to the 
progressive deterioration of functional performance in people with COPD and the 
chronic nature of the condition. It was decided, with advice from the steering group17 
meetings at the PR service, to lower the threshold for the definition of “moderate” of the 
effectiveness index. It should be noticed that those definitions could be tailored to the 
meet the requirements of various clinical settings:
• An effectiveness index of a value from 0 to 49 is defined as low.
• An effectiveness index of a value from 50 to 79 is defined as moderate.
• An effectiveness index of a value from 80 to 100 is defined as high.
Similar classifications of definitions were used to describe the performance index, 
health status index and health gain index.
17 This is the Collaboration for Leadership in A pplied Health Research and Care, South Y orkshire 
(CLAH RC SY) COPD  them e steering group m eeting. As this PhD project was adopted by 
CLA H RC SY, the author regularly attended the steering group m eetings and provided 
presentations o f  results and updates on the progress o f  the project.
216
Phase3: Clinical testing Chapter 6: Determination o f  the usefulness o f  TELER “function” indicators
However the steering group at the PR centre suggested adopting the same 
definitions for maintenance index provided by Long hand data, as it was found relevant 
to this group of patients.
• A maintenance index of a value from 0 to 30 is defined as unstable clinical 
condition.
• A maintenance index of a value from 31 to 60 is defined as marginally unstable 
clinical condition.
• A maintenance index of a value from 61 to 100 is defined as stable clinical 
condition.
Patient outcome is described as good, satisfactory or poor based on the definitions 
of the effectiveness and maintenance index.
Good patient outcome
Treatment that had two characteristics:
1. The treatment was of either high or moderate effectiveness.
>  The value of the Effective Index is 80 -  100.
>  The value of the effectiveness index is 50-79.
2. The patient’s clinical condition was stable.
>  The value of the Maintenance Index is 61-100.
Satisfactory'patient outcome
Treatment that had two characteristics:
1. The treatment was of either moderate or low effectiveness.
> The value of the Effective Index is 50 -  79.
> The value of the effectiveness index is 0-49.
2. The patient clinical condition was marginally unstable.
>  The value of the Maintenance Index is 31 - 60.
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Poor patient outcome
Treatment that had two characteristics:
1. The treatment was of either moderate or low effectiveness.
> The value of the Effective Index is 50 -  79.
>  The value of the Effective Index is 0 -49.
2. The patient clinical condition was unstable.
>  The value of the Maintenance Index is 0 - 30.
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• Qualitative analysis 
Qualitative analysis provides a description of the duration of treatment, the number of 
clinical contacts, a tracking of scores, the effectiveness of treatment and patient health 
status at admission and discharge in terms of performance index and health change index.
Qualitative analysis involves linking the treatment record, the performance record, 
and the clinical notes. However, as treatment was standardised for all patients during the 
whole rehabilitation program, no changes were introduced to treatment except for reducing 
the intensity of training when patients reported that they were feeling unwell. It is worth 
mentioning that this is a national malpractice of the current delivery of PR. Current delivery 
of PR is based on protocols that is delivered to the group of patients. However, the design 
of PR protocols is not consistent and there is no evidence to support a certain protocol. This 
emphasise the need for tailoring PR interventions to the individualised needs of the patient. 
This is discussed into further details in the overall discussion of the thesis.
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13.3.2.2 Analysis at the level o f  the group
TELER data at the level of the group is analysed quantitatively using statistical 
significance and TELER index.
" The analysis o f  collated TELER data is guided by the hypothesis that a change or 
lack o f  change, seen in a patient was produced by the treatment the patient had 
received. The improvements or lack o f  changes exhibited by a group o f  patients 
therefore maybe explained as the collective outcome o f  the totality o f  treatment that had 
been delivered. I f  instead the group o f  clients had exhibited deteriorations then the 
deteriorations are attributable to lack o f  effectiveness in the treatment” (Le Roux 2003, 
PP: 75).
The analysis of the collated TELER data is in two parts. The first part is 
concerned with the outcome of treatment this involves providing evidence of the 
effectiveness and efficiency of treatment. The second part of the analysis describes the 
quality of the treatment using the TELER index.
Analysis of the outcome o f treatment
The effectiveness analysis provides statistical evidence of the outcome of 
treatment through the calculation of statistical significance of the improvements that the 
group had experienced (Le Roux 2003). The efficiency analysis provides evidence of 
the appropriate allocation of inputs to produce the desired outputs.
Efficiency of care is defined by the Agency for Health Care Research and Quality 
website as:
"An attribute o f  performance that is measured by examining the relationship between a 
specific product o f  the health care system (also called an output) and the resources used 
to create that product (also called inputs). A provider in the health care system (e.g., 
hospital, physician) would be efficient i f  it was able to maximize output fo r  a given set 
o f inputs or to minimize inputs used to produce a given output."
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For the purposes of this analysis this definition is used as a guidance for planning 
the analysis. Therefore it is required to define the outputs and inputs while identifying 
the perspectives upon which these definitions are based. As the purpose is to provide 
evidence of efficiency of the delivery in clinical setting rather than standardised 
research setting, it was decided to adopt definitions that represent the perspectives of 
patients, clinicians, and mangers.
Following consultation during the steering group meetings17 at the PR service 
which included patients’ representatives, clinical and financial managers, 
physiotherapists, nurses and other PhD students. It was decided that an input of 
common interest is “time units” and the output of common interest is “clinically 
significant change”. Table 13 shows the framework that guided the efficiency analysis. 
This was based on the typology for the evaluation of efficiency provided by the Agency 
for Health Care research and Quality.
T able 13 T he fram ew ork  that guided the efficiency analysis
Metric Perspective Objective Output Input
Cost per clinically
significant
im provem ent
•  Consum ers o f  
health care.
•  C linicians.
•  M anagers.
Identify the 
optim um  
duration o f  
PR.
Total num ber o f
clinically
significant
changes in
functional
perform ance
Total num ber o f
treatm ent
contacts.
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Analysis o f the quality o f treatment
This analysis is concerned with providing informative evidence about the quality 
of treatment to the managers and policy makers. The description is provided by the 
TELER index and is based on the assumption that the clinically significant 
improvements experienced by the group had been the outcome of its treatment. The 
description is in four parts which show:
1. The overall extent of the group's functional loss and potential for improvement 
on admission.
2. The overall extent of the group's change on discharge.
3. The overall extent of the effectiveness with which the group's treatment had 
been delivered.
4. The success in maintaining the group's overall condition at all times during 
treatment (Le Roux 2003).
Whether the aim of the analysis is to provide evidence of outcome of treatment 
(effectiveness and efficiency) or evidence of the quality of treatment, it is worth noting 
that the group could be analysed at different levels, depending on the definition of the 
group Table 14.
T able 14 D ifferent levels o f  group analysis and their d efin itions (Le Roux 2003).
Levels of group 
analysis
Unit of study Variable under study Definition of group
At the level o f  the 
problems presented
Group Functional problem An assem bly o f  
functional problem s.
At the level o f  patients 
in group
Group Functional problem An assem bly o f  patients 
and a patient is defined 
as an aggregate o f  
problem s
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13.4 Results of clinical testing
All the 10 patients completed the baseline assessment. Below is a table listing the 
titles of the TELER indicators used and the number of participants who completed each 
indicator Table 15. Indicators were chosen by the participants according to their 
relevance and importance to them. Functional walking, slope walking and talking and 
going upstairs were chosen by all participants.
Table 15 Number of patients completing each of the TELER function indicators
Indicator Title Number of patients
G eneric activity indicator 5
Functional w alking 10
Slope w alking and talking 10
Going upstairs 10
Show ering 2
Bending to do an activity 8
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13.4.1 Results of Responsiveness
13.4.1.1 Quantitative analysis o f  responsiveness (Chi-Square test)
The aim was to assess the differences in the distribution of clinically significant 
changes and no changes on CAT and TELER "function" indicators. Therefore a 
definition of clinically significant change is required.
TELER "function" indicators were designed and calibrated to measure clinically 
significant change. Thus the individual was defined as changed when the change index 
was not zero at the end of treatment. Clinically significant change is not defined on 
CAT. For the purposes of this analysis, clinically significant change on CAT was 
defined as a change of at least one score or more on each scale of the 8 scales on the 
questionnaire. Thus a change of 8 scores in the total is required to define the patient as 
changed on CAT. Appendix C.5 shows the probability distribution of both CAT and 
TELER. A total of eight patients were included in this analysis because CAT data was 
missing for two patients. Table 16 shows the distribution of change and no change on 
both TELER and CAT
• The Null hypothesis was that there was no difference between the “distribution 
of change and no change” recorded on TELER and the “distribution of change 
and no change” recorded on CAT.
• The alternate hypothesis was that there is a difference between the “distribution 
of change and no change” recorded on TELER and the “distribution of change 
and no change” recorded on CAT.
• A significance level of 95% confidence was set before calculation, P<0.05.
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Table 17 shows the calculation of the expected values corresponding to the 
distribution o f changed and not changed on both TELER and CAT.
• The expected value for the cell in row 1 at column 1 is (the probability that a 
subject will have the characteristic “change” on both CAT and TELER by 
chance) x (grand total).
• The probability that a subject will have the characteristic “change” on both CAT 
and TELER by chance is (the probability that a subject will have the 
characteristic “change” on CAT by chance) and (the probability that a subject 
will have the characteristic “change” on TELER by chance).
• The probability that a subject will have the characteristic “change” 
(improvement or deterioration) on CAT by chance is 2 4- 3.
• The probability that a subject will have the characteristic “change” on TELER 
by chance is also 2 4-3.
• The probability that improvement, deterioration and no change occurs by chance 
on each scale is ^ ^ , and  ^respectively.
• Independence is ensured by collecting the data on TELER and on CAT by two 
different clinicians.
• When the measurement made on CAT is made independently o f the 
measurement made on TELER, (the probability that a subject will have the 
characteristic “change” on CAT by chance) and (the probability that a subject 
will have the characteristic “change” on TELER by chance) is (2 4- 3) x (2 4- 3). 
The expected value therefore is (2 4- 3) x (2 4- 3) 4- 8.
• On the contingency tables: C denotes changed, and NC denotes not changed.
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T able 16 D istribution  o f  changed  and not changed on both T E L E R  and C AT
CAT
TELER C N TOTAL
C 2 6 8
N 0 0 0
TOTAL 2 6 8
T able 17 E xpected values correspond ing to the distribution  o f  changed and not changed on both T E L E R  and
C A T
CAT
TELER C N TOTAL
C (f x f  x 8) -  8 
= 3.56
(f X J X 8) -E 8
= 1.78
5.34
N (§ x ^ x 0) -e 8 
= 1.78
( | x 5 x 0 ) v 8 
= 0.89
2.67
Total 5.34 2.67 8.01
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Table 18 Chi square calculation
(O -  E)2 E values
TELER
CAT
Total
Change No change
Change 0.68 10.00 10.68
No change 1.78 0.89 2.67
Total 2.46 10.89 13.35
• Degrees of freedom =1
• Tabulated x 2 = 3.84 at P = 0.05 and df = 1
• The total of the (O -  E)2 -s- E values, namely 13.35, shows statistical
significance. The critical chi-square value at the 95% confidence level is 3.841.
Since the calculated x 2 > tabulated x 2 , this is at the 95% confidence level, the
null hypothesis is rejected and the alternate hypothesis is accepted. There is a
difference between observed and expected changes and no changes recorded on both
TELER and CAT. As TELER has enabled the recording of more changes then it is 
more responsive to changes.
It is worth noting that the CAT “no change” value of 10.00 is a massive outlier in
•  2 comparison with the other three (O -  E) -s- E values. This prompts the question “how
much of the statistical significance is due to the outlier, and how much is due to a lack
of similarity between TELER and CAT?”
To examine the effect of the outlier it is replaced by the corresponding expected 
value. If the new total does not show statistical significance, then the outlier caused the 
statistical significance. If the new total does show statistical significance, then the 
outlier had no effect on the statistical significance.
The expected value corresponding to the outlier in Table 6 is the average of the 
other three values, namely (0.68 + 1.78 + 0.89) - 0  = 1.12. Now the total of the (O -  
E)2 -5- E values is 0.68 + 1.12 + 1.78 + 0.89 = 4.47, which shows statistical significance
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and implies that TELER and CAT are not equally responsive. As TELER shows more 
changes than CAT, TELER is the more responsive to clinically significant changes.
13.4.1.2 Qualitative analysis o f  responsiveness
Patient MH was selected because he experienced the largest number of clinically 
significant changes. The TELER form under consideration is shown in (Appendix 
C.6).The form shows that during the two months starting from 19-August-2010 and 
ending 14 October-2010, the patient received 12 treatment sessions and one 
maintenance. This is a total of 13 treatment contacts.
It could be argued that this patient had used all 6 function indicators, so he had 
more chances to record more clinical changes. However one of the indicators that he 
used was not changed. On the “Generic activity” driving; the patient reported being on 
code 0 on assessment and on all occasions after that except on the 10th and 11th 
session. The reason the patient was reporting inability to drive was due to "symptoms", 
particularly coughing, and lack of confidence (Appendix C.7). The indicator 
“Showering” did not change because the patient was not able to get a bath seat. The 
only reason he could not shower was because he could not do it while standing and it 
was very difficult for him to rise from setting on the floor bath or to squat.
On the 23-August-2010, the second treatment session; the patient was not changed 
on all indicators except two, the “functional walking” and the “bending to do an 
activity” indicators. The patient explained the three clinically significant improvements 
on the “bending to do an activity” indicator as a result of improved confidence and 
education resulting in improved ability to control breathlessness and being able to 
perform the activity (Appendix C.7). Other improvements (one clinically significant 
improvement on the functional walking, slope walking and talking and going upstairs) 
occurred on the 5th and the 6th sessions, which is mid-way during treatment.
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On the 7th treatment session the patient experienced one clinically significant 
deterioration on the functional walking indicator, the patient explained this by the 
changing weather, and a feeling that his chest is rough suggesting that he might be 
having an infection. No formal clinical test was performed to diagnose the presence of 
infection on that occasion (Appendix C.7). It is not known why scores on slope walking 
and talking have not changed. One explanation might be that the functional walking 
indicator was more responsive than other indicator “slope walking and talking”. It could 
also be that the patient has avoided the slope walking outside due to the fact he was 
feeling rough. However, when he was asked to perform it on the treadmill it was 
observed that he is still on code 2. The other indicators represented indoor activities and 
therefore were not affected by the colder weather.
On the 8th treatment session the patient regained the lost function on the 
functional walking indicator, however he experienced a clinically significant 
deterioration on the “going upstairs” indicator. On the 10th session the patient regained 
the loss of function on the going upstairs indicators and experienced one clinically 
significant improvement on both of the “Generic activity-Driving” and the “functional 
walking” indicator.
On the 12th session the patient experienced two clinically significant 
improvements on the “going upstairs” indicator, but one clinically significant 
deterioration on the functional walking indicator, the patient attributed this to rough 
chest and cold weather affecting his walking performance outside home. Again no 
change on “slope walking” indicator suggests functional walking is being more 
responsive to changes (Appendix C.7).
Improvement on the going upstairs even when the patient said his chest was 
feeling rough was explained by the patient by the fact that going upstairs is indoor so 
the weather has no influence, moreover the patient reported that a rough chest
230
Phase3: Clinical testing Chapter 6: Determination o f  the usefulness o f  TELER “function” indicators
“breathlessness” does not prevent him from going upstairs, because he could stop for a 
rest (Appendix C.7).
13.4.2 Results of the analysis at different levels
1 RIn what follows the terms “score” and “code” have the following meanings
Code: The number o f clinically significant functions o f a particular type a 
subject is able to perform.
Score: The total number o f clinically significant functions o f all types a subject 
is able to perform.
The terms “statistical significance” and “clinical significance” on the TELER 
“function” indicators have the following meanings18:
Statistical significance: Shows a change/outcome could not have occurred by chance 
and has some cause.
Clinical significance: A change/outcome that is not statistically significant could have 
occurred by chance and is not attributable to some cause. This does not make the 
change/outcome any less real to the patient or clinician, and when it occurs before 
treatment the change/outcome will still require treatment. Clinical significance rather 
than statistical significance therefore is the proper basis for analysing clinical 
change/outcome.
13.4.2.1 Results o f analysis at the level o f the individual 
• Quantitative analysis 
This analysis includes the calculation o f statistical significance. It is worth noting 
that statistical significance at the level o f the patient could be shown in two ways:
1. The statistical significance o f the change of scores on all indicators used by one 
patient.
18 The definitions were provided by Mr A.A. LeRoux , the developer o f  the TELER method o f  
measurement.
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2. The statistical significance of the outcome of treatment “statistical significance 
of the outcome score on three indicators used by all patients”
1. Statistical significance of the change of scores on all indicators used by one 
patient.
The numbers of improvements or deteriorations that are statistically and clinically 
significant on all indicators used by one patient are presented in
Table 19 and Table 20 for patient CM and patient MH respectively. In both Table 
19 and Table 20, data above the dashed line represent no change or deterioration, data 
below the dashed line represent clinically significant changes, and data below the thick 
line represent clinically and statistically significant changes. The calculation of 
statistical significance at the level of the individual patient is based on calculating the 
probability of chance occurrence of improvement, or deterioration or no change. A 
statistically significant change has a probability of occurrence that is very small to be 
explained by chance. That is the probability of occurrence is smaller than the arbitrary p 
value of 0.05 (LeRoux 2003).
T able 19 The sign ificance o f  a num ber o f  im provem ents/deteriorations on a T E L E R  in d icator by code on 
adm ission and code on d ischarge. Patient CM
Code on discharge
Code on admission
0 1 2 3 4 5
0
1
2
3
4 1 1
5 1 2
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T able 20 T he sign ificance o f  a num ber o f  im provem ents/deteriorations on a T E L E R  indicator by code on 
adm ission  and code on d ischarge. Patient M H
Code on discharge
Code on admission
0 1 2 3 4 5
0 2
1
2 1
3 1
4 1
5 1
Similar tables of data distribution were developed for all patients (Appendix C.8). 
A summary is presented in
Table 21 shows the number of total clinically significant changes and the number 
of total statistically significant changes at discharge for each patient on all indicators 
used.
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Table 21 Sum m ary o f  c lin ically  sign ificant versus statically  sign ificant changes
Patient
Code.
Number of clinically significant 
changes
Number of statistically significant 
changes
AW 2 0
CM 6 1
DP 2 0
JT 5 0
JF 8 0
MB 8 0
MP 2 0
MH 10 1
NS 4 0
TB 1 0
2 .  S t a t i s t i c a l  s i g n i f i c a n c e  o f  t h e  o u t c o m e  o f  t r e a t m e n t
This could be calculated on three indicators used by all patients. Statistical 
significance analysis of the outcome of treatment provides evidence of effectiveness of 
treatment delivered and is calculated by the TELER software.
The outcome scores for improvements experienced by each patient on three 
indicators completed by all patients “functional walking, slope walking and talking, 
going upstairs” is presented in Table 22. An admission score is the total of the outcome 
on the three indicators on admission that is the total number of the counts of clinically 
significant changes experienced on all of the three indicators. An outcome score is the 
total of the outcome on the three indicators at discharge. The statistical significance of 
an outcome count of changes is dependent on the admission count of changes on the 
three indicators. Statistical significance is calculated by the TELER software and in this 
case only the outcome of patient MH was statistically significant at the end of treatment 
on the three indicators.
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T able 22 O utcom e scores on three T E L E R  indicators sta tistically  sign ificant at the 5%  one-tailed  level
Patient
Code
Admission count of changes
Outcome count of changesjSt
indicator
2nd
indicator
3rd
indicator Total
AW 2 2 4 8 10
CM 2 2 5 9 14
DP 3 2 4 9 10
JT 3 2 3 8 12
JF 3 2 4 9 12
MB 1 1 2 4 6
MP 2 1 3 6 8
MH 1 0 1 2 9
NS 3 2 4 9 11
TB 2 2 4 8 8
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Table 23 show s the clin ical and statistical sign ificance o f  the outcom e o f  treatm ent on all indicators used by 
each patient.
Patient code Clinically significant improvements
Statistically significant
Yes No
AW 2
CM 6 V
DP 2 V
JT 5 V
JF 8 V
MB 5 V
MP 2 V
MH 10 V
NS 4 V
TB 1 V
• Qualitative analysis of outcome 
Patient MH was selected because he experienced the largest number of clinically 
significant changes. However, the outcome of treatment was not statistically significant. 
The TELER form under consideration is shown in (Appendix C.6). The form shows that 
during the two months starting from 19-August-2010 and ending 14 October-2010, the 
patient received 12 treatment sessions and one maintenance. This is a total o f 13 
treatment contacts.
The outcome of treatment on the three indicators “functional walking, slope 
walking and talking and going upstairs” was statistically significant, this is shown in 
Table 22. This means there is sufficient evidence that the outcome is not a chance effect 
and maybe explained by treatment (PR) received.
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However, Table 23 shows that the overall outcome of treatment on all indicators 
was not statistically significant. This means there is insufficient evidence to conclude 
that the outcome was treatment effect. However, with reference to the clinical notes it 
could be seen that the patient expressed improvement in some functions and attributed 
this to benefits gained from PR, specifically improved capacity and control of 
breathlessness.
Patient’s qualitative report o f improved functional performance could be verified 
by reference to the performance record. In the performance record the performance 
index shows that on admission the patients’ problems were assessed as an 87% loss of 
function. The performance index on discharge was 47%. The corresponding change 
index shows a recovery of 38% of the lost function. This was accompanied by an 
improvement o f 8% on the health change index.
The performance record also shows that the value of the effectiveness index has 
dropped on the 7th treatment session to 88% and dropped further by the end of 
treatment to 78%. This means that the treatment was not delivered with maximum 
effectiveness. This was accompanied by increased variability in patient’s status and a 
reduction in the maintenance index towards the end o f the treatment. This instability 
was explained by the patient as a result o f chest infection and increased breathlessness.
The performance record and the therapist’s notes therefore show that the patient 
improved during treatment but was unable to experience the full benefit of 
physiotherapy. A moderate value of the effectiveness index and a maintenance index 
showing the patient condition was marginally unstable suggest that the patient outcome 
was satisfactory.
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Tracking score changes on the TELER sheet it was noticed that the showering 
indicator was not changing because the patient was not able to perform the function 
without a bath seat. The patient was referred to the OT to arrange for a home visit and 
prescribe environmental modifications. This shows how this TELER “function” 
indicator has informed clinical decision making by identifying the specific type of  
intervention that the patient needs, in this case OT. Also it was shown that the driving 
indicator was not changing. This was explained by lack of confidence due to fear of loss 
of control as a result o f coughing. However, no specific advice was provided for the 
patient to address this problem.
13.4.2.2 Results o f analysis at the level o f the group
Results o f quantitative analysis a t the level o f functional problems presented 
(Outcome of treatment/Analysis o f effectiveness)
An overall number of TELER function indicators tracing on admission and discharge is 
provided in Table 24.
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• Degrees of freedom (df): This is the number of indicator codes minus 1. Here 
df = 6 - 1 = 5 .
• Tabulated x 2 =  11.07 at P = 0.05 and df = 6
• The total of the (O -  E) + E values, namely 15.55, shows statistical 
significance. The critical chi-square value at the 95% confidence level is ll .0 7 .
• Since the calculated x 2 > tabulated x 2 # this is at the 95% confidence level, the 
null hypothesis is rejected and the alternate hypothesis is accepted.
Results o f quantitative analysis at the level of functional problems presented 
(Outcome o f treatment/Analysis o f efficiency)
• The total number of clinically significant improvements experienced by the 
group is 45(Appendix C.8 - Table 20).
• The total number of treatment contacts received by the group is 128, and the 
average number of contacts per patient is 12.8 (Appendix C.8 -Table 21).
• The number of contact/Clinically Significant Improvement = 128/45= 2.84.
• Cost per contact19 =120 Minute.
• Cost per Clinically Significant Improvement = 2.84*120= 341.3 Minutes.
19 This is the routine duration o f  one rehabilitation session at the PR service.
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Results o f quantitative analysis at the level of patients in the group (Quality of
treatment)
The Analysis at the level o f the group -the quality o f treatment is presented in Appendix 
C.8.
The quality of treatment delivered to the group is presented in Table 27, this is 
described in terms o f the number o f clinically significant improvements at the end of 
treatment, the improvements as a percentage of total change “effectiveness index”, the 
stability o f patients’ clinical condition “maintenance index” and the excellence of 
treatment. From admission to the date of discharge, 50% of patients received treatment 
of satisfactory quality, 20% of patients received treatment of good quality and 30% of 
patients received treatment with poor quality. It could be seen that patients who 
received poor quality treatment had a moderate effectiveness index at the end o f 
treatment, but the maintenance index shows that their clinical condition was unstable 
resulting in the loss o f some of the improvements gained. Patient MH has experienced 
the largest number o f clinically significant changes but his maintenance index show that 
his clinical condition was marginally unstable resulting in a satisfactory but not good 
quality o f treatment at discharge. These findings highlight the importance, but the 
difficulty o f the maintenance o f the clinical condition in this group o f patients.
These findings could be further examined by calculating the percentage of 
treatments the maintenance index was =100 and the percentage o f contacts the 
maintenance index was < 100. Table 28 shows that in relation to maintenance o f the 
clinical condition this group could be classified into three subgroups. 10% of patients 
were easy to maintain, 50% difficult to maintain, and 40% very difficult to maintain. It 
could be seen that there was only one patient “CM” who was easy to maintain and a 
concentration of patients in the other two groups.
This could be explained by reference to the clinical characteristics o f the patients 
and the performance index. Patient CM has the highest performance index on 
admission. By examining the clinical notes, it could be seen that he was the only patient
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who did not experience an exacerbation, a chest infection or any other clinical or 
psychological complications during treatment. This raises two important points.
First is the relevance of the delivery of standardised intervention for the whole 
group. Second is the importance of critical incidents during the course of treatment and 
its impact on functional performance. For example patient DP was admitted with a high 
performance index “70”, but was not able to experience the full benefits of treatment, 
because she had multiple drop outs due to depression as a result of a family death.
All patients who were admitted with a low performance index were either 
unstable or marginally unstable on discharge, this presented in Table 29. However, 
evidence of the association between the performance index on admission on 
maintenance index on discharge is inconclusive. This is because of the 70% of patients 
who were admitted with moderate performance index, on discharge 29% were unstable, 
42 % were marginally unstable and 29% were stable. This further emphasises the 
importance of the effects of critical incidents such as exacerbations, chest infections, 
and clinical and psychological complications on the maintenance of the benefits of PR. 
Table 26 shows the critical incidents experienced by each patient during treatment 
extracted from the clinical notes.
T able 26 C ritical incidents experienced  by each patient during treatm ent
Patient code Critical incident
A W Chest infection
CM N ot reported
DP Fam ily death
JT U pper airways infection
JF N ot reported
MB Exacerbation o f  COPD
MP Deep vein throm bosis
MH U pper airways infection
NS Upper airway infection/Stopped 
sm oking gained w eight-reduced 
fitness
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T B  Exacerbation o f  COPD
The effectiveness of treatment received by the group in relation to the 
performance index on admission is shown in Table 30. 20 % of patients were admitted 
with a low performance index however the effectiveness index on discharge was 
moderate. 80% of patients were admitted with moderate performance index of those 
75% had a moderate effectiveness index on discharge and 25% of those admitted with 
moderate performance index had a high effectiveness index on discharge.
Further examination of the patients who were discharged with high effectiveness 
index reveals that one of them had the highest performance index on admission “CM” 
suggesting an influence of the performance index on admission on the potential for 
experiencing treatment with high effectiveness. However the other patient had a 
moderate performance index on admission that is not amongst the highest in the group 
“JF”. What those two patients had in common is that both of them did not experience a 
critical incident that might influence functional performance during treatment.
The extent of functional loss on admission and on discharge is presented in Table 
31. It could be seen that 30 % of patients were admitted with low performance index, 
those had low to moderate performance index on discharge. 70% of patients had 
moderate performance index on admission, those had moderate to high performance
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index on discharge. On important finding was that one patient was admitted and 
discharged with low performance index. However, this patient has experienced the 
largest number of clinically significant improvements amongst the group. This prompts 
further examination of the case.
Although this patient had a low performance index on discharge he had actually 
the largest health change index on discharge. The maintenance index also shows that 
this patient had a marginally unstable clinical condition on discharge, which is not 
enough to explain the low performance index on discharge despite the large number of 
improvements experienced. This patient used six TELER indicators.
Analysis of statistical significance shows that this patient had experience only one 
statistically significant change on the indicators used, which is a movement from code 2 
to code 5 on the bending to do an activity indicator. However, analysis of statistical 
significance of the outcome of treatment on 3 indicators shows that his outcome was 
statistically significant. Therefore, an explanation of this case is that this patient had 
experienced small but multiple improvements on all the indicators.
This suggests that patients admitted with a low performance index might have a 
small potential to improve due to limited resources, implied by the small functional 
capacity, available to enable improvement. However, they have the potential to 
experience multiple clinically significant improvements on a number of functions that is 
relevant and important to them. This also prompts the importance of not relying on one 
index in evaluating the quality of treatment as this patient had a low performance index 
on discharge, but a large number of clinically significant improvements.
Health status index on admission and on discharge is shown in Table 32. The 
findings suggest that all patients except one had high health status index on admission 
and discharge. Not surprisingly the one patient who had moderate health status index on 
admission and on discharge is MH, who had a low performance index on admission and
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on discharge and used all the indicators expressing a large number of deficits requiring 
treatment.
This finding is difficult to interpret given the difficulty of treating this group of 
patients highlighted in previous findings due to the instability of the clinical condition 
across the group. One explanation might be that health status index is standardised for 
the number of deficits treated. The assumption is that the lager the number of deficits 
treated the worst the clinical condition. This might not be relevant to this group of 
patients. This is because patients with COPD experience functional limitations with
• • 90almost all of the functions of daily life .
In this study when an indicator was not used it was because the patient had given 
up the activity due to its high difficulty and low relevance, or is completely dependent 
on a carer for performing the activity. Thus lower number of indicator used might 
suggest greater disability not otherwise.
Health status index on admission and health change index on discharge is 
presented in Table 33. It is though that the fact that all patients except one had high 
health status index on admission is misleading due to the reasons identified earlier. 
However, a low health change index could be explained by the high variability of the 
clinical condition and the difficulty of the maintenance of improvements gained.
The overall extent of the group’s functional loss on admission, the extent of 
effectiveness with which group treatment had been delivered and the success in the 
maintenance of the patients’ clinical condition are presented in Table 34. The results 
show that on admission 30% of patients had low performance index suggesting high 
functional loss, and 70% of patients had moderate functional performance index 
suggesting moderate functional loss. Despite the finding that on discharge 80% of 
patients had moderate effectiveness index and 20% of patients had high effectiveness 
index. The results show that 70% of patients had experienced low change index, and 
only 30% had experienced moderate change index. This could be explained by the
20 This is known to the researcher from clinical experience, the findings o f  the qualitative study, and the 
ICF core set o f  activities and participations for CO PD  which includes a large range o f  daily 
life functions (ICF research branch 2010).
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difficulty o f the maintenance o f change in this group o f people with 30% of patients 
having a maintenance index on discharge showing that they were unstable and 60% of 
patients were marginally unstable.
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T able 28 The percentage o f  treatm ents the m aintenance index w as = 100  and the percentage o f  contacts the 
m aintenance index w as < 100
Patient Code Maintenance index (%contacts)
< 1 0 0 = 1 0 0
AW 80% 20%
CM 0 100%
DP 100% 0
JT 45% 55%
JF 55% 45%
MB 82% 18%
MP 58% 42%
MH 58% 42%
NS 99% 1%
TB 67% 33%
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T able 29P erform ance index on adm ission versus m aintenance index on discharge
Performance index on admission
Maintenance index on discharge
Unstable
Marginally
unstable
Stable Total
Low 1 2 0 3
Moderate 2 3 2 7
High 0 0 0 0
Total 3 5 2 10
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T able 30 P erform ance index on adm ission versus effectiveness index on discharge
Performance index on admission
Effectiveness index on discharge
Low Moderate High Total
Low 0 2 0 2
Moderate 0 6 2 8
High 0 0 0 0
Total 0 8 2 10
Table 31 Perform ance index on adm ission versus perform ance index on d ischarge
Performance index on admission
Performance index on discharge
Low Moderate High Total
Low 1 2 0 3
Moderate 0 4 3 7
High 0 0 0 0
Total 1 6 3 10
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Table 32 Health status index on adm ission versus health status index on discharge
Health status index on admission
Health status index on discharge
Low Moderate High Total
Low 0 0 0 0
Moderate 0 0 1 1
High 0 0 9 9
Total 0 0 10 10
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T able 33IIealth  status index on adm ission versus health status index on discharge
Health status index on admission
Health change index on discharge
Low Moderate High Total
Low 0 0 0 0
Moderate 1 0 0 1
High 9 0 0 9
Total 10 0 0 10
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T able 34  P erform ance index on adm ission , and C hange index, effectiveness index and m aintenance index on 
discharge
Value of 
index
Performance 
index on 
admission
Change index 
on discharge
Effectiveness 
index on 
discharge
Maintenance 
index on 
discharge
0-9 1 1
10-19 1 2
20-29 2 3
30-39 1 2
40-49 1 1
50-59 3 1 3 3
60-69 2 2 1
70-79 2 2 3
80-89 1
90-99
100 1 1
Total 10 10 10 10
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14 Summary of key clinically significant findings of the analysis of TELER data 
Summary o f the results of responsiveness analysis
• Quantitative analysis of responsiveness using chi-square test shows that there is 
a statistically significant difference between the distribution of change and no 
change recorded on TELER and the distribution of change and no change 
recorded on CAT. As TELER has recorded more clinically significant changes, 
it is suggested that TELER is more responsive than CAT.
• Qualitative analysis of responsiveness was performed to establish the 
importance of the ability of the clinician to detect and report clinically
significant changes recognised and experienced by the patient. Changes in
functional performance were reliably detected by the clinician and attributed to
influencing factor experienced by the patient. A number of factors that
influenced changes in functional performance were identified. These included 
contextual factors “personal and environmental” and symptoms “breathlessness” 
Improvements were attributed by patients to the beneficial effects of PR and 
included improved confidence and improved control of breathing. 
Environmental modifications were prescribed but not implemented. The analysis 
also identified differences in the change on the indicators between indoor and 
outdoor activities. With outdoor activities being more affected by influencing 
factors.
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Summary o f the results o f clinimetric analysis
1. Results of analysis at the level of the individual
• Results of quantitative analysis at the level of the individual showed that all 
patients experienced clinically significant changes.
• Analysis o f statistical significance of changes on all indicators used by one
patient showed that only two patients experienced one statistically significant
change each.
• Analysis of statistical significance of the outcome on three indicators used by all 
patients showed that only one patient experienced statistically significant 
change.
• Qualitative analysis at the level of the individual provided a method for
interpreting patient’s outcomes by reference to the treatment record,
performance record and clinical notes. Three important issues emerged in the 
qualitative analysis that should be considered in the interpretation of patient’s 
outcome and making clinical decisions, these are:
1. The impact of clinically significant changes achieved on patient’s 
satisfaction with the treatment delivered.
2. Identifying health condition “critical incidents” experienced by the 
patient during treatment that might influence functional performance 
such as an exacerbation of COPD, chest infection, upper airways 
inflammation, other clinical complications, and psychological 
distress.
3. Identifying contextual factors that might influence functional 
performance, this includes personal and environmental factors.
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2. Results of analysis at the level of the group
• Quantitative analysis of treatment effectiveness at the level of the group showed 
that by the end of treatment all patients experienced either no change or 
improvement of the TELER codes on all indicators used.
• There was a statistically significant difference between the distribution of the 
change “improvement” and no change on all indicators, suggesting that the 
group received an effective treatment.
• Quantitative analysis of treatment efficiency showed that the cost per one 
clinically significant contact was 341.3 minutes, which equals an average of 
approximately 3 clinical contacts.
• Quantitative analysis of the quality of treatment showed that 50% of patients
received satisfactory treatment, 20% of patients received good quality treatment
and 20% received poor quality treatment.
• The inability of the group to experience the full benefits of treatment was 
attributed to the difficulty of the maintenance of clinical condition in patients 
with COPD. The results showed that the variation in the clinical condition of 
10% of patients was easy to control, for 50% of patients it was difficult to 
control, and for 40% of patients it was very difficult to control.
• The findings of this study suggest that it is difficult to predict response to
treatment or the patent of recovery based on baseline clinical characteristics,
such as performance index on admission. However, the data shows that a 
possible association might exist between performance index on admission and 
the performance index on discharge, the extent of effectiveness with which 
group treatment had been delivered, and the maintenance of clinical condition of 
the group.
• Patient admitted with low performance index were either unstable or marginally 
unstable on discharge. Patients admitted with moderate performance index 
were unstable, marginally unstable, or stable on discharge. Patients who had 
stable maintenance index on discharge have not experienced any critical 
incidents during the treatment.
• On discharge all patients had received treatment with moderate to high 
effectiveness.
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• The use o f health status index was not informative in this group as patients who 
used smaller number o f indicators had more functional limitations than patients 
who used larger number o f indicators; this contradicts the assumption upon
91which health status index is calculated . It could be argued that this might be a 
data collection problem and that when the patients decided not to use an 
indicator that should be used then the codes o f the indicators should be entered 
as 0 on the data sheet. A caveat here is that if the patient decided that this 
function is not relevant anymore because it was given up, then including it and 
scoring it as 0 might overstate functional loss when the results are 
communicated to the patient.
• Low health change index on discharge in this group could be explained by the 
difficulty o f controlling the variability in the clinical condition in patients with 
COPD.
21 The heath status index is based on the assumption that the use o f  larger number o f  indicators indicates 
more functional loss. In this study patients might have used less indicators because they 
have given up the functions described by some indicators, and therefore they are more 
functionally limited.
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Discussion of Phase 3: Clinical testing
The aim of the clinical testing study was to demonstrate the usefulness of TELER 
“function” indicators in terms of its responsiveness to clinically significant changes and 
providing data appropriate for clinimetric analysis when used in clinical PR setting. 
However, before providing a discussion of the usefulness and of TELER “function” 
indicators it is important to identify the context of the clinical testing to ensure the 
validity of the interpretations of the results of the analysis of TELER data.
14.1 Identifying the context of the clinical testing study
Identifying the context of the study requires examining the purpose of 
measurement in the current study, identifying the nature of the data subjected to 
analysis and the level of measurement, and identifying the reliability of measurement.
14.1.1 The purpose of measurement in the clinical testing study
The purpose of measurement in this clinical testing was the collection and 
analysis of data on the improvements in functional performance experienced by patients 
with COPD participating in PR program. The aim was not to establish the effectiveness 
of PR, therefore inferences withdrawn from the clinical testing is based on TELER 
evaluation not attribution.
It is important to recognise the difference between the TELER evaluation and the 
TELER attribution. In TELER evaluation the clinician has an assumption that the 
treatment is effective. Therefore, the observed patterns of change or lack o f change are 
compared with expected patterns of change or lack of change. In TELER evaluation a 
correspondence between the observed and expected pattern of change or lack of change 
is taken as evidence of effective treatment, and lack or correspondence is taken as lack 
of change.
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In TELER attribution it is required to determine whether an observed pattern of 
change or lack o f change is unlikely to have occurred by chance. An observed pattern of 
change or lack o f change is unlikely to have occurred by chance when it is statistically 
significant. In TELER attribution the guiding principle is uncertainty about the cause of 
an observed pattern o f change or lack of change. When used in an appropriate research 
design TELER attribution does identify the cause of the observed pattern o f change or 
lack o f change which is unlikely to have occurred by chance.
14.1.2 Identifying the levels of measurement using the TELER indicator
It has been highlighted earlier the clinically significant outcomes are different to 
clinically significant changes. This implies that the level of measurement o f a clinically 
significant outcome is different to the level o f measurement of a clinically significant 
change. Clinically significant outcomes are represented as the definitions o f the codes 
on the TELER indicator. Each code presents a clinically significant outcome that is 
defined in reference to theoretical and clinical knowledge and patients’ and clinicians’ 
experience. These codes are represented by “numerals” and provide an ordinal level of 
measurement (LeRoux 2003).
On the other hand clinically significant change is the amount o f clinical change 
that is required to achieve the next clinically significant outcome on the TELER 
indicator. That is on the TELER indicator there are six clinically significant outcomes. 
To achieve code 5 on the indicator the patient should experience five clinically 
significant amounts of change. The fact that this is an ordinal scale the amounts of 
change between two successive codes on the indicators are not equal. Therefore the 
amount o f clinically significant change required to achieve one clinically significant 
outcome could not be quantified. However, the number of changes required for 
achieving a certain clinically significant outcome on the scale could be counted. 
Counting entities does not require equality. It is similar to counting persons with all the 
inherent differences between people counted. Counts of clinically significant changes 
are represented by numbers that could be subjected to operations o f algebra (Michle 
1983). Lord states:
"The numbers do not know where they came from" (Lord 1953, P: 751).
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Therefore, data for the quantitative analysis uses the counts of clinically 
significant changes and not the numerals representing the codes of the indicator.
14.1.3 Reliability of TELER “function” indicators
Three important theoretical principles should be considered when evaluating the 
reliability of the TELER “function” indicators. First, functional performance is 
continuously changing in patients with COPD. Therefore consistency of measurement 
could not be used as an evidence of reliability. Second, TELER “function” indicators 
are designed to measure change within the individual patient. This requires high 
reliability because error cannot be eliminated by averaging. Third, appropriate use of 
the TELER method requires that the clinician has adequate knowledge, o f what 
constitutes a change and to record the change reliably each time it occurs.
When attempting to establish evidence of the reliability of indices generated 
qualitatively by patients it should be noticed that these will vary naturally because of 
their highly individualized nature, resulting in multiple contextual factors influencing 
the change. Thus assessing reliability using traditional statistics would provide results 
that are misleading and difficult to interpret (Guyatt et al. 1987a).
Reliability of measurement in clinical setting could be increased by reducing 
measurement error each time the measurement is performed at the level of the 
individual. This could be achieved by ensuring that the observer “the clinician” has 
adequate knowledge and skills in identifying and recording “true” change when it has 
occurred in systematic and consistent manner. One way by which TELER ensures 
consistency is by defining the codes of the indicators using statement that have singular 
meaning. That it is it could be interpreted in one way only. Moreover, adequate training 
on the use and implementation of TELER system is mandatory to ensure reliability.
In the context of this study measurement was jointly performed by the patient and 
the researcher. The measurement was recorded by the researcher who received 
extensive training on the TELER method and a one to one support provided by TELER 
limited.
Having established the context of the clinical testing a discussion of the usefulness 
of TELER function indicators in terms of its responsiveness and providing data 
appropriate for clinimetric analysis is presented next.
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14.2 A discussion of the usefulness of TELER function indicators in clinical
setting
It has been highlighted earlier that the usefulness of TELER function indicator is 
determined by establishing evidence of responsiveness and appropriateness of data 
generated for clinimetric analysis.
14.2.1 Responsiveness of the TELER “function” indicators
Evaluation of the responsiveness of the TELER “function” indicators is based on 
the following theoretical principles:
1. The clinician has the knowledge to recognise a clinically significant change 
when it has occurred and record it.
2. The categories o f the construct “functional performance” are defined so that 
they are mutually exclusive and exhaustive. That is the definition of the codes 
on the scale should allow for identifying the clinically significant differences 
between the codes.
In other words detecting clinically significant changes in functional performance 
requires a measurement scale that has construct validity and a reporter “patient or 
clinician” who has the knowledge to recognize and record a change when it has 
occurred.
Responsiveness of TELER “function” indicators was established using 
quantitative and qualitative methods. The difference between the distribution of change 
and no change on both TELER indicators and CAT was calculated using Chi square 
test. CAT was selected because it is a feasible tool for clinical practice that could be 
completed by patients and clinicians. The results suggest that there is a clinically 
significant difference between the distribution of change and no change on both TELER 
and CAT. The fact that there are more changes reported on TELER suggests that the 
TELER “function” indicator is more responsive than CAT.
It is worth mentioning that CAT and TELER data were collected by different 
clinicians. However both were clinicians with similar experience and level of training, 
and are expected to have comparable levels of knowledge. The difference could be 
explained by the fact that definitions on CAT lacked precision.
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The definition of the codes of the TELER function indicators allow for recording 
more clinically significant changes than CAT. This is because the codes on the 
indicators define clinically significant outcomes that are meaningful to the patient and 
the clinician. Therefore, these changes could be recognised, observed and recorded.
14.2.2 The appropriateness of TELER data for clinimetric analysis
A full clinimetric analysis requires the measurement to accurately record the 
clinical phenomena experienced by the patient and observed by the clinician. This 
includes a number of components that constitute the elements of the clinical encounter. 
These components were collated from a number of papers on clinimetric and the 
implementation of measurement in clinical setting (Feinstein 1983, Greenfield and 
Nelson 1992, Higginson and Carr 2001, and Sperlinger 2002):
1. Identifying changes in the clinical problem “functional performance” and the 
factors influencing it.
2. Identifying the benefits experienced by patients as a result of treatment 
delivered
3. Identifying problems that prevented the patients form experiencing the full 
benefits of treatment.
4. Identifying the clinical characteristics of the group and the pattern of 
recovery.
5. The process of clinical decision making, clinical reasoning and judgment 
based on evidence grounded in the outcome of measurement at the level of 
the individual in clinical settings.
Evidence o f the appropriateness of data generated by TELER function indicators for 
clinimetric analysis is provided by identifying how the analysis of the TELER data has 
informed each one of the components of the clinical encounter.
1. Identifying changes in the clinical problem “functional performance” and the 
factors influencing it.
It was established that TELER “function” indicators were responsive to changes 
in functional performance. The definition of the codes on the indicators enabled the 
recording of change when it has occurred, and was observed by the researcher and 
recognised by the patient.
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The TELER method of measurement enables the identification of changes in 
functional performance by two main methods. The first method is by providing a trace 
of scores on the data sheet of TELER software; this provides session by session 
information on change. The second method is by the calculation o f a change index; this 
provides an estimate o f the overall change at the end o f treatment.
The measurement o f functional performance is performed each time the patient 
attends the PR session and data is recorded on the data sheet. This provides a 
longitudinal follow up of changes in functional performance during PR. The 
meaningfulness of the changes recorded is implied by the definition o f the codes o f the 
indicators and has been discussed earlier during development. However, it is the 
responsibility o f the clinician to respond to the recorded changes whether this was an 
improvement or deterioration. The response o f the clinician is in the form of 
maintaining treatment, altering treatment, or withdrawing treatment. Changes in 
functional performance occur in the form of improvements or deteriorations.
The clinical relevance of improvements recorded on TELER function indicators
In the context of PR recording the ability to recognise and record an improvement 
when it has occurred reliably and systematically, provides invaluable clinical 
information. This includes information regarding the number o f sessions required to 
induce an improvement, the maintenance o f improvements, and the maximum potential 
improvement for a particular patient.
In this clinical testing study all patients experienced improvements during the 
course o f treatment. This was expressed as a positive change index for all patients at the 
end o f treatment. However, all patients only experienced a low to moderate change 
index on discharge. This suggests that there are other factors than treatment influencing 
the change experienced by patients. Another explanation might be the lack o f specificity 
of the intervention. This will be further discussed in the overall discussion.
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Of the patients 60% started to experience improvements on the 5th treatment 
session. Other patients experienced earlier improvements after the 1st session. These 
improvements were on the “showering” and “bending to do an activity” indicators. 
These early improvements were attributed by patients to environmental modifications, 
improved breathing control and learning a better technique for performing the activity 
that resulted into energy conservation during performance. For example patient JF 
explained the early improvement on the showering indicator from code 2 to code 4, 
after the 1st session, by having a shower seat, so that she does not have to stand during 
showering, and sitting in the towel and “drip dry” instead of actively drying herself.
Other improvements occurred later on the 8th, 9th and 12th treatment sessions 
these included functional walking, slope walking and talking, and going upstairs. These 
activities are related to moving from one place to another and are associated with high 
ventilatory demand, and the involvement of the large muscles of the lower limbs 
resulting into increased oxygen consumption (Palange et al. 2000). Therefore, inducing 
a change in these activities required a combination of improved physiological capacity, 
self-efficacy and control of breathlessness.
Results of a recent systematic review on the minimum duration of PR required for 
inducing changes in Health Related Quality of Life and walking tests were reported by 
the authors to be inconclusive (Beauchamp et al. 2009). The authors explained their 
findings by the heterogeneity of the literature and lack of standardised outcome 
measures. The findings of this study suggest despite the heterogeneity of the population 
of people with COPD, TELER “function” indicators enabled the clinician to identify the 
treatment session when clinical improvements in functional performance started to 
occur. This provides the information required to make clinical decisions on the optimum 
length of PR based on the individual’s needs, clinical characteristics and response to 
treatment.
Solanes et al. (2009) investigated the minimum duration required to induce a 
plateau in HRQoL in patient with COPD attending outpatient PR. The authors reported 
The number of patients achieving stability after 8 weeks, showing continued 
improvement after 8 weeks, and demonstrating an erratic pattern of change was as 
follows: for physical function measured on CRQ (56%), (37%) and (7%) patients.
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This study shows an explicit example o f the difficulty o f making clinical decisions 
based on research studies. In this study the authors identified the inclusion criteria, as an 
age under 65, no home oxygen use, clinically stable nutritional status, no exacerbation 
in the last month or changes in medication in the last 4 months. This striving for 
homogeneity and stability in research samples to reduce bias and improve control, 
precludes useful inferences from these studies about the individual in the clinical 
context.
This emphasises the need for a measurement tool that enables clinimetric analysis 
and inform clinical decision making. The decision about the duration o f treatment 
should be individualised and based on when the specific individual starts to experience 
improvements, and the nature of therapeutic input required to induce an improvement in 
functional performance.
Another important point is the need for a paradigmatic shift in research methods. 
This shift should enable more realistic evaluation for complex interventions such as PR 
in heterogeneous population such as COPD (MRC 2008) and (Pawson 2003).
The clinical relevance of deteriorations recorded on TELER function indicators
Due to the progressive nature o f COPD one o f the aims o f treatment is the 
prevention of deteriorations in functional performance. This information is provided by 
the TELER software in the form of maintenance index.
However, the data shows that this is a difficult aim to achieve in this group. This 
is due to the progressive nature of the disease and to the multidimensional nature of 
functional performance. Functional performance is influenced by a number o f factors. 
Changes result from the interaction of factors related to the disease and contextual 
factors. Therefore linking clinical notes with the trace of score changes is crucial to 
enable identifying the factors that resulted in the deterioration and target the treatment 
to alter these factors.
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2. Identifying the benefits experienced by patients as a result o f treatment 
delivered
This is information is provided by the TELER method in the form of effectiveness 
index. The effectiveness index shows improvements as a percentage of total change. 
Despite the instability in the clinical condition the data shows that by the end of 
treatment all patients had experienced moderate to high effectiveness. The data 
presented here confirms positive changes reported by patients in the qualitative study in 
functional performance. It also confirms the beneficial effects of PR on functioning, 
which was shown in terms of improvements in the walking tests (Dolmage et al. 2011) 
and physiological parameters (Laccasse et al. 1996). However TELER function 
indicators show how these physiological improvements have translated into improved 
day to day functioning at the level of the individual patient.
3. Identifying problems that prevented the patients form experiencing the 
full benefits o f treatment.
Whilst this is a matter of clinical reasoning and clinical knowledge of the 
clinician, the TELER method provides the tool that enables the clinician formulate 
explanations of the clinical problems that precluded or delayed full recovery. In a 
chronic condition such as COPD this is a question of maintenance. This requires the 
clinician to identify the point in treatment when he/she lost control over the clinical 
condition of the patient. More importantly is identifying the factors that resulted in this 
loss of control.
This information is presented on the TELER form as the maintenance index. 
Maintenance index is calculated by the TELER software throughout the treatment. The 
maintenance index provides information on the variability of the patients’ clinical 
condition. While this group o f patients experienced large variability in their clinical 
condition, the important issue is the explanation of this variability. By reference to the 
clinical notes it was identified that patients started to show instability, a short time 
before, during, and a short time following a critical incident. This information is very 
important. This because clinical stability and lack o f exacerbation is a standard 
inclusion criteria in almost all research studies on PR. Clinically variation in the clinical 
condition was the main factor the precluded experiencing the full benefit o f PR.
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4. Identifying the clinical characteristics o f the group and the pattern of  
recovery
As this clinical testing study is concerned with the evaluation of functional 
performance in clinical PR setting, the clinical characteristics of the group is best 
described in terms of the performance index. The performance index shows current 
performance as percentage of optimal performance. On admission 30% of patients had a 
low performance index and 70% of patients had moderate performance index, on 
discharge 10% of patients had low performance index, 20% of patients had moderate, 
and 30 % had high performance index.
A caveat here is that it is important to consider other indices when making 
decisions about the pattern of recovery. During analysis one patient was identified who 
had a low performance index on admission and on discharge. However this patient has 
experienced the largest number of clinically significant improvements.
The pattern of recovery was heterogeneous across the group with some patients 
experiencing small improvements on all indicators and others experiencing large 
improvements on small number of indicators. The pattern of recovery of the functional 
loss was partially described by performance index on admission. The other main factor 
that influenced the trajectory of change of functional performance in this group was the 
occurrence of a critical incident that had an impact on functional performance. A critical 
incident could be related directly to COPD such as an exacerbation, or to other clinical 
condition. The critical incident in this study was also described in terms of 
psychological disturbance resulting from a social or family incident.
An important point to highlight here is that functional performance is influenced 
by a number of factors and might change instantaneously as a result o f these factors 
such as the weather. Therefore, in the context of this study was described as a critical 
incident that resulted in deterioration of functional status that was maintained over two 
points of clinical contacts. Another way of verifying this is by calculating statistical 
significance of the movement on the indicators. However, it remains important to 
consider clinical significance when making clinical decisions.
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Existing research studies that attempted to investigate the pattern o f recovery 
following PR stratified patients at baseline based on physiological variables (Antonelli- 
Inclazi et al 2003), (Takigawa 2007a), (Takigawa et al. 2007b), and (Trooster et al. 
2001), functional variables (Berry et al 1999), and (Plankeel et al 2005), or based on the 
severity o f symptoms (Wedzicha et al 1998) (Trooster et al 2001). Results were 
inconclusive and contradicting. This could be explained by the variability o f PR 
protocols used in each study, and variability in the baseline characteristics of 
participants in different studies.
This study has contributed to the knowledge about the pattern o f recovery and 
response to PR by providing qualitative evidence that functional performance is 
influenced by a number o f factors upon which is physiological capacity and symptoms. 
Therefore, a direct measure o f functional performance is essential to enable the 
description o f the pattern of recovery following PR. However, it should be ascertained 
that explanations should be contextualised. Moreover, the findings o f this study suggest 
that a general descriptive pattern that could be applied to all individuals within the 
group in unlikely to occur in the current knowledge about COPD, PR, and the factors 
influencing functional performance. Particularly that this group o f patients show clinical 
variability in clinical status that is difficult to control.
In this study the pattern of recovery o f functional performance reflected an 
individualised experience o f recovery that is influenced by the progression of the 
disease as well as personal and environmental factors. Therefore, clinical decisions 
should be individually based and treatment interventions should be tailored to target the 
needs and the circumstances of the individual patient. The TELER “function” indicators 
were shown to be a useful clinical tool that enables tracing change scores at the level of 
the individual and describe the pattern o f recovery o f the individual patient.
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5. The process o f clinical decision making, clinical reasoning and judgment 
based on evidence grounded in the outcome o f measurement a t the level of 
the individual in clinical settings.
A crucial feature of the TELER method that facilitates making clinical decisions 
is the note making system. Linking treatment record, clinical notes, and the performance 
record enables the clinician to generate explanations of changes experienced by the 
patient. Moreover, it enables evidence based selection and targeting of interventions to 
address the needs and experience of recovery of the individual patient.
The knowledge about the functional performance, the factors influencing it, and 
the changes in the construct in response to PR that emerged during the three phases of 
this thesis has provided new insights that could guide the process of clinical reasoning 
in PR setting during the treatment of people with COPD.
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15 Introduction to the overall discussion
This overall discussion will summarise and reflect on the methods and findings of 
this research. The discussion will be tailored to support the conclusion that a new 
outcome measure of functional performance for people with COPD that is underpinned 
by theoretical specifications and is appropriate for implementation in clinical PR setting 
has been developed following a rigorous research process. In order to achieve this, the
overall discussion is presented in two main parts, these are:
1. Identifying the need for the measurement of health outcomes in clinical setting.
2. The contribution of this thesis to the knowledge in the area. This includes:
• A reflection on the suitability of the methodologies used within this 
thesis for the development of the outcome measure, and the new 
knowledge that emerged during different phases. This includes
identifying the specifications of a clinical outcome measure, the
development of a conceptual framework for the measurement of 
functioning, and new insights into the experience of functional loss 
in people with COPD
• A discussion of the appropriateness of the TELER “function” 
indicators for measurement in clinical settings
• A discussion of the new knowledge that has emerged during the 
clinical testing about the delivery and response to PR.
This is followed by a discussion of the limitations of this research, dissemination 
of research findings and future research.
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16 The need for measurement of health outcomes in clinical settings
This thesis responds to the worldwide drive for developing and evaluating 
interventions required for tackling the epidemic of non-communicable diseases (WHO 
2008). The WHO predicted that chronic conditions will become the leading cause of 
disability worldwide in (2020), inflicting substantial costs on health care systems (WHO 
2008). This comes at a time when the health care systems work under the challenge o f  
making efficiency savings, but maintaining quality, through productivity and innovation 
(Department o f Health 2010a). This challenge could not be met without appropriate 
outcome measures that provide informative data about the quality and outcome o f  
treatment.
The clinical case studies presented in the clinicians’ guide for Meeting the
99challenge o f the QIPP agenda, suggested enhanced recovery and facilitated early 
discharge as two methods o f meeting the demands of the prevailing fiscal policy 
(Department of Health 2010a). This suggests that clinicians treating patients with 
chronic conditions need appropriate measurement tools and systematic clinical records 
to enable them to trace changes in the individual patient. Measurement at the level of  
the individual provide valuable information for making informed, evidence based 
clinical decisions in response to the documented changes in the patient’s clinical 
condition.
Moreover, appropriate measurement of health outcome in clinical settings enable 
clinicians to detect deteriorations once they have occurred and act upon them. This will 
ultimately result in the delivery of specifically targeted interventions that enhance 
recovery and facilitate discharge.
Despite the financial challenges the WHO warned that if not managed 
appropriately chronic conditions will strain the economic structures inside and outside 
the health system. This would result from the increased rates of readmissions, increased 
severity o f cases requiring more expensive interventions including surgeries and 
intensive care, and increased disability resulting in the increased need for environmental 
modifications and professional care at home and in the community (WHO 2008).
22“Quality Innovation Productivity and Prevention”
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This suggests that financial savings should be thoughtfully planned to ensure that 
it does not result into indirect substantial increases in the economic burden. Such 
planning could not be achieved without outcome measures that provide veracious 
evidence to managers to make informed decisions about rationing resources.
The above discussion suggests that in order to meet the requirements for 
measurement in clinical setting, a clinical measurement tool is required. This 
measurement tool should be able to measure changes in the clinical condition at the 
level of the individual, detect early changes and provide clinically informative data that 
enables swift management o f the deteriorations to facilitate early discharge. During the 
phase o f conceptualisation it was identified that a measurement tool that is appropriate 
for measurement in clinical PR setting currently does not exist. This PhD research has 
filled this gap by developing a new outcome measure, the TELER “function” indicators, 
which is appropriate for measurement in clinical PR settings.
During the clinical testing phase it was shown that the TELER method of 
measurement provided the appropriate clinical tool for tracing changes in the clinical 
condition at the level of the individual. The clinical note making system enabled 
identifying the underlying causes o f change. It is assumed that this will facilitate 
making evidence based clinical decisions by addressing changes with targeted 
interventions specific to the needs o f the individual, and the nature o f the problem 
presented. Ultimately this will enhance the experience o f care o f the individual and 
facilitate early discharge by early detection of deteriorations and taking specific and 
individualised clinical actions.
Moreover, the TELER method of measurement provided information that could 
enable early discharge while avoiding too soon readmission. This is achieved by 
calculating a maintenance index that reflects the stability o f the clinical condition. This 
ensures that the patients are not discharged without being clinically stable. However, 
due to the progressive nature of COPD, it is expected that patients will experience 
deterioration in functional performance following discharge. Therefore, patients should 
be equipped with a patient reported outcome measure that enables them to detect early 
changes in functional performance and communicate those to health professionals or re
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admit themselves to PR. The fact that TELER “function” indicators are grounded into 
patients’ narratives suggest that they have the potential to be used as a patient reported 
outcome measure. This is further discussed in the future research section.
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17 The contribution of this thesis to the knowledge in the area
During the phase of conceptualisation, improving functioning was identified as 
the central aim of PR in the management of people with COPD. However, it was found 
that the construct functioning was poorly defined in the literature, resulting into plethora 
of measurement tools for the measurement of quality of life, health status and functional 
status of people with COPD. However, the conceptualisation of the constructs of these 
outcome measures was imprecise and lacked specificity by measuring more than one 
thing at the same time. Therefore, this PhD research has improved the knowledge in the 
area be reviewing the models of functioning, and developing a new framework for the 
measurement of functioning in people with COPD. This model was based on the 
theoretical underpinnings of COPD, PR, and models of functioning.
Moreover, during the phase of conceptualisation it was identified that despite the 
established effectiveness of PR in clinical trials at the level of the population, four main 
problems remained unresolved.
1. Physiological improvements realised form PR were not translated into improved 
day to day functioning.
2. Outcome measures used in clinical trials did not fulfil the requirement of the 
theory of measurement and measuring scales.
3. Outcome measures used in clinical trials were not appropriate for measurement 
in a clinical setting, and did not provide informative clinical information, when 
used at the level of the individual.
4. Clinical problems in the delivery of PR service. These clinical problems 
included the inconsistency in research reports regarding the optimum duration of 
PR, the appropriate mix of components, the pattern of recovery of functional 
loss during PR, and the maintenance of the outcomes after PR.
A new outcome measure was developed during this PhD research to fill the 
current gap in the clinical measurement of the functional outcomes of PR. Functional 
performance was identified as a clinically significant outcome of PR, and an outcome 
measure of functional performance for people with COPD that is appropriate for 
implantation in clinical PR settings, was developed.
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Evidence o f the appropriateness of the TELER “function” indicators for the 
measurement o f functional performance in clinical PR settings was ensured by adequate 
“conceptualisation” and thoughtful consideration of the theoretical knowledge. This 
enabled the selection of the appropriate methods for “development” and “clinical 
testing”. This has ultimately resulted in an outcome measure that is valid, reliable, and 
responsive when used in the population and context for which it was developed. This 
has also resulted in clinical data that is informative for patients, clinicians and mangers.
The next section is a reflection on the methodology used within this thesis to 
develop the new outcome measure.
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17.1 A reflection on the suitability of the methodologies used within this thesis for 
the development of the outcome measure
Whilst a number of documents provided guidance on the development and 
evaluation of complex intervention (MRC 2008) and (Walach et al. 2006), none 
provided similar guidance on the development of outcome measures for the evaluation 
of such interventions in clinical setting. This thesis contributes to the development of 
knowledge in this area by providing an example of a rigorous process for developing an 
outcome measure of a complex intervention “PR”. This part of the discussion examine 
the methodologies used pre development, during development and post development 
and its impact on the quality of the TELER “function” indicators.
17.1.1 Selection of the TELER method of measurement
During the phase of development it was shown how the TELER method fulfilled 
the theoretical underpinnings identified during the conceptualisation phase. However, 
certain points should be further discusses.
First is the measurement of individualised outcomes. It should be noticed the 
TELER method provides a conceptual tool for measurement. However, it is the 
responsibility of the user, whether this is a clinician or research, to ensure that the 
definition of the indicators constitute individualised outcomes. This could be achieved 
by selecting an appropriate method for defining individualised outcomes. However, it 
remains to be established whether these outcomes could be influenced by the 
intervention based on the theoretical underpinnings and clinical experience.
Second is the measurement of clinically significant change. It is important to 
differentiate between “clinically significant outcome”, and “clinically significant 
change”. Clinically significant outcomes are abstract concepts that should be defined 
from the perspective of the patient and the potential of the intervention to alter these 
outcomes. On the other hand “clinically significant change” is the changes experienced 
by the patient in the “clinically significant outcomes”. This change could be induced or 
could occur spontaneously over a continuum of recovery.
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Current methods of measuring clinically significant change define cut-off point 
to classify patients into changed or not changed. The selection of the cut-off point is 
based on establishing a relationship between mean scores and global ratings of change 
and no change (Kazdin 1999). This method creates two main problems. First it is based 
on mean scores. This results in the lack of representation of the individual patient. The 
misclassification of one patient reporting him/her self improved as non-improved and 
vice versa has already been reported in the literature (Beaton et al. 2000).
The second problem is that this method suggests that during treatment there is a 
potential for one clinically significant change. This is not true, because changes occur 
over a continuum of recovery. Changes occur in small steps and might require long time 
to develop. Current methods provide very little information about change that could not 
inform clinical decision making. A TELER function indicator is an outcome measure of 
clinically significant change and provides information on whether the patient improved, 
deteriorated or not changed during treatment. Each of this information prompts different 
clinical actions.
On the TELER method evidence of true clinically significant change is 
established by the observation of change and recording observed change on the 
measurement scale. This requires defining the pattern of the occurrence of change, and 
the ability of the reporter “patient or clinician” to detect change and record it on the 
scale. Points on the scale should be defined based on empirical evidence or clinical and 
theoretical knowledge. During the phase of conceptualisation it was found that the 
knowledge of the natural history of COPD and the pattern of the development of 
disability is incomplete. Therefore, the trajectory of change in functional performance 
should be defined from the experience of patients living with the disease. This was 
achieved during calibration and is discussed next.
17.1.2 Validity of TELER “function” indicators
Evidence of validity is provided by establishing that the outcome measure conforms 
to the theoretical specifications of the outcome measure established in the phase of 
conceptualisation, this is shown in Figure 19. During the phase of conceptualization 
theoretical assumptions about the specifications of the outcome measure were 
formulated.
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Evidence of construct validity is established by identifying what should be 
measured “functional performance” and how it should be defined in terms that are 
clinically significant. When the clinical knowledge for defining clinically significant 
outcome is incomplete or when the aim is the measurement o f individualised outcomes, 
then a synthesis of available clinical knowledge, theoretical knowledge, patients’ 
experience, and clinicians’ perspective is required (McDowell 2006).
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17.1.3 Identifying and defining “functional performance”
TELER “function” indicators measure the construct functional performance. A 
critical literature review of the models of functioning resulted in a framework for the 
measurement of functioning. The model describes the dimensions of functioning and 
the factors influencing it. Functional performance was shown to be a dimension of 
functioning. Domains of functional performance were identified as “activities and 
participation”. In the framework a number of factors were identified to influence the 
construct functional performance “health condition or the disease, environmental factors 
and personal factors”.
Functional performance was defines as "the physical, psychological, social, 
occupational, and spiritual activities that people do in the normal course o f  their lives 
to meet basic needs, fu lfil usual roles and maintain their health and wellbeing." (Leidy 
1994, P: 198).
During the phase of conceptualisation, a number of models describing functioning 
in people with COPD were identified. However these models provided a framework for 
the assessment and classification of functional problems. This research has developed 
the knowledge in this area by developing a multidimensional framework for the 
measurement of functional outcomes. This was achieved by adequate definition and 
conceptualisation of the domains of functioning resulting into specific and precise 
definition of the constructs, identifying the interaction between the constructs, and the 
influencing contextual and disease related factors.
Whilst this framework was based on critical review and synthesis of the literature 
on the models of functioning in chronic conditions, its validity was further verified 
during the qualitative study. The results of the qualitative study showed that “functions- 
activities and participations” and “factors influencing activities” emerged as two main 
themes on the thematic chart.
Appendix B.7 shows a classification of patients’ narratives on the theme “factors 
influencing the performance of activities”. It could be seen how the identified factors 
from narratives fit in the classification of the factors influencing activities identified in 
the theoretical framework.
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In the qualitative study performance of activities was described in terms in “being 
able to do” a statement that is very close to that provided by the theoretical definition 
“activities people do”. An example is provided from the narrative of patient #2, she said 
describing her current level of functional performance:
“I'm not able to do as much as I  did then, I mean two years ago ”
This notion of “ability” implies that other than the factors influencing activities 
there is some sort of limitation imposed on the ability to perform. This limitation was 
described by the framework as “functional capacity”. Patients describe the limitation 
imposed by capacity on performance by saying:
“I do so much then I  have to rest, and then go back to it and do things. But you know I know my own way, 
that I  can only do so much, and I can push myself that little bit more. But I know when I've got to stop. 
I've gone to rehab and I  push my limits as far as I can go doing the exercises and things like that. And 
doing that I know when my limits finish, you know, so I know when to stop ’’
This suggests that the construct of functional performance and the factors 
influencing it was a valid representation of the patients’ experience o f performing 
functional activities, because they are grounded in the narratives of patients. It follows 
that there is a qualitative evidence of the construct validity of TELER “function” 
indicators. This evidence is derived from theoretical conceptualisation of the construct 
and validation by empirical qualitative evidence.
Another theoretical requirement was that the outcome measure should measure 
individualised outcomes. This requires using a valid method of item selection and 
reduction that preserve patients’ perspective and needs. During the qualitative study 
patients described a wide range of activities. The narratives of patients were classified 
using the activities’ core set of the ICF. The core set was generated using consensus 
methods involving experts. This suggests that the set of activities generated during the 
qualitative study is consistent with expert opinion on what constitute a problematic 
activity for patients’ with COPD. Moreover, it serves to validate the ICF core set of 
activities sand participation for COPD from the perspective of patients.
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Theoretically, a valid item reduction method should preserve patients’ perspective 
on what is important. Item reduction methods reported in the literature included 
statistical methods of reduction (Garrod et al. 2000) or expert opinion (Molen et al. 
2003). The result is a set o f items that could not be validated by direct reference to the 
patient. In this study the final item reduction procedure was performed by patients in the 
focus group. The set o f activities selected was found to be consistent with the activities 
reported by other qualitative (Williams et a l 2007).
However, this evidence shows that TELER “function” indicators actually measure 
“what should be measured”, but not how it should be measured to provide clinically 
significant definitions of the codes. To provide such evidence the author refers to the 
process of construction o f the indicators.
17.1.4 Defining clinically significant outcomes
This requires using clinical knowledge to define the categories o f the construct 
“functional performance”. However, during the phase of conceptualisation it was found 
that currently the knowledge about the progression of functional limitation in COPD is 
incomplete. Therefore, the only way to ensure a valid definition o f the codes on the 
indicators is by referring to the experience o f functional limitations o f patients and the 
clinical perspectives o f experts.
The use o f patients’ narrative to evaluate outcomes has been reported in the 
literature. France and Uhlin (2006) reviewed a number of studies that used narratives as 
an evaluation tool of the treatment in psychosis. They concluded that use o f narrative, 
particularly the change in narratives was a valid and reliable method o f evaluating 
outcomes in this group o f people. Paterson and Britten (2000) compared narratives to a 
standardised questionnaire in the evaluation o f the outcomes of medical consultations. 
They concluded that the standardised questionnaire failed to demonstrate all outcomes 
important to the patients that were generated from the narratives. This highlights the 
importance of narratives in providing a valid representation of the attribute that should 
be measured, particularly when theoretical and clinical knowledge are lacking.
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When developing a measurement scale it should be noticed that a measuring scale 
has two components: the scale, a “reference manual” or “aide-memoire”, and the 
translating medium, the “mechanism” that converts an attribute into a point on the 
measuring scale (LeRoux 2003). In COPD clinical and theoretical knowledge about the 
pattern of progression of disability is incomplete (Barnes and Kleinert 2004). Therefore, 
the translating medium is a synthesis of the experience of the patient represented by 
narratives and available clinical knowledge. This ensures fulfilling one of the logical 
requirements of measurement that is the definition of categories of the construct so that 
they are mutually exclusive and exhaustive.
A caveat here is that describing the full pattern o f the development of functional 
limitation based on the experience of each patient involves two assumptions. First all 
patients have experienced the full trajectory of change from maximum functioning to 
complete loss of function. Second the patient is able to fully remember the stages of 
functional loss as they developed. Neither logic nor empirical evidence from the 
qualitative study suggests that either of the two assumptions is true. The first 
assumption is fallible because none of the patients who participated in the study has 
experienced complete functional loss in all of the activities. The second assumption 
invites memory bias.
Therefore, the generation of indicator codes from narratives was guided by a 
theoretically established knowledge. That is, the level of functional performance varies 
between patients, and each patient performs at a certain level across the continuum of 
performance (Eisner 2011). COPD results in physiological impairment. The extent of 
impairment is described in terms of functional capacity and creates a limit on the 
functional performance (Liedy 1994). Although the amount of this limitation could not 
be measured, and actually varies between patients, available knowledge suggests that 
patients could not function beyond the limits created by physiological and pathological 
impairment because these are irreversible (Eisner 2011).
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Having established that, it follows that patients are similar in that they all have 
limits on the potential for performance. This was presented on the indicators as optimal 
performance. Another assumption is that when the disease has severely progressed then 
capacity becomes very low imposing greater limits on performance. This results in 
increased difficulty in performing the activity and triggers adverse physiological 
responses manifested by increased breathlessness. This creates the point when the 
patient “give up the activity”, that is they are unable to perform the activity anymore.
Having established the upper and the lower boundaries of functional performance,
the intermediate categories should be established. These are represented by functional
capacity utilization (Leidy 1994). Patients vary in the utilization of functional capacity.
While this is influenced to a certain degree by patient’s choice, it is also influenced by
the factors influencing activity such as symptoms, personal factors and environmental
factors. While these do not constitute the translating medium of the construct being
measured, they should be acknowledged as the sources o f variation in the level of
performance. They explain the varying levels o f performance experienced by patients.
They also constitute the factors that are potentially modifiable by the intervention “PR”,
91once maximum physiological gain has been achieved . Therefore, patients’ narratives 
were used as translating medium converting intermediate levels of performance to 
points on the scale.
Whether the narratives represent all possible patterns of functional performance 
prompts the question o f transferability. It is important to recognise the limitation o f any 
method of establishing knowledge within a certain context when considering the 
transferability o f this knowledge to other contexts (Pawson 2003). However certain 
measures were implemented to ensure that this has a potential in providing adequate 
representation. First, saturation was reached before terminating the study. After the 
fourth interview no new patterns were emerging. However, another two interviews and 
a focus group were performed after saturation. Second, during clinical testing patients 
were asked if  they felt that they are performing in a different way that is not presented 
in the codes on the indicators. None o f the patients claimed so.
23 This knowledge was established in chapter4
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However, it remains plausible that new patterns may emerge. A possible solution 
is provided by the flexibility of the TELER method. The TELER method enables the 
clinician to define codes on the indicators relevant to the needs of their patients, given 
that they have adequate clinical knowledge about the condition and the intervention (Le 
Roux 2003). Currently, the codes on the new developed TELER “function” indicators 
are the only available description of the pattern of functional loss in a population of 
people with COPD.
17.1.5 Identifying the level of measurement and the mathematical properties of 
the resulting scale
An isomorphism between the observed structure of the construct being measured 
and the assigned mathematical structures should be established. TELER “function” 
indicator is an ordinal scale, therefore it should be shown that categories on the scale 
are, connected, transitive, and asymmetric. This is shown by using one TELER 
“function” indicator as an example.
Bending to do an activity
0. Unable to touch table in front.
1. Able to bend forward with back upright and reach forward.
2. Able to bend forward and touch feet distance but unable to maintain.
3. Able to bend forward touch feet and maintain position but unable to do another task.
4. Able to bend forward perform an activity but has to rest before completing the task.
5. Able to bend forward maintain it and complete the task.
It was shown earlier that each code on the scales represents a level of performance 
that was generated from the patients’ narratives. That is each statement is unique 
because it describes a level of performance that requires a different set of resources and 
skills “connectivity”. That is moving down the scale the patient requires more resources 
to enable him/her to perform at a higher level. A patient performing at a higher level has 
the resources required to perform at the lower levels but not the higher ones. That is 
higher levels of performance are related to lower levels but not vice versa 
“Asymmetry”. If the patient has the resources to perform at code 4, then he/she has 
more resources than a patient performing at code 3, but fewer resources than a patient 
performing at code 5. It follows that a patient on code 5 has more resources than a 
patient on all the previous codes “transitivity”. An explanation is provided next.
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• On code 0 the patient does not have the physiological capacity, or the flexibility 
required to bend.
• On code 1 the patient has partial physiological capacity and partial flexibility 
that enables her/him to bend forward with back straight and adequate upper limb 
control to reach forward.
• On code 2 the patient has adequate flexibility but not adequate physiological 
capacity, once this patient bends forward the abdominal contents are pushed 
upward creating pressure on the diaphragm. This pressure displaces the 
diaphragm from the position o f the maximal mechanical efficiency to less 
efficient position. If the patient has adequate physiological capacity, he/she will 
be able to maintain the position and achieve code 3. If not this is code 2.
• On code 3 the patient does not have adequate physiological capacity to do 
another task that requires more ventilatory reserve.
• On code 4 the patient has more ventilatory reserve that enables him/her to do 
another task but not complete it.
• On code 5 the patient has adequate physiological capacity and flexibility to 
achieve the task.
This suggests that there is an isomorphism between the mathematical structure of 
the ordinal scale and the structure o f the phenomenon “bending to do an activity”. 
Therefore, the indicator fulfils the requirement o f the theory o f measurement and 
measuring scale. Finally as required by theory and the TELER method o f measurement 
the arbitrary unit of measurement was defined as “one unit o f clinically significant 
change”.
288
Overall discussion
17.2 A discussion of the appropriateness of the TELER function indicators for
measurement in clinical settings
Evidence of the appropriateness of TELER “function” indicators for measurement 
in clinical settings require examining the feasibility of TELER function indicators in 
clinical settings, and the usefulness of TELER function indicators in providing 
informative data.
Feasibility of application has been frequently described in reports on developing 
outcome measures. It was described in terms of time required to complete measurement, 
and the resources required to perform and record measurement. During the clinical 
testing it was found that completion of indicators by patients in the presence of the 
therapist required on average about 10 minutes. This is very reasonable particularly 
when compared with other outcome measures like the CRQ which requires 20 minutes.
However, it is important to notice that time required for completion should not 
only be assessed in terms of length, but also in terms of relevance and importance to the 
patients. If a certain outcome measure required 10 min to be completed, but provided 
very limited information, then it is not feasible. Assuming that on average the number 
of patients attending at the department on a certain day is 40, and then this is a waste of 
400 minutes, completing the outcome measure. This should have been better invested in 
treatment, unless the outcome measure provides information that could support clinical 
decisions and inform the treatment (Lakeman 2004).
This raises the question of how informative are TELER “function” indicators. 
This is discussed at the level of the patient, at the level of the clinician and at the level 
o f the group.
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17.2.1 The type of information required by the patient
17.2.1.1 Providing feedback about the outcome to the patients
During the qualitative study patients reported that one of the important sources of 
feedback about their progress is clinical tests. However, they explained that most of the 
time they could not interpret the results. Moreover, Higginson and Carr (2001) 
suggested that reporting progress of treatment to the patient is one of the important aims 
of measurement in clinical settings.
The fact that TELER function indicators are grounded in patients’ narratives and 
reflects their experience of functional performance suggest that scores recorded on the 
TELER indicators are recognised and interpretable by the patient. Evidence of this was 
provided during the qualitative analysis of the outcome of treatment at the level of the 
individual, as the patient was able to identify the factors influencing change and relate 
different components of the PR program to the type of change in the scores on the 
indicators.
17.2.1.2 Detect exacerbations
Exacerbation is manifested as an aggravation of the symptoms, and might present 
as increased fatigue, depression and sleeplessness resulting from a worsening lung 
condition (Rodriguez-Roisin 2000). During the phase of conceptualisation it was 
highlighted that emphasis on early detection and treatment of the COPD exacerbation is 
needed. This requires equipping the patients with tools that enable them to recognize 
their exacerbation and initiate therapy promptly may, or seeking professional support. 
This will ultimately reduce complications and decrease the risk of hospitalization.
The clinical hallmark of exacerbation is increased symptoms and altered 
psychological status; both were identified as factors influencing functional performance. 
TELER function indicators are tailored, and it was shown during clinical testing that 
they correspond to factors influencing functional performance. Moreover, TELER 
function indicators provide a longitudinal trace o f scores. This enables the detection of 
deterioration when it has occurred.
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The fact that exacerbation is a worsening o f patient’s condition beyond day to day 
variation is addressed by the TELER method in two ways. Firstly, it allows the 
calculation o f statistical significance allowing for the verification of true change from 
random change. Secondly, one change on TELER indicators is clinically significant; if 
this change was maintained over a clinically significant period o f time then it is a 
change beyond the normal variation and should prompt clinical action. However, the 
length of the clinically significant period o f time remains to be established.
TELER function indicators enable the detection o f deterioration in a clinical 
parameter “functional performance” that is directly related to exacerbation. However, it 
is currently the only measurement tool that could quantitatively differentiate between 
day to day variation and a clinical COPD exacerbation.
17.2.2 The type of information required by the clinician
Clinicians require information that enables them to provide evidence based 
practice, and making informed clinical decisions. Therefore they require information 
that enables designing appropriate treatment plan, detecting and responding to changes 
in the patient’s status, and deciding when to discharge the patient.
The TELER function indicators provide a longitudinal follow up o f clinically 
significant outcomes; this enables the clinician to detect the point in time when the 
patient starts to experience the benefits of the treatment. Moreover, the trace o f codes on 
the TELER data sheet enables the clinician to detect deterioration once it has occurred. 
The fact that the codes on the TELER function indicator are clinically significant 
outcomes, and a change from one code to another represent a clinically significant 
change enables the clinician to make clinical inferences based on changes in patients’ 
scores. Linking the codes on the data sheet with clinical notes enables the clinician to 
identify the factors that has resulted in the deteriorations or the improvements. This 
provides the clinical information required to take informed clinical actions.
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Currently the TELER method of measurement is the only method in the area of 
PR that enables the calculation of a quantitative estimation of the variability of the 
clinical condition at the level of the individual patient “maintenance index”. Given that 
variation in the clinical condition is a recognised clinical feature of COPD emphasise 
the significant of using the TELER method in clinical PR settings for patients with 
COPD. The maintenance index enables the clinician to ensure that the patient is not 
discharged unless the clinical condition is controlled and stable.
17.2.3 The type of information required by managers
Managers require information that enables them to make informed decisions about the 
rationing resources. In the current NHS structures there are service providers and 
commissioners. Service providers are interested in the outcome “effectiveness and 
efficiency” of treatment, while commissioners are interested in the outcome of 
treatment “effectiveness and efficiency”.
During the clinical testing study evidence was established that TELER function 
indicators provide relevant information of interest to service providers. This information 
includes the clinical characteristics of the group of patients treated, the overall outcome 
of treatment, the duration of treatment required to establish improvement and 
maintenance of effect. Moreover qualitative evidence of the quality of treatment based 
on the performance index and maintenance index was provided.
Moreover, during the clinical testing it was shown the TELER data collected at 
the level of the individual could be aggregated to provide group data of interest to 
commissioners. This data was analysed to provide evidence of the effectiveness of 
treatment in terms of statistical significance. Evidence of the efficiency o f treatment was 
calculated using the time units required to induce one clinically significant change.
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17.3 A discussion of the new knowledge that has emerged during the clinical
testing about the delivery and response to PR.
Current clinical problems in PR are described in terms o f the provision and the 
outcomes o f clinical PR services at the level of the individual and at the level o f the 
group. Issues related to the provision were identified during the phase of  
“conceptualisation” and include the optimum duration o f the program, the components 
of the program, the pattern o f recovery, and the prediction o f response to PR.
When discussing the new knowledge that has emerged during the clinical testing 
two important points should be recognised. Firstly, the findings are based on a 
prospective follow up o f patients over a period o f time; therefore causality could not be 
established unless TELER was implemented within an appropriate research design. 
Secondly, conclusions withdrawn from the clinical observation are limited by the small 
sample size. Therefore interpretations are not conclusive but provide guidance for 
further investigation. The findings also highlight the value of the developed TELER 
“function” indicators in solving current clinical problems in the provision o f PR 
services.
17.3.1.1 Duration o f PR
Current guidance on the optimum duration o f PR is based on the average response 
of patients to PR. Evidence form research studies suggest that the longer the program 
the greater the benefits gained (ATS/ERS 2004). This presents two main clinical 
problems, the first is the longer the program the less likely it is that patients adhere to 
the full length and complete the program. The second problem is the cost implications 
in longer programmes, this is particularly important when recognising that research 
evidence that supported the longer duration did not provide evidence o f cost 
effectiveness o f the longer programs.
This PhD research has contributed to the knowledge about the optimum length of 
PR. Firstly, during the qualitative study, patients reported that they find it more 
beneficial to have shorter intensive programs, but more frequent back up after the end of 
PR. Secondly, During the clinical testing it was found that most of the patients started to 
experience improvement on the 5th session, suggesting that 5 session o f PR is the 
minimum number of sessions required to induce a physiological change in capacity.
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Moreover, it was found the number of sessions required to induce an 
improvement is dependent on the type of the activity and the nature of therapeutic input 
required inducing change. Activities such as showering, bending to do an activity, and 
generic activity indicator improved quicker because the nature of therapeutic input was 
to in the form of environmental modification, education, control of symptoms, and self­
management techniques. While activities such as going upstairs, slope walking and 
talking, and functional talking required longer to improve. This is because these 
activities could not improve without adequate physiological change in capacity. This 
physiological improvement requires a long time to develop.
The findings of the clinical testing suggest that the decision to discharge the 
patient should be an individualised decision, and is should be based on the variability of 
the clinical condition of the patient. Patients should not be discharge until they have 
achieved the maximum potential improvement that requires an intervention to occur and 
a stable clinical condition.
17.3.1.2 Components o f  the PR program
PR is a complex, multidisciplinary intervention. During the phase of 
conceptualisation it was identified that there is no consensus on the most effective 
components and the optimal combination of interventions. The findings of the 
qualitative study and the clinical testing suggest that this should be tailored to meet the 
need of the individual patient depending on the pattern of recovery experienced by the 
patient.
During clinical testing it was observed that some patients experienced large 
improvement on a small number of indicators. This pattern of improvement was 
attributed to improved physiological capacity experienced by the patient reflected as 
reduced breathlessness and improved exercise tolerance. This emphasise the importance 
of the exercise component for this group of patients. However, other patients 
experienced small number of improvements on a large number of indicators; these 
patients attributed improvements to improved self efficacy and control of breathlessness. 
This emphasise the importance of the education and self-management components of 
the program.
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If the performance record o f the TELER function indicators was linked to the 
treatment record and the clinical note making system, then it provides valuable 
information of the specific components required to induce improvements in functional 
performance at the level of the individual patient. This will eventually result into 
improved effectiveness and efficiency o f treatment delivered.
These findings suggest that, while delivering a mix of intervention is required to 
address all the factors influencing performance, the influence o f certain factors on 
performance is more pronounced in one patient than the other. Therefore, PR 
components should be targeted to address the specific needs o f the individual patient 
and the observed response to treatment. The TELER method of measurement provides 
the clinically relevant information that enables making informed decisions about 
selecting appropriate components for the individual patient.
17.3.1.3 Predicting the response to PR
Predicting the outcomes of PR requires identifying baseline characteristics that 
might determine which patients would benefit more from treatment (Garrod et a l 2006)
It is important to recognise that current knowledge suggest that COPD is a 
heterogeneous disease and is manifested differently by each patient. Attempts to predict 
the pattern of recovery during PR based on clinical parameters were inconclusive. The 
clinical testing findings suggest that performance index on admission and the 
occurrence of a critical incident should be considered jointly when attempting to predict 
patient’s response to treatment. The extent of improvement was limited by the 
variability of the clinical condition, and the variability was linked to the occurrence o f a 
clinical incident. The findings of the clinical testing suggest a possible association 
between performance index on admission and, performance index and effectiveness 
index in discharge.
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The performance index on discharge is influenced by the effectiveness of 
treatment and the stage o f the disease. The effectiveness of treatment is influenced by 
the appropriateness of the treatment delivered and variability in the clinical condition. 
This suggest while performance index have the potential to predict the response of 
treatment at the level o f the individual when implemented in an appropriate research 
deign. However, other factors such as the stage o f the disease and the variability o f the 
clinical condition should also be considered suggesting that a combination o f factors 
rather than one factor might have greater potential in predicting response to PR.
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18 Limitations of the research
18.1 Limitations related to the process of development
The codes on the TELER "function" indicators were developed from the 
perspective o f patients recruited during this research process. However, different 
groups of patients were recruited for the indepth interviews, the two focus groups and 
the clinical testing. Therefore, the codes on the indicators were reflective of four 
different cohorts o f patients recruited at different time periods. However, a common 
limitation amongst the four cohorts of patients is the exclusive white ethnicity. This is 
particularly important, because there is emerging evidence that the risk for the 
development and the severity of COPD is different amongst different ethnicity, with 
black race being associated with greater COPD severity (Eisner et a l 2011).
Nevertheless, new TELER indicators should be developed according to the goals 
of treatment agreed between the individual patient and the clinician. The process 
presented in this thesis provides guidance for the development o f new indicators.
It is important to recognise that TELER indicators generated during this study 
resulted from the synthesis of clinical and theoretical knowledge, and empirical 
qualitative evidence. The fact that the indicators were grounded in the narratives o f the 
patients, suggest that response shift should be considered (Eton 2010). While this will 
not affect the measurement generated form the indicators as the scientific structure o f  
the indicators preclude invalid recording of scores. For a change to be recorded it should 
be recognised by the patient and observed by the clinician. However it remains 
plausible that these indicators might become irrelevant to the patients, new indicators 
should be developed then.
Another limitation is that the indicators were validated form the perspective o f  
clinicians involved in development “five physiotherapists, one occupational therapist 
and one COPD nurse”. Mutli professional team should be involved, as the delivery o f  
PR is multidisciplinary. However, the researcher attended the steering group17 meetings 
of the rehabilitation centre and provided a presentation o f the research process. This has 
provided insight from other health professionals.
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18.2 Limitations related to clinical testing
An important limitation o f the clinical testing study is that sample size was small 
and not random. However, this sample size was selected because the aim was to 
evaluate the newly developed TELER “function” indicators within a real clinical 
context. A number o f 10 represent the standard size of the group attending the PR at the 
site of clinical testing. Moreover, the design of the clinical testing study was a 
prospective follow up o f patients. Therefore, the findings should be interpreted carefully 
considering the context and the design o f the study. However, the sample size and the 
design provided a realistic insight into the nature and diversity o f clinical data. It also 
showed that if collected and documented systematically using the appropriate 
measurement tool and method of measurement, clinical measurement could provide 
informative data to the patients, clinicians and managers.
It should also be noticed that functional performance changes continuously and is 
affected by many contextual factors. The fact that TELER "function" indicators were 
developed to account for different factors influencing performance suggests that they 
might change on day to day basis. However, this change does not prompt clinical action 
as it is a natural variation. In the clinical testing some patients reported deterioration due 
to weather or "feeling rough" at that particular point in time.
To overcome this problem during clinical testing a change was not considered as a 
change that requires clinical action, unless it was maintained over two points of 
measurement. However, the clinically significant period of time required to differentiate 
day to day variation form change that requires a change in the treatment delivered 
remains to be establishes.
18.3 Limitations related to the TELER method of measurement
This is related to barriers for implementation. Implementation o f TELER method 
in clinical settings requires adequate training of staff and patients on the use o f the 
indicators, to ensure reliability. Moreover, clinicians should be trained on the use o f the 
TELER software, the entry o f data and the generation of patients’ reports. There are 
also cost implications related to cost and software licensing.
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Another important issue related to the implementation is clinicians’ resistance to 
changes in the routine delivery of care. Moreover, currently clinicians use assessment 
tool as outcome measure. Clinicians should be educated about the difference between 
and assessment tool and a measurement tool. This requires increasing the awareness of 
the clinicians about the importance of appropriate measurement in clinical settings and 
the impact this has on the effectiveness and quality of care delivery as well as providing 
appropriate documentation and legal protection.
19 Dissemination and communication of the research findings
The findings of the qualitative study were communicated via oral presentations at 
a local university conference and a national conference. These are:
Okasheh R., Mawson S., Tod A. (2008). Patient set goals of pulmonary 
rehabilitation. The Faculty of Health and Wellbeing Research Day “Oral presentation”.
Okasheh R., Mawson S., Tod A. (2009). Measurement of functioning following 
Pulmonary Rehabilitation: What matters to people? The 5th Qualitative Colloquium-East 
Anglia “Oral presentation” .
The development of TELER “function” indicators were presented via a poster 
presentation at two international conferences (Appendix D .l). These are:
Okasheh R., Mawson S., LeRoux B., Tod A. (2010). Development and validation 
of a new measurement tool of functional performance for use in pulmonary 
rehabilitation in people with COPD “Poster presentation”. CLAHRC national 
conference.
Okasheh R., Mawson S., LeRoux B., Tod A. (2010).Development and validation 
of a new measurement tool of functional performance for use in pulmonary 
rehabilitation in people with COPD “Poster presentation”. COPD7
A journal Publication plan was formulated and submitted to the Health and Social 
Care Research Centre/ Sheffield Hallam University. This is presented in Appendix D.2.
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20 Future research
Future research includes three main streams. The first is related to developing new 
TELER indicators for PR. The second is related to the implementation of TELER 
“function” indicators in clinical PR settings and in the clinical education of 
undergraduate and post graduate clinicians. The third is related to using the newly 
developed TELER “function” indicators within an appropriate research design to 
resolve clinical problems in the provision o f PR.
20.1 Future development of TELER “function” indicators
During this PhD research qualitative evidence o f the validity and reliability of the 
TELER “function” indicators at the level of the individual was established. The validity 
and reliability were ensured by adequate conceptualisation and using appropriate 
methodologies for development. Moreover, the responsiveness o f the indicators was 
tested during the phase o f clinical testing and evidence was established qualitatively at 
the level o f the individual, and quantitatively at the level o f the group. However, before 
the introduction o f the TELER method as a research tool, the psychometric properties of  
the TELER indicators at the level of the group should be established considering the 
principles of the theory o f measurement and measuring scales.
During the qualitative study, personal factors were identified amongst the factors 
influencing functional performance. Moreover, during the clinical testing it was 
identified that the components of the PR program that influenced improvement differed 
based on the needs o f the individual. While some patients reported improved self 
efficacy as the cause of improvements, others reported improved physiological capacity 
as the cause of improvements experienced. New indicators o f self efficacy and an 
appropriate research design that examine the association between functional 
improvements and physiological improvements are required. This will improve the 
knowledge and support clinical decisions about which components of the PR to include 
for the individual patient.
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Moreover, facilitated early discharge necessitates that patients are equipped with 
skills and tools that enable them to monitor their own condition and self manage the 
changes that might occur to avoid readmission. The use o f TELER function indicators 
as a patient reported outcome measure should be examined. The National Institute for 
Health Research Collaboration for Leadership in Applied Health Research and Care, 
South Yorkshire NIHR/CLAHRC SY-COPD theme has funded a post-doctoral study on 
the usefulness o f TELER function indicators as a patient reported outcome measure at 
home and local community settings.
20.2 The implementation of TELER “function” indicators in clinical PR settings 
and in the clinical education of undergraduate and post graduate clinicians
During this research it was identified that there was a critical gap in the 
knowledge of clinicians in the delivery of PR, and particularly physiotherapists about 
the principles o f measurement in clinical setting. Moreover, a limited number of 
research reports addressed the issue of outcome measurement in clinical PR settings. 
Therefore, the author is involved in a project that is supported by Longhand data, to 
implement the TELER method of measurement in the education o f undergraduate 
students at the faculty o f the Rehabilitation Science/University o f Jordan. Moreover the 
researcher is currently part a member o f the supervisory team of another PhD student 
undertaking a project on measurement in low back pain.
With support from Longhand data, the newly developed TELER “function” 
indicators will be implemented in a clinical PR program at the University o f Jordan 
Hospital. However, in order to do this a preliminary project that includes the translation 
and the cultural adaptation o f the indicators will be performed supported by the Higher 
Research Department/University of Jordan.
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20.3 Using the newly developed TELER “function” indicators to resolve clinical
problems in the provision of PR.
It is worth mentioning that the new scientific domain of realistic evaluation and 
the evaluation of complex interventions provides opportunities for new methods of 
clinical research. This will include the standard randomized trials and observational 
cohort studies as well as other observational methods such as case control studies, and 
cross sectional surveys (MRC 2008). The TELER method of measurement will bring to 
these observational methods the appropriate tool for the measurement of outcomes.
A number of the clinical problems in PR require further investigation, using a 
realistic evaluation approach (Pawson 2003) and (MRC 2008). This includes the 
optimum duration of the program, the appropriate mix of components, and the 
prediction of the response to PR, improving concordance, and the maintenance of 
benefits o f PR following discharge. While currently no funding is secured for these 
projects, a number of potential national and international funders have been located and 
will be contacted in due course. This includes the European Respiratory Society “ERS 
Fellowship in memory of Walther Guerrero Ciquer” which supports scientists from low- 
medium income countries, the Medical Research Council “The methodology research 
program”, and the United States Agency for International Development 
“USAID’VJordan.
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21 Conclusion
This research program has succeeded in its aim o f developing a new outcome 
measure o f functional performance for people with COPD that is appropriate for 
implementation in clinical PR settings. It has developed an outcome measure that is 
feasible and useful in clinical PR settings. The process used rigorous, iterative and novel 
approach that included predevelopment phase “conceptualisation”, Development, and 
post development “clinical testing”.
The outcome was the development of a set o f specifications o f an appropriate 
outcome measure for implementation in clinical settings; this could guide the selection 
of measurement tools for clinical practice. A new framework for the measurement of 
functioning that could guide the development of new outcome measures for different 
domains o f functioning based on clinical needs. And a new outcome measure o f 
functional performance that is the currently the only one in the area that is underpinned 
by adequate conceptualisation, provides clinically informative data through full 
clinimetric analysis. The new tool has the potential for being used as a patient reported 
outcome measure to provide follow up post discharge, and to resolve current problem in 
PR
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Appendix A.l: Physiological response to exercises
Physiological response Effect Evidence Expected impact 
on exercise 
performance
Increased  fat free m ass and 
reduced  fat m ass.
Im proved  body  com position  
and body m ass index.
B ernard  et al. 
(1999)
Im proved  m uscle 
strength.
C onversion  form  fast low  ox idative 
fatigable fibre type (type II) to a 
slow  high ox idative fatigue 
resistan t fibre type (type I)
R educed afferen t 
chem oreflex  (reduction  in 
b rea th ing  stim ulus) 
resu lting  in reduced  
dynam ic hyperin fla tion .
im proved effic iency  o f  
peripheral m uscles
W hittom  et 
al. (1998)
R educed
percep tion  o f  
dyspnoea.
Table 1 Physiological response to  exercises
6
Increased m itochondrial num bers 
and increased  ac tiv ity  o f  
m itochondrial enzym es such as 
c itrate synthaze and 3 hydroxy  acyl 
-C oA  dehydrogenesis.
Im proved aerobic capacity  
o f  peripheral m uscles and 
delayed onset o f  lactic 
acidosis production
Jolley and
M oxham
(2009)
D elayed onset o f  
fatigue.
Increased cap illary  con tac ts in 
proportion  to increase in fibre cross 
sectional area.
Facilitate oxygen delivery  
and extraction
M ador et a l 
(2001)
Im proved  exercise 
to lerance.
R educed lactic ac idem ia at iso 
w ork  rate, com pensation  for 
decline in in tracellu lar pH  and 
PC r/Pi. F aster P C r recovery .
R educed  decline in m uscle 
pH  and PC r/P i, resu lting  in 
preservation  o f  g lycogen  
stores.
C asaburi et 
al. (1991), 
Sala et al. 
(1999)
D elayed onset o f  
fatigue. Im proved  
exercise  to lerance.
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I Sheffield Hallam University
<FacuCty ofjfeafth and cWett6eing
PARTICIPANT INFORMATION SHEET 
Patient set goals of pulmonary rehabilitation: Perspectives on functional 
and physical activities of daily living
You are invited to participate in a study to explore your views about the 
activities of daily living you consider important and wish to set as treatment 
goals for pulmonary rehabilitation.
“Why I have been asked to take part in this study?”
We have designed a study to give people the chance to voice their needs and 
tailor the treatment goals to meet the demands of their everyday life.
“How long will the study last?”
The whole study will last about one month. You will be involved for an hour on 
one or two occasions.
“What will it involve?”
If you agree to participate in this study you will be asked to join a group 
gathering held at the place where self support groups for patients with chronic 
lung disease usually meet. The researcher will talk to the group and ask them 
about activities of daily living they wish to set as treatment goals for pulmonary 
rehabilitation. You have also the option of attending an individual interview.
1 0
“Where the study will be done?”
The study will be carried out in the community where self support groups 
usually meet. If you opt for attending the individual interview you would agree 
with the interviewer on the place of the interview. This could be a meeting room 
at the university, community centre, or your own home.
“How often will I have to come?”
One or two times.
“What If I don’t wish to take part?”
It is completely up to you. There is no problem.
“What if I change my mind during the study?”
You are free to withdraw from the study at any time.
“What will happen to the information from the study?”
All information will be kept entirely confidential. The data will be destroyed at the 
end of the study. No individual will be identifiable in the report. You will be 
informed of the results of the study if you wish.
“What if I have further questions?”
If you have any questions, please contact:
Rasha Okasheh
PhD physiotherapy student
Sheffield Hallam University
Faculty o f health and wellbeing
Collegiate Hall
Room A214
S10 2BP
E-mail: R.0.Okasheh@shu.ac.uk tel.: 0114 225 2458
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Faculty of Health and Wellbeing Research Ethics Committee 
Health & Social Care Research Ethics Review Group 
Report Form
Title: Patient set goals of pulmonary rehabilitation:
perspectives on functional activities of daily living.
Principal Investigator: Rasha Okasheh
Recommendation:
Comments:
Please see review sheet for comments.
Acceptable: /
Not acceptable, see comments: 
Acceptable, but see comments:
Signature:  .......................  ........... D ate:. . . .1 .( 5 ./ b .£ ............
Peter Almark,
Chair
HSC Research Ethics Review Group
Please remember that an up-to-date project file must be maintained for the duration 
of the project and afterwards. The project file might be inspected at any time.
Note: Approval applies until the anticipated date of completion unless there are 
changes to the procedures, in which case another application should be made.
Comments from the Ethics Committee have been addressed.
Signature of Tutor / Director of Studies / Supervisor:
....................... . . . . ......................................  Date:
Name of Tutor / Director of Studies / Supervisor: /p fo P , \n  *
Appendix B.3: Consent form- Qualitative study
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I Sheffield Hallam University 
1TacuCty offfeaCth an dcWeCC6eing (JfeaCtfi andSociaC Care (Research Center)
CONSENT FORM
Patient set goals of pulmonary rehabilitation: Perspectives on functional 
and physical activities of daily living 
Please give your consent to participating in the study by answering the 
following questions (please tick the boxes)
Have you read the information sheet about this study?
Have you been able to ask questions about this study?
Have you received answers to all your questions?
Have you received enough information about this study?
Which investigator have you spoken to about this study?
Are you involved in any other studies? YesD Non
■ If you are, how many?
Do you understand that you are free to withdraw from this study?
■ At any time? YesD NoD
■ Without giving a reason for withdrawing? YesD NoD
Do you agree to take part in this study? YesD NoD
Your signature will clarify that you have had adequate opportunity to discuss the 
study with the investigator and have voluntarily decided to take part in this 
study.
Please keep your copy of this form and the information sheet together.
Signature of participant.....................................................Date..............................
Name (Block letters):...............................................................................................
14
YesD NoD
YesD NoD
YesD Non
YesD Non
Signature of investigator:.............................................
Appendix B.4: Topic guide -  individual interviews
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Opening:
(Establish rapport) Hello, my name is Rasha I'm a PhD student at Sheffield 
Hallam University. We've met before and I'm here today further to our last 
telephone chat. I'm really pleased that you are interested in taking part in this 
study.
(Consent)To start with could you please take 10 min to read the participant's 
information sheet and sign the consent form? The interview will be recorded, 
however no names will be mentioned in the reports and the tapes will be 
destroyed at the end of the study. Only the researcher and the supervisory team 
will have access to the data.
(Introduction)The interview will last for about 45 minutes; it is divided into three 
sections. The first section is about the physical activities you do everyday. Then 
we'll move to the second section where we'll chat about how you manage 
difficulties while undertaking the activities. Finally we'll talk about your goals and 
expectations from a pulmonary rehabilitation program.
(Motivation) I hope to use this information to develop a measurement tool for 
functioning following pulmonary rehabilitation. Your contribution is valuable as 
we are hoping that this tool will focus on the individual and reflects your needs.
Before we start I'm here today to conduct the interview. I don't have access to 
your medical records, so could you please start by telling a bit about your lung 
condition, when did it start? What was the diagnosis, how do you feel now, is it 
stable, improving or worsening....etc?
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Functional performance
What are the activities you need and want to do in your daily life, but can't 
because of illness?
How important are these activities to you?
Why are these activities important? 
prompts:
Responsibilities
Role in the family, work...etc.
How difficult is it to perform them?
Prompts:
How much effort do you put into this and when would you give up.
Distress
Duration
Is there anything that you do that would help you do the activity?
Prompts:
Skills
Devices (assistive physical aids)
Strategies
17
Self management
That was great (name) we are moving now to the second section where we'll 
chat about self management issues
Do you undertake any particular steps (or do anything) to control your 
symptoms?
I would like you to think about a time when you tried to do (the named activity) 
and were successful?
How did that feel?
Now, I would like you to think about a time when failed to do the (activity)?
How did that feel?
Are there times when you feel down and unable to do or complete?
How do you overcome these downs?
18
Goal setting
The last section is about your expectations from pulmonary rehabilitation...
If you were starting a pulmonary rehabilitation program and you have been 
asked to identify a number of activities or functions that you would like to 
achieve from attending pulmonary rehabilitation what would these goals be? 
Please try to be specific about your functions or activities.
What do you think you need to do to achieve that function or activity?
Prompts:
Any particular steps 
Use of services 
Assistance from others 
What do you need to learn in order to perform the function or activity?
Prompts:
Control symptoms.
Control feelings
Learn how to be committed.
Learn how to control anxiety and depression.
Increase efficacy.
How difficult would it be to achieve the function or activity?
Do you believe you would be able to achieve them?
How long do you think you need to be able to perform function or activity?
What are the physical or practical outcomes that you expect from being able to 
perform the function or activity?
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How committed are you to your goals? (How hard are you prepared to work)
Prompts:
Effort
Time
Perseverance.
What are the difficulties do you expect to face?
Prompts:
Symptoms or something related to illness.
Access.
Quality of service 
Lack of support.
Lack of adequate feedback.
Would anything help you to overcome these difficulties?
Prompts:
Support from others 
Persistence to achieve goals.
Learning new strategies.
How do you expect to find out about how well you are doing?
Is there any specific sort of feedback you will find helpful?
Prompts:
Feedback from family member or health professional
20
Closing
(Maintain Rapport) I appreciate the time you took for this interview. Is there 
anything else you would like to tell me?
(Action to be taken) I should have all the information I need. Would it be alright 
to call you at home if I have any more questions? Thanks again.
21
Appendix B.5: Topic guide-Focus group.
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Doctoral  R esearch  Prog ram
D eve lopm en t  of a m e a s u r e m e n t  tool  of func t ion ing  in peop le  with  
Chronic  Obs truc t ive  P u lm o nary  Disease (COPD)
Phase  1: qua l i ta t iv e  s tudy  "Pa t ien t  se t  goals  of p u lm o n a ry  
reh a b i l i t a t io n :  Pe rsp ec t iv es  on func t iona l  ac t iv i t ies  of daily  l iv ing”
This study is part o f a doctoral research project that aims to find the best way o f 
measuring the outcomes o f pulmonary rehabilitation, we have done 11 individual 
interviews so far and the aim o f this focus group, is to give the opportunity as a group to 
tell us more about the functions and activities o f daily life that are important to you so 
that we could use those as a bases for the measurement o f improvement following 
rehabilitation, and to give us the opportunities as researchers to clarify some o f the new 
interesting finding that resulted from the individual interviews.
Stage 2: Focus g roup
To s t a r t  wi th  I wou ld  like to h e a r  from you a b o u t  the  t im e  w hen  you 
w ere  f i r s t  d iagnosed  with  COPD.
Prom pts :
When was that?
Who confirmed the diagnosis?
What health problems or symptoms did you have (breathing problems) before 
diagnosis?
How has your life change since then?
In terms o f activity.
In terms o f role.
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Is t h e r e  any act iv i ty  th a t  you find p a r t i c u la r ly  p ro b le m a t i c  now you 
have  COPD?
Prom pts :
Putting shoes on/off 
Hovering/ dusting 
Bathing
Walking to market 
Carrying shopping basket
Why do you find th is  act iv i ty  difficult?
W hat  do you do to m anage  the  difficulty?
How i m p o r t a n t  a re  these  ac t iv i t ies  to you?
Prom pts :
How do you feel when you can't do them, or face difficulties doing them?
Could anybody else do it for you or help you doing it? (How does that feel?)
How does  y o u r  level of act iv i ty  va ry  th r o u g h o u t  the  
d a y /y e a r / s e a s o n s ?
Prompt:
Is there a time o f day/year/season when it’s more difficult to be active?
When is this?
Why?
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Could you th in k  a b o u t  an ac t iv i ty  t h a t  you s t a r t e d  to do b u t  s to p p e d  
be fore  com ple t ing  it?
Prom pts :
What was the activity?
Why did you stop?
When did you stop? (After how long)
What was the consequence o f  stopping? e.g. did you do something else? How did it 
make you feel?
What did you do to manage the problem?
I would  l ike to h e a r  from a b i t  a b o u t  the  e n v i r o n m e n t  a t  hom e,  if 
you w e re  to change  som e th in g  in y o u r  hom e  to give you a b e t t e r  
qua l i ty  of life w h a t  would  th a t  be?
Do you th in k  th e r e  is a l ink  b e tw e e n  be ing  physica l ly  act ive  an d  
being  m en ta l ly  active?
The ones  who have  done  p u lm o n a ry  re h a b i l i t a t io n  before ,  how  did 
it  help?
Prom pts :
What has improved?
Think about an activity that you couldn't do before rehabilitation but managed after it, 
or an activity that has become less problematic.
A lot  of p eop le  t a lk e d  a b o u t  be ing  m ore  conf iden t  a f t e r  p u lm o n a r y  
re h a b i l i t a t io n  how was that?
If you w e re  a b o u t  to s t a r t  a new r e h a b i l i t a t io n  p ro g ram ,  w h a t  w ou ld  
your  goals  be?
Prom pts :
What would you like to be able to do?
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What would you like to improve?
How did the education during rehabilitation affect your perception of the disease? 
Appendix B.6: Index of themes and subthemes
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Diagnosis
Response or impact 
Delay
Having the diagnosis 
Emotional response
Social response
Characteristics of the disease 
Chest infection 
Exacerbation
Medication 
Time of use
Use of oxygen
Quitting smoking 
Feelings 
Triggers to quit 
Timing
Activity
Level
Change or difference
Variation
Goals
28
F a c t o r s  i n f l u e n c i n g  a c t i v i t y
Aging
W e a t h e r
S y m p t o m s
Type
Severity
Impact
F e e l i n g s
R e c o g n i z i n g  l i m i t s  
S t o p p i n g  a c t i v i t y
G i v i n g  u p  a c t i v i t y
P r i o r i t i e s
M a n a g e m e n t  o f  a c t i v i t i e s
P l a n n i n g
M o d i f i c a t i o n
E n v i r o n m e n t
S l o w i n g / p a c i n g
S u p p o r t
From others
Using mechanical aids
Finding alternatives
Reduced physical effort
Reduced risk o f  infection
P u l m o n a r y  r e h a b i l i t a t i o n
E x e r c i s e  v s .  A c t i v i t y  
B e n e f i t s
F u n c t i o n a l  i m p r o v e m e n t
Q u a l i t y  o f  l i f e
E d u c a t i o n
G o i n g  o u t  m o r e
S e l f  e f f i c a c y
G o a l s
U n c e r t a i n t y
D i f f i c u l t y
L i m i t a t i o n
N o  b a c k u p
L i m i t e d  r e s o u r c e s
A c c e s s
D r o p  o u t s  
L o w  u p t a k e
P e r c e p t i o n s  o f  t h e  d i s e a s e  
C a u s e s
C o n s e q u e n c e s  
N o  t r e a t m e n t /  n o  c u r e
L i v i n g  w i t h  i t
P r o g r e s s i o n
M a n a g e m e n t  
H a v i n g  c o n t r o l
B e i n g  i n  c o n t r o l
Being an expert
Keeping o top o f  it
P s y c h o l o g i c a l  i m p a c t  
K e e p i n g  a c t i v e  
S o c i a l  i n t e r a c t i o n / i s o l a t i o n  
P e o p l e  a t t i t u d e s
S t i g m a  o f  t h e  d i s e a s e
S o u r c e s  o f  f e e d b a c k
S e l f
P a r t n e r
H e a l t h  p r o f e s s i o n a l s  
T e s t s  a n d  i n v e s t i g a t i o n s  
R e d u c e d  u s e  o f  N H S  
O t h e r  p e o p l e  
E m p l o y m e n t  
O c c u p a t i o n  
E m p l o y m e n t  s t a t u s
Appendix B.7: Validation of the framework for the measurement of 
functional performance
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using patients narratives
44
Table 4 Generic activity indicator
T h e m e N a rra t iv e P e r fo rm a n c e
d e s c r ip to r
M anagem ent o f  
ac tiv ities/recognizing  
lim its/g iv ing  up
There m ight be one or tw o things that I  ju s t  
can't do.
W ell I  gen era lly  s to p p e d  now. I  h a d  to do D IY  
ba t I  don't do now
I gave up the  activ ity
M anagem ent o f  
ac tiv ities /recogn izing  
lim its /stopping  activ ity
w ell I  now  g e t out o f  breath  when I'm d igging  
in the garden, but I'm s till engaging, but I've 
h a d  to stop  because I  can't breathe
I cou ld  still do it bu t 
it w ou ld  get m e out 
o f  b reath
F actors in fluencing  
activ ity
perfo rm ance/S ym ptom s
A fter about h a lf  an hour I  g e t breath less an d  
then I stop. Oh dear...w ell I  never actually  
p a n te d  fo r  breath, I  do ten d  to  breathe m ore 
quickly, when I  g e t breathless. "So it is n ’t  often 
I  g e t breath less as such.
A fter about h a lf  an hour I  g e t breath less an d  
then I  stop. A n d  then I perh aps carry on an d  do  
another h a lf  an hour. So i t ’s never h appen ed  
that yo u  have to  stop  activ ity?  C om pletely  no, I  
w ork fo r  h a lf  an hour then have an hour rest 
then do another h a lf  an hour. Yes an d  this 
when I  s it down, and  relax  and  then I  s ta r t m y  
breath ing techniques and  then th a t helps
I cou ld  do the 
activ ity  bu t I have to 
keep  stopp ing  for 
rest
M anagem ent o f  ac tiv ities/ 
S low ing  /pacing
everyth ing I do I  do in slow  motion, I do it a t 
m y own p a c e  an d  I  do it slow ly, an d  everyth ing  
is rea lly  slow  because I  have to do it slow  
because I  can't do it quickly, because when I  
sta r t to g e t quicker I  g e t m ore breathless. But 
w hatever I  do  I  take m y own tim e
I cou ld  do  the 
activ ity  w ithou t 
stopp ing  bu t it takes 
longer than  usual 
(slow  p rocess)
Factors in fluencing  
ac tiv ity /im pact
I  en joy that. Walking, which th e y ’ve  g o t me  
doing at rehab, mmm I  like to walk, but I d o n ’t  
like to w alk in their p ace , they drive you. 
E ventually I ’m running which is p ro b a b ly  g o o d  
because this does g e t m e out o f  breath  that ge ts  
m e out o f  breath  after about 5 minutes.
I cou ld  do the 
ac tiv ity  w ithou t 
stopping  fo r a  re s t in 
a norm al ra te  bu t I 
w ou ld  start b rea th ing  
rap id ly
I could  do  the 
activ ity  w ithou t 
stopping  in a  norm al 
rate m ain ta in ing  
con tro lled  brea th ing .
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Table 5 Bending to do an activity
T h e m e N a r ra t iv e P e rfo rm a n c e
d e s c r ip to r s
M anagem ent o f  activ ities /recogn iz ing  
lim its/g iv ing  up
I  don't ben d  down, I  c a n ’t 
ben d  it's very  difficult to  
ben d  up an d  dow n very  
difficidt
I cou ld  no t bend  forw ard
M anagem ent o f
activ ities /m od ifica tion /support/m echan ica l
aids
I  p u t m y fo o t  h igher up, I 
p u t it on som eth ing rather  
than m e b en d  dow n to it, I  
p u t m y fo o t  on som ething  
that's h igher up, so  I'm 
not bending dow n as far, 
so  I'm not bending right 
over I'm bringing the fo o t  
to  me
I could  bend  forw ard  bu t 
cou ld  no t reach  m y  feet
M anagem ent o f  ac tiv ities/recogn iz ing  
lim its/stopping  activ ity
Factors in fluencing  activ ity  
perfo rm ance/S ym ptom s/im pact
To ben d  dow n very  
difficult, as I  sa id  earlier  
bending pu sh es everyth ing  
up onto yo u r  lungs, so  
y o u r  lungs being sm all 
capacity  anyway, then 
you 've  m ade them even  
sm aller, w hen ben d  over  
because everyth ing pushes  
up onto them, so  there is 
m ore pressu re  on them
I cou ld  bend  reach  m y feet 
bu t I could  no t keep  it to 
p u t shoes
Factors in fluencing  activ ity  
perfo rm ance/S ym ptom s/im pact
the actual bending down  
to p u t on som eth ing on 
yo u r f e e t  is because the 
illness in m y lungs an d  I  
ben d  dow n so  everyth ing  
pu sh es up, so  everyth ing  
on m y lungs, so  that in 
its e lf  m akes p u ttin g  socks 
an d  shoes on rea lly  rea lly  
difficidt
I cou ld  bend  forw ard , and 
m ain ta in  it
F acto rs in fluencing  activ ity / 
sym ptom s/im pact
M anagem ent o f  
activ ities /m od ifica tion /slow ing-pacing
som etim es I  can't ben d  to 
fa s ten  m y shoes, I  m ean I  
have to g e t back
I cou ld  bend  forw ard , 
m ain ta in  it, and  start 
do ing  ano ther activ ity  
w hile  bend ing  (pu tting  on 
shoes, hovering ) bu t th is 
w ould  get m e ou t o f  
b reath , so tha t I need  to  
ge t back  fo r a  res t before  
com pleting  the ac tiv ity
Perform ance o f  ac tiv ity /level/varia tion som etim es I p u t shoes on 
an d  never think about it
I could  bend  forw ard , 
m ain ta in  it and fully  
com plete  an o ther ac tiv ity  
w ithou t resting
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T ab le 6 F u n ction a l w a lk in g
T h e m e N a rra t iv e s P e r fo rm a n c e
d e sc r ip to r s
M anagem ent o f  ac tiv ities /  
m od ifica tion / support/ 
m echanical aids
I  c a n ’t w alk fa r  m y breath ing  
an d  osteoarthritis I  use a w alker
I could  no t w alk  I'll get 
b reath less after stand ing  and 
tak ing  few  steps
M anagem ent o f  
ac tiv ities /m od ifica tion / slow ing- 
pacing
like when you 're  ge ttin g  ready  to  
g o  out because you 're  go in g  out 
y o u r  adrenaline goes up 
naturally so  yo u  have to  learn to 
do it slowly, do it in s tages so  
yo u r  adrenalin  doesn't g e t 
pu m pin g  too fa s t  so  y o u  don't g e t  
breathless.
I  f in d  it difficult to  breathe, 
w alking in town, p e o p le  don't 
notice
I cou ld  w alk  inside o r around  
hom e bu t no t any fu rther
M anagem ent o f  
ac tiv ities /m od ifica tion / slow ing- 
pacing. Factors in fluencing  
activ ity  perfo rm ance/ 
Sym ptom s / im pact
But w h atever I  do  I  take m y own 
time, even walking, when  
an ybody is w alking with m e they  
have to w alk a t m y pace, I  can't 
w alk a t their pace , their p a c e  is 
fa r  too  fa s t  f o r  me.
I could  w alk  ou tside hom e b u t 
m y pace  is far slow er than  
o ther peop le
M anagem ent o f  
activ ities /m od ifica tion / slow ing- 
pacing
I  f e e l  breath less after g o in g  to a 
walk, but I  recover quicker 
because I'm breath ing now from  
here (pointing to abdom en) 
in stead  o f  here (pointing to  
upper chest). It's the diaphragm  
you 've  g o t to bu ild  yo u r  
diaphragm . M ost p e o p le  breathe  
fro m  the chest, so  they've to stop. 
So you 've  g o t to bu ild  yo u r  
diaphragm  m uscles up. A n d  yo u  
can do it a little  b it longer
I could  w alk  ou ts ide hom e w ith  
a norm al pace  b u t I have  to 
keep stopping  fo r a res t
Factors in fluencing  ac tiv ity / 
sym ptom s/im pact
I  mean he and  I  w ill g o  fo r  a  
walk, an d  se t o ff  m arching, i f  he 
starts talking H is lung ju s t  
ceases up an d  he c a n ’t w alk  very  
fa s t
1 cou ld  w alk  ou ts ide  hom e 
w ith  a no rm al pace  w ithou t 
stopping fo r a  res t b u t since I 
start ta lk ing , I ge t b rea th less
Factors in fluencing  ac tiv ity / 
sym ptom s/im pact
Well, w alking I  cou ld  w alk  3 
m iles a long the beach an d  th a t’s 
no problem
W alking  ou ts ide  is no t a 
prob lem
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T ab le  7 w a lk in g  uph ill
T h em es N a rra t iv e s P e r fo rm a n c e
d e sc r ip to r s
M anagem ent o f  
ac tiv ities /recogn izing  
lim its/g iv ing  up
I've done this fo r  a  couple o f  
times, an d  I  s ta r te d  fig h tin g  fo r  
m y breath
U nable to  w alk  uphill
Factors in fluencing  ac tiv ity / 
sym ptom s/im pact
I f  I  w alk  up to the top  o f  that 
lane (about h a lf  a m ile) I ’ll g e t 
breath less before ge ttin g  there
A ble to  w alk  a few  steps 
uphill bu t gets b reath less 
and stops
M anagem ent o f  
activ ities/m od ifica tion / slow ing- 
pacing . F actors in fluencing  
activ ity  perfo rm ance/ 
Sym ptom s /  im pact
when I'm w alking uphill I  g e t out 
o f  breath, an d  I have to rest
A ble to  w alk  uph ill w ith  a 
slow  pace* and needs to 
keep stopping  fo r a  rest
M anagem ent o f  
ac tiv ities /m od ifica tion / slow ing- 
pacing
F acto rs in fluencing  ac tiv ity / 
sym ptom s/im pact
an d  w e actually lived  on a  little  
hill, bu t a very  steep  h ill and  
w hile she w ere w alking up or 
ride  very quickly she turned to 
w alking up an d  stru gglin g  she  
keeps stopp in g
A ble to w alk  uphill w ith  a 
norm al pace b u t has to 
keep stopp ing  for a rest
P erform ance o f  
activ ity /varia tion
I f  it is warm  an d  n ice then I  
cou ld  take it a t m y own p a c e
A ble to  w alk  uphill w ith  a 
norm al pace w ithou t 
stopping  fo r a rest
A ble to  do h ill w alk ing  
and ta lk ing
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T ab le 8 G o in g  u p sta irs
T h e m e s N a rra t iv e s P e r fo rm a n c e
d e sc r ip to r s
M anagem ent o f  
ac tiv ities/recognizing  
lim its/g iv ing  up
I  w o u ld n ’t go  downstairs, because  
everyth ing w as upstairs I  w as 
fr ig h ten ed  to g o  dow nstairs so  I  g o t  
a sta ir  lift p u t in so  I  cou ld  m ove up 
an d  down sta irs
U nab le to  go  upstairs
M anagem ent o f
activ ities /recogn iz ing
lim its /stopping
I  s top  after 2 I  c a n ’t  ’ carry on A ble to  take  a  few  steps 
d istance upsta irs  bu t gets 
b reath less and stops
M anagem ent o f  ac tiv ities / 
m od ifica tion / slow ing-pacing .
Factors in fluencing  activ ity  
perfo rm ance/ S ym ptom s / im pact
I  s ta r t m oving about upstairs an d  I  
f e e l  as I  d id n ’t have the nebidiser, 
som ething is no t alrigh t here I  s it 
dow n a  b it an d  see  i f  it eases off.
A ble to  w alk  upstairs 
d istance bu t stops a fte r a 
few  steps (2 o r 3)
M anagem ent o f  
activ ities /m od ifica tion / slow ing- 
pacing
Factors in fluencing  ac tiv ity / 
sym ptom s/im pact
w alk upstairs an d  that take me 
som e doing  I ’m rea lly  exhausted by  
the tim e I  g e t to the top  I  c a n ’t do it 
a ll a t once I  do it in threes
A ble to  w alk  upstairs w ith  
a norm al pace  speed  bu t 
has to  keep  s topp ing  fo r a 
rest
P u lm onary  rehab ilita tion / 
b enefits/ functional im provem ent
I t ’s so r t o f  doubling; I  mean i t ’s 
taking me h a lf  the tim e to go  
upstairs
A ble to  w alk  sta irs w ith  a 
norm al pace w ithou t 
s topping  for a rest
Factors in fluencing  ac tiv ity / 
sym ptom s/im pact
G oing upstairs, th a t’s no p rob lem  
a t all. I ’m not that b a d  yet.
A ble to  w alk  stairs w ith  a  
norm al pace w ithou t 
stopp ing  for a res t and do 
ano ther function
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T ab le  9 S h o w erin g
T h e m e N a rra t iv e s D e sc r ip to rs  o f  
p e r fo rm a n c e
M anagem ent o f  activ ities /  
m od ifica tion / support/ others
I  g e t the w ife to assist m e when I'm 
struggling, she has to help me
U nab le to  show er 
independen tly
Factors in fluencing  ac tiv ity / 
sym ptom s/im pact
show ering  p rob lem  I  think one o f  
the p rob lem s is everyth ing that is a 
lo t o f  arm movem ent, especia lly  
over the h ea d  like w ash ing the hair
A ble to  w ash  head  and  body  
in sitting  b u t unab le  to  get 
dried
M anagem ent o f  
ac tiv ities /m od ifica tion / slow ing- 
pacing.
M anagem ent o f  activ ities /  
m od ifica tion / support/ 
m echan ical aids
I  g e t in I  g e t in the sh ow er an d  I've 
g o t a sea t in there I  g e t in the 
show er I  sh ow er o ff  an d  then I  have  
to s it dow n in the tow el to drip dry
A ble to  w ash  m y  head  and 
body  w hile  sitting  bu t 
unable  to  ge t dried
M anagem ent o f  
activ ities /m odifica tion / slow ing- 
pacing
Y ou ’ve h a d  y o u r  show er but i t ’s 
rea lly  a h a rd  w ork tryin g  to g e t 
d rie d  w ith  a  bath sheet, so  I  dry my 
top  an d  then use a sm all tow el to  
dry m y fe e t
A ble to  w ash  m y  head  and 
body  w hile  stand ing  and  get 
d ried
Factors in fluencing  ac tiv ity / 
sym ptom s/im pact
I  m ean show ering  drains me 
strength, but i t ’s  drying, when I  
fin ish  I ’m rea lly  d ra in ed  an d  I ’m 
upstairs f o r  another hour to  so r t o f  
recoverin g
A ble to  show er b u t feels 
exhausted
A ble to  show er
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Appendix B.10: Topic guide for focus group -validation by patients.
Focus group (Validation by patients): Perspectives of people w ith COPD on TELER function  
indicators for use in pulmonary rehabilitation for people w ith COPD
This focus group is planned at two stages the first stage is a discussion of the outcome and the 
second stage is a discussion of the order of improvement.
S tagel: The follow ing treatm ent outcom es w ould be presented on a flipchart:
Participants are asked to  read the outcom es, and a brief description o f each outcom e is 
provided.
Able to do the activity (any activity selected by the patient) and maintains controlled 
breathing.
Able to achieve functional walking 
Able to do hill walking and talking 
Able to put shoes on 
Able to do walk up stairs and talk 
Able to shower
Q l: Do th o se  ou tcom es m atter to  you?
Prompts:
Is it important to be able to do theses activities?
If you were not able to do them, how would that affect your daily life?
Q2: Is that w hat you expect to  achieve follow ing pulm onary rehabilitation?
Prompts:
Do you see theses outcomes as something that could be improved by pulmonary 
rehabilitation?
Q3: Are there any outcom es that m atters that are not listed?
Prompts:
Is there anything missing?
52
Any other important activities that we did not cover?
Q4: Considering th ese  ou tcom es do you think you could go any further?
Prompts:
Is that the maximum possible improvement?
Do you think you could push your limits any further?
Stage 2: TELER function indicators are presented on a flipchart, one indicator at a tim e: 
Participants are asked to  read th e  indicators
Q l: if vour condition is improving, do you se e  it improving in that order?
Prompts:
What would be an improvement from which you are at now?
If you look at the steps of improvement is there any missing step that you have experienced?
53
Appendix B .ll: Scientific meeting-Invitation letter.
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Centre for Health and Social Care.1 Research
Invitation to a sc ien tific  m eeting:
Pulm onary R ehabilitation perform ance ind icators for COPD
We have the pleasure o f inviting you to participate in a scientific meeting on the 
"Development and validation o f  TELER functional performance indicators fo r  use in 
Pulmonary Rehabilitation fo r  people with Chronic Obstructive Pulmonary Disease".
The meeting will take place on the 2nd o f March 2010 at Sheffield Hallam University, 
Sheffield.
Aim of the m eeting
The objective o f the scientific meeting is to obtain expert validation o f a newly 
developed measurement tool that measures functional activities following pulmonary 
rehabilitation. We are inviting academics and clinicians to participate from local and 
national organizations. Participants will be experts in measurement, respiratory 
physiotherapy, pulmonary rehabilitation, or the TELER method o f measurement.
Meeting plan
We are aiming to make the day interesting and useful to you as well as informative to 
us.
The day will consist o f three parts.
1. A presentation of the protocol by which the TELER function indicators were developed.
2. An introduction to the TELER method of measurement.
3. A structured discussion to generate consensus on the TELER function indicators. These 
indicators will then be tested in clinical practice at Rotherham Breathing Space.
If you would like to participate in this meeting we would be grateful if  you could 
respond as soon as possible to Rasha (R.O.Qkasheh@shu.ac.uk). Her full contact details 
are bellow.
We look forward to hearing from you soon.
Yours sincerely,
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Rasha Okasheh
Rasha O kasheh
PhD stu d e n t/H e a lth  and W ellbeing  
H ealth and Social Care R esearch C entre  
Sheffield  Hallam U niversity  
C ollegiate  H all/ 31  C olleg iate  C rescent 
R.O.Okasheh(a)shu.ac.uk 
Tel: 0 1 1 4  22 5  5 8 9 8
Professor Sue Mawson
Director N1HR CLAHRCfor South Yorkshire.
Susan.mawson&sth.nhs.uk
Professor o f Rehabilitation
Centre fo r  Health and Social Care
Sheffield Hallam University
s.i. mawson&sh u.ac.uk
Visiting Professor o f Rehabilitation
ScHARR
The University o f Sheffield
Dr Angela Mary Tod 
Principal Research Fellow 
Centre for Health and Social Care 
Research
Sheffield Hallam University 
Montgomery House 
32 Collegiate Crescent 
Sheffield S10 2BP 
+44 (0)114-2255675 
+44 (0)114-2255377
Appendix B.12: A questionnaire for the assessment of the validity of the 
TELER "function" indicators.
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Appendix C: Phase 3 "Clinical testing"
• Appendix C . l : A list o f the instruments used for routine clinical assessment.
• Appendix C.2: Ethics approval-Clinical testing
• Appendix C.3: Participant information sheet-Clinical testing.
• Appendix C.4: Consent form-Clinical testing.
• Appendix C.5: The probability distribution o f both CAT and TELER.
• Appendix C.6: The TELER form / Patient MH.
• Appendix C.7: Qualitative analysis o f factors influencing activity/Patient MH.
• Appendix C.8: Analysis tables and graphs -  Clinical testing.
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Appendix C.l: A list of the instruments used for routine clinical assessment.
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Table 10 Pre and post PR data on routine assessment tools
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Appendix C.2: Ethics approval-Clinical testing
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g e sRotherham
12.0710 
Mrs Ohasheh 
Apartment 14 
Lindley Hieghts 
2 Lindley Place 
Sheffield 
S5 6UX
RFT Ref: - 00250 Please quote this number on alt correspondence 
REC Ref No : 10/H1310/37
Dear Mrs Okasheh
Re: Usefulness of TELEH in evaluating pulmonary rehabilitation
The Research and Development department has completed the governance appraisal for the above 
study.
Documents reviewed ________________   ._________ ________ _________
Document Version Date
Rec application 12 May 2010
Protocol 2.5 15 June 2010
Investigator C V 12 April 2010
Consent form 15 June 2010
Information sheet 15 June 2010
Self management diary 12 May 2010
On behalf of the Research & Development Lead, Jo Abbott, I am writing to confirm that your research 
proposal has been approved on the understanding and provision that you will adhere to the following 
conditions:-
That the research should:
• Be conducted in accordance with ICH GCP guidelines and that you and your team are familiar with 
issues of informed consent within research having completed the ‘Good Clinical Practice’ training 
within the last 2 years
• Comply with the requirements of the Research Governance Framework for Health and Social Care 
(2nd DH 2005)
• Comply with regulatory requirements and legislation relating to: clinical Trials, Data Protection, 
Health & Safety, Trust Caldicott Guidelines and the use of Human Tissue for research purposes
You must also:
• Request written approval for any change to the approved protocol/study documents that you or the 
Chief Investigator wish to implement
• Ensure that all study personnel, not employed by NHS Rotherham hold either a letter an honorary 
contract with the Trust or a letter of access issued by the Trust, before they have access to any 
facilities, patients, staff, their data, tissue or organs
• You complete and return the standard progress report form on a six monthly basis from the date on 
this letter. This form should also be used to notify the R&D department when your research is
completed At the point of completion, please submit your findings, any publication or presentations 
of your findings.
• For monitoring purposes, you should maintain an up to date site file with all relevant information. 
This may be used for audit purposes in the future. Research documentation should be retained for 
fifteen years after the study has been completed.
• If you decide to terminate this research prematurely, you send a report to this office within 28 days, 
indicating the reason for the early termination.
• You advise this office of any unusual or unexpected results that raise questions about the safety of 
the research Also, any adverse events experienced during the course of research projects must be 
registered with the Trust Risk manager according to local policy.
The project must be started within 1 year of the date on this letter.
If you have any further queries do not hesitate to contact the Research office.
Yours sincerely
Angela Ross 
Research Coordinator
Enc Monitoring/Progress Report Form 
Site file contents list
R otherham  R esea rch  A lliance
Research & Development DLE91, D Level, PGME corridor
Leads in Research & Development Miss D Patel & Jo Abbott
Research Coordinator Dr Angela Ross Direct Lins 01709 30773974177 Email ar.gela.rossQrothgen.nlrsvh 
In partnership with NHS Rotherham and Rotherham Community Health Services
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Appendix C.3: Participant information sheet-Clinical testing.
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Sheffield Hallatn University
PARTICIPANT INFORMATION SHEET 
Testing the usefulness and responsiveness of TELER function indicators during 
Pulmonary Rehabilitation “PR” in people with Chronic Obstructive Pulmonary
Disease “COPD”
You are invited to participate in a research study to test a new tool for tracing 
improvement in functions and activities during Pulmonary Rehabilitation. Before you 
decide to take part in the study please take time to read the following information. If 
you have any questions or you want more information do not hesitate to contact me on 
the address provided at the end o f this information sheet.
Thank you for reading this.
“What is the title of the study?”
Testing the usefulness and responsiveness o f TELER function indicators during 
Pulmonary Rehabilitation (PR) in people with Chronic Obstructive Pulmonary Disease 
(COPD)
“What is the purpose of the study?”
During my PhD I have developed a new way o f measuring the benefits a person may 
gain from attending pulmonary rehabilitation. This measures how you perform daily life 
activities. The measure has been developed to be used by patients themselves to help 
them record changes in their ability to do these activities giving them more knowledge 
and more control about their progression during pulmonary rehabilitation. To test this 
measure I would like to give it to a group o f people with COPD and ask them to score 
themselves using a diary within their own home, and compare their scoring with the 
ones collected at Breathing space by the Physiotherapist.
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“Why I have been asked to take part in this study?”
You have been invited to participate in the study because you were diagnosed with 
COPD and referred to pulmonary rehabilitation.
“Do I have to take part?”
It is up to you whether or not to take part. If you decide to take part you will be given 
this information sheet to keep, and you will be asked to sign a consent form. If you 
decide to take part you are still free to withdraw from the study at any time and without 
giving any reason. If you decide not to take part in the study or if  you withdraw later, 
this will not affect the standard of care you receive from any health or social care 
service.
“What will happen if  I want to take part?”
You will be given a consent form to sign, and the process will be explained again in 
details.
“How long will the study last?”
The whole study will last about 6 months. You will be asked to score yourself each 
week during the 6 weeks rehabilitation program.
“What will it involve?”
If you agree to participate in this study you will be asked to complete the routine 
assessment that is usually done with patients attending pulmonary rehabilitation. Also 
you will be asked to select 3 activities form a set o f daily life activities and rate your 
performance of these activities using the new measure. After this you will be given a 
diary of these activities and score each activity 3 times weekly until the end o f your 
rehabilitation program.
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“Where the study will be done?”
The study will be carried out in Breathing space when you attend for your pulmonary 
rehabilitation session
“Will taking part cost me?”
No.
“What If I don’t wish to take part?”
It is completely up to you. There is no problem if  you decide not to take part in the 
study and this will not affect the standard o f care you receive form any health or social 
care services.
“What if I change my mind during the study?”
You are free to withdraw from the study at any time without giving any reason.
“What will happen to the information from the study?”
All information will be kept entirely confidential. No individual will be identifiable in 
the report. You will be informed o f the results o f  the study if  you wish.
“Will my taking part in the study be kept confidential?”
Yes, all the information collected about you during the study will be kept strictly 
confidential. You will be identified by a code number rather a name, your name will not 
be disclosed.
“What if there is a problem?”
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. If you are harmed by taking part in the study, 
there are no special compensation arrangements. If  you wish to complain, or have any 
concerns about any aspect o f the way you have been approached during this study, the 
normal National Health Service Complaints mechanisms should be available to you. 
You can contact Mrs. Angela Green for details or if  you have internet access you can 
make a complaint directly using the following links: 
http://www.direct.gov.uk/en/Diol 1 /DoItOnline/DG 4018299 
http://www.nhs.uk/servicedirectories/pages/hospital.aspx?id=rhqng&v=4
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"Who has reviewed this study?"
All research in the NHS is looked at by an independent group o f people, called a 
Research Ethics Committee to protect your interests. This study has been reviewed by 
South Yorkshire Ethics Committee.
"Further information/independent advice"
The Patient advice and liaison service is available
Monday to Friday 8.30 am to 
5.00pm and can be contacted 
In the following ways:
By calling in to the Patient 
Services Department,
Level D o f the main hospital 
By calling direct on 01709 307646 
By calling the free phone number 0800 9531303 
E-mailing: pals@jothgen.nhs.uk
Writing to:
Patient advice and liaison services 
Level D
Rotherham General Hospital 
Moorgate Road 
Rotherham 
S60 2UD
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“What if I have further questions?”
If you have any questions now or later, please contact me at the address below:
R a s h a  O k a s h e h
P h D  p h y s i o t h e r a p y  s t u d e n t
S h e f f i e l d  H a l l a m  U n i v e r s i t y
F a c u l t y  o f  h e a l t h  a n d  w e l l b e i n g
C o l l e g i a t e  H a l l
R o o m  A 2 1 4
S 1 0  2 B P
E - m a i l :  r . o . o k a s h e h @ s h u . a c . u k
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Appendix C.4: Consent form-Clinical testing.
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CONSENT FORM
Testing the usefulness and responsiveness of TELER function indicators during 
Pulmonary Rehabilitation (PR) in people with Chronic Obstructive Pulmonary Disease
(COPD)
Please give your consent to participating in the study by answering the 
following questions (please tick the boxes)
Have you read the information sheet about this study?
Have you been able to ask questions about this study?
Have you received answers to all your questions?
Have you received enough information about this study?
YesD NoD
YesD NoD
YesD NoD
YesD NoD
Are you involved in any other studies? YesD NoD
■ If you are, how many?
Do you understand that you are free to withdraw from this study?
■ At any time? YesD NoD
■ Without giving a reason for withdrawing? YesD NoD
I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.
YesD NoD
I understand that the information will be kept on paper and computer database and that 
access will be restricted to the researchers. YesD NoD 
I agree to take part in this study? YesD NoD
Your signature will clarify that you have had adequate opportunity to discuss the 
study with the researcher and have voluntarily decided to take part in this study. 
Please keep your copy of this form and the information sheet together.
Name of participant Date Signature
Name of researcher Date
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Signature
Appendix C.5: The probability distribution of both CAT and TELER.
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erformance Index
hange Index
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A d d  p i c t u r e  to l i b r a r y  
S l i d e  S h o w
P robability  d is tribu tion
Total
N um ber
o f
profiles
Prob(T otal) C um ulativeP rob(T otal)
T E L E R
indicator
code
0 1 5.965 86E-07 5 .96586E -07
1 8 4.77269E -06 5 .36927E -06
2 36 j 2.14771 E-05 2.68464E -05
3 120 7.15903 E-05 9 .84367E -05
330 0.000196873 0 .000295310
5 792 0.000472496 0 ,000767806 5 ‘
6 1,780 0.001061923 0 .001829730
7 3,368 0 .002009302 0.003839032
8 6,147 0.003667215 0 .007506246
9 10,480 0.006252222 0 .013758469 .
10 16,808 0.010027419 0.023785888
11 25,488 0 .015205786 0 .038991674
12 36,688 0.021887551 0.060879225
(T3) 50,288 0 .030001122 0.090880346 4
14 65,808 0 .039260138 0.130140484
15 82,384 0 .049149149 0.179289633
16 98,813 0.058950462 0.238240095
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135,758 0.080991335 3
21 133.288 0.079517768 0.459504332
22 125,588 0.074924055 0 .379986565
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\  27 50,288 0.030001122 0.090880346 2
28 36,688 0.021887551 0.060879225
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Probability  that a score on  each  o f  the e igh t sym ptom s is m arked  at random :
• (1 ■* 6 )8 =  5 .95374E -07; alternatively
• 1 -t-1,676,204 =  5 .96586E -07
► E rror =  * 0 .002036  or +0.2036% ; a lternative ly
► R ounding erro r in (1 + 6 )8 =  -0 .2033%
CAT Probability Distribution, Longhand Data Limited, 01.06.11/ z. 27
Appendix C.6: The TELER form /  Patient MH.
Appendix C.7: Qualitative analysis of factors influencing activity/Patient MH.
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Appendix C.8: Analysis tables and graphs -  Clinical testing.
• Analysis at the level of the patient- the significance of a number of 
improvements/deteriorations on a TELER indicator by code on admission and 
code on discharge: Table 12 to 19.
• Analysis at the level o f the group -  the outcome of care /efficiency o f care: 
Table 20-22.
• Analysis at the level o f the group -the quality o f care: Table 23- 30.
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Table 20 Number of patients by the number of clinically significant improvements at the end of trea tm en t
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Table 26 Performance index on admission versus maintenance index on discharge
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Table 27 Performance index on admission versus effectiveness index on discharge
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Table 30 Health status index on admission versus health change index on discharge
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Appendix D: Overall discussion
• Appendix D. 1: Poster presentation.
• Appendix D.2: Journal publication plan.
95
s o
CO
G0)
c/icuSMauV■M
C/ioa.
Q
X>M
T3Gaaa<
c .<
Ap
pe
nd
ix 
D.2
: J
ou
rn
al 
pu
bli
ca
tio
n 
pl
an
E
_Q3oo
"DcutooQ .
O
CD
T 3
3CUO13<
rHrH
OfM
i_CU
-QE
CU4—*Q .<U00
rH rH
rH rHrH O orH CM CMO t— i_fM CU CUi_ St sCU_Q E Eo cu cu4—> > >u o oo 2
CDco
£
CL
CU>4->U
13
_Qo
u
' coi_
s
u
CU
CDcoE
3
CL
CU>4-1u3
-Qo
u
" co
s
u
c c C>. . 2  L_ 4-> fc* s ^  sCD C CD C CD CC  CU C  CU C  CUo > O > O >E £ E £ E £3 °- 3 CL 3CL T3 CL T3 CL T3o c o c o c~  CD -  CD ~  CD
1-  c t -  C t— c™ o CO o ,co o^  4-> 4-> ^  4-<*+- CD tr co U -  CDO .4-; O .tf O .-M
CD £ CD £ CD
1 ^ 1 5 1 5
■S o•H DC °  a.
o. c4—13<
CUDOc<
cd 52 
- c  $
52 CD CDCC 2
«  5
CD ^  -X
o  «
DC CO
T 3 CU T 3
O 3 O
1— OO H
JD _CD
CU cu CUDO s DOc to c< CD <
c O co CD oto
$ S.oo
to
CD CD CDl—DC
t " -O n
DOC
u
_ c
to
CUEou4-<=5 CU
°  3
S E o cu 
*±u  —  C cu3  JZ
CCUEcuI -  — 
V)ZJ fjCDCU ± f
£_cy
Q .ocuCL
to  CD
°  4=ro loU  CD Scu
cu
CDCUE
CUEou4—*3
O
DOC
Q
CLo
u
• • CD CM U  
to  '~co .E
^  DO^  E
c  £
£ =  —  CDS 73Q . V4_
°  to
cd o : u o1 I
S -2~  QD u llj
§ C
00 CULU —  • -
co4->CDT3
75>
T 3
c
CD4->ccuE
CL_ocu>cu□
c
.03VjCD
Q .
> -
~a3
CD3cr
uCD
"cdco4~>uc3<4—
co
tocu>4->ucuCLtot_CUCL
DC o
co4->CDT3
75>
cd n
T 3  CU 
—  CL CD X  >  LU
T 3
CCD CD
CUU
£CU00
no
o
c
o4—*CD33
75>
T 3
C
CD4->ccuE
CL_o
CU>CU
O
DOc
u
DC
Q .
CD
C
DOC
